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Abstract  
Since the introduction of vaccines, millions of lives have been saved. Yet, infectious diseases 
continue to contribute to deaths in underdeveloped countries, with over 2 million children dying per 
year from preventable diseases such as diphtheria, pertussis and tetanus. Despite the advantages of 
vaccines, there are also some risks and disadvantages associated with vaccines and their delivery 
such as the need for medical personnel for administration, refrigeration of the vaccine, disease 
transmission associated with needles and potential adverse side effects due to adjuvants. While 
intramuscular and subcutaneous injections are most frequently used for vaccine administration, 
these sites are poor in antigen-presenting cells. The skin, the largest immunological organ, by 
contrast contains a dense network of antigen-presenting cells, important in the uptake of antigen and 
presentation to naive T-cells, and has received increased interest as a target site for vaccine 
delivery. Intradermal immunisations have achieved significant dose-sparing over conventional 
immunisation routes. However, using existing needle designs, intradermal injections can be difficult 
to administer into the thin dermal layer due to the proportionally large scale of the needle. This has 
led to the development of alternative skin-based delivery methods, such as microneedle arrays.  
Here, the Nanopatch™ is an array containing 3364 microprojections of ~110 µm in length, which 
was used to deliver the vaccine into the viable epidermis and dermis of the skin. With an 
unprecedented >100-fold dose-sparing reported by the Nanopatch™ in comparison to conventional 
immunisation strategies with an influenza split virion vaccine, the mechanisms behind this skin-
mediated ‘adjuvant’ effect are not clear. Danger signals released by stressed, damaged or dead cells 
have resulted in enhanced immune responses in a similar manner to chemical adjuvants. Co-
administrations of dead cells with vaccines have led to enhanced immune responses. While the 
adjuvanting effects of dead cells have been well established, the local or wide-spread level of cell 
damage inflicted by vaccine delivery devices have not been studied in the context of 
immunogenicity. Thus, the underlying hypothesis of this doctoral thesis was that Nanopatch™ 
projections penetrating the skin could convey a ‘physical immune enhancer’ effect similar to an 
adjuvant as a direct result of local tissue damage/ cell death by the device itself, responsible for the 
enhanced immunogenicity relative to needle-based routes. 
The extent of cell death after Nanopatch™ application and intradermal injection was investigated, 
characterised and quantified by Confocal/ Multiphoton microscopy, Western Blot and flow 
cytometry. A distinct pattern of dead cells was obtained with significantly higher levels (~65-fold) 
of cell death in murine ear skin following Nanopatch™ treatment than intradermal injection. 
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Measured skin cell death was tuneable by changing projection density but not shapes, and was 
associated with modelled stresses of ≥1 MPa. 
Immunogenicity studies demonstrated consistently and statistically significantly higher anti-IgG 
endpoint titres (up to 50-fold higher) in Nanopatch™ than intradermally injected groups after 
delivery of a split virion influenza vaccine, with a 10-fold dose-sparing effect. Importantly, co-
localisation of delivered antigen with both, live and dead cells was necessary for immunogenicity 
enhancement. Overall, higher inflammatory responses and longer-lasting antigen depot formation 
were associated with Nanopatch™ immunisations but not with intradermal injections. The findings 
indicated a correlation between co-localisation of antigen cell death caused by the Nanopatch™ and 
enhanced immunogenicity with split virion influenza vaccine as model antigen.  
Collectively, the data presented within this doctoral thesis propose a ‘physical immune enhancer’ 
effect by the Nanopatch™ that increases immune responses to vaccines. Elucidating the key 
differences between intradermal and microneedles or microprojections such as the Nanopatch™ 
may contribute to understand the different mechanisms between skin immunisation routes. This 
work contributes extensively to the field of skin-based immunisations by providing insights on how 
device-induced cell death and the resulting inflammation may affect immunogenicity. This physical 
immune enhancer effect has the potential to mitigate or replace chemical-based adjuvants in skin-
based vaccine delivery. 
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MIP maximum intensity projection 
mL millilitre 
MN microneedle 
MPL monophosphoryl lipid A 
MPa megapascal 
MPA microprojection array  
MPM multi photon microscopy 
mRNA messenger ribonucleic acid 
MSU monosodium urate 
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MW molecular weight 
NALP3/ NLRP3 NACHT, LRR and PYD domains-containing protein 3 
NFκB nuclear factor kappa-light-chain-enhancer of activated B-cells 
NIR Near-Infrared 
NK natural killer cells 
NLR NOD-like receptor 
NOD nucleotide oligomerisation domain 
NP Nanopatch™ 
O/N overnight 
OVA Ovalbumin  
PAMPs pathogen associated molecular patterns 
PARP poly adenosine diphosphate ribose polymerase 
PDMS polydimethylsiloxane 
PI Propidium Iodide 
PLGA poly(lactic-co-glycolic acid) 
PRR pattern recognition receptor  
PS phosphatidyl serine 
QA Quil-A 
RAGE receptor for advanced glycation endproducts 
rcf  relative centrifugal force 
RNA ribonucleic acid 
ROI region of interest 
RT room temperature 
s second(s) 
s.c. subcutaneous, subcutaneously  
SC stratum corneum  
SD standard deviation 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM scanning electron microscope 
s.s. skin scarification 
ss single stranded (e.g. ssRNA) 
Tcm central memory T-cell 
TCR T-cell receptor 
Tem effector memory T-cell 
Th T-helper cell 
Treg regulatory T-cell 
Trm tissue resident memory T-cells 
TEWL Trans Epidermal Water Loss  
TLR Toll-like receptor 
TNF tumor necrosis factor 
VE viable epidermis  
VLP virus like particle 
W Watt 
WHO World Health Organization 
WT wild type 
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Chapter 1  
Context of the study 
The introduction of vaccination is the most important medical development to combat diseases, 
leading to better health and longevity. Still, vaccine-preventable diseases such as diphtheria, 
pertussis and tetanus result in unnecessary child deaths in developing countries. This is 
predominantly due to the vaccines being administered by needles, requiring trained personnel and 
maintenance of a cold-chain for vaccine stability. Further disadvantages associated with vaccines 
and vaccine delivery include side effects, reactogenicity and needle stick injuries that may transmit 
highly infectious diseases such as human immunodeficiency virus (HIV) and hepatitis B [1]. With 
new emerging technologies, these problems could be overcome by administering vaccines via the 
mucosal or intradermal route. Both possible administration routes have challenges to overcome. 
With a new approach of vaccine delivery in form of microneedles (MN), capable of delivering 
drugs and vaccines into the skin, a new era of vaccine delivery has emerged within the last decade. 
Recently, these MN have been advanced on the nanoscale level [2], known as Nanopatch™ (NP). 
Studies have shown that immunisation by NP required less than 1/100th of the intramuscular (i.m.) 
dose to achieve comparable if not higher antibody-specific immune responses [3]. The skin’s high 
density of antigen presenting cells (APCs) offers one potential explanation for the MN eliciting 
such strong immune responses. No studies have been conducted so far assessing the importance and 
impact of cell damage and cell death caused by MN upon immune responses after vaccine delivery.  
The doctoral work in this thesis focussed on the role of cell damage caused by the NP in vaccine 
delivery and its importance in antibody-mediated immune responses. The outcomes of this PhD 
project will contribute to the scientific field of cutaneous needle-free vaccine delivery. More 
specifically, this project will provide an understanding of the cellular damage and death inflicted by 
immunisation devices that may contribute as an effective vaccination strategy employed by the NP. 
This is based on the current knowledge and resources within the author’s research group (D2G2), 
skin immunisation field as well as current literature on skin, its cellular components, cell damage 
caused by mechanical stimulus and stress, danger signals and cutaneous vaccine delivery based on 
MN delivery.  
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1.1 Hypotheses and aims 
The purpose of this doctoral study was to elucidate the role of cell damage and cell death in vaccine 
delivery targeted into the skin. This was based on the overall hypothesis that tissue damage and 
cell death caused by delivering vaccines into the skin using the NP would have a direct impact 
on enhancing influenza-specific antibody responses as well as the inflammatory innate 
immune responses. Specifically, this project aimed to investigate the role of cell damage caused by 
the NP in vaccine delivery as well as its importance in inflammatory responses and was based upon 
the following hypotheses:  
i. Sub-Hypothesis 1: 
NP application induces a level of cell damage that is localised to the application/ vaccine 
delivery site only (Chapter 4).  
ii. Sub-Hypothesis 2: 
The amount of cell damage can be directly modulated by changing NP application 
conditions (projection shape, application velocity etc); using a computational modelling 
approach, a cell death threshold to which skin cells succumb, can be predicted for NP 
applications (Chapter 5).  
iii. Sub-Hypothesis 3:  
Increasing the cell death increases influenza-specific antibody responses/ titres after targeted 
delivery by NP of vaccine to these sites (Chapter 6).  
iv. Sub-Hypothesis 4:  
NP application induces greater local inflammatory responses and higher inflammatory 
infiltrates than i.d. injections, which contribute to an enhanced immune response after 
targeted co-delivery of vaccine to skin (Chapter 7).  
The specific aims of this project were: 
• To characterise and quantify cell damage over time after NP application; 
• To use intradermal injections for comparative purposes due to the same tissue being 
targeted; 
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• To determine the impact of application parameters on cell damage and investigate the local 
inflammatory response following NP application;  
• To deliver vaccines using the NP under conditions known to induce specific levels of cell 
damage, and characterise the resulting immune and inflammatory responses; and 
• To study how the level of cell death affects the resultant innate immune responses including 
inflammatory infiltrates.  
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Chapter 2  
Literature Review 
This chapter will outline a detailed literature review, giving an overview of vaccination and vaccine 
delivery techniques, with an emphasis of the skin’s immune system, cutaneous vaccine delivery 
devices including MN followed by an in-depth review of immune enhancers such as adjuvants and 
their roles in immunisations. Special emphasis is placed on the immunological importance of 
immunogenic cell death observed and investigated during vaccine administration. For clarity 
purposes, some terms have been defined in Table 2.1. 
Table 2.1: Terminology and their respective definition used in this thesis. 
Term Definition  
Cutaneous immunisation Immunisation (administration of antigen) into the skin 
Intradermal immunisation  Delivery of antigen into the dermis (which may diffuse into the 
epidermis) 
Transcutaneous immunisation Immunisation through the skin by means of topical application, passive 
transport etc of the antigen 
Classical MN An array containing needles of ≤1 mm  
(BDSoluvia has a single MN of 1.5 mm in length) 
Nanopatch™ An array containing short projections (~100 µm) at a high density 
(>10,000/ cm2) 
2.1 Introduction to vaccines and vaccination  
2.1.1 A brief history of vaccines and vaccination 
To date, vaccination is considered as the most effective and cost-beneficial intervention for 
preventative and prophylactic protection against infectious diseases. The introduction of variolation 
has led to the world-wide eradication of smallpox, and was followed by vaccinations leading to a 
>90% reduction of Polio outbreaks, as well as a significant reduction of pertussis, diphtheria, 
varicella, measles and tetanus cases, saving millions of lives from preventable diseases, such as 
influenza, worldwide [4, 5]. Immunisations have not only led to drastic improvements in third 
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world and emerging countries, but also in developed countries such as Australia. With the 
introduction of immunisation strategies, the incidents of common vaccine-preventable diseases 
diminished 200-2000-fold (Table 2.2).  
Table 2.2: Vaccine preventable diseases and their death rates in Australia.  
Number of vaccine-preventable deaths listed per average population and decade in Australia. Grey-shaded areas are 
representative of the decade in which immunisation strategies were implemented. Adapted from [6] and represented as 
rates.  
Period (by 
decade) 
diphtheria pertussis tetanus poliomyelitis measles average 
population 
1926-1935 0.0617 0.0425 0.0133 0.0065 0.0167 6,600,000 
1936-1945 0.0388 0.0235 0.0091 0.0086 0.0114 7,200,000 
1946-1955 0.0073 0.0050 0.0073 0.0118 0.0058 8,600,000 
1956-1965 0.0004 0.0005 0.0025 0.0011 0.0019 11,000,000 
1966-1975 p<0.001 p<0.001 p<0.001 p<0.001 0.0011 13,750,000 
1976-1985 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 14,900,000 
1986-1995 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 17,300,000 
1996-2005 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 19,310,000 
 
These implemented vaccination strategies were the direct result of the early success of variolation, 
commonly referred to as inoculation or topical application of the smallpox. While inoculations or 
administering parts of lesions and scabs via the skin have been used since the 17th century, with 
some reports of protection even dating back to 430 BC [7], the principle behind vaccination was 
only indicated in the late 18th century. This is when Edward Jenner realised that milkmaids 
following exposure to cows were protected from smallpox. Jenner hypothesised that exposure to 
cowpox could therefore also provide protection from the closely related virus causing smallpox. 
Jenner concluded that some sort of cross-protection may be possible that could be transferrable 
between individuals. Upon inoculation of a small boy with cowpox virus from a milkmaid’s skin 
lesions and subsequent exposure to fresh smallpox, the little boy became resistant against infection. 
This gave Jenner sufficient empirical evidence of protection against cowpox. Due to its origin, the 
term vaccine/ vaccination was derived from the Latin word ‘vacca’, meaning cow. Vaccinations 
using a live/ attenuated smallpox virus, in addition to a world-wide smallpox eradication program, 
have led to the eradication of smallpox, as announced by the WHO on May 8, 1980 [7].  
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These achievements however would not have been possible without the significant contributions by 
Louis Pasteur, who noted in the late 19th century that living organisms (e.g. bacteria and viruses) 
could cause disease and contamination that were not of spontaneous origin. These organisms 
however could be inactivated through heat – these days a process known as pasteurisation. Later, 
the two scientists Paul Ehrlich and Ilya Metchnikoff were celebrated as ‘the founders of 
immunology’ with their significant contributions in the fields of infectious biology and drug 
discovery, respectively [8]. It would not be until mid-1900s however that the immune system was 
understood to a level underpinning the importance of immunological memory, the backbone of 
vaccination. More importantly, the combination of chemical and biological advances to generate 
less virulent forms of viruses resulted in more tolerable vaccines. In the late 20th century, advances 
such as genetic engineering and recombinant protein expression led to many new vaccines being 
produced and licensed for use in humans and animals. Nowadays, vaccinations are widely 
accessible within the developed world, leading to fewer cases of infectious diseases than in the past. 
As described in Table 2.2, vaccinations in Australia and world-wide have become significant in 
saving lives, especially in children. In addition, the prophylactic vaccination against infections such 
as human papillomavirus (HPV), known to cause cervical cancer in women or cancerous infections 
in men, is expected to reduce cancer-causing infections by up to ~70% [9, 10].  
Vaccines can be subdivided into different subgroups, depending upon their origin and fabrication 
method with an overview provided in Table 2.3 [11, 12]. While vaccination using whole organisms 
or live viruses results in the strongest immune responses, these are also known to result in several 
side-effects (i.e. local inflammation, systemic inflammation, actual infection of the individual etc). 
Advanced vaccine developments have therefore led to safer vaccines by inactivating viruses, 
developing subunit, conjugate or polysaccharide vaccines amongst others. These however often 
require the addition of immune enhancers, so-called ‘adjuvants’, to increase, prolong or bias the 
resulting immune responses [13]. The advantage of including adjuvants in vaccines can increase or 
extend the immune response to the vaccine, increase sero-conversion rates in the elderly, result in 
dose-sparing as well as fewer vaccination doses required [14]. Despite their immune enhancing 
effects, adjuvants can also cause serious side effects such as granuloma formation (e.g. alum [15]) 
or be too reactogenic for use in humans (e.g. Quil-A, QA; complete Freund’s adjuvant, CFA). With 
very few adjuvants approved in co-delivery of vaccines, the search for more immuno-stimulatory 
agents but with little or no adverse side effects is desirable; adjuvants will be reviewed in more 
detail in section 2.4. These overall improvements for more complex vaccine design, as well as 
multi-valency and/ or requiring multiple administrations for protective immunity can increase the 
cost per vaccine dose. Thus, dose-sparing becomes an important attribute of vaccination. While the 
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first vaccinations were carried out by skin scarification (i.e. disruption of the skin’s epidermal layer; 
s.s.), most of today’s vaccines are delivered by means of hypodermic needle and syringe into 
muscle (i.m.), subcutaneous tissue (s.c.) or into skin (i.d.) [16]. Vaccines can also be given via the 
mucosal route, although this delivery route requires specific formulations to prevent degradation of 
the antigens within the gastrointestinal tract, while enabling sufficient absorption but avoiding low 
bioavailability [17, 18]. Mucosal delivery routes of vaccines will not be further discussed in detail 
as these were beyond the scope of this thesis. Based on the success of the original skin inoculation 
process, the skin has received increased interest as a suitable immunisation site despite difficulties 
in reliably delivering vaccines into the skin. These will be further discussed in section 2.2.  
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Table 2.3: Overview of the most common vaccine types.  
Information collated from [4, 11, 12, 19-24].  
Vaccine type Advantages Disadvantages  Further information Examples 
Live, 
attenuated 
vaccines 
- Elicit strong cellular and humoral 
responses due to pathogen associated 
molecular patterns (PAMPs) 
- Conferring/ resulting in long-lasting 
immunity with only 1-2 vaccine doses 
required 
- Ability of virus to multiply in host, 
thus less virus required for injection to 
induce protection 
- Use of whole virus stimulates response 
to antigens in their natural 
conformation 
- Sabin: can be administered orally (less 
expensive)  
- Live virus can infect vaccinee 
(especially immune compromised 
people) 
- Attenuated form can very rarely 
revert to its virulent form  
- Cannot be given to 
immunosuppressed people 
- Costly process of manufacture and 
transportation 
- Costly as doctor/ nurse are required 
for administration 
- Refrigeration essential for high 
level of immunogenicity  
- Smallpox (Edward Jenner in 1700s)  
- Pathogen is grown in animals or tissue culture 
under spec. conditions to make it less virulent 
- Currently in use in humans 
 
Bacillus Calmette-Guérin 
(BCG) for tuberculosis; 
measles, mumps, rubella 
(MMR); poxvirus 
(smallpox, chicken pox 
etc); Sabin oral polio; 
yellow fever; rotavirus 
Inactivated/ 
killed vaccines 
- Use of whole virus stimulates 
immunity to antigens in natural 
conformation on virus surface (which 
is essential for neutralising antibodies)  
- Contains PAMPs 
- Risk of infection very low (if the 
inactivation is efficient) 
- Can be used on immuno-compromised 
people 
- Generally considered as safer than 
live, attenuated vaccines 
- Can be shipped in freeze-dried form  
- Retain longer shelf-life than most 
other vaccines 
 
- Virus cannot multiply, hence large 
number of virions are required to 
stimulate immunity (i.e. higher 
dose or multiple injections)  
- May require periodic boosters to 
maintain immunity, only humoral 
immunity can be induced 
- Mutations can occur (e.g. in 
influenza viruses) 
- Highly reactogenic (fever, pain, 
redness swelling at injection site) 
- Costly as doctor/ nurse are 
required for administration, 
refrigeration 
- Inactivated by heat, chemicals or radiation 
without altering antigens 
- Influenza: virus grown in cavity of embryonated 
eggs, purified by zonal centrifugation, 
inactivated by chemicals or detergents, e.g. β-
propiolactone and disrupted by sodium 
taurodeoxycholate.  
- Polio: made by growing virulent virus in tissue 
culture, inactivate virus’ replication with 
formaldehyde 
- Currently in use in humans 
 
Influenza; Salk polio 
vaccine (IPV); rabies; 
typhoid; cholera; tetanus; 
hepatitis A 
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Vaccine type Advantages Disadvantages  Further information Examples 
Subunit 
vaccines 
(sometimes 
referred to as 
Toxoid vaccines 
= diphtheria 
and tetanus) 
- Vaccines not infectious 
- Can be given to immunosuppressed 
people 
- Fewer side effects  
- Adjuvants slow antigen release for 
more sustained immune stimulation 
- Can bind TLRs on macrophages and 
DCs to stimulate production of 
inflammatory cytokines 
- Some antigens have limited ability 
to induce protective immunity  
- Antigens may not retain native 
conformation, hence protein does 
not stimulate immune system 
sufficiently (compared to whole 
organism vaccine) 
- Costly as doctor/ nurse are required 
for administration, refrigeration 
- May require adjuvants to enhance/ 
boost immune responses 
- Contains purified antigen, not the whole 
organism 
- Can contain multiple antigens 
- Adjuvants increase effectiveness 
- These vaccines use predominantly the capsid 
proteins of the virus 
- Subunit vaccines are safe for immuno-
compromised patients as they cannot cause the 
disease 
- Currently in use in humans  
Acellular Bordetella 
pertussis, diphtheria 
toxoid (DT) and tetanus 
toxoid; hepatitis B; 
influenza 
 
Conjugate 
vaccines 
- May provide longer-lasting protection 
(and memory) 
- Can protect infants 
- Can reduce carriage of bacteria 
amongst individuals 
- Can result in herd immunity 
 
- Costly (doctor/ nurse for 
administration), refrigeration 
- Moderate to high production cost 
- May require adjuvants to enhance/ 
boost immune responses 
- Specially developed against pathogens whose 
polysaccharide capsules protect them from 
phagocytosis 
- Small antigen coupled to larger conjugate, leads 
to better recognition by the immune system 
- 1st generation taken off market 
- 2nd generation of HIB vaccines successful: 
polysaccharides conjugated to carrier proteins 
- Currently in use in humans 
- Consist of polysaccharides isolated from the 
specific microbe 
 
Haemophilus influenzae 
type B (HIB); 
Pneumococcal 
Streptococcus 
pneumonia; 
Meningococcal 
Neisseria meningitidis 
Recombinant 
vaccines 
- Vector can be chosen 
- Vector can be easy to grow and store, 
thus reducing production cost 
- Unwanted antigens can be eliminated 
from vaccine 
- Proteins expressed on virus more 
likely to have their native 
conformation 
 
- Vector cost to develop as genes for 
desired antigens must be located, 
cloned and expressed efficiently in 
new vector 
- Vectors can be easy to grow 
- Generally don’t require adjuvants 
due to danger signals provided by 
the vector 
- Costly as doctor/ nurse are required 
for administration, refrigeration 
- Vector expressing antigen used as vaccine or 
- Antigen purified and injected as a subunit 
vaccine  
- Genes of desired antigen inserted into vector 
(virus with low virulence) 
- Some currently in use in humans with others 
being in experimental/ clinical trial stages 
 
Hepatitis B 
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Vaccine type Advantages Disadvantages  Further information Examples 
Recombinant 
vector vaccines/ 
virus like 
particle (VLP)-
based vaccines/  
DNA vaccines 
- Humoral and cellular immunity are/ 
can be induced 
- Good safety record to date 
- Safe and stabile,  
- Ease and low cost of manufacturing 
DNA vaccines (ideal candidate for 
new vaccines). 
- HPV requires adjuvant 
- DNA vaccines in experimental 
phase; very new, no adverse side 
effects are known yet 
- Initial concerns regarding in vivo 
transfection, was an inefficient 
process, muscle cells achieving 
greatest uptake and expression; 
low antigen level production, 
inefficient cellular delivery of 
DNA plasmids, poor stimulation 
of innate immunity; are believed 
to be causes of low potency of 
DNA vaccines in larger mammals. 
- Recombinant proteins resembling the virus but 
by being devoid of genomic DNA, are 
completely incapable of causing disease or 
pathogen replication  
- DNA vaccines in experimental phase  
- Gene of interest (of desired antigen) located and 
cloned into vector 
- If delivered i.m., cells express pathogen DNA 
which stimulates immune system 
- Requires circular plasmid with genes encoding 
antigen and promoter/ terminator for expression  
- Some currently in use in humans with others 
being in experimental/ clinical trial stages 
HPV 
 
 11 | P a g e  
2.1.2 The rationale behind vaccination 
To understand the principle of vaccinations, it is important to comprehend how the immune system 
works. Vaccines, containing a killed, weakened form or a subunit of a pathogen, aim to teach the 
immune system how to respond to an infection and establish memory cells, without making the 
person experience symptoms of disease. This enables a faster immune response upon a re-encounter 
with the pathogen in early stage of infection. Once a vaccine is administered, cells in the 
surrounding tissues release proteins, i.e. chemokines and cytokines, upon contact with antigen, 
attracting leukocytes to the site of injury and in most cases leading to the uptake and processing of 
antigen within APCs [25]. This local accumulation of innate immune cells combined with their 
release of bio-molecules (chemokines and cytokines) contribute significantly to the inflammation 
frequently observed in the form of redness and swelling at the injection site [26, 27]. More 
precisely, antigen presenting cells (APCs; i.e. macrophages and dendritic cells, DCs) [28] 
efficiently phagocytose antigens, and migrate to draining lymph nodes (dLN), where immune cells 
accumulate. In the dLN, peptides are displayed on DCs via their major histocompatibility 
complexes class II (MHC II) to lymphocytes, e.g. naive T-cells for activation [29-31]. T-cells are 
distinguished from any other cells by their surface molecules, which are also known as clusters of 
differentiation (CD). This recognition process via MHC II causes CD4+ and CD8+ T-cells to 
undergo a cellular proliferation [32]. Activated T-cells can then exit the dLN as effector T-cells. 
Once exited, T-cells enter the circulation, where they interact in combination with the B-cells to 
form part of the adaptive immune system [19].  
Infected cells are eliminated by T-cells in a cell-mediated immune response. Derived from the 
thymus, T-cells specifically recognise and kill infected cells by forming antigen complexes with 
MHC to specific receptors on their surface. More specifically, T-cells can be further subdivided into 
cytotoxic T lymphocytes (CTL), T helper cells (Th cells) and regulatory T-cells (Treg). CTLs 
release cytotoxic molecules (granzymes and perforin) to eliminate infected cells by binding to MHC 
I expressed on their cell surface as a result of an infection [19, 26]. T-cells secrete cytokines and 
chemokines attracting additional immune cells to combat the pathogen and thereby helping in 
activating CTLs. B-cells, derived from the bone marrow, can result in three types of responses: 
neutralising antibody secretion, opsonising antibody secretion or complement cascade activation 
[19]. Neutralising antibodies bind to the pathogen’s receptors, displayed on its surface, preventing it 
from entering into the host’s cells. Opsonising antibodies can bind to pathogens, which immobilises 
it and facilitates its uptake by phagocytic cells. In contrast, the complement cascade involves 
opsonising complement proteins and removal of the pathogen. Additionally, when antibodies are 
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come into contact with their matching antigen, B-cells are stimulated to divide into larger plasma 
cells, secreting large quantities of specific antibodies to further immobilise the pathogen. After an 
infection, some B- and T-cells are converted into long lasting memory cells. The former circulate 
through the blood while the latter reside in periphal tissues such as spleen, tissues (skin) and LNs 
[33, 34]. These memory cells therefore protect the individual by memorising the pathogen specific 
antigens and bind them with antibodies if they invade again. This is also known as the adaptive 
immune system, as it is able to adapt to defend against specific pathogens.  
2.1.2.1 Immune system 
The immune system is a network of tissues, cells and molecules widely dispersed throughout the 
body. It has evolved to generate an effective immune response to an invading pathogen or vaccine 
by combining the innate (or natural non-specific) and the adaptive (or antigen-specific) immune 
system. Together, they form a complex surveillance network to distinguish self from non-self 
antigens. The adaptive immune system comprises both cellular immune and humoral responses, 
comprised of e.g. T-cells and antibodies secreted by B-cells, respectively. The hallmark of an 
adaptive immune response is that it is highly specific for a particular antigen, and that often it 
results in long-lasting protection. A small number of antigen-specific T cells persist as memory  
T-cells after the antigen has been eliminated [35, 36]. In case of re-exposure, the immune system 
can reactivate these memory cells and thus elicit a fast and strong immune response [36]. 
Components of both, innate and adaptive system are shown in Table 2.4 and discussed in more 
detail in the sections below.  
Table 2.4: Components of the innate and adaptive immune system.  
Both, innate and adaptive systems consist of various cell components secreting different bio-molecules. Adapted from 
[19, 37].  
 Innate system Intermediate  Adaptive system 
Cellular 
components 
Monocytes and macrophages 
Granulocytes (neutrophils, 
eosinophils and basophils) 
Mast cells 
DCs 
Natural killer cells (NK cells) 
 
Natural killer T-cells 
(NK T-cells) [37] 
B-cells/ plasma cells 
T-cells 
 
Secreted 
components 
Complement 
Cytokines 
Lysozyme 
Acute phase proteins 
Interferons  
 Antibody production 
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2.1.2.2 The innate immune response 
The innate immune system is the oldest form of host defence against pathogens and is present in 
almost all multi-cellular organisms to reduce infections [38]. It represents the first line of defence to 
pathogens and includes: 1) natural barriers such as skin and mucosa, 2) cellular effector/ phagocytic 
cells including granulocytes (i.e. neutrophils, basophils and eosinophils, all specialised leukocytes), 
macrophages, natural killer cells (NK) and DCs, and 3) soluble components in form of interferons 
(IFN), interleukins (IL), tumour necrosis factor-alpha (TNF-α) and other cytokines (Table 2.4) [26]. 
These components enable a fast response upon exposure to a foreign pathogen, leading to 
phagocytosis of pathogens, lysis of infected or dying cells as well as antigen processing and 
presentation [39]. However, it is a non-specific reaction and therefore neither improves or 
accelerates with repeated exposure nor generates long-lasting protective immunity.  
Once passing the first natural barrier, pathogens encounter the innate cellular effector cells as well 
as soluble components, secreted shortly after stimulation to initiate inflammation, while chemokines 
are produced to recruit other lymphocytes to the site of infection. Cytokines are small secreted 
proteins that stimulate innate and adaptive immune responses by upregulating surface molecules 
(e.g. MHCs), increasing cellular growth, inducing cellular activation and attraction of surrounding 
cells [19]. Additional soluble mediators include complement, active phase proteins and lysozyme, 
all playing important roles in early stages of the immune responses and inflammation [19]. Both, 
macrophages and phagocytic cells are important cellular mediators in innate immunity involved in 
the uptake and antigen processing and in the resulting development of inflammation and immune 
responses [40]. Soluble mediators such as complement proteins, cytokines and chemokines are 
secreted by neutrophils, macrophages, mast cells, NK cells as well as keratinocytes early after 
infection, leading to DC activation and maturation that direct downstream immune responses [19, 
26, 41-43].  
In the skin, DCs and macrophages sample the surroundings for pathogens and foreign antigens and 
process these to display them on their MHC complexes. Phagocytic properties of activated 
macrophages and granulocytes (e.g. neutrophils) are also essential in innate responses by clearing 
foreign material [44]. DCs possess unique functions crucial for sensing pathogens and evoke 
immune responses [39]. Keratinocytes fulfil a special role by being able to transfer antigen to DCs, 
thus capable of acting as non-professional APCs [44-46]. In addition, a number of ways have 
evolved to recognise pathogens, through e.g. receptor-specific ‘sensors’, also known as pathogen-
recognition receptors (PRRs). Exposed to danger-associated molecular patterns (DAMPs) and 
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PAMPs, DCs, keratinocytes and other cells (Table 2.5) respond through these PRRs and can 
significantly shape the immune responses. Similarly, DCs found throughout various tissues are 
responsible for priming of naive and memory T-cells in immune responses. Once activated, DC take 
up antigens and migrate to the lymph nodes (LN) to interact with T-cells and initiate a subsequent 
adaptive immune response.  
Toll-like receptors (TLRs) represent the most studied PRRs, found on DCs and various other cell 
types. PRRs are sensors of pathogens via PAMPs or danger and stress signals via DAMPs, which 
allows the innate system to distinguish between different types of pathogens. This enables the 
generation of an appropriate immune response, leading to inflammation and/ or cell death along 
with recognition of danger signals (DAMPs) [47]. In mice, 13 TLRs are currently known and can be 
classified by recognition of lipids, nucleic acids or their location within the cells [48]. Intracellular 
location of some TLRs most likely assists in avoidance of self-recognition, predominantly by DCs. 
Upon binding of PAMPs or DAMPs to TLRs, adaptor molecules from within the cytosol lead to  
up- or down-regulation of genes within the cells. Furthermore, DCs mature and upregulate their 
MHC molecules upon interaction of co-stimulatory molecules (i.e. CD40, CD80, CD86) with the 
corresponding T-cell antigen receptor (TCR) [49]. This leads to T-cell activation and pro-
inflammatory cytokine secretion [49]. If recognition by TLRs is unsuccessful, pathogens including 
viruses and bacteria can also be sensed by nucleotide oligomerisation domain (NOD)-like receptors 
(NLRs) and C-type lectin receptors, which jointly contribute to immune activation in response to 
stimuli, e.g. infection or tissue injury [50]. PRRs are therefore important linkers between the innate 
and adaptive immune responses (Table 2.5). 
Table 2.5: Toll-like receptors in mice.  
TLRs Recognising 
compounds 
Examples  Location  References 
TLR 1, 2, 4, 6 Lipids Glycolipids, 
lipoproteins, LPS 
Cell surface [49, 51] 
TLR 3, 7, 8, 9 Nucleic acids  ds or ssDNA and 
RNA, CpG) 
Intracellular [49, 51] 
TLR 1, 2, 4, 5, 6, 10, 11 Bacterial products  Flagellin, HSP, 
Profilin 
Cell surface [49, 51] 
TLR 12, 13 Unknown  Unknown  Cell surface [49, 51] 
     
Cell type Distribution  [51]   
Keratinocytes TLR 2, 4, 7, 9    
LCs TLR 2, 3, 4, 7, 9    
dDCs TLR 9    
mDCs TLR 1, 2, 3, 4, 7, 9    
pDCs TLR 7, 9    
Macrophages/ monocytes TLR 3, 4, 7, 9    
Mast cells TLR 2, 3, 4, 7, 8, 9    
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2.1.2.3 Adaptive cellular response 
In contrast to the innate immune response, the adaptive responses provide a long-lasting and 
specific protection against the invading pathogen [19]. The adaptive cellular immune response is 
mostly mediated by antigen-specific B- and T-cells [52]. Subsets of T-cells can be distinguished by 
their functional differences and diverse expression of surface markers. Naive T-cells differentiate 
into different sub-populations following antigen:MHC-complex formation via interaction with the 
TCR. Further, they are guided by secreted cytokines of the innate immune system. Two major 
effector T-cell populations exist: activated CD4+ T-cells and naive CD8+ cytolytic T-cells (also 
cytotoxic T-cells, CTL) that recognise antigen in conjunction with MHC II and MHC I molecules, 
respectively. T-cells recognise antigen if they are presented by the MHC on a cell via the TCR. 
T-cells can only identify processed antigen presented in fragments via MHC complexes on the 
surface of APCs. This alone however does not activate CD4+ T helper cells (also T-helper, Th 
cells). Rather, upregulation of co-stimulatory molecules (CD80 and CD86) on DCs interacting with 
the respective TCRs (CD28) and inducing cytokine secretion is required [53]. In particular, 
cytokines stimulating T-cell growth (IL-2) and Th cell polarisation (IL-4, IL-17, IFN-γ, TGF-β) are 
required [49, 53]. Once activated, Th cells can be further subdivided into five subsets based on their 
cytokine profiles they secrete [54-56]. These include immune responses mediated against 
intracellular organism (Th1), extracellular pathogens (Th2), microbial infections by bacteria or 
fungi (Th17), tissue infections, assistance in wound healing or tissue remodelling (Th22), 
autoimmune diseases and maintaining self-tolerance (Treg) [55, 56]. Short-term stimulation of 
naive T-cells results in development of naive T-cells producing several cytokines, in particular IL-1 
produced by macrophages and keratinocytes that can activate Th cells [28].  
Th1 cells respond to intracellular pathogens by activating phagocytic cells such as macrophages as a 
result of the secretion of predominantly IFN-γ [55, 57] and support immunoglobulin G2a (IgG2a) 
antibody production, stimulating the cell-mediated cellular response. Further, Th1 cells secrete 
macrophage migration inhibitory factor (MIF), which contributes to recruitment and activation of 
macrophages [58]. IFN-γ produced by Th1 cells also blocks secretion of IL-4 and IL-10 by Th2 
cells. Moreover, Th2 cells interact with B-cells and assist in their proliferation, including antibody 
production. Th2 cells primarily secrete IL-4, IL-5, IL-10, IL-13 and IL-25 assisting in IgG1 and IgE 
antibody production, driven by pathogens and allergens [55]. IL‐3, GM‐CSF and TNF‐α are 
secreted by both Th1 and Th2 cells. IL-25 can further enhance the Th2 responses and can lead to 
chemokine expression of e.g. RANTES and eotaxin, resulting in eosinophil recruitment [55]. Th17 
cells have only been described more recently, with IL-17a and, IL-21 and IL-22 being the key 
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associated cytokines [59, 60]. Interestingly, upregulation of IL-17a can also stimulate  
pro-inflammatory cytokine production of IL-6 and IL-8, leading to activation and recruitment of 
neutrophils in bacterial infections. Tregs secrete predominantly the immuno-suppressive cytokines 
IL-10 and TGF-β [53].Importantly, CD4+ T-cells and other immune cells including B-cells, mast 
cells, eosinophils, macrophages and DCs also produce IL-10 [61], which has been described as an 
anti-inflammatory cytokine to reduce excessive host tissue damage due to the inflammatory 
responses [55].  
Imbalances between Th1 and Th2 responses frequently lead to diseases such as asthma and allergies 
(strong Th2 response) and also leprosy, where both Th1 and Th2 can contribute [62, 63]. Taking 
leprosy as the best studied example of Th1/ Th2 imbalances in humans, the tuberculoid leprosy 
leads to a Th1-bias with pathogen growth being restricted within the skin lesions accompanied by a 
predominance of CD4+ T-cells with IL-12 and IFN-γ secretion [62]. This is in contrast to the  
Th2-biased responses of lepromatous leprosy, where infectious and skin lesions are disseminated 
and uncontrollable, associated with IL-4 and IL-10 secretions by CD8+-cells; this in turn supresses  
IL-12 and IFN-γ secretion [62, 63]. Within the cell-mediated immune responses, differentiation of 
CD4+ Th cells is dependent upon several factors; in particular which cytokines are present at the 
time of priming stimulates T-cells differentiation (Th1, Th2 etc). Co-delivery of adjuvants can not 
only increase specific humoral responses but can also be used to favour either Th1 or Th2 responses 
or induce a balanced Th1/ Th2 response (reviewed in more detail in section 2.4). 
In vaccine administration, the type of immune response induced can be altered depending upon 
several factors including: route of antigen delivery, type of vaccine (whole, inactivated, subunit 
etc), frequency, duration and amount of administered antigen dose as well as the use of adjuvants 
[48, 64, 65]. Immunisations using live influenza vaccine are predominantly Th1-biased while 
immunisations with inactivated influenza virus are more Th2-biased as demonstrated by Moran et 
al. [66]. They also showed that even with live viral challenge after inactivated influenza 
immunisations, the immune responses remained Th2-biased. Still, influenza vaccines should 
preferably induce a balanced Th1/ Th2 response as they will lead to viral clearance via IFN-γ 
secretion and viral neutralisation via antibody production, respectively [67]. By requiring both,  
Th1/ Th2 responses, the timing of cytokine secretion is essential: IFN-γ also leads to a reduced 
differentiation of Th2 cells [66, 68] while IL-4 produced by Th2 also suppresses secretion of IL2 
and IFN-γ by Th1 cells. Interestingly however, depletion of CD4+ or CD8+ T-cells still resulted in 
clearance of viral infections, indicating that B-cells as well as CD4+ and CD8+ cytokine-secreting  
T-cells contribute to the immune response [66, 69]. Moreover, Baumgarth et al. also showed that  
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T-cell responses differ between different infected organs [69]. IFN-γ secretion in lung tissue was 
much higher than in dLN, together with CD4+/ CD8+ T-cells and predominantly CD4+ T-cells. This 
indicates that depending upon the selected analysis method (blood versus tissues versus dLN) the 
measured Th1/ Th2-biased responses to influenza and pathogens in general, can differ. Generally, if 
a bias towards either Th1 or Th2 is present, addition of adjuvants can assist in skewing the 
responses either way, e.g. alum towards Th2, while CpG (oligonucleotide sequences present in 
bacterial DNA that have immuno-stimulatory abilities) skews towards Th1 responses [14, 70]. It is 
important to note that in mice, IgG1 is associated with a Th2-like response while a Th1 response is 
associated with the induction of IgG2a, IgG2b, and IgG3 antibodies [71].  
2.1.2.4 Adaptive humoral response 
The adaptive humoral response is facilitated by B-cells that originate from the bone marrow. In 
contrast to the adaptive cellular response, B-cells can recognise the antigen in its unprocessed, 
soluble form via their B-cell receptors, composed of membrane-bound IgM or IgD. B-cells 
represent 5-15% of the circulating lymphocytes [19], with their principal role being to produce 
specific antibodies to antigen, capture antigen and contract into memory B-cells after activation.  
B-cells can be activated in a T-cell dependent (protein antigen) and independent (bacterial poly-
saccharides) manner. In the T-cell-dependent manner, naive B-cells take up and process antigen and 
display it as a peptide-MHC II complex on its cell surface. B-cells become activated by interacting 
via their CD40 receptor (a co-stimulatory molecule) with CD40L on activated CD4+ T-cells, whilst 
TCRs (CD28) bind to the peptide:MHC II complexes [72]. The T-cell-independent process still 
requires activation via its antigen receptor, the peptide-MHC II complex, while the second signal 
can be a DAMP/ PAMP such as LPS or bacterial DNA binding via TLRs on the B-cell. Presence of 
cytokines (e.g. IL-4) is essential for clonal expansion and differentiation of B-cells into plasma 
cells, ultimately leading to the secretion of humoral/ soluble receptor molecules, the antibody. 
Activated B-cells within the germinal centre eventually become memory B-cells in lymphoid 
tissues. Upon re-encounter with pathogens, these can rapidly proliferate and secrete antibodies.  
2.1.2.5 Memory cells 
Upon exposure to pathogens, B- and T-cells combat the resultant infection [19]. To enable long-
lasting and faster immune responses, memory cells are required. Of the initial activated effector  
T-cells, only 5-10% differentiate into memory T-cells, which can be further subdivided into effector 
memory (Tem) and central memory (Tcm) cells [36]. Tem provide a fast and efficient effector 
function by secreting IFN-γ and perforin and can be found predominantly in peripheral tissues, 
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where pathogen re-exposure is likely to occur [36]. Tcm by contrast provide a delayed response 
following successful proliferation. Tcm are predominantly located in secondary lymphoid organs 
and can be distinguished from Tem by CCR7 and CD62L expression as well as poor effector cell 
functions [36].  
2.1.3 Conventional vaccine delivery techniques 
The hypodermic needle and syringe is the most commonly used vaccine delivery device for 
parenteral delivery. Traditionally, the i.m. and subcutaneous s.c. route are the most frequently 
administered due to ease of administration. In contrast, i.d. injections are less frequently performed. 
Initially developed in 1853 by Pravaz and Wood, the needle and syringe’s design has revolutionised 
vaccine and drug delivery and since has been refined but not significantly changed since its first 
introduction [73]. Vaccine delivery routes are described in more detail in section 2.2.  
While all current vaccination techniques require medical trained staff for administration, i.m. and 
s.c. injections are easily performed. i.m. injections are predominantly administered at a 90° angle 
into the deltoid or vastus lateralis muscle, s.c. injections are given at a 45° angle into the fatty tissue 
underlying the cutis and above the muscle (Figure 2.1). s.c. injections are commonly known to 
yield slower adsorption by the body than other parenteral vaccination routes [74, 75].This is thought 
to be due to uptake via blood capillaries and to a lesser extent by lymphatics [75]. Despite the 
success of hypodermic delivery of vaccines leading to disease eradication and prevention, several 
disadvantages have been associated with them. More specifically, any needle use (vaccination-
related or not) may lead to needle-stick injuries [76].  This risk is further increased when multiple 
immunisations are required for one vaccine [77],  or when cross-contamination through needle 
reuse occurs. Also, some patients perceive injections as uncomfortable or painful [78-82], which 
may lead to reduced immunisations due to needle-phobia [83]. Lastly, reconstituted vaccines 
require refrigeration and trained medical personnel for administration. In addition, either route of 
delivery may not be optimal with regards to dose-sparing use of vaccines [84]  as well as mounting 
effective immune responses [3]; especially the muscle, which is known less immunogenic than 
other tissues [85].   
The low abundance of APCs in the muscle and subcutaneous tissue may partially explain the larger 
doses required for i.m. injections in comparison to skin-based immunisations as seen in various 
clinical trials [77, 84, 86-93] Since i.m. and s.c. injections bypass the skin’s immune system and 
instead deliver vaccine and other antigens into i.m. or s.c. tissue with very few resident populations 
of APCs (see section 2.2.2), the immune system may require additional signals to mount a 
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sufficiently high response to yield protection. These signals can be provided in form of co-delivered 
adjuvants [94, 95] or treatment [96, 97] leading to the release of danger signals (e.g. DNA or ATP 
amidst many others). An excellent alternative to adjuvants is the delivery of vaccines into the  
APC-rich skin. Current techniques may not be as suitable to reliably deliver a set amount of antigen. 
This led to other, newer vaccination techniques being investigated, which include – amongst many 
others – i.d. injections using small needles and MNs (Figure 2.1). Considering that many of the 
currently available vaccines could be suitable for skin-based deliveries (with minor formulation 
adjustments, [98]), the biggest hurdle yet to overcome is a suitable delivery device able to precisely 
deliver the vaccine into the upper skin layers, while yielding high patient compliance, without pain, 
achieving consistent dose delivery and reliable administration between users. More importantly, 
understanding the structure and components of the skin as well as its immune sentinels can assist in 
optimising a delivery system likely to contribute to the enhanced immunogenicity of skin-based 
immunisations over conventional (i.m. or s.c.) administration routes.  
 
Figure 2.1: Common vaccine delivery techniques.  
The skin is composed of three main layers of which the epidermis represents the first line of defense against pathogens, 
while the underlying dermis contains connective tissue, blood and lymphatic vessels, nerves and various fibres such as 
elastin and collagen. Standard hypodermic needle injections can deliver vaccine into the muscle, subcutaneous or 
intradermal tissue. More recent advances focus on epidermal and dermal delivery only by using microneedles or the 
Nanopatch, delivering their payload into the VE and dermis, yet, above the nerve endings and therefore reducing pain 
sensation. APCs can capture antigens, and migrate to local lymph nodes through the lymphatics to stimulate DCs and T-
cells. A high ratio of APCs per area or volume allows and increased antigen processing over i.m. or s.c. injections. 
Schematic shown is not to scale. Modified and reprinted with permission from [99].  
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2.2 The immunological function of the skin  
2.2.1 The skin  
The skin is the largest immunologically active organ and represents the first barrier to overcome by 
pathogens, physical, chemical and biological agents [100]. It is subdivided into three distinct layers: 
the outermost epidermis, the dermis and the underlying hypodermis or also known as subcutaneous 
tissue (Figure 2.1). Each of these layers have been further classified morphologically and consist of 
various cell types, fibres, tissues and other components [101]. The epidermis and dermis are of 
particular importance in immune responses due to the presence of APCs, macrophages, T-cells but 
also keratinocytes, as discussed in section 2.1.2.  
 
Figure 2.2: Micrograph of murine skin.  
The skin is generally composed of three distinct layers, from the top, the epidermis, dermis and hypodermis. Each of 
these consists of sub-layers. Murine ears contain dorsal and ventral sides of epidermis and dermis only, separated by the 
cartilage. The epidermis is subdivided into the stratum corneum (SC) and the viable epidermis (VE), the latter being 
made up of the stratum granulosum, stratum spinosum and stratum basale. The stratum lucidum is located between SC 
and stratum granulosum and found only in thick skin layers such as hand palms. Specialised skin cells of the VE 
include Langerhans cells, Merkel cells and melanocytes. Here, naive murine ear skin was subjected to paraffin 
embedding and sectioned at 10 µm intervals followed by H&E staining. The SC contains ~10 corneocyte layers orderly 
arranged. Original magnification 40x. SC: stratum corneum; VE: viable epidermis. 
The thicknesses of these layers can vary between and within each species depending upon the 
ethnicity, sex, age and location [102]. The epidermis is further subdivided into stratum corneum 
(SC) with the viable epidermis (VE) beneath it. According to literature reports, the human SC is 
approximately 10-20 µm [103], the VE roughly 30-110 µm [104] and the dermis 1-2 mm thick 
[105], while in murine ear, the epidermis was measured to be 17.5 ± 2.1 µm [106] with the dermis 
reported to be approximately 25-60 µm thick [107], followed by a ≥40 µm cartilage layer 
containing chondrocytes (Figure 2.2). Hereafter, the focus will be on murine skin and its sub-layers 
only. As the outermost layer of the skin, the SC is the rate limiting barrier for skin absorption in 
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transdermal delivery, protects from radiation and prevents intrusion of foreign bodies [108-110]. It 
is composed of desmosome-interconnected corneocytes, i.e. terminally differentiated flattened 
keratinocytes [108, 111-113], and can consist of up to 10 layers in murine skin (Figure 2.2) [114, 
115]. The corneocytes are composed of keratin filaments, a tough and protective fibrillar protein 
forming as a part of epidermal differentiation, and are tightly joined by desmosomes and embedded 
in a dense matrix of various other proteins to restrict the pathway to large molecules into the VE. 
Corneocytes also vary in size and measure on the surface of the SC approximately 20-40 µm in 
width and only 0.5 µm in thickness [113, 115].  
In the underlying VE, keratinocytes represent the vast majority of all cell types found within this 
layer (90-95%). Maturing keratinocytes are known to undergo a keratinisation and differentiation 
process, in which they change their morphology, which allows them to be classified into three 
distinct cell layers (stratum lucidum not present in mice): stratum granulosum, stratum spinosum 
and stratum basale [101, 115, 116] as shown in Figure 2.2. The basal layer, located between VE 
and dermis is responsible for constant keratinocyte regeneration by division of epidermal stem cells 
[115, 117]. Keratinocyte proliferation results in morphological changes when migrating from the 
basal layer towards the SC, resulting in a volume increase of both cell and nuclei. Subsequently, 
keratinocytes become corneocytes after losing their cell organelles and nuclei, particularly visible in 
the stratum granulosum and stratum spinosum, a process called skin cornification [111, 118]. This 
cornification process has been reported to take approximately 10 days dorsal mouse skin [119]. 
Other specialised cell types of the VE include keratinocytes, melanocytes (8%), Langerhans cells 
(LCs; 3-5%), Merkel cells (<1%), dendritic epidermal T-cells (γδ T-cells) as well as lymphocytes 
and macrophages [28, 34, 108, 115], with their functions being discussed in section 2.2.2. LCs are a 
specialised type of APC [120, 121] that function in immune surveillance in the skin. By contrast, 
Merkel cells are found clustered near the epidermal junction (Figure 2.2), have been linked to 
neural sensitive endings [122]. Melanocytes are strictly confined to the basal layer expressing 
melanin to protect against UV light damage [34, 101].  
The dermis is situated below the VE and approximately 70 µm thick in mice. It is a highly elastic 
and vascular multilayer, made of connective tissue including collagen, reticular and elastin fibres 
surrounded by proteoglycans [108] with a passive tension incorporated through a network of 
collagen and elastin fibres [123-125]. It comprises two layers, the upper (papillary) and lower 
(reticular) layer, distinguishable by thin collagen type III and dense collagen type I, respectively. 
Type I represents around 80-90% of the total collagen content [126]. Collagen together with elastin 
provides elasticity and strength to the skin. The latter is found throughout the dermis, interspersed 
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between an extracellular matrix containing fibroblasts, blood vessels and their capillary loops, nerve 
endings, as well as skin appendages including sweat ducts, sebaceous glands and hair follicles. 
Immunologically active cells include macrophages, mast cells lymphoid cells, αβ T-cells,  
γδ T-cells, NK T-cells as well as various DC subsets which will be discussed in more detail below 
[28, 34, 46, 108, 127, 128].  
2.2.2 The skin’s immune sentinels  
With the skin representing the first line of defence, immunologically active cells within the skin 
function as sentinels and form the second line of host defence (see section 2.1.2). Its sentinels 
include tissue-resident phagocytes, APCs, T-cells, mast cells as well as innate lymphoid cells (iLCs) 
amongst others. Based on the current knowledge, within the VE of murine skin reside several 
distinct types of immune cells that include LCs, tissue resident CD8+ T-cells (Trm-cells), dendritic 
epidermal T-cells (DETCs, a type of γδ T-cells) and mast cells [33, 34] as depicted in Figure 2.3. 
There are two types of DCs in the VE: LCs and inflammatory dendritic epidermal cells (iDECs), 
although the latter are found in inflamed epidermis only [28].  
 
Figure 2.3: Skin anatomy and cellular components. 
The epidermis contains several strata and various cell types; keratinocytes, LCs, melanocytes and various subsets of T-
cells. Other specialised cells in the dermis include dDCs, pDCs, various subsets of T-cells, mast cells, macrophages and 
fibroblasts; not shown are iDCs, collagen and elastin fibres. Image reproduced with permission from [28]. 
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2.2.2.1 Langerhans cells 
First discovered in 1868, Paul Langerhans described LCs as intra-epidermal cells with long 
dendrites in the stratum spinosum and stratum basale [120, 129]. Morphologically, LCs can be 
described as elongated cells, containing dendrites reaching throughout the VE for foreign material, 
with a polymorphic nucleus and Birbeck granules but no desmosomes [101]. Based on CD207+ 
stained cells imaged by Multiphoton microscopy (MPM), a total of 1052 ± 109 LCs/ mm2 in murine 
ears were quantified [106] and is in agreement with reports by others measuring  
~980 LCs/ mm2 in dorsal skin of mice expressing the enhanced yellow fluorescent protein (eYFP) 
in LCs [130]. These numbers can however vary depending upon the location, gender and age of the 
animal [131, 132]. It was not until much later that the bone marrow-derived LCs were discovered to 
play a role in immunity [127, 133-135]. Their strong immunogenic properties and contribution to 
innate immunity [136, 137] is controversial as they may also act as mediators of tolerance [136, 
138-142]. However, are predominantly sessile [130, 143], reportedly for up to 48h in murine ears 
after administration of CpG, lipopolysaccharide (LPS) or papain [64] before migrating to the dLNs. 
Their reported functions span anti-microbial immunity, skin immuno-surveillance, induction phase 
of the contact hypersensitivity and in the pathogenesis of chronic inflammatory diseases of the skin 
or mucosa as well as induction of tolerance [30, 132, 144, 145]. Interesting, yet conflicting with 
previous data, were the results by Igyarto et al. who found that LCs are required for Th17 responses 
(induce inflammation and tissue damage in auto-immune diseases such as psoriasis) but are 
dispensable for CTL responses in mice [146]. 
When skin becomes damaged by physical or chemical insults, various cells including LCs and 
keratinocytes become activated and release pro- and later anti-inflammatory cytokines, assist in 
wound healing to re-establish a homeostatic environment [28, 34, 147]. LCs can be characterised by 
Birbeck granules [100, 121] and the expression of the surface marker Langerin (CD207), which 
belongs to the group of type II transmembrane proteins (C-type lectin) [148]. Since some dDCs also 
express CD207+, LCs can be distinguished from those by expression of an additional marker 
EpCAM, the epithelial cell adhesion molecule [149], and lack of CD103 expression [46, 141, 150]. 
Despite the discovery of LCs over a century ago, their roles however have not been fully 
understood. For instance, migration and antigen uptake was predominantly seen in dDCs rather than 
LCs [46, 130, 151], although others have observed LC migration and/ or antigen uptake [132, 152, 
153]. Moreover, by depleting LCs from Langerin diphtheria toxin receptor mice (Lang-DTR) 
infected with vaccinia virus by skin scarification, Seneschal et al. suggested that LCs may be 
dispensable for eliciting protective T-cell responses [151]. Using the radio-resistance of LCs (other 
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DCs are not radio-resistant), Shklovskaya et al. and others have investigated the contribution of 
dDCs to T-cell responses and found that LCs mediate tolerance independent upon the stimulus 
including adjuvants [140]. Interestingly, Wang et al. showed that LCs were dispensable in 
epicutaneous immunisations via an occlusion patch using OVA in murine ears due to fast migrating 
DCs [154]. In flank however, LCs were required for enhanced T-cell responses. 
2.2.2.2 Dendritic cells 
In contrast to LCs, dDCs are derived from bone marrow progenitors and are self-renewing [134]. 
These are very mobile and continuously patrol the dermis for pathogens as seen in vivo using MPM 
[130]. In an infection, dDCs take up antigen and migrate to dLN within 2 days; dDCs migrate 
earlier than LCs, which peak on day 4 post infection in the dLN [155]. dDCs were first described as 
a separate DC subset a century after the discovery of LC [156] due to the belief that C-type lectin 
was only present on epidermal LCs [120, 157]. The discovery of dDCs expressing CD207+ in 2007 
[120, 158, 159] led to extensive research in finding distinguishable cell surface markers enabling a 
clear differentiation of LCs and dDCs. Differentiated by their surface molecules, there are at least 
five different subsets of dDCs have been found and described within both sub-layers of the dermis 
[46, 100, 121, 132, 160, 161] with their phenotypes shown below in Table 2.6.  
Table 2.6: Phenotype of the five skin DC subsets present in murine dermis.  
Five types of dDCs have been identified within the dermis and can be differentiated due to their different expression 
levels of surface markers including Langerin (CD207), two forms of integrin (CD11b and CD103) and epithelial cell 
adhesion molecules (EpCAM). dDCs clearly differ from LC found in the VE. All express MHC II. Legend description: 
Langerhans cells (LC), dermal dendritic cells (dDC), ++ very high expression, + high expression, int intermediate 
expression, -/ low low expression, - no expression; N/A, not available. Adapted from [46] and [161]. 
  Mouse cell surface markers Proportion of 
MHC II+ 
subset      CD207 Cd11b CD11c CD103 EpCAM 
Epidermis           
 epidermal LCs resident ++ int + - ++ ~ 100% 
Dermis        
 LC in transit  ++ int + - ++ ~6.5% 
 CD207+ CD103+ CD11b+dDC resident ++ low + + - / low ~3% 
 CD207+ CD103- CD11b+ dDC resident + low + - - / low ~2.5% 
 CD207- CD103- CD11b- dDC resident - - / low + - - ~17% 
 CD207- CD103- CD11b+ dDC resident - high + + - ~65% 
 CD301+ CD207- CD103+ 
CD11b+ dDC 
resident - low + + - / low N/A 
 
One of the suggested explanations of the observed enhanced immunogenicity via the skin was the 
high abundance of APCs within the skin. Examples of known APCs within the skin include LCs 
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(within the VE), migratory LC, CD207+ DC as well as CD207- DC with their subtypes and 
macrophages (the four latter all within the dermis) [139]. The reported impact and contribution of 
LCs and dDCs upon skin-based immunogenicity remains controversial [34, 162]. While an 
adenovirus-based viral vector vaccine showed that the mounted CD8+ T-cell responses were 
attributable to CD11c+ MHC IIhi CD8α- EpCAM- CD11b+ CD207- DCs, the results indicated that 
LCs and CD207+ dDCs were dispensable [162]. Other studies demonstrated the uptake of dermally 
deposited antigen by LCs and dDCs although they did not assess in detail which subpopulation was 
essential [153, 163]. While detailed characterisation of involved LCs/ dDCs in MN-based delivery 
of antigen has not been published, several studies have shown CD11c+ activation in skin and/ or LN 
post Quantum dot/ antigen-uptake [164, 165].  
Circulating monocytes are known to differentiate into inflammatory monocyte-derived DCs in 
tissues, in particular following inflammation due to increased vascular permeability and chemokines 
released by surrounding cells [166]. However, antigen processing and presentation by inflammatory 
monocyte-derived DCs may be less effective than by other DCs [167]. Separately, plasmacytoid 
DCs (pDCs) were shown to quickly infiltrate skin following injury (tape stripping), forming a 
complex with self-nucleic acid, and through TLR7/9 lead to secretion of IFN-α/β and antimicrobial 
peptide [168], also known as danger signal [169]. Recognition of ssRNA or DNA via TLR7 or 
TLR9 enables pDCs to produce IFN. Depletion of pDCs resulted in delayed innate inflammatory 
responses due to impaired cytokine release as well as delayed re-epithelisation of damaged skin 
[168]. This pDC population could therefore be important for generating a pro-inflammatory 
environment and danger signal release in skin-based immunisations, e.g. skin penetration induced 
by classical MN and NP projections, leaving small microchannels behind [170]. 
DCs can be activated in a direct and indirect manner through PRR activation following exposure to 
pathogens by recognition of their PAMPs or via tissue damage following pathogen invasion, 
leading to recognition of released DAMPs, respectively [121]. Cutaneous immunisation routes have 
been shown to result in antigen uptake by skin DCs (LCs and dDCs) [153, 163, 171]. Some groups 
have suggested specific antigen targeting to DCs [172] with several successful studies targeting LCs 
or dDCs by i.d. injections [163]. Delivery of antigen to skin DCs via their Clec9A receptor resulted 
in strong CD4+ T-cell responses with a T-follicular helper cell phenotype [173]. Importantly 
however, the type of injection can affect the antigen uptake [174]. For example, following s.c. 
injections, antigen could either drain readily to the nearest dLN where it was taken up by LN-
resident DCs or be taken up by migratory DCs that that migrate to the dLN [174]. Similar 
differences of antigen uptake have been reported with i.d. injections, where some antigen reached 
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the dLN via the lymphatics [175, 176] while immunisation with a MN, led to predominantly antigen 
being taken up by skin DCs prior to being transported to the dLN [165].  
Importantly, CD11c+ dDCs have been shown to take up antigen as early as 30 min post MN 
immunisation of fluorescently labelled influenza antigen [164]. While the majority of dDCs express 
CD11b, only two subtypes also express CD103+. These CD103+ subsets were shown to be able to 
cross-present antigen [141, 150, 177]. Belonging to the CD8+ DC-like group, the CD103+ dDCs 
have demonstrated their importance in cross-presenting antigens to CD4+ and CD8+ T-cell 
responses as well as in viral clearance [150, 151, 177]. While early data sets suggested that LCs 
could cross-present in vivo [171], Bedoui et al. were later able to show that CD103+ dDCs were 
cross-presenting APCs of dermal origin [150], irrespective of the presence of LCs [46]. CD103+ 
dDCs have also been linked to cross-present keratinocyte-derived self-antigens to CD8+ T-cells [46, 
150]. Separately, a new dDC subtype has only recently been identified as CD301+ cells [160, 161]. 
This subtype with the phenotype CD301b+ CD207- CD103- CD11b+ CD11c+ EpCAM -/low was found 
to be essential to elicit Th2 responses to s.c. injected OVA adjuvanted with papain or alum [160].  
2.2.2.3 T-cells  
Through intravital imaging of transgenic mice (having DC subsets that express fluorescent 
markers), DETCs (CD103+ CD207-) were found to move slowly through the dense VE [34], 
remaining sessile but extending their dendrites to sample for invaders’ antigen [178]. Another 
epidermal T-cell type are the Trm-cells [34]. Using a Herpes-simplex virus (HSV)-1 model, it was 
shown that CD8+ T-cells were found predominantly within previously infected tissue [33, 179]. In 
graft-studies, those Trm-cells were removed from the circulation although those within the VE 
remained sessile, suggesting that these cells are separated from those of the dermis [179]. Dermal γδ 
T-cells are morphologically and phenotypically district from DETCs and do not express the Vγ5 
TCR [180]. Representing a more amoeboid shape (no dendrites), dermal γδ T-cells scout the dermal 
layers although much slower than αβ T-cells. Although not as well studied yet, γδ T-cells appear to 
be involved in innate responses and tissue repair [181], leading to neutrophil influx, and may 
contribute to psoriasis due to their high IL-17 secretion [180]. Other immunologically active cells 
include macrophages and mast cells, both found throughout the VE and dermis. The former are very 
heterogeneous population, widely distributed within the skin layers and around blood/ lymphatic 
vessels, important in wound healing and tissue repair [180, 182] while the latter evokes a more 
prominent Th2-response. Very recently, innate lymphoid cells have been found in psoriasis-infected 
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skin patrolling the dermis and interacting with mast cells [128, 180], providing another cellular 
sensor for pathogens.  
2.2.2.4 Keratinocytes  
On another note, although not classified per se as immune cell, keratinocytes can also play a special 
role [44]. Not only due to their high abundance in the VD (~95%), but also due to their ability to 
secrete various cytokines including IL-1α, IL-1β, IL-6, IL-10, IL-18 as well as GM-CSF and TNF-α 
in addition to antimicrobial peptides (β-defensins and cathelicidins) [28, 34]. Secretion of these 
cytokines enables interaction with DCs in the skin. Importantly, keratinocytes have also been shown 
being able to cross-present antigen [44], thus act as non-professional APCs, indicating that they 
may not be able to prime naive T-cells but are likely to induce recall responses [28, 139]. While 
keratinocytes produce the inactive forms of IL-1α and IL-1β, the mature forms can only be secreted 
upon activation through the inflammasome [183], although recent evidence suggests alternative 
pathways (see section 2.4.5). These cell types and their approximate locations are schematically 
shown in Figure 2.3. Other important components within the skin contributing to the immune 
sentinels are the so-called inflammasomes and will be discussed in more detail in section 2.4. 
2.3 Cutaneous immunisation 
Antigen and adjuvants delivered cutaneously permit local sampling and uptake by APCs that are 
present in high numbers in both, VE and dermis. Several early studies have demonstrated that 
topical application of heat-labile enterotoxin to skin using a patch led to reduced and less severe 
traveller’s diarrhoea [96]. However, most forms of cutaneous immunisation require a disruption of 
the skin’s barrier to a certain degree, enabling passage of antigen as well as adjuvants into the skin 
[48, 184-186]. The barrier disruption can occur by means of chemical or physical origin and can be 
considered as a physical injury that induces local damage or tissue trauma. The immune system 
responds to the trauma with the release of danger signals from damaged cells, such as heat shock 
proteins (HSP), monosodium uric acid (MSU), dsDNA etc. That danger signals can lead to DC 
activation, and result in pro-inflammatory cytokine release, has been well established [169, 187]. 
Danger signal release and their roles in shaping the immune responses will be discussed in more 
detail in sections 2.4 and 2.5.3.  
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2.3.1 Cutaneous vaccine delivery by intradermal injection 
Smallpox immunisations have routinely been carried out through scratching the skin surface, also 
known as s.s., followed by topical application of the cross-reacting cowpox or vaccinia virus. These 
days, bifurcated needles are dipped into the vaccine and then repeatedly used to prick the skin. 
Several decades later, in the early 20th century, the cutaneous immunisation technique injecting 
liquid with a needle was first described by Mantoux who administered it almost parallel (<30°) into 
the skin, resulting in a bleb formation (Figure 2.4a) [188]. i.d. injections are one possible 
alternative to conventional immunisation routes as they take advantage of the skin’s unique immune 
system, delivering the antigen into the vicinity of APCs such as dDCs, and the network of draining 
lymphatic vessels required to carry antigen to the dLN to elicit an immune response (Figure 2.4b).  
Immunisations via skin by i.d. have demonstrated similar or improved immunogenicity with a  
~5-10-fold dose-sparing against influenza [77, 84, 86-89], rabies [90] or HBV vaccines [91, 92] 
compared to standard i.m. routes. For instance, in an i.d. influenza vaccine delivery study, Leroux-
Roels et al. [93] showed that a single dose (9 µg) with a reduced antigen dosage was at least as 
immunogenic as an i.m. administration (15 µg). Lower doses (3 µg and 6 µg) were immunogenic 
but to a lesser extent than i.m. Similarly, promising results were obtained in influenza studies 
conducted by Auewarakul et al. [84] and Kenney et al. [77] in which a protective immune response 
was elicited against influenza by delivering only one fifth of the normal i.m. dose. These results 
further underpin the immunological importance of the skin as immunisation site. However, i.d. 
injections are perceived to be difficult to perform accurately and can be highly variable between 
administrators [189]. This is due to the fact that this route of administration requires well trained 
medical staff to give reliable and reproducible vaccine administrations into a 1-2 mm thick tissue 
layer [88, 189]. As outlined in section 2.2.1, a high variability of skin properties between 
individuals [102]. This contrasts a study by Laurent et al. who did not note any differences in skin 
thickness with respect to age, gender or ethnicity [190]. Further complexities in i.d. administration 
may also arise due to age, sun exposure and elasticity of the skin as well as its hydration levels (see 
section 2.2.1). These variations must be accounted for to ensure consistent antigen delivery into the 
dermis. 
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Figure 2.4: Standard intradermal injection and formation of a bleb in humans.  
An i.d. injection causes a wheal or bleb formation due to vaccine/ fluid being injected into the compact dermis. (a) i.d. 
injection into a human forearm using a 27G needle and (b) a schematic of the bleb formation following i.d. injection, 
leading to cellular infiltration and cell activation with vaccine drainage to the LN. Images (a) and (b) reproduced with 
permission from [191] and [192], respectively. 
Though, conflicting achievements of the dose-sparing potential seen with i.d. injections have been 
reported. Some studies reported comparable serological responses to influenza vaccine delivered 
i.d. than by the standard i.m. delivery [86, 88, 189]. On the other hand, Auewarakul reported that 
i.d. delivery of influenza vaccine elicited significantly lower antibody responses administering 1/5th 
of the standard i.m. dose in humans [84]. Yet, the obtained antibody responses were still regarded 
sufficiently protective according to the European Medical Agency criteria (EMA) assessing clinical 
efficacy (amongst various other guidelines) [193]. Additionally, 15 µg of haemagglutinin per 
influenza strain delivered i.d. using a BD microinjection system induced superior 
haemagglutination inhibition (HI) titres and seroprotection rates than the same dose administered 
i.m. in elderly patients [189]. By contrast, no significant improvement of antibody responses was 
seen when 3, 6, or 9 µg influenza vaccine were compared between i.d. with i.m. routes although 
higher local inflammatory responses were seen in i.d. groups [194]. Using a trivalent influenza 
vaccine, Hung and colleagues compared two i.d. devices at low doses consisting of either a single 
needle (BD SoluviaTM, 1.5 mm in length) or an array of 3 MNs (MicronJet600TM, 0.6 mm long) 
against i.m. immunisations [195]. Interestingly, highest seroprotection rates and geometric mean 
titre-fold increase were generated by the MN array using 3 µg. Other studies using MN immunised 
with significantly higher influenza vaccine doses (made from VLPs or whole inactivated virus), 
ranging from 0.3 to 6 µg [89, 196, 197].  
Following characterisations of the bolus distribution as well as the resulting bleb formation in pig 
skin and human volunteers confirmed by echography and histology, Laurent et al. found a broader 
distribution of saline with the BD Micro Injection System within the papillary and reticular dermis 
than with i.d. [198]. Additionally, the pain perception was generally lower in subjects receiving i.d. 
injections with the BD Micro Injection System than i.d. by Mantoux technique [198]. Later, this 
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device demonstrated promising and consistent immunogenicity results in elderly post unadjuvanted 
i.d. delivery in comparison to MF-59-adjuvanted i.m. control groups; the immunogenicity results 
fulfilled the EMA [199, 200]. Shortly afterwards, the MicronJet by NanoPass Technologies (used in 
Van Damme’s study [88]) obtained clearance by the FDA while Sanofi Pasteur also obtained 
approval for their influenza vaccine in a prefilled syringe for i.d. delivery in Europe (Intanza® and 
IDflu®; containing 9 µg HA/ strain for 18-59 or 15 µg HA/ strain for ≥60 year old people [199, 
201]). It was later approved by the FDA for use in 18-64 year old patients (9 µg, Fluzone®) as well 
as in Korea (IDflu® 9 µg for 18-59 and 15 µg for ≥60 year old patients).  
This dose-sparing potential could have a significant impact upon the society (more supply and 
better overall health compliance), on patients (more affordable due to lower cost/ vaccine dose) and 
on the industry (dose-sparing, hence lower production cost while being able to sell more doses). An 
estimate of the total cost saving based on the dose-sparing potential however has not yet been 
established for the majority of vaccines. Identifying the cost-saving would be highly important to 
any country with limited resources including developing countries to encourage and offer 
economical vaccination strategies to its citizens [202]. While showing a dose-sparing potential of 
i.d. over i.m., multiple disadvantages have limited the wider usage and acceptance of this technique. 
These drawbacks include the need of highly skilled and trained personnel, perception of pain 
following administration (due to the bleb formation [198]) and difficulties in obtaining reproducible 
results [203]. Currently, there are three licensed vaccines for i.d. immunisations available on the 
market worldwide (with few being regulated locally) – none of which contain adjuvants: FluZone® 
(Sanofi Pasteur; using an ID injector system), BCG for tuberculosis via a multiple-puncture and 
rabies as mentioned above. Vaccinia is rarely administered nowadays due to its eradication although 
some specific groups, e.g. scientific personnel, are still immunised with bifurcated needles. 
Despite predominantly positive results with i.m. immunisations, i.d. injections represent several 
limitations such as pain due to the bolus injection [198, 205], consistent vaccine delivery and local 
reactions, unsuitability of several adjuvants due to high reactogenicity in skin [206]. These 
limitations formed the motivation and hypotheses behind the work presented within this thesis. For 
example, while s.s. was used in the 18th century to deliver smallpox vaccination, several reports 
have suggested that increased local inflammation and reactions following i.d. than i.m. or s.c. may 
be responsible for the enhanced immune responses [199]. Disruption of the epidermis by 
scarification has recently been demonstrated as essential for elicitation to vaccinia virus vaccine-
mediated immunity, and was ineffective when delivered by i.m. injection [207]. Although 
scarification can yield high variations between different users, it is an interesting approach. 
 31 | P a g e  
However, it is unlikely that the FDA would approve adjuvants or scarification for cutaneous 
deliveries that result in visible lesions of considerable sizes or large local inflammation. In 
summary, based on the current knowledge and studies performed assessing cutaneous vaccine 
deliveries, controlled inflammation and cell death are therefore may play a pivotal role in 
transcutaneous immunisations.  
2.3.2 Other devices used in cutaneous vaccine delivery 
Several different approaches for vaccine delivery exist and are currently being studied for cutaneous 
drug and vaccine delivery. Difficulties include disrupting the SC and possibly the underlying VE to 
allow molecules to pass through without causing excessive skin damage, enabling unwanted 
pathogens to enter. With molecules required to be ≤500 Daltons (Da) for passive diffusion, antigens 
and viruses are significantly larger (in the order of several kDa or >1 nm [208]), thus requiring 
assistance for enhanced penetration/ diffusion of the molecules. This has led to several passive 
approaches for drug/ molecule delivery via the skin by means of reformulated vehicles (i.e. particles 
contained in applied cream), chemical/ physical disruption or passive diffusion such as nicotine 
patches. Larger molecules still require mechanical support to facilitate crossing of the SC into the 
VE and underlying dermis. Some delivery techniques applicable for various molecules (including 
antigens) include tape-stripping, biolistic injections [209], electroporation [210-212], iontophoresis 
[213] as well as ultrasound [214, 215] amongst others; tattooing devices for vaccine delivery will be 
discussed separately (section 2.3.3). While biolistic injections have been used in mass vaccination 
campaigns, other cutaneous vaccine delivery devices are still in their early stages of development 
[216, 217]. An alternative cutaneous vaccine delivery technique includes the bifurcated needle that 
has been used to deliver the smallpox vaccine for decades, although is rarely used these days due to 
the eradication of smallpox [218]. An overview of the most commonly used devices for 
immunisations into or via the skin is shown in Figure 2.5 and is represented in tabular form below 
(Table 2.7). Due to the resemblance of the tattooing device to the NP, i.e. creating multiple 
punctures in the skin, section 2.3.3 has been dedicated to tattooing devices for vaccinations. 
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Figure 2.5: Overview of several cutaneous immunisation routes. 
Depicted are liquid jet injection, microinjection, MNs, tattoo vaccination, powder particle injection and gold particle 
injection. Image reproduced with permission from [199]. 
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Table 2.7: Overview of cutaneous vaccine delivery techniques. 
Technique Description and 
examples  
Advantages  Disadvantages References  
Abrasion Tape stripping, sand-paper, 
microderm-abrasion devices;  
Anthrax, influenza, adenovirus 
vector, heat-labile toxin from 
E. coli against travellers' 
diarrhoea, vaccinia 
Applied to mice, guinea pigs 
and humans 
Simple method 
Fast partial or complete SC removal 
Passive diffusion of molecules/ antigens  
Topical application of MVA particles 
(~290 nm) resulted in protection against 
tumour challenge in mice 
Does not enable large molecules to diffuse 
Pathogens can enter skin 
Difficulties in gauging delivered antigen amount 
Induces local inflammation and cytokine upregulation; 
cellular damage has not been extensively investigated 
May require reformulation of current vaccines to enable 
diffusion/ transport through the skin 
[96, 97, 184, 
219-222] 
 
 
 
 
Electroporation Short electric pulses of high 
voltage 
DNA vaccines, various drug 
molecules, peptides 
Tested in mice, pigs and 
humans  
Application times can be short (<10 min) 
 
Can require longer application times (>30 min) for thicker 
skin/ larger molecules; may require insertion of electrode 
needle into skin 
Electric pulses may cause pain 
Predominantly only suitable for small molecules 
(<10 kDa) 
Dependent upon hydration of the skin 
Disrupt lipid barriers in the skin and/ or permeabilises cell 
membranes 
May require reformulation of current vaccines to enable 
diffusion/ transport through the skin 
[18, 82, 108, 
210-213, 216, 
217, 223-231]  
 
 
 
 
 
 
 
 
Iontophoresis  Electric pulses of low voltage 
Various drug molecules 
Tested in mice, pigs and 
humans 
 
In general, short application times (<10 min) 
Assists in passive diffusion of molecules 
through the SC and epidermis in general 
Devices become smaller, hence more practical 
 
Can require longer application times (>30 min) for thicker 
skin/ larger molecules 
Predominantly only suitable for small molecules 
(<10 kDa) 
Dependent upon hydration of the skin 
[18, 82, 108, 
210-213, 216, 
217, 223-231]  
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Technique Description and 
examples  
Advantages  Disadvantages References  
Liquid jet 
injectors 
 
Diphtheria, tetanus, pertussis 
(DTP) combination vaccine, 
smallpox, rabies, hepatitis A, 
influenza, measles 
(the WHO considered single 
use nozzles for the IPV 
eradiction campaign [232, 
233]) 
Mass-vaccination campaigns  
High throughput of vaccinations (up to 600/ h) 
Option for reusable nozzles  or ’auto-disable’, 
single use nozzles 
Pain, bruising, bleeding 
Hepatitis outbreak in 1990s due to cross-contamination of 
blood droplets (WHO does not recommend its use) 
Accuracy of penetration depth (i.d., s.c., i.m.) dependent 
upon device design, pressure of gas etc; difficult to 
maintain constant between individuals 
[83, 103, 184, 
199, 234-239] 
 
Ballistic injectors 
(particle delivery/ 
gene gun/ powder 
immunisation) 
Material coated onto (gold-) 
particles  
DNA vaccines, antigens 
Used in humans (clinical 
trials), pigs  
Can deliver micron-sized particles (1-100 µm) 
into the skin 
Needle free 
Can potentially target dermis from VE 
separately 
Minimal or no training required 
Shock waves/ stress may function as immuno-
stimulant 
Enhanced vaccine stability due to coating onto 
the particles 
Expensive 
Cause extensive cell death at the application site 
Painful, can cause bleeding 
Requires adjustment of particles size and (helium) gas 
pressure to deliver particles into the desired skin layer 
Requires reformulation of current vaccines to enable 
diffusion/ transport through the skin 
Cause shock waves/ stress to the tissue and cells 
[184, 199, 209, 
235, 240-242] 
 
 
 
 
 
 
Ultrasound Tetanus toxoid 
Tested in mice and humans 
Shock-wave associated activation of LCs 
Effect similar to physical adjuvant  
Disruption of skin short-lived 
Reduces skin’s resistance (could enables pathogens to 
enter via formation of ‘acoustic cavities’ 
[184, 214, 215, 
243, 244] 
 
Tattoo 
vaccination 
DNA vaccines in general, 
haemagglutinin expressing 
DNA, HPV, adenovirus 
Tested in mice and non-
human primates 
Induces higher humoral and cellular responses 
than adjuvanted i.m. immunisation  
Tattooing devices already approved by the 
FDA  
Strong immune responses (humoral and 
Expensive, cumbersome equipment required 
Painful, can cause bleeding 
Local inflammation, erythema and cell death by oscillating 
needle penetrating the skin 
No enhanced immune responses with highly virulent 
[184, 245-256] 
see section 
2.3.3 
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Technique Description and 
examples  
Advantages  Disadvantages References  
 cellular) for most tested antigens when 
compared with i.m. or s.c. routes 
Negligible effect of antigen stability 
Successful immunisation in non-human 
primates with HIV vaccine 
Induce danger signals which can augment 
cellular/ humoral responses 
Suitable for current liquid formulations 
 
particles (e.g. adenovirus) 
Delivery depth can vary between skin immunisation sites 
and/ or patients 
Due to multiple punctures of the skin, risk of infection 
May require training  
Hazardous waste 
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2.3.3 Tattoo devices for vaccination 
Several studies have used a tattooing device for DNA delivery [247-249, 254-256]. Some studies 
investigated tattooing for vaccine delivery in comparison to i.m. immunisations using hypodermic 
needles [246, 249, 250]. Tattooing devices contain of one or multiple short needles, oscillate at high 
frequencies [~100 Hz; 245] and deliver DNA vaccines (antigen-encoding plasmids) or inks [247] by 
puncturing the skin surface into the dermis [247, 248]. DNA delivered by tattooing devices resulted 
in higher immune responses than i.m. or s.c. using plasmids encoding eGFP or HIV-1 gp120 [245], 
HIV-1 env plasmid [252], or major capsid protein L1 of HPV type 16 [249, 250] as well as DNA 
encoding fluorescent biosensors [255]. However, local erythema, haemorrhage, inflammation and 
necrosis in tissue subjected to tattooing of a glycerol vehicle ± dye particles have been reported by 
Gopee et al.; a control group including tattooing without any liquid or saline was not included 
[247]. While mostly tested in mice, tattooing of HIV-1 env plasmid in rhesus macaques led to up to 
100-fold increase in antigen specific T-cell responses in comparison to i.m. delivery [252].  
Further, Bins et al. observed a correlation between antibody and T-cell responses: a single long 
tattooing exposure (16s) of DNA immunisation to skin resulted in high antibody, low T-cell 
responses. By contrast, three consecutive single short exposures (4s) resulted in median antibody 
but high T-cell responses [253]. Replacing one of the triple immunisations (given in 2-day 
intervals) with a mock injection did not enhance the immune responses, suggesting that  
co-localisation of danger signals released from the repeated needle perforations in the skin, with 
antigen together promoted the enhanced responses when compared with i.m. injections. Cellular 
damage or danger signals though were unfortunately not assessed although it is likely that released 
DAMPs attracting inflammatory cells (including neutrophils) may have exerted a dampening effect 
on antibody response [257]. Moreover, better protection and immunity were achieved with DNA 
tattooing of HPV16 [249, 250] and influenza A [248] when compared with s.c. or i.m. 
immunisations. While peptide-based vaccines delivered by i.d. DNA tattooing were more effective 
in mounting cellular and humoral responses than s.c. immunised groups, this was not seen when 
live adenoviral vector was delivered via DNA tattooing [251]. The authors proposed that the highly 
virulent nature of adenovirus and viral particles contained high levels of PAMPs that caused a pro-
inflammatory environment stimulating the immune system. Repeated needle penetration therefore 
was ineffective in inducing an inflammatory DAMP-enriched environment.  
While the mechanisms of DNA uptake following tattooing resulting in higher immune responses 
than i.m./ s.c. injections have not been fully elucidated, several propositions have been brought 
forward as possible explanations, which correlate well with the underlying hypothesis of this 
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doctoral thesis. In particular, that 1) enhanced DNA uptake by APCs [247]; 2) non-APCs may 
contribute to DNA uptake [255]; 3) extended expression of encoding protein [253]; 4) inflammation 
and skin trauma caused by the tattooing needle enhancing innate and adaptive immune responses 
[247, 250, 251]; this has also been summarised by Oosterhuis et al. [248].  
2.3.4 Microneedle arrays 
Three decades ago, a new form of potentially pain-free [258] cutaneous delivery has emerged, 
namely MN [259, 260]. Specifically, solid MNs were first described in 1985 by Najafi et al. [259, 
260], although it was not until the late 1990s that Henry et al. [261] demonstrated the potential use 
of MN as a minimally invasive device for delivering therapeutics across the skin. With the 
mechanical and structural properties of the skin being highly variable, consistent penetration of 
single MN can be challenging. In particular, MN must be long enough to enable sufficient 
penetration depth into the skin [262], but not be too thin to break under the insertion force. By 
manufacturing MN arrays that contain multiple projections of several 100 µm to ~1000 µm in 
length, consistent penetration depth and projection breakage can be reduced. These ‘classical MN 
arrays’ are designed to pierce through the SC, and deliver consistent antigen or drug diffusion and 
dissolution into the VE and upper dermis [263] while reducing pain sensation and blood vessel 
rupture. Promising results have been obtained in animal studies and the first pre-clinical trials. A 
schematic overview solid and hollow MNs are represented in Figure 2.1 and Figure 2.5.  
With ongoing research, it became evident that the needle design was crucial to the success of MNs 
[264]. Projection densities of MN vary greatly, ranging from a single needle/ cm2 (BD Soluvia™), 
multi-pronged MN over >10,000 [265] up to ~20,000 projections/ cm2 [266] with needle lengths 
ranging from 30 µm [266] up to 1100 µm [265, 267]. The correct geometry and projection 
arrangement across the array [268-270] combined with the material’s physical properties are 
important parameters to enable insertion and penetration of MN arrays into the skin and the SC 
[268, 271]. Thus, depending upon the targeted skin layer and the active compound to be delivered, 
different MNs forms and shapes have been designed (Figure 2.6). By reducing the required dose 
for each vaccination, and with low production costs, MNs have a potential to reduce the overall cost 
per vaccine administration [239, 272]. Importantly, a recent study presented feasibility data of very 
low or no pain associated with MN applications in comparison to i.m. injections [273]. In addition, 
trials of self-application may contribute to wider vaccination coverage in the future [274].  
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Figure 2.6: Microneedles used in the delivery of therapeutics produced in various shapes and lengths and their 
application to skin.  
(a) Solid microneedles 150 µm tall, (b) solid microneedles measuring 1000 µm in length, (c) solid microprojections of 
330 µm and a 25G needle shown adjacent to the array, (d) microprojections of 50 – 200 µm length, (e) hollow 
microneedle of 500 µm length with a 27G needle beside it, (f) application methods of MN applied onto the skin 
followed by (g) topical drug delivery or release of drugs from the coated, dissolving or releasing projections. Images 
reproduced and adapted with permission from  (a) [261] (b) [267] (c) [275] (d) [276] (e) [277], (f)-(g) [185].  
Hereafter, MN arrays will be broadly classified into four major categories in which the active 
compound is delivered by: 1) being coated onto solid MN [3, 170, 266], 2) hollow MN [268, 278, 
279], 3) drugs encapsulated in dissolving, biodegradable and/ or polymeric MN, potentially 
beneficial in controlled release [197, 280-284] and more recently also 4) swelling MN for drug 
delivery [285] or as a sealant to close wounds [286]. 
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2.3.4.1 Solid microneedles 
Within the last decade, many research groups were able to manufacture classic MN and classic MN 
arrays using different materials and methods, such as laser cutting from metals like titanium [287] 
or stainless steel [267, 288, 289] and deep reactive ion etching (DRIE) technique of silicon [266, 
290] as well as by using polymers [197, 282, 291] and sugars [280, 292]. Furthermore, many 
different applications for MN have since been investigated including drug and vaccine delivery 
[267, 293], protein delivery [283] as well as a diagnostic device for disease biomarkers [294] and an 
interlocking device to seal or close wounds [286]. Application of solid MNs followed by topical 
application of dyes or other drug molecules such as calcein and bovine serum albumin (BSA) have 
shown to result in significantly higher permeability when compared to topical application alone 
[262]. Similarly, nanoparticles of 200 nm in diameter were able to enter the microchannels formed 
by the penetrated projections [295]. Overall, more consistent penetration and penetration depths 
were achieved by using a MN applicator at higher velocity rather than manual [170, 295].  
As depicted in Figure 2.6, several different approaches to deliver molecules exist. In particular, for 
solid MNs, a dip coating [266, 288, 289, 296], jet coating [266] or even spray coating [165, 297] 
approach have been tested, each of them with their own advantages and disadvantages. Excess 
antigen loss may be the result of excess coating solution in the dipping containing or lost in the 
spraying process. With high projection densities, jet coating may be more suitable than dip coating 
as capillary forces counteract the consistent coating layer [266]. Thus, depending upon the MN size 
or number of projections, and the coating solution itself, the coating approach may have to be 
altered to suit the experimental requirements.  
Several dyes, drugs and antigens such as sulphorhodamine B, Coomassie Blue, insulin, BSA, 
influenza virus like particles have been tested and successfully delivered to epidermis and dermis 
[267, 281, 298, 299]. Vaccines successfully delivered by MNs include, but are not limited to, 
inactivated influenza [3, 300], influenza VLPs [296, 298, 301], recombinant influenza virus 
haemagglutinin [302], inactivated Chikungunya virus [303], HPV VLPs [304] as well as plasmid 
DNA encoding against WNV [303], Hepatitis C [305] as well as HSV [306, 307]. Solid MNs have 
also been shown to be efficient at mounting immune responses (cellular and humoral) in animal 
studies when compared with i.m. injections[308]. As expected, immunogenicity results were dose-
dependent although MN with longer (600 µm) projections have not yielded enhanced 
immunogenicity when compared with shorter (225 µm) projections in guinea pigs [262]. 
Interestingly, increased projection numbers did only increase immune responses at high antigen 
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doses, but not at low doses. Whether this was due to bilateral immunisations and hence targeting 
double the number of dLN was not assessed [262]. Thus, it appears to be advantageous to produce 
rather shorter MN, reducing the pain by not penetrating as deep into the skin. This was recently 
confirmed in a randomized, repeated measures study, where human volunteers compared the pain 
between i.m. and application of solid MNs [273]. Interestingly, on a pain-rating scale of 1 to 100, 
the MN was rated at 1.5 while i.m. injections rated at 15 [268]. In addition, patient compliance 
studies further illustrated a better acceptance of MN arrays used for mock immunisations over i.d. 
injections, due to less swelling, redness and pain observed at the application site [82, 274]. One of 
the shortest MN devices for vaccine delivery reported in the literature is the NP with projection 
lengths ranging from 40-110 µm to target both LC and dDC within the VE and dermis, respectively 
[266], and will be separately discussed in section 2.3.5.  
In general, administration of solid MNs achieved equivalent if not increased immune responses to 
DT [51], influenza [89, 196, 289, 309-311], OVA [262, 266, 275, 280] and others when compared 
with i.m..s.c. or i.d. injections. Whole inactivated influenza vaccine coated onto solid metal MN led 
to prolonged protection (6 months) and higher serological memory responses when compared to s.c. 
immunisations as assessed by antibody titres, viral clearance and lung inflammation in addition to 
lethal challenge [300, 312]. Similarly, a single immunisation with an influenza subunit vaccine 
containing 3 µg of A/Brisbane coated onto solid metal MN resulted in increased cellular and 
humoral responses, including enhanced influenza-specific IgG antibody titres, neutralising antibody 
titres, HI titres as well as T-cell responses (IFN-γ secretion) up to 9 months post immunisation. 
MN-immunised mice were also protected against lethal challenge 3 months after immunisations. 
MN immunisations resulted in a balanced Th1/ Th2 response (IgG2a:IgG1), with a Th2 prevalence 
at later time-points (≥3 months). i.m. injections by contrast showed significantly higher Th1 
responses than MN injections, thus resulting in predominantly Th2 responses [309]. This Th cell 
bias in MN groups [309] was in accordance with results by others [196, 197, 311]. Sullivan et al. 
who compared i.m. to dMN immunisation of the mouse-adapted inactivated PR8 strain [197]. 
Interestingly, a change in isotypes was noted with the addition of trehalose as stabiliser, where MN 
groups evoked predominantly Th1 responses. This Th cell bias is important since split, inactivated 
and subunit influenza vaccines are known to be better at inducing humoral than cellular 
immunogenicity [313]. Overall, it appears that MN-based immunisations can induce strong cellular 
Th1 immune responses.  
Other vaccines delivered by MN includes the measles vaccine, which was administered by MN and 
s.c. [314]. Using trehalose as stabiliser [289], the measles vaccine was stable at room temperature 
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for one month with only one log of loss in viral titre when coated onto MNs [314]. Immunisation of 
cotton rats resulted in comparable neutralising antibodies between s.c. and MN groups at equivalent 
doses, although no dose-sparing was noted [314]. A hepatitis C DNA vaccine was successfully 
delivered by MN, eliciting CTL responses in mice [305].  
2.3.4.2 Dissolving microneedles 
In contrast to solid MNs that are surface coated, dissolving MN (dMN) have the antigen 
incorporated into their projections, and therefore deliver the vaccine following dissolution [315]. 
First reported in 2006 [316], releasing insulin within 1h following administration, dMN display 
many advantageous properties over solid and hollow MNs, in particular being manufactured from 
dissolving, swellable and degradable materials that are already approved by the FDA [197, 283, 
317, 318]. In general, dMNs are expected to yield improved logistics due to smaller storage and 
disposal size, ease of use, reducing hazardous sharps waste and minimising required waste disposal. 
However, since dMN also penetrate and dissolve within the skin, no sharp projections remain on the 
dMN patches, and could potentially be classified as hazard-free although a risk remains of body 
fluids including blood remaining on the dissolved projections [318]. Complexities of dMN 
production include designing a suitable geometry, strength and stability, while dissolving upon 
insertion into the skin. This has led to dMN production of diverse materials such as polymerising 
monomeric vinyl pyrrolidone using ultraviolet light [283], compressed and dried carboxymethyl 
cellulose (CMC) [280], a polymer combination of polyvinyl alcohol and polyvinylpyrrolidone [281, 
319], a combination of CMC with amylopectin and BSA [282, 318], hydrogel particles in poly-
(lactic-co-glycolic) acid [320], sodium hyaluronate and hydrolysed collagen or sodium hyaluronate, 
dextran 70 and Povidone [321], polymetamethyl acrylate (PMMA) and other polymers [246, 322] 
etc. Importantly, these materials can influence the dissolution time-frame, thus leading to controlled 
release over time [282] or fast dissolution upon rehydration [197, 280-282]. Examples of various 
shapes of dMN are shown below in Figure 2.7. 
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Figure 2.7: Dissolving microneedles made from water-soluble and biodegradable polymers in various shapes. 
Images were acquired using confocal microscopy or bright field microscopy and have been reproduced with permission 
from [185].  
Immunogenicity results using dMN have yielded similar results to solid MN immunisations. 
Promising results were published by Sullivan et al. [197], where a polymer-based dMN containing 
inactivated influenza virus encapsulated as lyophilised powder within a biocompatible polymer, 
resulted in strong antibody and better cellular immune responses with a more efficient viral 
clearance when compared with conventional i.m. influenza vaccine delivery. Impressively, a  
1000-fold more efficient lung virus clearance after MN administration 3 months post challenge was 
seen, suggesting that MN immunisation stimulate better memory immune responses. Nevertheless, 
Sullivan et al. [197] and Zaric et al. [322] required 2-3-fold longer application times than other 
dMN [280], possibly attributable to the materials for the dMN used and projection sizes. Raphael et 
al. used a similar approach to fabricate dMN arrays from a PDMS mould of NPs, and incorporated 
a split influenza vaccine in CMC [280]. Robust antibody responses were generated; however, no 
cell-mediated immunity or challenge studies were reported. Meanwhile, various studies using dMN 
for drug and vaccine delivery have been published [197, 281, 282, 314, 318, 321], predominantly 
delivering influenza vaccine. Recently, de Muth et al. utilised a very elegant approach of producing 
a two-system dMN, containing a slow release dMN tip made of PLGA adjoined to a water-soluble 
poly-acrylic acid (PAA) base [323]. Upon insertion into the skin, the base would quickly dissolve, 
leaving the PLGA-tip in the skin and resulting in a slow molecule (OVA and PolyI:C, the latter a 
synthetic dsRNA adjuvant) release. Superior and multi-functional CD8+ T-cell responses were 
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measured post MN immunisations when compared to i.d. and i.m. immunisations. In addition, 30% 
higher Tcm responses along with enhanced IFN-γ and TNF-α secretion upon stimulation were 
measured in dMN groups while antibody responses were comparable to i.d. and i.m. groups [323]. 
Overall, dMN may be a useful method for patients to quickly self-administer vaccines without pain, 
leaving potentially no harmful sharps behind and reducing hazardous waste [197, 318].  
2.3.4.3 Swelling microneedles 
Recently, MNs have been fabricated from materials that can swell upon exposure to a hydrated 
environment such as skin. These MN have been fabricated from so-called hydrogels [285, 320, 324-
326] and a poly(styrene)-block-poly(acrylic acid) swellable tip with a non-swellable polystyrene 
core [286]. Studies by Donnelly et al. [285, 324-326] and Kim et al. [320] have indeed successfully 
delivered into the skin of rats and humans fluorescein-BSA, dyes as well as larger molecules such 
as insulin, penetrating ~250 µm into human forearm skin [326]. Importantly, application times 
varied between 0.5-6h with full skin recovery (i.e. re-established skin barrier function) achieved by 
24h post-treatment [326]. Successful self-application in humans for swelling MNs have also been 
reported [324]. By contrast, Yang et al. focussed on using swellable MN to adhere onto soft tissue 
without damaging the tissue by using staples or using chemical adhesives which can cause irritation 
and inflammation upon application. While they were reported not to adhere strongly to skin, this 
may be a beneficial factor should they be used in skin-based vaccinations to cover the immunisation 
site while (slowly) dissolving within the skin. Immunogenicity experiments using swelling MN 
have not been conducted yet but it would be interesting to assess the innate immune responses to an 
inserted and swelling MN with respect to inflammatory environment co-localising with antigen.  
2.3.4.4 Hollow microneedles 
Another form of MN consists of a hollow compartment within the MN shaft (Figure 2.8), allowing 
a controlled release of drugs or vaccines over time as well as the delivery of liquid drug 
formulations into skin [279, 327]. Considerations in the design of hollow MNs include the material 
as well as the shape, length and material and vary depending upon the targeted therapeutic. One of 
the main challenges in designing hollow MNs lies in their mechanical properties [282], providing 
sufficient strength for being inserted into the skin without breakage and mechanical failure. In 
addition, some form of fluid mechanics in form of a pump [328] or pushing the liquid via a plunger 
[88] may be required to deliver the liquid formulation into the skin. Thus, hollow MN are often 
applied with low force and velocity into the skin [327]. Increased injection volumes have been 
reported to induce more pressure in humans that may result in pain [205]. Hollow MN have been 
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produced from by laser machining of metal tubes [284, 329], silicon [330], dry/ wet/ 
electrochemical etching [330], electrode discharge machining but also from heated and stretched 
glass capillaries [327]. Difficulties may arise in producing consistent hollow shapes with constant 
pore volumes that do not clog following insertion into the skin. More importantly, passive diffusion 
as well as active delivery (i.e. by means of a connected pump) can be achieved.  
 
Figure 2.8: Representative hollow microneedles produced from silicon, glass or polymers. 
Hollow MN manufactured from silicon (a-e, h, j), glass (I and k) and polymer (f); images acquired by scanning electron 
microscopy. Images were reproduced with permission from [185].  
Controlled insulin delivery using a pump was successfully achieved [290, 328, 331], resulting in 
comparable or even better results than s.c. injections. In particular, faster onset and offset times for 
hollow MN delivery than s.c. control groups were noticeable in the study by Norman and 
colleagues. In a study by Van Damme et al., influenza vaccine was administered i.d. four hollow 
MN attached to a standard syringe and compared to i.m. injections [88]. Immunogenicity results 
with only 20-40% indicated comparable immunogenicity to i.m. injections of the doses based on 
geometric mean titres, seroconversion and seroprotection. The insertion of a hollow MN containing 
the inactivated polio vaccine led to comparable antibody responses assessed by IgG titres and virus 
neutralising antibodies in comparison to i.m. and i.d. injections after a single immunisation [327]. 
Overall, hollow MNs have shown to function as suitable application methods for continuous and 
slow release of drugs and vaccines in general.  
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2.3.4.5 Advantages and disadvantages of microneedles 
Previous studies have shown that i.m. injections are often painful [258, 274] and can require 
multiple administrations for a single vaccine, e.g. tetanus or HPV, to elicit effective protective 
immunity [11]. By contrast, pain-free vaccine administrations have been achieved in small human 
acceptability trials by using MN arrays [258, 264, 274, 290, 332], comparing i.m. injections directly 
with MN applications [273]. The pain-free perception of MN-application [258, 290] may be due by 
the short and small projections, only targeting the epidermis and upper dermis, and therefore not 
reaching to the nerve receptors in the reticular dermis. In addition, patient compliance studies 
further illustrated a better acceptance of MN arrays used for mock immunisations over i.d. 
injections due to less swelling, redness and pain observed at the application site [82, 274]; similar 
observations were made when pain of i.m. and MN application were compared, with 10-fold less 
pain experienced with MN than i.m. injections [273]. Overall, MN arrays have the potential to 
decrease of cross-contamination can occur, reduce avoidance of immunisations due to absence of 
needles (needle-phobia) and a potential of cost reduction per administration due to lower dosage 
and removal of the cold-chain requirement [239]. However, with the current cost of a needle 
vaccination of approximately 0.06 USD per immunisation, injection needles are inexpensive. Thus, 
alternative methods bypassing the drawbacks of conventional parenteral injection routes with 
needles must be cost-effective. 
Other major advantages of using classical MNs in drug and vaccine delivery included a 
minimisation or avoidance of bleeding [262], and significant dose-sparing [88, 89, 333]. By 
inducing protective immunogenicity, a dose-sparing could therefore potentially lead to a reduction 
in cost per administration with the potential of saving more lives in future vaccine shortages [77]. 
Even with the promising results and the observed dose-sparing, the mechanisms of how vaccine 
delivery via MN functions remains to be elucidated. It is interesting that little if any research has 
been conducted investigating the cell damage and cell death caused by the vaccine delivery 
techniques itself considering that danger signals released by dying and dead cells as well as 
necrotic, but not apoptotic or healthy cells, are known to activate DCs that are required for antigen 
presentation [334, 335]. Lastly, rapid dissolution of coated vaccines within the skin [3] and within 
the skin’s interstitial fluid [272] may enable self-administration with little or no training [272, 318].  
Application of MN to animals, predominantly mice, often requires removal of hairs, unless sites 
with reduced hair follicle density such as ears are selected [3, 266]. Several other publications 
reported the use of depilatory cream to remove excessive fur prior to MN application and/ or 
immunisations when mice, rats or monkeys were immunised on their backs [89, 314, 336]. Whilst 
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this procedure may result in more consistent penetration of MN projections and therefore consistent 
if not enhanced payload delivery efficiency by MN projections, the effects of the depilatory cream 
used prior to immunisations on the innate and humoral immune response have not been reported by 
these authors. Research has shown that the reactive agent potassium thiglycollate weakens the 
disulphide bonds, and may induce increased cell damage causing neutrophil and monocyte 
infiltration following i.p. injection [337]. Although time-points for hair removal varied broadly 
(immediately [89, 130, 296] or up to 48h prior to immunisations [164, 197, 338]), local 
inflammation and apoptosis were reported several hours after application of depilatory cream or i.p. 
injection of thioglycollate [339]. Further, influx of leukocytes (i.e. neutrophils and lymphocytes) 
and macrophages have been reported and seem plausible, considering depilatory creams contain 
thioglycollate (known to attract neutrophils) and achieve complete removal of SC within minutes 
[340, 341]. Interestingly, hair removal creams, or plucking/ shaving hairs have also been reported to 
facilitate enhanced antigen uptake through skin and therefore can enhance immune responses [342, 
343].  
Lastly, while some MN vaccine delivery techniques use commercially available vaccines [309, 344, 
345] or some with minor reformulation of the vaccine through adding a vaccine stabiliser,  
e.g. trehalose [296, 346, 347]), it is likely that these changes may require pre-clinical, and clinical 
Phase –III trials although with fewer participants (accelerated process) as 1) the vaccine has already 
been approved and 2) the stabilising agent (here trehalose) are FVA-licensed. Considering that the 
vast majority of MN are produced of either biodegradable materials or are currently being 
manufactured of FDA-approved materials (metal, silicon etc) that are used in surgical 
reconstructions or implants, are therefore likely to obtain FDA-approval in the future. However, 
essential studies however include assessing the possibility of needle breakage in the skin and its 
effect of the immune system. On a separate note, current disadvantages and limitations that are yet 
to overcome in MN-based vaccine delivery include consistent penetration depths. While this is 
manageable in animal experiments, variation of the subcutaneous fat layer can significantly affect 
penetration depth. This will have to be carefully considered as the delivered dose per MN could 
vary. These are the most prominent limitations and disadvantages of the MN-based vaccine delivery 
device that could affect their translation into humans.  
2.3.5 The Nanopatch™ 
The NP is an ultra-high density (>20,000/ cm2) silicon microprojection array, designed to pierce the 
SC and deliver dyes, plasmids, antigens etc that are dry-coated onto the NP projections into the VE 
and dermis. The key difference between the NP and classical MNs is its high number of 
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projections/ cm requiring dynamic application to penetrate the skin, while maintaining a short 
projection length and narrow spacing between projections (Figure 2.9). NPs have been 
manufactured from either silicon in a DRIE process [348] or as dissolving NP from CMC [280]. 
Standard NP arrays measure 4 x 4 mm with projections of ~110 µm in length, a base diameter of 
~28 µm and a tip of ≤1 µm, although shorter NP projections (40 µm) have previously been applied 
in earlier studies for shallower penetration depths into the skin [3, 170, 266, 303]. Based on its 
dynamic application (1.9-2.5 m/ s), more than 95% of the projections successfully penetrate into the 
murine ear skin [170], delivering between 30% [3, 304] and ~80% [349] of the coated antigen with 
the majority of coated antigen released in the first 30s [3]. Penetration depths of standard NPs reach 
~70 µm in mouse ears (see Chapter 5), almost reaching the cartilage (see Figure 2.2c and Figure 
5.5) although shallower penetration depths can be achieved with lower application forces and/ or 
shorter projections [170]. Based on published acceptability data of 750 µm long steel MNs applied 
to human study subjects [273], the NP is likely to be well tolerated based on the shorter NP 
projection length, unlikely to reach nerve endings in the human dermis triggering pain.  
 
Figure 2.9: Nanopatch™ by digital image acquisition or scanning electron microscopy.  
(a) DRIE wafer containing several hundred NPs, (b) 31G needle used for i.d. injections next to a 4x4 mm NP for size 
comparison, (c) 9 NP projections in the field of view, visualised by scanning electron microscopy. 
Initially designed to deliver antigen and other molecules to target specifically the APCs within the 
VE and dermis based on probabilistic models [345], more recent evidence however suggests that 
additional factors other than APCs are essential for improved immune responses [344]. Specifically, 
that a combination between cell death inflicted by the projections, co-localising with antigen, 
danger signals and live cells [344] and possibly increased dermal antigen delivery to dDCs 
(unpublished observations) are favourable in mounting enhanced immune responses when 
compared with i.d. or i.m. injections. To date, the NP has been used to deliver multiple dyes, 
antigens and plasmids such as sulphur rodamine, Coomassie Blue [280, 349], OVA [280, 349, 350], 
trivalent split virion influenza [3, 280, 345, 350], HPV [304], West Nile viral plasmid [303], whole 
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Chikungunya virus [303], DNA vaccine encoding for HSV-2-gD2 [306, 307], as well as live viral 
vector malaria vaccine [347] amongst several other antigens.  
The most significant achievements of the NP in immunisations include an >100-fold dose-sparing 
without adjuvant [3] and up to ~900-fold dose-sparing when adjuvanted influenza vaccines [345] 
were administered i.m.. Importantly, the coated NPs were shown to be thermo-stable for 6 months 
at 23 °C with trivalent influenza vaccine as assessed by HI assays [351] while adenovirus (live 
ChAd63 vaccine) was thermo-stable when formulated with trehalose and sucrose as stability 
enhancers for up to 10 weeks at 37 °C [347]. Others have reported enhanced stability of trivalent 
influenza vaccine when formulated with trehalose for 1 month at 4 °C and 25 °C, however this was 
not seen when stored at 37 °C as assessed by HA activity [346]. Induction of CD8+ T-cell 
responses, important for protection in immunisations were successfully achieved with unadjuvanted 
OVA or adjuvanted (QA or CPG) OVA [350]. Enhanced T-cell responses were also seen with live 
viral vector malaria vaccine that were comparable to i.d. injections [347]. It must be noted however 
that dose-delivery efficiencies were difficult to match between NP and i.d. and are likely to be of 
different magnitudes, which could explain why both immunisation routes resulted in similar 
immunogenicity results after a single immunisation [347]. Long-term immunogenicity has been 
assessed up until 2 months post-immunisations of trivalent influenza vaccine, where a reduction of 
HI titres but only marginal decrease of antibody titres was noted [3].  
While the advantages of the NP include fast release kinetics of coated agents (dyes, antigens etc), 
shallow penetrations depths and hence being minimally invasive, proven thermo-stability, high 
cellular and humoral immune responses elicited with several antigens, potential limitations of the 
NP are acknowledged. In particular, large scale production using the current DRIE silicon process 
may be challenging. Moreover, the coating process requires to be advanced towards large scale 
fabrication. Not only is this attributed to the current coating process (e.g. only 8 µL coating solution 
volume per 4 x 4 mm2 NP) but also to the resulting vaccine wastage from coating solution 
remaining on the projections or the base of the NP – as less than 100% of coated materials are 
delivered per NP. While other avenues of manufacturing material are currently being pursued (i.e. 
dMN and polymer-based MN[352]), further research and scale-up models are necessary to assess 
whether the total cost of NP per immunisation is comparable to cost of a conventional needle and 
syringe – if required. Despite the promising published results obtained in mice and unpublished 
studies of enhanced immune responses in rats, pigs as well as rhesus macaques, feasibility data has 
not been tested in humans yet, the most important species as the end-consumer.  
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Another application area of the NP includes the use as a diagnostics tool. In this application, it is 
termed microprojection array (MPA), referring to its longer projections (150-250 µm). As 
biomarker tool, MPAs have been used to capture specific biomarkers from blood and tissue fluids 
from skin through surface modifications [294, 352-355]. Thus far, surface-modified MPA have 
successfully captured OVA-specific IgG [353], NS1 protein [354] and influenza-specific IgG from 
skin [355]. Projected into the future, surface-modified MPAs – containing longer projections than 
the NP – may therefore enable the capture of multiple biomarkers on one patch, with an integrated 
or separate read-out, providing high-throughput analyses from blood and/ or tissue fluids.  
2.3.6 Cell death and innate immune responses to vaccine delivery devices 
While immune responses to vaccines have been thoroughly studied as illustrated above, the local 
immune responses to delivery devices have received less attention. As outlined in Table 2.7, 
several cutaneous vaccine delivery techniques are currently being investigated. Ultrasound for 
instance is a relatively non-invasive method for skin permeabilisation. Tested in vitro with 
sonication, over 70% of cells were found to die at high intensities (0.54 MPa), presumably via an 
apoptotic pathway [214] – immune responses were not assessed in this particular study. Using 
tattooing devices, the effect of repeated needle penetration was investigated [247]. Not only was a 
local inflammation and haemorrhage in the treated murine tissue area visible, but also necrotic cell 
death in the epidermis as determined by histology. Dermal necrosis and inflammation persisted for 
up to 14 days in treated skin. This study however lacked control groups using the tattooing device 
but without a carrier (e.g. ink) to assess the tissue necrosis inflicted by the device itself rather than 
the carriers. Separately, Bins et al. delivered a DNA vaccine containing influenza A nucleoprotein 
epitope with tetanus toxin producing strong T-cell responses; however, innate immune responses to 
the tattooing device were not assessed despite proposing that repeated needle perforations may 
prolong unspecific inflammatory signals and promote danger signal release [253].  
Skin scarification using vaccinia virus resulted in significantly higher Tem and Tcm responses as 
well as in better protection than i.d., i.m. or s.c. immunisations, where local inflammation and 
cytokine release have been postulated as a possible explanation [207]. Moreover, a recent study 
assessed the impact of i.d. and s.s. immunisation routes on immunogenicity following vaccinia virus 
exposure [356]. Protection studies following s.s. alone resulted in 85% protection against lethal 
challenge in rabbits. S.s. prior to i.d. immunisations was found to result in over 70% protection – 
but only ~15% when scarification was performed after i.d. immunisation. This suggested that the 
damage induced by scarification itself contributed to protection against vaccinia upon challenge 
[356]. In addition, i.d. and s.s. immunisation routes resulted in mirror-image microarray heat maps 
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and gene upregulation appeared [356]. Importantly, neutrophil and monocyte infiltrations were 
more prominent in the VE, dermis and in particular in the s.c. tissue in the first 24h post-treatment. 
The authors proposed this scarification process may evoke responses similar to adjuvants.  
A laser-based treatment prior to i.d. injection resulted in no inflammation or ulcer formation, but led 
to enhanced cellular and humoral immune responses following i.d. influenza vaccine delivery. 
Cutaneous administration of adjuvants by contrast resulted in lesions, ulcers and strong 
inflammatory infiltrations [206]. No infiltrations or lesions were seen in control groups receiving 
i.d. injections of saline. Not surprisingly, MN application itself induced significant upregulation of 
pro-inflammatory cytokines (IL-1β, TNF-α), leading to chemokine production (e.g. MCP-1,  
MIP-1α, MIP-2) and further cell recruitment to the site of administration, presumably due to the 
mechanical distortion of the skin layers and cells [164]. Pro- and anti-inflammatory cytokine and 
chemokine productions were further enhanced with MN-delivered inactivated influenza virus [164]. 
Based on the cytokine profiles, no clear trend towards a Th1 or Th2-specific cytokine expression 
was noticeable [164]. The cytokine results are in agreement with findings by Vitoriano-Souza et al., 
who studied innate immune responses following i.d. injections (50 µL) into dorsal skin of mice 
using adjuvants [186]. Adjuvants administered i.d. led to increased cytokine secretion in skin, 
inflammatory cell presence in blood were measured following adjuvant administration [186]. 
Adjuvants and cutaneous adjuvant delivery will be discussed in more detail in section 2.4. 
Overall, immunisation methods resulting in shallow tissue damage such as tattooing, s.s. or MN 
applications, yielded comparable if not better immunogenicity results when compared to 
conventional i.m., s.c. or i.d. delivery routes. These studies also illustrated that current adjuvants 
(designed for i.m. injections) given i.d. may not be suitable as immuno-potentiators due to their side 
effects such as excessive inflammation. This supports the work presented within this doctoral thesis, 
in which a skin immunisation delivery device (the NP) represents a suitable alternative to existing 
immunisation devices and conveys a potential physical immune enhancer effect. Predominantly due 
to the application force (velocity), and high protection density (>20,000 cm-2) penetrating the skin, 
cytokine and danger signal release co-localising with antigen are expected. Together, if NP 
application induces cell death in the VE and dermis, this could shape and enhance the type as well 
as level of immune responses following cutaneous vaccine delivery.  
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2.4 Classical immune enhancers in vaccination 
2.4.1 Introduction to adjuvants  
Derived from the Latin word adjuvare, ‘adjuvant’ can be translated as ‘to help’ to enhance immune 
responses to humoral and cellular immune responses to antigens [13]. These agents can stimulate 
the immune system by inducing a co-stimulatory response in DCs, macrophages and/ or B-cells 
which in turn increase the immune response to an administered vaccine [4, 12, 357]. While initially 
believed to produce an antigen reservoir, resulting in slow and/ or constant release of antigen over 
time [4], more recent evidence suggests that adjuvants function more as inflammatory agents using 
diverse mechanisms. These can include inflammatory cell infiltration, danger signal release 
(extracellular DNA, ATP, HMGB-1 etc), activation of NLRs/ TLRs as well as inflammasome 
activation, which can act as potent APC activators [70, 95, 334, 358-360]. Moreover, various 
studies have demonstrated that adjuvants can also guide antibody isotypes and avidity as well as 
induce immune responses to weak antigens or compromised individuals hence steering the adaptive 
immune response towards the desired response [361]. Although not required in all vaccines [362], 
e.g. influenza vaccine for adults [363], adjuvants are particularly important in vaccines that do not 
elicit strong immune responses by themselves, e.g. HPV vaccine [23], hepatitis B or where dose-
sparing is desirable to provide wider coverage, e.g. in case of pandemic influenza [359].  
Four classes of adjuvants are currently approved for use in humans: aluminium salts (alum), oil-in-
water emulsions (MF59, AS03, AF03), virosomes and AS04, the latter consisting of alum and 
monophosphoryl lipid A (MPL). Of those, only two FDA-licensed adjuvants are available within 
the US, i.e. alum and AS04. Importantly, these adjuvants are only approved in combination with the 
respective vaccine; adjuvants have not been licensed as a stand-alone product yet. Other adjuvants 
approved outside the USA include AS03 (administered with the 2009 H1N1 pandemic influenza 
vaccine, licensed in Europe and Canada) and Montanide ISA 51 (a therapeutic lung cancer vaccine 
is licensed in Cuba) [359] amongst others. Details of adjuvants currently licensed for use in humans 
are outlined below in Table 2.8.  
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Table 2.8: Mode of action of current adjuvants licensed for use in humans.  
Adjuvant 
class 
Adjuvant 
(licensed in) 
Components Proposed mode of action Effect on innate/ 
adaptive immune 
response 
Examples of 
vaccines 
References 
Aluminium 
salts 
Alum (1924) Aluminium 
hydroxide or 
aluminium 
phosphate 
- No depot effect 
- Conflicting evidence of NALP3 activation  
- Independent of TLR (sometimes TLR4) 
- Enhanced local secretion of cytokines and 
chemokines 
- Recruitment of leukocytes including 
eosinophils, monocytes and macrophages 
- Enhanced antigen presentation 
- Enhanced antibody 
responses 
- Predominantly Th2 
responses 
- Minor Th1 responses 
HPV (Gardasil®), 
hepatitis A, hepatitis 
B, DTP, HIB  
[364-372] 
Oil-in-water 
emulsion 
MF59 (1997, 
Novartis) 
Squalene, 
Tween 80, 
sorbitan 
trioleate 
(Span85), 
citrate buffer 
- No antigen depot effect 
- ASC-dependent but independent of caspase-1 
or NALP3 
- TLR-independent but requires MyD88 for 
antibody responses 
- Enhanced local secretion of cytokines and 
chemokines 
- Recruitment of leukocytes including 
neutrophils, monocytes and macrophages 
- Enhanced antigen uptake by APCs 
- Antigen-loaded neutrophils and monocytes in 
dLNs 
- Activation of muscle cells 
- Released ATP potentiates alum’s 
adjuvanticity 
- Balanced Th1 and 
Th2 responses 
- Enhanced antibody 
responses 
Influenza vaccines: 
Fluad®; H5N1 
pandemic: 
Aflunov®; H1N1 
pandemic: Focetria® 
and Celtura® 
[94, 373-
378] 
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Adjuvant 
class 
Adjuvant 
(licensed in) 
Components Proposed mode of action Effect on innate/ 
adaptive immune 
response 
Examples of 
vaccines 
References 
Oil-in-water 
emulsion 
AS03 (2009, 
GSK) 
Squalene, 
Tween 80, α-
tocopherol 
- Dependent upon co-localisation of antigen 
upon administration 
- Increased local cytokine production but also 
in dLNs 
- Enhanced cell recruitment including 
monocytes and neutrophils 
- Antigen loaded monocytes in dLNs 
- Enhanced antibody 
responses 
- Elevated memory 
responses  
H1N1 pandemic: 
Pandemrix® 
Arepanrix® 
[379, 380] 
Oil-in-water 
emulsion 
AF03  
(Sanofi, never 
marketed or 
used 
commercially) 
Squalene, 
Montane 80, 
Eumulgin B1 
PH, buffers 
 
- Antigen and adjuvant require co-localisation 
- Increased transient local cytokine 
productions  
- Transient recruitment of neutrophils, 
monocytes, DCs into injection site 
- Antigen-loaded APCs  
- NFkB activation (muscle and dLN) 
- Dose-sparing 
- Antigen and adjuvant 
require co-
localisation 
- Enhanced antibody 
response  
- Enhanced Th2 over 
Th1 responses 
Pandemic influenza 
H1N1v Humenza™ 
(Spain only) 
[376, 381] 
Combination 
of alum salt 
and oil-in-
water 
emulsion 
AS04 (2005, 
GSK) 
Aluminium 
hydroxide, 
MPL, TLR4-
agonist 
- Activation and signalling via TLR4 
- Activation of APCs 
- Enhanced local secretion of cytokines and 
chemokines 
- Enhanced antigen-bearing DC and monocyte 
recruitment to the dLN (to a lesser extent 
locally) 
- Enhanced antibody 
responses 
- Favours Th1 
responses 
HPV (Cervarix®); 
worldwide licensed; 
hepatitis B 
(FENDrix®, Europe-
wide licensed) 
[382, 383] 
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Adjuvant 
class 
Adjuvant 
(licensed in) 
Components Proposed mode of action Effect on innate/ 
adaptive immune 
response 
Examples of 
vaccines 
References 
Virosomes Virosomes 
(2000, Berna 
Biotech) 
Lipids, 
haemagglutinin 
- Platform to deliver antigen 
- Structural similarity to influenza virus, 
exposing haemagglutinin and neuraminidase 
on its membrane surface 
- Preferential binding and uptake by APCs 
through these surface proteins  
- Uptake via receptor-mediated endocytosis, 
no endosomal degradation 
- Antigen presentation can occur by MHC I or 
MHC II to CD8+ and CD4+ T-cells 
- Enhanced antibody 
responses 
- Enhanced CTL 
responses 
Influenza vaccines 
(Invivac® and 
Inflexal®V) and 
hepatitis A 
(Epaxal®, 
HAVpur® and 
VIROHEP-A®) 
[384] 
 55 | P a g e  
2.4.2 Mode of action 
Despite decades of use, the underlying mechanisms of adjuvants are not yet fully understood. 
Figure 2.10) represents a generalised mode of action that can be broadly applied to the majority of 
adjuvants in use – both those licensed and those in research. Upon i.m. injection, some but not all 
adjuvants can form an adjuvant-antigen depot. Following injection, an increased local cytokine and 
chemokine release is initiated by tissue resident cells, which is further stimulated by infiltrating 
inflammatory cells from the blood stream. Infiltrating APCs can then interact and bind to adjuvants 
using several cell surface receptors, including but not limited to PRR activation, NLRs, TLRs 
amongst others. These can then sense danger molecules such as DNA, ATP, HSP70, MSU, that are 
released by dying cells or cells exposed to adjuvant. This can lead to the inflammasome formation 
containing NACHT, the apoptosis-associated speck-like protein containing CARD (ASC) and 
caspase-1 domains. Upon successful formation, caspase-1 is required to convert pro-IL-1β and IL-
18, leading to the inflammasome activation. NALP3 is the most studied inflammasome, although 
others such as AIM2 may also be involved, especially in skin immunisations [385].  
Upon activation of the inflammasome, the antigen is internalised and processed. This initiates the 
secretion of (adjuvant)-specific cytokines and chemokines, which then trigger additional cell 
infiltration (immune cell recruitment including APCs). DCs upregulate their co-stimulatory 
molecules (CD80, CD86) and MHC II+ and migrate towards the dLNs, where they interact with  
T-cells. Depending upon the cytokine environment, it may either result in Th1-biased (cellular 
responses leading to IFN-γ secretion, and involvement of macrophages, CD8+ T-cells: CTLs, NK 
cells) or Th2-biased responses (humoral responses leading to IL-4, IL-5 and IL-13 secretion and 
antibody responses). Humoral and cellular responses will then generate long-lasting memory T- and 
B-cells, which enable a faster response in a real infection.  
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Figure 2.10: Current known modes of action of adjuvants.  
Several mechanisms by which adjuvants function have been proposed, in particular through PRRs and their respective 
ligands. Adjuvants can bind to multiple PRRs and induce cytokine and chemokine production, leading to specific Th 
responses, which in turn result in cellular infiltration via chemotaxis. Binding of adjuvants or danger signals to PRRs 
have also been linked to inflammasome activation, resulting in the conversion of pro-IL-1β and pro-IL-18 into their 
mature forms. Multiple mechanisms for one adjuvant are possible, such as alum, reportedly resulting in binding of 
PRRs, leading to DC activation and antigen uptake, may lead to inflammasome activation and ultimately induce 
inflammatory cell infiltration. (1) Potential adjuvant depot formation, leading to a slow antigen release over time; (2) 
release of chemokines and cytokines; (3) this release attracts inflammatory cells to the site of adjuvant administration 
causing an inflammatory micro-environment; (4) recognition of adjuvant via PRRs on the cell’s surface, leading to 
further cytokine/ chemokine release resulting in (5) maturation and activation of APCs. Antigen is then shuttled to the 
dLN by activated DCs and macrophages to stimulate naive T-cells and later B-cells for CD8 T-cell and antibody 
responses, respectively. Adapted and reproduced with permission from [70, 360]. 
Additionally, other adjuvants are currently being extensively used in research or tested in clinical 
trials. Examples include MPL, CpG oligonucleotide sequences, ISCOMs (immuno-stimulating 
complexes; ISCOMatrix), PolyI:C etc. The first three are one of the most studied and best 
categorised adjuvants regarding their mode of action [386, 387]. MPL is licensed within the AS04 
adjuvant while MPL in AS02 as well as CpG and ISCOMatrix are currently being tested in clinical 
trials [13, 14, 70, 359, 360, 388]. These adjuvants however were beyond the scope of this thesis.  
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Whilst the previous sections focussed on adjuvants in general, this section will focus in more detail 
on the currently known modes of action of three selected adjuvants: 1) alum and 2) MF59, both 
licensed for use in humans; 3) QA, currently used in experimental work and veterinary medicine.  
2.4.2.1 Aluminium salts 
Aluminium salts encompass a range of combinations with aluminium hydroxide and aluminium 
phosphates being the most common formulations. Despite the potentiating effect of alum noticed in 
the early 1920s, and Glenny’s observation suggesting an antigen depot effect resulting in slow 
antigen release over time [389], it was not until several years ago that alum’s mechanism was 
systematically investigated. Earlier proposed mechanisms of alum included concentration-
dependent adsorption of antigen onto alum particles, antigen depot formation at the injection site, 
stimulation and recruitment of immune cells due to complement activation to the injection site, 
macrophage activation, eosinophilia, cellular stimulation through inflammasome activation etc 
[reviewed in 390, 391]. In 2008, several groups concurrently investigated the effect of alum on the 
NALP3 inflammasome activation. Previous work by Shi et al. demonstrated that injured cells 
released endogenous danger signals that induce DC maturation and enhance immune responses to 
antigen [392, 393], including uric acid [394]. This finding was important as Kool et al. proposed 
that alum administration promoted adaptive immune responses through the release of MSU crystals 
[395] that activated the NALP3 inflammasome, although through different pathways [368].  
Likewise, Eisenbarth et al. also found that alum induced high levels of cell death in vitro. However, 
NALP3 inflammasome activation was not the result of excessive ATP release from damaged cells 
as confirmed by testing macrophages of P2X7R-/- mice for IL-1β production. Instead, they proposed 
multiple stimuli may have led to NALP3 activation, which was found to be essential for the 
immuno-stimulatory effects of alum [95]. Isolated peritoneal macrophages from NALP3-/-, ASC-/- 
and caspase-/- mice were unable to produce active IL-1β and IL-18 along with significant antibody 
responses in the same study. This demonstrated that NALP3 inflammasome activation was essential 
for alum’s adjuvanticity and for producing mature cytokines [95]. This contradicts findings by 
others who noted that NALP3 was not required to potentiate antibody responses to alum-adjuvanted 
human serum albumin [369]. Since then, various other reports have confirmed, expanded or 
contradicted the existing data [365, 373, 396, 397]. Further research is currently being undertaken.  
Extracellular dsDNA accumulated around the dead cells at the injection site and when treated with 
DNAse, humoral responses decreased in OVA and alum treated mice, suggesting that danger 
signals in form of host DNA mediates alum potency [358]. This correlates somewhat with other 
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findings of transient and little ATP-release upon i.m. injection [94] as well as NALP3 activation 
following DNA and ATP release from necrotic cells [398]. Another danger signal reportedly 
required for NALP3 inflammasome activation following alum administration was HSP70 [399]. 
Based on the proposed role of alum in inflammasome activation, it would be interesting to evaluate 
and cross-compare other DAMPs reported to be involved in the NALP3 activation pathway. 
Extracellular ATP and DNA, HMGB-1, HSP70, MSU, potassium, calcium, IL-1β, IL-18 and IL-33 
have shown in at least one study to activate the inflammasome [400, 401]. Thus, it appears that 
inflammasome activation and its related pathways are more complex than initially assumed, 
suggesting that there may be more multiple activation pathways.  
Several reports indicated hesitations regarding the antigen depot effect of alum [70]. Evidence of no 
antigen depot formation following alum injection was presented by Hutchison et al., who suggested 
that antigen depot formation was not the leading mode of action for alum’s adjuvanticity [364]. 
Specifically, excision of the antigen depot site as early as 2h post-immunisation did not 
significantly affect OVA-specific cellular and humoral responses. Hutchison’s studies further 
substantiated earlier results by Holt, where removal of the antigen deposition site 7 days after 
immunisation did not affect immunogenicity [402]. Unfortunately, Hutchison and colleagues did 
not include controls that compared unadjuvanted excised versus not excised sites as well as 
adjuvanted injection sites with depot excised versus not excised. These experimental groups would 
have been important to exclude the possibility that the excision in itself resulted in a highly pro-
inflammatory micro-environment, with significant DAMP release from cells exposed to alum but 
also necrotic cells due to the incisions. In particular, since s.s. has been described as inducing a pro-
inflammatory immune response that contributes significantly to the subsequent immunisation [356]. 
Li et al. assessed NALP3 inflammasome activation via uric acid release after administration of 
alum, QA, or chitosan [403]. Overall, uricase (a hydroxylase, which catalyses the oxidation of uric 
acid to uric acid salt) treatment however did not evoke a significant difference in the resulting 
immune responses, showing that NALP3 inflammasome activation by particulate adjuvants is not 
dependent of uric acid release from damaged or dead cells. In summary, conflicting results 
regarding the involvement and activation of the inflammasome as well as involved pathways for  
IL-1β/ IL-18 secretion have been proposed. Comparing these experimental setups is complicated 
not only by large variations in quality and purity of reagents distributed under the common term 
‘alum salts’but also by the use of different mouse strains [360, 366]. Overall, the current 
information on alum’s mechanism of action points to an enhanced antigen uptake following alum 
administration related to an increased APC presence at the injection site, together with induction of 
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a highly inflammatory environment, induction of cell death, cellular infiltration and predominantly 
enhanced Th2 responses.  
2.4.2.2 MF59 
As briefly outlined in Table 2.8, MF59 is a TLR-independent but MyD88-dependent adjuvant, 
commonly administered i.m. due to being an oil-in-water emulsion adjuvant. Its potency has been 
demonstrated when MF59 induced significantly more gene upregulation than other adjuvants 
following i.m. administration [375]. In the study by Mosca et al., MF59 upregulated just under 500 
genes, while CpG and alum upregulated ~380 and alum ~320 genes, respectively. Importantly, 
administration of MF59 led to an increased influx of MHC II+ and CD11b+ cells [375] as well as 
neutrophils, monocytes, eosinophils, myeloid DCs and macrophages to the injection site [373] as 
shown in Figure 2.11. Associated with the infiltration of inflammatory cells was an increased 
cytokine secretion [375]. In comparison, CpG induced higher levels of cytokines (IL-12p40, CCL5, 
CCL2, CXCL1 and IL-5) than MF59 (IL-5) or alum when assayed from sera, the latter not inducing 
any of the tested cytokines. Without IL-12p40 and IL-5 being upregulated at the injection site, these 
results suggested a more systemic rather than a local response [375]. This inflammatory 
environment of infiltrating cells further facilitated APC activation and antigen uptake to the dLN 
[373].  
It was not until recently when Ellebedy et al. made the interesting discovery that ASC (which forms 
part of the NALP3 inflammasome), but not NALP3 or caspase-1 were essential for the adjuvanting 
effect of MF59 [377]. Since inflammasomes and caspase-1 activation are frequently the result of a 
cell exposed to danger signals (DAMPs and PAMPs), it is interesting to speculate whether MF59 
itself or the resulting inflammatory responses may lead to the release of danger signals, which 
directly lead to activation and formation of ASC. More specifically, these results indicated that ASC 
was essential in mounting the memory B-cell responses against monovalent H5N1 influenza 
vaccine, although in an inflammasome-independent pathway, as tested in ASC-/- mice. Absence of 
ASC led to significantly reduced humoral responses due to B-cells not being able to undertake 
class-switching from IgM to IgG [377]. By contrast, immunisation strategies using NALP3-/- and 
caspase-1-/- mice showed no significant differences in humoral immunity, when compared to wild 
type mice, suggesting that ASC contributes to the humoral immunity following H5N1 influenza 
immunisation – independent of inflammasome activation. These results are interesting and open 
new opportunities to investigate novel pathways other than currently known, for example with parts 
of the inflammasome being formed independently of others (i.e. ASC).  
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ATP was shown to be essential in the mode of action of the oil-in water emulsion adjuvant MF59 
[94]. i.m. injection of MF59 (± OVA as model antigen) led to the release of ATP, a danger signal, 
which enhanced the adjuvanticity of MF59. ATP-release was transient and negligible following 
alum, calcium phosphate or incomplete Freund’s adjuvant (IFA) [94]. Interestingly, ATP was 
required by MF59 to induce CD4+ T-cell and secondary antibody responses, but not for primary 
antibody responses, as seen following a reduced inflammatory stimuli in MF59 immunised groups. 
By contrast, neither alum nor IFA required ATP, as shown by the co-administration of the  
ATP-hydrolysing enzyme apyrase [94]. While the source of ATP was not investigated, the authors 
proposed that muscle cells, which are rich in ATP, are most likely the source of released ATP. In 
particular since a local increase of ATP was measured within the first 3-6 min after immunisation. 
This extracellular ATP is likely to attract inflammatory cell infiltration, which was confirmed in a 
separate study, where neutrophils, macrophages, monocytes and DCs infiltrated [373]. This influx 
was also greatly diminished following apyrase administration. Attempts at co-injecting ATP with 
influenza vaccine did not boost the immune responses, suggesting that the immune enhancing effect 
of ATP may depend upon a local extracellular ATP concentration gradient and time-dependent 
release by the cells around the i.m. injection site alongside with cellular recruitment and other 
DAMPs. Of note, McDonald et al. have previously shown that neutrophils migrate towards a 
chemotaxis- and necrotaxis-gradient following the induction of sterile tissue injury with necrotic 
cells [404]. These findings advocate that danger signals other than ATP (e.g. dsDNA, HSPs, 
HMGB-1 etc) are likely to be involved in enhancing the adjuvanticity of MF59. This is in 
agreement with other studies, where alum’s adjuvanticity was linked to extracellular DNA and uric 
acid or MSU [95, 372, 395, 405].  
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Figure 2.11: MF59 mode of action.  
Schematic of the current understanding of MF59’s mode of action. (a) i.m. injection of MF59 adjuvanted antigen into 
humans. (b) Tissue resident immune cells (monocytes, macrophages and DCs) become upregulated and respond to the 
DAMPs and PAMPs by releasing cytokines and chemokines (CCL2, CCL4, CCL5, CXCL8), which lead to increased 
inflammatory cell infiltration. A local inflammatory environment results in inflammatory DCs (iDC) to infiltrate. 
Antigen uptake leads to differentiation into APCs which then transport the antigen into the dLN, where B- and T-cells 
are being activated, leading to antibody production. Image reproduced with permission from [376].  
2.4.2.3 Saponins: Quil-A and QS-21 
QA belongs to the family of saponins, and is derived from the bark of Quillaja saponaria Molina 
from South America [406, 407]. A highly efficient adjuvant, it produces predominantly Th2 
responses but also enhances Th1 responses, along with strong CD8+ T-cell responses to co-
administered antigens [350, 408-411]. However, its toxicity and side effects do not allow its use as 
an adjuvant in humans, prompting local reactions and irritations, granulomas [412] as well as 
haemolysis of cells through pore formation in the cell membranes [413]. However, saponins 
including QA have been used in several veterinary vaccines [406]. Its mode of action is not fully 
understood but several hypotheses have been put forward. In particular, Oda et al. studied the 
relation between haemolytic activities, functional side chains and the resulting adjuvanticity. 
Interestingly, and in contrast to previous reports [413, 414], Oda’s results did suggest that 
adjuvanticity did not correlate with haemolytic activity, but rather their functional groups and the 
overall conformation of the molecules. Within the aglycones (triterpenoids), acyl groups and sugar 
side chains were found not to affect immunogenicity [415]. By contrast, Sun et al. concluded that 
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saponin’s side chains and the glycosyl groups could affect haemolytic activities, adjuvanticity and 
type of immune responses [416]. Moreover, saponins in general have been shown to cause local 
reactions and inflammation [406] along with enhanced cytokine productions [345, 350, 410]. A 
more purified and less toxic version of QA is QS-21 [415], which was shown to induce high 
antibody-specific responses as well as CD8+ T-cell responses against several pathogens including 
HIV-1 and other antigens, and has also been delivered i.d. with BSA into mice [383, 409].  
Li et al. investigated the activation of the NALP3 inflammasome following administration of 
particulate adjuvants that include alum, QA, or chitosan [403]. Administration of uricase did not 
result in a significant difference in immune responses. Although the effects of saponins activating 
the NALP3 inflammasome are currently unknown, and conflicting results of NALP3 activation in 
alum adjuvanted immunisations have been reported (see above, section 2.4.2.1), the results of Li et 
al. are indicative of particulate adjuvant-induced NALP3 inflammasome activation is independent 
of uric acid and MSU released by dying/ dead cells.  
2.4.3 Advantages and disadvantages associated with adjuvants 
The advantages of adjuvants are directly linked to its role to potentiate the response of the immune 
system to an adjuvant by enhancing infiltration and activation of APCs, antigen uptake as well as 
the potential reduction of required antigen [360]. Protein antigens for instance mount an acceptable 
humoral response but only minor, if any, T-cell responses are generally generated. The addition of 
an adjuvant can significantly enhance not only humoral and cellular immune responses as outlined 
above but also broaden the immune responses by mounting responses against hetero-subtypes 
(sections 2.4.1 and 2.4.2). Overall, patients can benefit from addition of adjuvants to vaccines: not 
only may multiple immunisations not be required anymore, but also protection levels are generally 
higher, and more importantly, adjuvantation may enable dose-sparing, which is particularly 
important in influenza pandemics as experienced in 2009 with H1N1 [360].  
With recent advances in vaccine technologies, using predominantly protein and peptide antigens, 
adjuvants are predominantly required to enhance B- and T-cell responses for long-lasting immunity. 
In 2009, the FDA approved a new combinatorial adjuvant termed AS04, a mix of alum and MPL; 
MPL for example stimulates TLR4. First licensed in an HPV vaccine (Cervarix®, Novartis), it has 
recently also been approved for a melanoma vaccine (Canada) and HBV vaccine specifically for 
haemodialysis patients in Europe. One of the most well-known vaccines containing alum is 
Gardasil®, one of the two prophylactic HPV vaccines currently on the market [23]. The addition of 
alum to Gardasil® was necessary to elicit sufficiently high antibody and T-cell responses. Even so, 
 63 | P a g e  
three immunisations are required for prophylactic protection [23]. With the discovery of cell surface 
receptors responding to danger signals (e.g. TLRs and NLRs), several new adjuvants have been 
fabricated stimulating TLR4, 7 and 9 etc [4]. Other TLR agonists currently under investigation as 
adjuvants include CpG (TLR9), flagellin (TLR5) and dsRNA (TLR3).  
Another vital benefit of using adjuvants is that – depending upon the adjuvant type, the species and 
route selected for adjuvanted vaccine delivery [65] – changes to the ratio of Th1:Th2 and/ or CTL-
biased immune responses are possible and can therefore the generate the preferred humoral/ cellular 
response [71]. While saponins [417] have been reported to result in enhanced Th1 responses 
following i.m. or i.n. administration with a DNA vaccine against HIV immunisation experiments 
similar to CpG [51], others reported a more balanced (IgG1:IgG2a ratio) response following the 
mucosal administration of saponins [408]. Further, antigen and species-dependency with 
ginsenosides have also been observed, inducing either Th1 or Th2 responses [418]; ginsenoside 
type Rb1 illustrated Th1 or Th2 responses following pneumococcal polysaccharide vaccine 
administration [419]. By contrast, ginsenoside Rg1 resulted in superior Th2 responses in 
conjunction with increased Th2 and decreased Th1 cytokine expression [420].  
In spite of the many advantages adjuvants bring with them, adjuvants also have several drawbacks, 
which can include fever, arthritis, anorexia, soreness at the injection site, lethargy, increased 
inflammation at the site of administration, granuloma formation (e.g. alum), cell death at the 
injection site (e.g. alum, QA, CFA), excessive reactogenicity for use in humans (e.g. QA, CFA) as 
well as their mode of action not being fully understood yet [13, 95, 360, 383, 388, 395]. For 
example, macrophagic myofascitis (muscle weakness) was first observed and described in 
conjunction with alum-adjuvanted vaccines [421, 422]. Reviews by GSK and Novartis vaccines 
containing adjuvants showed overall a very high safety profile with minor side effects such as 
erythema or pain at the injection site [359, 383].  
Whilst most of the adjuvants currently licensed or in development have been tested i.m., very few 
have been tested in cutaneous immunisation routes. Vitoriano-Souza et al. studied innate immune 
responses following i.d. injections (50 µL) into dorsal skin of mice using multiple adjuvants [186]. 
Cutaneous delivery of IFA, saponin as well as MPL [186] led to cytokine production, leukocyte and 
macrophage influx that were most prominent at the site of administration as early as 1h post 
injection. Delivering multiple adjuvants (MPL, CpG, R837 – also known as Imiquimod, alum or 
combinations thereof) i.d. into murine ears, all adjuvants caused lesions in the skin [206].  
Co-delivering two adjuvants resulted in large ulcerations, extensive inflammation and cellular 
infiltration [206]. Similarly, MPL and CpG also induced lesions although of smaller sizes as well as 
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higher inflammation and cellular infiltration in MPL than CpG. Systematic studies investigating the 
cutaneous tolerability of adjuvants are currently incomplete or not available. This outlines the 
necessity to research tolerable adjuvants for cutaneous immunisations, of either chemical or 
physical origin (e.g. laser-based, MN or NP induced). Other adjuvants, currently being assessed in 
clinical trials or developed under experimental conditions are briefly summarised below in Table 
2.9. Alternative adjuvants are discussed in more detail in section 2.4.5.  
Table 2.9: A collection of adjuvants currently being developed in laboratories or being tested in clinical trials. 
Data collated from [14, 350, 359, 360, 383, 423]. 
Adjuvant  Components Proposed mode 
of action 
Effect on innate/ 
adaptive immune 
response 
Examples 
of tested 
vaccines 
AS01 Liposome-based mix 
containing MPL and QS-21  
TLR4 (MPL), mode 
of QS-21 currently 
not known 
Enhanced antibody 
responses, CD 8+ T-cells (do 
not alter Th1:Th2 responses) 
malaria  
AS02 Emulsion-based mix 
containing Squalene, Tween 
80, α-tocopherol, MPL and 
QS-21  
TLR4 (MPL), mode 
of QS-21 currently 
not known 
Enhanced antibody 
responses (do not alter 
Th1:Th2 responses) 
Tuberculosis, 
HIV/ AIDS, 
malaria, 
hepatitis B  
CAF01 Trehalose dimycolate, 
cationic liposomes 
Mincle Enhanced antibody 
responses, mixed Th1 and 
Th17 responses, CD 8+ T-
cells 
Tuberculosis  
CpG Synthetic DNA 
ologonucleotides containing 
CpG motifs (guanine linked 
by one phosphate to cytosine) 
TLR9 Enhanced antibody 
responses, Th1, can 
stimulate CD 8+ T-cells 
when conjugated 
Hepatitis B, 
therapeutic 
cancer 
vaccines 
Flagellin Flagellin isolated from 
Salmonella typhimurium  
TLR5 Enhanced antibody 
responses, mixed Th1 and 
Th2 responses 
Influenza, 
Plague 
(Yersinia 
pestis) 
Imiquimods 
(R848) 
Imidazoquinoline derivatives 
(synthetic) 
TLR7 and/ or TLR8 
and MyD88-
dependent, activate 
DCs 
Enhanced antibody 
responses, Th1, can 
stimulate CD 8+ T-cells 
when conjugated  
Aldara, tested 
against 
tumours in 
therapeutic 
cancer 
vaccines, 
OVA 
ISCOMs Saponins, cholesterol, 
phospholipids 
TLR-independent but 
MyD88-dependent, 
antigen shuffling into 
cytosol of DCs, 
cytokine and 
chemokine secretion  
Enhanced antibody 
responses, mixed Th1 and 
Th2 responses, can stimulate 
CD 8+ T-cells when 
conjugated 
Influenza, 
recombinant 
dengue virus, 
OVA 
PolyI:C Synthetic derivative of 
dsRNA 
MDA5, TLR3 Enhanced antibody 
responses, Th1, CD 8+ T-
cells 
Influenza, 
hepatitis B 
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2.4.4 Safety concerns  
Adjuvants have been used for ~100 years (alum) and with close to 200 million doses (of oil-in-
water emulsions such as MF59 and AS03) with an overall excellent safety record [359, 383, 424]. 
While earlier adjuvants such as IFA (used in polio and influenza immunisations around the 1950s) 
or ‘adjuvant 65’ had been used successfully used in humans, their use was eventually discontinued 
due to high local reactogenicity or lower adjuvanticity when purified raw materials were used in the 
manufacturing process, respectively [359].  
Of the currently four licensed i.d. vaccines, only the BCG contains multiple TLR agonists (TLR2, 4 
and 9) from the live attenuated Mycobacterium bovis, thus not requiring any additional chemical or 
synthetic adjuvants. Since other vaccines have shown dose-sparing of influenza vaccine delivered 
i.d. over i.m., no need for an adjuvant has been expressed in other i.d. vaccines thus far. However, 
for potential vaccine candidates currently in experimental or clinical trials (delivered i.m., s.c., i.n. 
or i.d.), the lack of FDA-approved adjuvants suitable for use in skin urges the scientific community 
to pursue other avenues to enhance cutaneous immunisation strategies. This is particularly 
important since increased cases of narcolepsy – an incurable sleeping disorder – in children and 
adolescents, following the administration of the AS03-adjuvanted influenza vaccine Pandemrix 
against the 2009 H1N1 pandemic [425-428]. While studies investigating the cause and link of 
Pandemrix are still underway, two key-points have been identified. Firstly, not only that that 
particular strain H1N1 was more immunogenic, but secondly, also AS03 (an oil-in-water emulsion 
made of squalene, Tween-80 and α-tocopherol) was a highly potent adjuvant, suggesting that the 
combination was possibly too immunogenic in the young recipients. These adverse events however 
were not recorded when the pandemic 2009 H1N1 was administered in the USA as unadjuvanted 
vaccine. This may suggest that the adjuvant rather than the antigen may be the cause, unless 
significant differences in the manufacturing process are found. Yet, marginally higher incidences of 
the Guillain-Barré syndrome (nerve inflammation resulting in temporal paralysis) were recorded in 
the USA following administration of unadjuvanted vaccines [429]; this was not seen in Europe. To 
add to this complexity, AS03-adjuvanted H1N1 vaccines administered in Canada and Brazil but did 
not lead to higher incidences of narcolepsy [428]. No link between MF59 and narcolepsy could be 
confirmed.  
Through several studies encompassing clinical trials with humans, it was found that not all 
adjuvants are suitable for every antigen. In particular, GSK developed the RTS,S malaria vaccine 
candidate [383]. With their AS03 adjuvant formulation, only 30% were protected while with AS02, 
over 85% of the recipients were protected [430]. The clinically tested AS02 was prepared from 
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AS03, MPL, a TLR4 agonist and QS21, representing a strong adjuvant mix. By contrast, AS03 
resulted in excellent protection in the young, adults and elderly [360]. Although unadjuvanted, 
analogous side-effects causing febrile seizures occurred following the administration of Fluvax® 
2010 (CSL) [431, 432]. While the studies have not been fully completed yet, it was found that the 
manufacturing process along with three new strains resulted in higher pro-inflammatory responses 
possibly due to higher viral RNA contents (DAMPs and PAMPs) than other split-virion influenza 
vaccines of the same season on the market [431-433]. This further illustrates the importance of safe 
vaccine design in combination with researching safe immune enhancers. In summary, despite a very 
good overall safety record [383, 434], adjuvants still bear certain risks regarding reactogenicity and 
adverse side effects due to new antigen-adjuvant combinations amongst others. Chemical adjvuants 
so far have never being licensed themselves by regulatory authorities such as the FDA as a stand-
alone product. Making use of endogenous immuno-potentiators as currently already in use in form 
of TLR-agonists (e.g. TLR4 in AS04 adjuvanted HPV vaccine Cervarix ®; [382]) may open new 
avenues for vaccination and potentially for diseases for which currently no vaccines exist [388]. In 
particular, if no chemical-based adjuvants have to be added to the vaccine formulation, the 
likelihood of possible adverse events is reduced. 
Due to the reactogenicity of some adjuvants, in particular when delivered cutaneously [186, 206], it 
is important that appropiate safety and efficacy studies are in place [372, 383]. Adjuvants are only 
approved for use as one component in combination with a specific vaccine antigen and other 
specific excipients, for which the entire product is then ‘licensed’ by the FDA. This can result in 
challenges and delays when designing an ideal adjuvant. Preferably, it induces high humoral and 
cellular responses, primes CD4+ and/ or CD8+ T-cells as well as increases antigen uptake without 
inducing excessive inflammation. This exemplifies that replacing chemical adjuvants with e.g. 
physical adjuvantation in form of MN or NP application, may represent a more suitable alternative 
to chemical-based/ synthetic adjuvants, in particular when already licensed vaccines will be 
delivered via a new skin-based delivery method (i.e. MN or NP) [344]. 
2.4.5 Alternative adjuvants 
All current licensed adjuvants are co-licensed with a particular vaccine, given i.m., and many of the 
adjuvants currently under development, have only been tested in i.m. or s.c. immunisations [200]. 
Depending upon the immunisation route, some adjuvants may be more beneficial than others. For 
instance, while some adjuvants such as alum have a good safety record when delivered i.m., 
cutaneous delivery however can cause major irritation and granuloma formation. Very few, if any, 
of those have been tested in skin-based immunisations such as i.d. injections and remain of concern 
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due to their reactogenicity as illustrated by Chen et al. [206, 435]. Administration of CpG, alum, 
MPL, R837 or combinations thereof to murine skin resulted in moderate to high lesion formation in 
addition to local inflammation, with R837 or MPL as combination causing the strongest reactions 
[206]. With such high reactogenicity of adjuvants in the skin, other approaches were explored.  
Although not considered as a ‘classical’ adjuvant, a relatively new form of adjuvant is termed laser 
vaccine adjuvant (LVA) [436], which used laser as a physical adjuvant to enhance responses, with 
several other groups reporting similar findings [437, 438]. First described in the 1990s assisting in 
drug, dye or molecule delivery [reviewed in 204], it was not until Chen and colleagues used a laser 
beam (0.3W for 2 min = 90 J/ cm2), directed against dorsal skin followed by an i.d. injection of 
OVA or influenza vaccine in mice [436], that its adjuvanting effects were recognised. Chen et al. 
measured significantly enhanced humoral (300-500% for OVA-specific antibody and up to 900% 
for influenza-specific antibody responses) and cellular immune responses [436]. This effect 
increased synergistically when co-administered with other adjuvants such as CpG and MPL. This 
boosting effect was effective even when immunisations were conducted several hours post laser 
treatment [435], but not when LVA was distal to the antigen injection site [436]. This suggests that 
spatial co-localisation of LVA with antigen is necessary for the immune enhancer effect. No tissue 
damage was evident by histologic examination (up to 3 days) and no inflammatory cytokine and 
chemokines were detectable by mRNA 6h post laser-adjuvanted immunisation [436]. However, 
some tissue damage was observed at higher power (>180 J/ cm2 or 0.3 W). Inserting an optical fibre 
rather than directing a laser beam into muscle prior to i.m. injections also resulted in better humoral 
and cellular immune responses. Lastly, control experiments excluded a photo-thermal effect by the 
LVA as a significant contributing factor. Using a non-ablative fractional laser, cell death and 
damage was later proposed as a possible explanation due to the induced pro-inflammatory cytokines 
and enhanced immune responses [reviewed in 204].  
2.5 Cell death and its endogenous immuno-potentiators and immuno-
stimulatory effects  
Polly Matzinger stipulated in the 1990s that the immune system is able to differentiate between 
‘self’ of dangerous and non-dangerous origin [439]. Since, this model has been significantly refined 
and extended [440]. Endogenous immuno-potentiators, modulators or stimulants (also known as 
natural adjuvants) can be released from virally infected, stressed, dying or dead cells, but seldom 
from healthy or apoptotic cells [334, 441]. Immuno-potentiators have one common effect: 
increasing the body’s response to particles or molecules released under particular circumstances, 
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thus clearing an infection and cellular debris. As stress, dying and dead cells are the main producers 
of endogenous adjuvants, different cell death types and roles will be discussed, followed by an 
overview of the danger signals, the latter also known as alarmins or DAMPs. 
Cell death forms part of healthy tissue homeostasis (cell turnover) but is also required to defend 
against pathogens, fight injuries and infections, e.g. when NK-cells in innate or CTLs in adaptive 
immune responses kill infected cells. However, dead cells can also stimulate the immune responses, 
leading to a faster and stronger response to antigens or assist in clearing infections. Thus, the 
immune system has developed mechanisms to differentiate between immunogenic and tolerogenic 
cell death. A key point to understand is how the immune system is able to differentiate between 
these two forms as several factors can contribute and define whether cell death is immunogenic or 
tolerogenic and which molecules are immuno-potentiators [441]. For this purpose, an overview of 
the most common forms of cell death and their effects on the immune system is summarised below. 
A review of several endogenous immune modulators and their modes of action are then followed by 
a summary of experimental approaches using dying or dead cells as endogenous adjuvants.  
2.5.1 Types of cell death  
Cell death is defined as when 1) the plasma membrane integrity of a cell is lost and/ or 2) cell and 
nucleus have undergone total disintegration and/ or 3) when neighbouring cells have engulfed the 
fragmented cell [442]. Depending upon the trigger, the most common forms of cell death include 
apoptosis, necrosis, autophagy, pyroptosis and more recently also necroptosis (Figure 2.8). 
Depending upon the type, duration and clearance of dead cells, its effect can be immuno-
stimulatory (secondary necrosis, necrosis, pyroptosis, necroptosis) or -modulatory (apoptosis and 
autophagy) with some exceptions. An overview of the most common and important cell death forms 
occurring in the skin or related to immunogenic or tolerogenic functions are depicted below (Figure 
2.12) and discussed in detail in the following sections. Of note, the different types of cell death can 
occur sequentially as well as concurrently, depending upon the form of cell death and the resulting 
the immune responses.  
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Figure 2.12: Pathways of cell death.  
Cells respond to various stimuli in various ways, depending upon the triggers. Programmed apoptosis is a pathway 
leading to cell death by initiator, then active executioner caspases to cleave cellular substrate without causing 
inflammatory responses. Characteristic morphological changes result in apoptotic bodies being engulfed by phagocytic 
cells, thus avoiding inflammation. In the absence of phagocytosis or massive induced apoptosis, apoptotic bodies may 
lyse and secondary or apoptotic necrosis can occur, thus releasing inflammatory contents into extracellular space. 
Autophagy features degradation of cellular components within the intact dying cell in autophagic vacuoles. The 
morphological characteristics of autophagy include vacuole formation, degradation of cytoplasmic contents, and slight 
chromatin condensation. Autophagic cells can also be taken up by phagocytosis, therefore generally not releasing any 
inflammatory stimulants. Oncosis eventually leads to necrotic cell death, and thus to the release of inflammatory 
cellular contents. Pyroptotic cell death is a programmed form of cell death that is dependent of the protease caspase-1, 
and leads to the release of IL-1β and IL-18, thus a pro-inflammatory pathway. Pyroptosis also features cell lysis and 
release of inflammatory cellular contents and is caspse-1, -7 and -11 dependent. Necroptosis is negatively regulated by 
caspase-8 although RIP-kinase-1/-3-dependent, resulting in an immunogenic pathway. Undoubtedly, other pathways 
exist that have not yet been described. Image reproduced and adapted with permission from [443]. 
2.5.1.1 Cornification cell death in the skin 
Continuous cell turn over occurs in the skin due to constant cell proliferation in the basal membrane 
of the VE. Previously, keratinocytes were believed to undergo an apoptotic cell death due to the 
expression of apoptotic markers such as Bcl-XL, Bcl-2 and Bax amongst others [444, 445]. More 
recently, evidence suggested that cornification, a sophisticated and specialised form of programmed 
cell death by terminally differentiating keratinocytes showed parallels with apoptosis [118]; 
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however, this was disproved by several groups as both events can clearly be distinguished, 
morphologically and biochemically, with corneocytes not being phagocytosed and the absence of 
active apoptotic caspases (i.e. caspase-3,-6,-7,-9) [111, 446, 447]. As skin cornification does not 
exhibit ‘standard’ apoptotic markers and is of non-immunogenic origin, it will not be further 
discussed here.  
2.5.1.2 Apoptosis 
Biologists have become increasingly interested in the role that cell death plays in normal 
development of multi-cellular organisms [448]. Initially described as programmed cell death [449], 
the morphological process of this highly conserved controlled self-destruction was later termed 
apoptosis [450, 451]. As a programmed form of cell death requiring ATP, biochemical events 
within the cell lead to morphological changes, which finally result in apoptosis. Morphologically 
characterised by an overall shrinkage of the cell and nucleus, chromosomal condensation and 
nuclear fragmentation into oligonucleosomes, loss of membrane integrity, loss of adhesion to 
neighbouring cells and blebbing on the cell surface [452-454], the cell membrane remains intact 
throughout this process (Figure 2.12). Subsequently, small apoptotic bodies are formed that consist 
of a plasma membrane bilayer surrounding damaged organelles and DNA fragments which are 
characteristic for apoptosis [455]. This is followed by a rapid phagocytosis of the apoptotic cells 
and apoptotic bodies by macrophages, avoiding any inflammatory response; although more recent 
evidence suggests that some apoptotic cells may cause minor local inflammation due to chemotactic 
molecules attracting macrophages [456, 457]. All these morphological changes are preceded by 
biochemical and molecular events, resulting in a relatively slow process, which can take several up 
to several hours from the onset to completion. While apoptosis is generally considered as a ‘silent 
death’ (i.e. non-inflammatory), there have been reports where inflammation was linked to apoptosis. 
This may be attributed to excessive presence of apoptotic cells that, when not cleared fast enough 
by phagocytosis, may lead to secondary necrosis (Figure 2.12), representing an immunogenic 
rather than tolerogenic cell death.  
One of the earliest measurable markers of apoptosis is activation of activated (cleaved) cysteine-
aspartic proteases, in short caspases that are key players in apoptosis [458-460]. All caspases 
contain a precursor form composed of a pro-domain, that once when activated, results in cleavage 
adjacent to aspartates to liberate one large and one small subunit of 17 kDa and 12 kDa, 
respectively, to form the active caspase-3. Caspase-3 is a key effector caspase with a short pro-
domain in the apoptosis pathway – along with caspase-6 and -7, amplifying the signal from initiator 
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caspases (i.e. caspase-2, -8, -9 and -10) and signalling full commitment to cellular disassembly. 
Further, caspase-3 (one of the hallmark proteins) is converted into its active form within the 
cytoplasm and then enters into the nucleus to exert its function [461]. In addition to cleaving other 
caspases in the enzyme cascade, caspase-3 has been shown to cleave poly(ADP-ribose) polymerase 
(PARP; active form 85 kDa), which enables the disintegration of apoptotic cells and is another 
marker of apoptosis [462]. A pan kinase inhibitor such as Z-FAD-VMAK can stop any caspase 
from its executing pathway. Initiator caspases are in turn activated via cytochrome c release from 
mitochondria as well as ATP, the latter also a possible danger signal. Apoptotic gene expression is 
also controlled by NFκB, which is a ubiquitous transcription factor. NFκB also controls the 
expression of genes involved in immune responses and the cell cycle. NFκB is a protein complex 
involved in cellular responses to stimuli, such as stress and cytokines, and plays a key role in 
regulating innate and adaptive immune responses. Activation of transcription factor NFκB 
suppresses apoptotic signalling by up regulating the expression of Bcl-2, an anti-apoptotic protein 
[463, 464]. Apoptotic signals can lead to two pathways: ‘intrinsic’ (mitochondria-dependent) or 
‘extrinsic’ pathway (death receptor and ligand dependent). The former occurs following contact 
with extracellular stimuli that dependent upon proteolytic activation of initiating and executing 
caspases and subject to regulation by Bcl-2 family proteins, while the latter depends upon receptor-
ligand interactions (e.g. Fas-FasL) interactions for initiation. Various methods of inducing apoptotic 
cell death have been established and include exposure to chemicals, drugs or UV radiation with 
concentrations and exposure times dependent upon the cell line or tissue [335, 357, 393, 465-468].  
2.5.1.3 Autophagy 
Autophagy can exert multiple functional roles, depending upon the cell’s functional state [469]. 
When a cell encounters stress, for example to nutrient starvation and deprivation, miss-folded 
proteins, defective cell organelles or accumulation of intracellular calcium, it quickly assesses the 
new situation to find different ways of adjusting, and thus avoiding (apoptotic) cell death [470]. 
This highly programmed form of cell death adapts to starvation by autophagy, a process in which 
the cell ‘eats itself’ by digesting unnecessary or damaged cell organelles within the cytoplasm 
(Figure 2.12, [471-474]), providing an alternative survival mechanism, especially during limited 
substrate supply. Ryter and colleagues described autophagy as a caspase-independent necrosis-like 
cell death, based upon its physiological appearances [474]. Following formation of an 
autophagosome containing ubiquitinated proteins, cytosol and mitochondria, fusion with a lysosome 
occurs. Degradation of cellular contents by hydrolases has been shown to result in a non-
inflammatory cell death pathway [453, 474]. This can be particularly advantageous in innate and 
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adaptive immune responses such as antigen presentation or bacteria degradation [400, 471, 472, 
475, 476].  
Based on the current knowledge, it has been proposed that some communication enables 
differentiation of up- and down regulation of apoptotic and autophagic proteins [474]. Autophagy is 
highly regulated by Beclin, a multiprotein complex. Beclin however can be downregulated by the 
anti-apoptotic Bcl-2 protein family members or pro-apoptotic caspase-3 [474]. In a separate study, 
epithelial cells subjected to cigarette smoke led to increased autophagic cell death as seen from 
autophagosome formation as well as apoptosis [477]. With recent findings indicating the onset of 
autophagy following necroptosis [478], and some evidence suggesting that autophagy can 
downregulate NALP3 inflammasome activation [479], the complexity of the different types on cell 
death and their effects on the immune sustem becomes evident. To what extent the down-regulation 
of autophagic proteins in inflammatory environments (e.g. tissue injury and cell death) may affect 
the immune system’s responses including inflammasome activation to immunisations requires 
further investigations.  
2.5.1.4 Pyroptosis 
This cell death type was first described in the mid-1990s, when murine macrophages were infected 
with the Shigella flexneri and underwent cell death that was independent of caspase-3, but highly 
dependent upon caspase-1 [480]. It can be stimulated by several microbial infections. Pyro, from 
the Greek meaning fire, describes the highly inflammatory nature of pyroptosis. Later, this highly 
inflammatory cell death was also found to be caspase-7- and -11-dependent but independent of the 
apoptosis caspases including caspase-3, -6 and -8 [400, 443, 474, 481]. Importantly, this cell death 
occurred predominantly in immune cells such as macrophages and DCs. Furthermore, pyroptotic 
cell death exerts common features of both necrosis and apoptosis, such as pore formation, 
cytoplasmic swelling, release of cytosolic contents (thus inflammatory) and secretion of cytokines 
in addition to nuclear fragmentation and DNA condensation, as shown in Figure 2.12 [482, 483]. 
2.5.1.5 Necrosis 
In contrast to the active and defined apoptotic process, necrosis is a passive, catabolic process, 
generally defined as a form of cell death caused by external forces such as mechanical forces, 
injuries, trauma or toxins [454, 484, 485]. Previously thought to be an uncontrolled form of cell 
death, recent evidence suggests a regulation of necrosis by multiple pathways [486-488]. One of the 
most recent publications suggested that necrosis can be subdivided in three isoforms: necroptosis, 
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mitochondrial-permeability-transition-dependent regulated necrosis and Parthanatos [482]. 
Morphologically, necrotic cells are characterised by a loss of plasma membrane integrity, allowing 
an efflux of intracellular ions and fluid, causing a swelling of cell membranes, the cellular 
compartments and resulting in chromatin disruption (see Figure 2.12) [334, 443]. Necrotic cells 
release high amounts of danger signals into the surrounding tissue, cytosolic contents into the 
extracellular milieu with DNA hydrolysis and organelle breakdown resulting in the lysis of the cell, 
evoking a large inflammatory response. This release is equivalent to endogenous danger signals or 
endogenous adjuvants [334].  
Many proteins or molecules released by necrotic cells have been reported to hold adjuvating effects, 
evoking an increased inflammatory response [169, 489-491]. Examples include but are not limited 
to dsDNA, ATP, MSU, HSP, IL-33 etc [169, 489, 492] and will be discussed in more detail in 
section 2.5.3. Several stimuli driving necrosis have also shown to have inhibitory effects on 
apoptotic pathways [470]. Overall, necrosis can be induced by various cell treatments and include 
most commonly exposure to 0.1-0.3% hydrogen peroxide [357, 465, 467, 492], 3-5 cycles of freeze-
thawing in liquid nitrogen and 56 °C water bath [335, 492] or even incubation in ethanol for 10 min 
or ice-cold methanol [493].  
2.5.1.6 Necroptosis 
Due to the same morphological characteristics with necrotic cells, necroptosis has only been 
recently identified as a separate form of cell death [494]. As one of the most recent cell death forms 
described, new pathways, ligands, inducers are reported on a frequent basis. It can be induced by a 
myriad of factors including FAS (CD95), FADD, TRAIL, TNF, IFN-γ, LPS etc but also PAMPs 
such as PolyI:C or LPS amongst others is characterised by its RIPK1/ RIPK3 kinase activities as 
well as negatively regulated by caspase-8 [495-499]. Other stimuli of death receptor ligands and 
microbe-associated molecular patterns have been reported [482]. Necroptosis has been associated 
with several diseases including viral infections, myocardiac diseases and ischemic brain injuries 
amongst others [469, 500]. It has been shown to have an important role in epithelial tissue [501], 
when FADD-/- mice developed significant skin inflammation, which was found to result in 
spontaneous RIPK-3 kinase-dependent necroptosis as well as HMGB-1 release [501]. Moreover, 
RIP1K kinase has been shown to increase inflammasome activation, IL-1α secretion as well as 
apoptosis [496]. Recently, some evidence suggested that HMGB-1 secretion from murine 
macrophages in vitro via TLR4 may be of necroptotic origin [502]. With a steady increase of 
knowledge about involved signalling pathways, cell receptors and required stimuli [496, 498, 502-
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507], a clear definition, identification, characterisation and contribution of necroptosis to 
vaccination studies in vivo in mice is yet to be established. A summary and comparison of the 
different cell death types has been summarised in Table 2.10. 
Table 2.10: Overview of cell death.  
Types and characteristic accompaniments followed by the four main cell death types. Not shown are cornification and 
autophagy. Information summarised from [441, 462, 498, 502-504, 508-510].  
Differentiation Apoptosis Pyroptosis Necrosis  Necroptosis  
Induced by Programmed cell 
death  
Programmed cell death, 
caspase-1, various other 
stimuli 
Sudden mechanical, 
physical, chemical 
insult 
Programmed cell 
death, induced by 
RIP1/RIP3, and 
various other stimuli 
Programmed (ATP 
dependent) cell 
death 
    
Cell morphology Swollen, apoptotic 
bodies (blebbing of 
membranes), 
nucleosomes, 
nuclear 
condensation, DNA 
fragmentation 
Loss of plasma membrane 
integrity, release of 
cellular contents, cell size 
increase, nuclear swelling 
& condensation, DNA 
fragmentation (nuclear 
integrity maintained); cell 
lysis 
Cell volume gain, 
rupture of cell 
membrane, release 
of cellular contents, 
DNA fragmentation; 
cell lysis 
Cell volume gain, 
rupture of cell 
membrane, release 
of cellular contents; 
cell lysis 
Caspase-dependent     
Inactive (cleaved) 
PARP 
  (independent of PARP)   
Active (cleaved) 
caspase-3 
    
Active caspase-1      
Active caspase-7      
Active caspase-11      
Caspase-8     
Cytochrome c 
release 
   ? 
Kinase-dependent      (RIP1, RIP3) 
Upregulated genes 
(Bcl-2, Bax etc) 
    (possible if 
apoptotic cells 
switch to 
necroptosis)  
Inflammatory/ 
Cytokine 
production  
    
Pathways Intrinsic, extrinsic Caspase-1 and -11 
dependent 
Caspase-
independent 
Caspase-
independent, 
although some 
evidence suggests 
caspase-8 
dependency 
Immunogenic      
Tolerogenic      
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2.5.2 Adjuvants and cell death 
Apoptotic and necrotic cells have been reported to act as immune-stimulants by releasing DAMPs 
that led to enhanced cellular and humoral immune responses to antigen [358, 441, 511-513]. 
Similarly, chemical adjuvants have shown to induce cell death and danger signals upon 
administration which can act as strong endogenous immune-stimulatory agents [357, 358, 439, 467, 
514]. Several studies have shown that adjuvants such as alum can induce (necrotic) cell death at the 
site of injection [95, 395]. In addition to inflammatory cells infiltrating to the injection site (e.g. 
neutrophils), an increased level of dying and dead cells is expected at later time-points due to 
inflammatory cells apoptosing or dying by programmed necrosis (necroptosis). Neutrophils in 
particular have a very short life span once activated and some – amongst other cells – will apoptose 
at the injection site. This has been observed with QA, when injected i.d. (see Figure 7.1). Not only 
were significantly higher levels of cell death observed several hours after administration in 
comparison to saline or influenza immunised groups, but this also correlated with enhanced immune 
responses and an infiltration of macrophage-derived cells (MacGreen mice) and inflammatory cells 
(neutrophils, macrophages, monocytes and DCs; Figure 7.2 and Figure 7.3) following 
immunisations with Fluvax®.  
Recently, a study by Wilson et al. investigated in more detail the mode of action of the adjuvant 
ISCOMatrix [386]. Not only did they find that ISCOMatrix activated the NALP3, ASC, Caspase-1 
inflammasome in APCs, which then resulted in IL-1β and IL-18 secretion, but also that ISCOMatrix 
induced rapid cellular ATP depletion and cell death in ex vivo studies using macrophages. 
Separately, laser-based adjuvant (LVA) has been described as a physical adjuvant using a laser 
beam against skin followed by an i.d. injection of OVA or influenza antigen in mice that enhanced 
significantly humoral and cellular immune responses similar to an adjuvant [436] and was 
synergistically enhanced by the addition of chemical adjuvants [206]. No tissue damage was evident 
by histologic examination and no inflammatory cytokine and chemokines were detectable by 
mRNA 6h post laser-adjuvanted immunisation. LVA-treatment was able to maintain its potentiating 
effect even when immunisations were conducted several hours after the laser treatment; although 
co-localisation of antigen with LVA-site was indispensable [435]. Using non-ablative fractional 
laser, cell death and damage were later suggested as a possible explanation for enhanced 
immunogenicity due to the induction of pro-inflammatory cytokines and inflammatory tissue 
[reviewed in 204]. Danger signals and IL-1β and IL-18 had not been investigated but are likely to 
be released by stressed or dying cells. While not all adjuvants induce immediate (e.g. necrotic or 
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necroptotic) cell death, it is clear that stressed, dying and dead cells release danger signals which 
have shown to activate inflammasomes [169, 489].  
Reports of needle insertions inducing local trauma in the skin post wound-suturing have recently 
emerged [515]. It has been suggested that sutures after operations or on larger wounds may increase 
local inflammation and skin trauma [515], potentially leading to (apoptotic and necrotic) cell death 
in the affected areas. Gopee et al. [247] investigated the effect of different tattooing inks in murine 
skin and different levels of cell death were evoked by the dyes. However, control groups receiving 
plain needle insertions or saline injections were not included. Thus, it is difficult to differentiate 
between the induced trauma and cell death by the ink versus induced by the tattooing device. 
Further, localised cell death was observed following hypodermic needle insertion into rat striatum 
(part of the fore brain) but was not investigated in regards to immunogenicity studies [516]. This 
finding correlated well with the results presented in this doctoral thesis [344]. Cell death resulting 
from ballistic delivery of micro-particles to the skin was recently reported [242]. Interestingly, cell 
death was also observed within 10 µm of the cell even though the micro-particles did not come into 
contact with the cell, suggesting that high micro particle density and shock waves or stresses can 
result in non-viable cells within the targeted area.  
Separately, different electroporation parameters were tested to assess their effects on skin viability 
in DNA vaccine delivery studies in rabbits [217]. The skin viability was unaffected post 
electroporation although inflammatory responses within the epidermis were observed 
microscopically and returned to baseline levels within one week. Using ultrasound for non-invasive 
transcutaneous drug and gene delivery, apoptotic and necrotic cell death were seen within 6h post 
sonication [214]. This ultrasound-induced cell death was significantly reduced by chelating cells 
with Ca2+ [214]. It was proposed that the chelating effect of Ca2+ assisted the cells to return to their 
homeostasis via removing excess internalised Ca2+.  
Clearly, the above mentioned studies outline the importance of investigating danger signal release 
from stressed, dying or dead cells as a potential endogenous danger signal modulator in vaccine 
delivery. To the best of the author’s knowledge, no reports have been published studying and 
quantifying DAMP release and cellular damage upon needle insertion or MN application into skin 
concurrent with vaccine delivery. Their possible immuno-stimulatory effect leading to enhanced 
immune responses shall be investigated.  
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2.5.3 Immunological and immuno-modulatory effects of danger signals  
To differentiate between immunogenic and tolerogenic cell death, the immune system has 
developed mechanisms to differentiate these [441]. A key point to understand is how the immune 
system is able to differentiate between these two forms as several factors can contribute or define 
whether cell death is immunogenic or tolerogenic [reviewed in 441].  
When infection, tissue damage or trauma occurs, an inflammatory cascade is triggered by the innate 
and adaptive immune system [517]. However, damaged cells can also release molecules emitting 
danger signals, also known as endogenous adjuvants. Examples thereof include extracellular DNA, 
ATP, cytokines, HSPs, oxidised mitochondrial DNA, HMGB-1, phosphatidyl serine (PS; flips to 
outer leaflet of plasma membrane). Danger signals can also be received in form of released in form 
of proteins (HMGB-1, HSP), nucleic acids (oligonucleotides, nucleosides) and degradation products 
like MSU – all with known danger indicating properties [334, 470, 517-519]. For instance, necrotic 
cells may expose molecules like actin filaments [520-522]. The DC receptor Clec9A, expressed on 
pDCs and CD8+ DCs [173], was recently found to bind f-actin as mechanism in response to necrotic 
cell death [520, 522, 523]. Targeting protein or OVA-plasmid vaccine conjugated to Clec9A have 
resulted in improved humoral responses in addition to increased CD4 T-cell proliferation, 
prolonged antigen presence in the blood alongside with prolonged acquisition of antigen by DC 
[173]. A list of the most common DAMPs, involved receptors and proposed mode of action (if 
known) is given below (Table 2.11).  
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Table 2.11: Overview of the most common danger signals (DAMPs) released by stressed, damaged, dying or dead cells.  
Danger signal  Relevant background information How released Known receptor(s) Reference(s) 
ATP ATP released by dying cells can activate macrophages, was shown to result 
in NALP3 activation and IL-1β secretion 
Autophagy, 
nutrient 
deprivation, 
necrosis 
P2X7, P2Y2, P2RX7 [404, 524] [94, 
525], 
DNA/ RNA  (mitochondrial) DNA can activate neutrophils as well as macrophages;  Necrosis, 
necroptosis, 
pyroptosis 
DNA: TLR9, AIM2 
RNA: TLR3/7/8  
[526-528] 
F-actin Clec9A receptors on DCs recognise F-actin filaments from exposed 
cytoskeletal proteins of damaged or dead cells. 
Necrosis, 
apoptosis 
Clecl9A on CD8a+ 
DCs 
[520] 
HMGB-1 Released passively from apoptotic or necrotic cells as well as actively 
following cytokine stimulation. HMGB-1 can form complexes with RNA, 
DNA, LPS, IL-1b, CXCL12, nucleosomes etc. HMGB-1 can bind to different 
cell surface molecules such as receptor for advanced glycan end products 
(RAGE), TLR2, 4, 9, IL-1R, REM1 etc depending upon what HMGB-1-
complex formation is present; can attract various immune cells and result in 
DC activation 
Necrosis 
(minimally 
apoptosis) 
TLR2/4/9, RAGE, 
TIM-3, TREM1 
[526, 529-531] 
HSPs  
(HSP70, HSP90) 
Endogenous proteins, respond following temperature increase, oxidative 
stress and other stresses; can attract neutrophils and monocytes, can activate 
macrophages and DCs via TLR4 and/or TLR2, can activate NK cells 
Necrosis, 
apoptosis 
TLR2/4 amongst 
others 
[532-534] 
[187, 527, 
535] 
Uric acid crystals/ 
MSU 
MSU is the crystalline form of uric acid, results in DC maturation and 
activation as well as inflammatory cell attraction (in particular neutrophils) 
Necrosis, 
apoptosis 
 NALP3 [394, 396] 
S100 units (S100A8, 
S100A9, S100A12) 
Antimicrobial heterodimeric complexes, pro-inflammatory activity, attract 
neutrophils and monocytes 
Necrosis RAGE [528] 
Interleukins (IL-1α, 
IL-1β, IL-18, IL-33) 
IL-1α is a cell-specific DAMP with strong pro-inflammatory characteristics; 
ILs are secreted following conversion of the pro-forms (IL-1 and IL-18) into 
their mature forms via caspase-1 activation.  
Necrosis IL-1R, IL-18R, ST2 
(IL-33) 
[386, 536-540] 
SAP130 Forming part of the small nuclear ribonucleoprotein (U2 snRNP) within the 
nucleus in viable cells; is released from necrotic cells, but not from live or 
early apoptotic cells. 
Necrosis, late 
apoptosis 
Mincle (Clecl4E) [527, 541] 
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Some DAMPs can exert dual functions such as represent intracellular transcriptions factors but also 
act as an extracellular inflammatory mediator; examples thereof include IL-1α and IL-33. Others 
are released by both living and dying cells, although in higher concentration by dying cells such as 
HMGB-1 [169]. As a sentinel for nucleic acids, HMGB-1 can form HMGB-1-nucleic acid 
complexes [526]. Depending upon the cellular release form of HMGB-1, its redox status may 
display chemo-attractant properties (active secretion, reduced HMGB-1), lead to cytokine-secretion 
(disulphide HMGB-1) or evoke no effects on the immune system (passive release of oxidised 
HMGB-1) [531, 542]. DAMPs, when exposed to surroundings cells (e.g. HSP on the cell’s surface) 
can facilitate antigen capture and thus enhance presentation after DC uptake; or with HSP on the 
surface, an interaction between dying cell and the engulfing APCs might be enhanced [reviewed in 
441].  
Many studies have investigated the potential of apoptotic cells activating DCs. Necrotic cells have 
also shown to induce DC and macrophage activation [335, 543, 544]. ‘Natural’ adjuvants in form of 
direct stress or signals from necrotic cells have shown that immature DCs are able to capture 
apoptotic and necrotic cells, but only exposure to necrotic cells induces DC maturation [334, 545]. 
More precisely, Gallucci et al. [334] showed that only necrotic but not apoptotic cells release HSP, 
induced DC maturation. Further, HSP70 showed to be able to protect cells from stressors and 
against several apoptotic and necrotic cell death inducers [335, 533, 546-548].  
As seen with many adjuvants, local increase of DAMP concentration also leads to cellular 
infiltration (monocytes, macrophages, neutrophils, APCs) which in turn further increase local 
secretion of pro-inflammatory cytokines, in particular IL-1α, IL-1β, IL-18 and IL-33. Overall, any 
immunogenic cell death type (necrotic, pyroptotic, necroptotic) can release DAMPs which evoking 
a local inflammatory response, resulting in a potentiating effect on co-administered antigens. Of 
note, some DAMPs like HMGB-1, can bind to several cell surface receptors (see Table 2.11) which 
can alter the immune responses or favour one response over another.  
Other important components within the skin contributing to the immune sentinels are the so-called 
inflammasomes. The inflammasome is a cytosolic multi-protein complex found in all myeloid cells 
that is able to sense various DAMPs and PAMPs. Since its first discovery, over 20 inflammasomes 
have been identified, including NALP1, NALP2, NALP3 (also known as NLRP3 or cryopyrin) 
[400], AIM2 (senses dsDNA) [549], IPAF [400] ASC [550] amongst others; NALP3 is currently 
the most characterised inflammasome [50] and commonly described in the skin as well as in 
relation to danger signals and adjuvanting effects [95, 386].  
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More specifically, the inflammasome complex is composed of the NALP3 scaffold: a NACHT-, 
LRR- and NALP family member that acts as a sensor for danger signals and the adaptor protein 
apoptosis-associated speck-like protein containing a CARD domain (ASC), which allows the 
recruitment of caspase-1 in the complex [187, 401, 551]. Several NLRs (NALPs and IPAF) together 
with ASC form a caspase-1-activating multi-protein complex, the inflammasome, which leads to the 
activation of caspase-1 that cleaves the pro-inflammatory cytokines pro-interleukin-1β (IL-1β) and 
pro-IL-18 into their active form and their subsequent secretion by activated macrophages [552].  
Several studies have shown that the NALP3 inflammasome can be activated by danger signals [50, 
396] and/ or necrotic cells [553], leading to an increased IL-1β and IL-18 secretion. Both cytokines 
play a central role in the pathogenesis and the course of inflammatory skin diseases. While post-
transcriptional activation of IL-1β can be mediated by inflammasomes, the mechanisms triggering 
IL-1β processing remain unknown. NALP3 activation can occur through several stimuli including 
danger signals such as ATP released by dead (necrotic) cells; it was also shown to be required for 
protective immunity against Influenza and other pathogens [536]. Further information the reader is 
referred to excellent reviews [398, 403, 551, 553, 554]. As previously mentioned, NALP3, ASC and 
caspase-1 were identified as essential factors in the adjuvanting effect that alum exerts [95]. OVA-
specific IgG1 antibody titres were significantly reduced in NALP-/-, ASC-/- and caspase-1-/- mice. By 
contrast, studies with MyD88-/- mice did not show any decrease in antibody production. The roles of 
the inflammasome(s) in protective immunity provide new and encouraging platforms to research 
new inflammasome-activating adjuvants. Further, studies by Yang et al. [357, 467, 514] showed 
that vaccine adjuvants can induce apoptotic and necrotic cell death, thus having the potential to 
impact the design of future vaccine adjuvants to manipulate a desired immune response.  
Disruption of the epidermis by scarification has also been demonstrated as essential for the 
elicitation of the vaccinia virus-mediated immunity and protection against challenge, whereas i.m. 
delivery was not protective [207]. Later, the skin scarification was found to be the essential 
component of eliciting higher humoral and cellular responses coupled to protection following lethal 
challenge studies [356]. Separately, as a result of tissue injury, neutrophils are the first cells 
recruited from the blood to the site of insult within minutes, predominantly via the P2X7 receptor 
[404, 555]. As seen in sterile inflammation studies, necrotic cells at the site of injury release ATP 
that activate the NALP3 inflammasome and further enhance neutrophil activation and immigration 
[404]. Neutrophil recruitment was dependent upon released ATP by necrotic cells at the site of 
injury, which in turn activated the NALP3 inflammasome. This requirement of released ATP and 
NALP3 was confirmed by significantly impaired neutrophil presence following the use of apyrase 
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(enzyme hydrolysing extracellular ATP) as well as Nalp3-/-, ASC-/- and P2X7R-/- mice [404]. 
Interestingly, neutrophil recruitment was restricted to ~150 µm around the tissue injury site. 
McDonald et al. suggested a necrotaxis and chemotaxis gradient from the necrotic cells, which 
maintain the inflammation and neutrophil infiltration local and centralised around the tissue injury 
[404] as schematically depicted below (Figure 2.13).  
 
Figure 2.13: Chemotaxis and necrotaxis following tissue injury result in neutrophil recruitment to the site of 
injury and necrotic cell death.  
Necrotic cells release DAMPs (e.g. ATP) which leads to IL-1β release by macrophages. Different concentrations of 
chemo-attractants and CXCR2 ligands lead neutrophils first into proximity of the necrotic cells (the chemotaxis zone), 
which can then be further attracted closer to the site of necrotic cell death (necrotaxis) by FPR1 ligands released by 
dying cells. Adapted from [556].  
Endogenous adjuvants in form of direct stress or signals from necrotic cells have shown that 
immature DCs are able to capture apoptotic and necrotic cells, but only exposure to necrotic cells 
induces DC maturation [334, 545]. More precisely, Gallucci et al. [334] showed that only necrotic 
but not apoptotic cells release HSP, inducing DC maturation. Further, HSP70 showed to be able to 
protect cells from stressors and against several apoptotic and necrotic cell death inducers [335, 533, 
546-548]. Additionally, necrotic but not apoptotic lysates induced translocation of NFkB to the 
nucleus activating DCs and subsequently the NFkB pathway [335] which is involved in organism’s 
responses to infection, stress or injury [557]. This is in agreement with current knowledge that 
danger signals from necrotic cells stimulate cytokine production and secretion, triggering a cascade 
of inflammatory events.  
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An apoptosis-inducing Bax plasmid was co-administered i.d. with an antigen-expressing plasmid 
and resulted in significantly elevated humoral and cellular responses to DNA vaccines [511]. 
Transfected cells were limited to the injected area with apoptotic cells providing a danger signal to 
resident and immigrating DC with no tissue damage. Similarly, the efficacy of apoptosis as an 
immuno-stimulant for a DNA vaccine against HIV was examined by inducing different levels of 
caspase expression [558]. The apoptotic activity of the selected mutant appeared to be too strong to 
increase immune responses or protective immunity against HIV infections. Appropriate levels of 
apoptosis appear to be favourable to enhance immune responses under specific conditions. Another 
study by Kojima et al. constructed bicistronic DNA vaccines that encode for HIV env and caspase-3 
mutant (casp3m) that are expressed via the encephalo-myocarditis virus internal ribosomal entry 
site (IRES) or cytomegalovirus (CMV) promoter-dependent translations [558]. While IRES-casp3m 
induced weak apoptosis and caused little reduction in antigen expression, CMV-casp3m elicited 
strong apoptosis and led to a marked decrease in the antigen expression. Therefore, IRES-casp3m 
augmented HIV-specific immune responses, and IRES-casp3m induced significant protection 
against the vaccinia-HIV chimeric virus. This suggests that excessive amount of cell death can have 
negative effects on the subsequent immune response.  
While apoptotic and necrotic cells have been injected or co-administered to boost the immune 
response – there are currently no studies investigating cell death caused by needles in the field of 
vaccine delivery. Profiting from the danger signals released following NP application to skin could 
induce endogenous adjuvants high enough or similar to chemical adjuvants – without the side 
effects and reactogenicity commonly encountered with adjuvants.  
2.6 Summary of literature review 
A new era of novel vaccines and alternative delivery routes via the skin brings along new 
opportunities and challenges regarding their safe delivery and enhanced immunogenicity, which has 
been responded to by the vaccine community. This literature review has given an overview of 
vaccination in general with a particular emphasis on current skin-based vaccination methods in use 
or being trialled to overcome existing challenges in delivering vaccine into the skin. The key 
limitations of current vaccine delivery by needle and syringe include but are not limited to: 1) large 
doses of antigens ± adjuvants required to elicit strong protective immunity; 2) cutaneous vaccine 
delivery is difficult with current immunisation tools; 3) current adjuvants predominantly not 
suitable for cutaneous delivery due to reactogenicity; 4) needle and syringe produce hazardous 
waste, transmitting blood-borne diseases and causing needle stick injuries; 5) reduced patient 
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compliance due to pain or needle phobia; and 6) high costs per vaccine dose limiting availability of 
the vaccine to areas of greatest need. This demonstrates that advances in cutaneous vaccine delivery 
techniques are highly sought after.  
Due to its large surface area and accessibility, along with the demonstrated dose-sparing potential 
and fast antigen uptake and processing by dDCs, the skin offers many advantages over conventional 
immunisation sites. Whilst common understanding supports that specific immunisation devices are 
required to deliver vaccines into the skin, new challenges such as suitable vaccine formulations, 
thermo-stable and skin-friendly adjuvants are yet to overcome. As currently no adjuvants exist that 
have been licensed by the FDA for use in skin, the search for an appropriate and safe immune 
enhancer is the focus of several research groups. Although others have presented LVA as safe 
alternative to adjuvant immune responses, this approach may not be suitable for developing 
countries or countries with poor medical coverage. Thus, instead of proposing new skin-tolerable 
adjuvants, an alternative embraces to use the immunisation device itself as a potential immune 
enhancer. To the best of the author’s knowledge, this has not been previously explored based on the 
published literature. Assessing the local damage inflicted by the immunisation devices themselves 
and dissecting the resulting innate immune responses and associated DAMP release provide 
fundamental opportunities in designing a new vaccine delivery approach: i.e. a skin-based 
immunisation device, resulting in dose-sparing, better patient compliance and ‘controllable’ 
adjuvant in form of cellular damage/ death induced by the immunisation devices itself as a physical 
immune enhancer.  
Here, the NP is being proposed as a physical immune enhancer for skin-based vaccine delivery. 
This is based on existing immunogenicity data showing >100-fold unadjuvanted dose-sparing and 
~900-fold adjuvanted dose-sparing with influenza vaccine over i.m. Manufactured from silicon 
[348] or CMC if dMN are to be used [280], both substances that have been approved for use in 
humans by the FDA, thus have a good safety record. However, the underlying mechanism(s) are yet 
to be elucidated. The evidence of endogenous danger signals amplifying humoral and cellular 
responses similar to adjuvants together with existing immunogenicity results by the NP form basis 
of the thesis’ underlying hypothesis that tissue damage and cell death caused by delivering 
vaccines into the skin using the Nanopatch™ would have a direct impact on enhancing 
influenza-specific antibody responses as well as the inflammatory innate immune responses.  
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2.7 Scope of the thesis 
According to the available published literature, no research has been found investigating the cell 
damage caused by hypodermic needles and syringes or MN with regards to vaccine delivery and 
immunogenicity, despite cell death being shown to increase immune responses in immunisation 
studies [247, 392, 516, 558, 559]. Thus, based on the current gaps found within the literature, the 
work of this doctoral thesis aims to investigate the cell death profiles in the skin following NP 
application in comparison to i.d. injection. This will link the effects of locally induced cell and 
tissue damage by immunisation devices with innate and antibody-mediated immune responses 
induced by the NP and i.d. injections. Investigating cell death types and DAMP release will 
contribute to the impact of immunogenic cell death and danger signals in vaccine delivery. This 
doctoral thesis will investigate whether MN-based devices such as the NP could be used as an 
alternative physical immune enhancer in vaccine delivery by inducing controlled levels and/ or 
forms of cell death. Overall, the broader scope of this thesis is to expand our current knowledge in 
skin immunisations and how device-inflicted cell damage and death could act as a physical immune 
enhancer.  
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Chapter 3  
Materials and methods 
3.1 Materials 
3.1.1 Animals  
Inbred specific pathogen-free female and male mice were obtained from University of Queensland 
Biological Resources Unit (UQBR) at the University of Queensland (UQ, St Lucia, QLD, Australia) 
and housed in the animal facility within the Australian Institute for Bioengineering and 
Nanotechnology (AIBN), University of Queensland, Brisbane, Australia. All mouse handling and 
experiments were performed following protocols approved by the Anatomical and Biological 
Science Animal Ethics Committee (Animal ethics protocol 520/08, 020/10 and 566/12), and in 
accordance with the guidelines of the Australian Code of Practice for the Care and Use of Animals 
for Scientific Purposes. Unless otherwise stated, n=5 were used per group for all experiments. 
Animals were euthanized by cervical dislocation or CO2 asphyxiation (prior to cardiac bleeds).  
Table 3.1: Inbred mouse stains used. 
Mouse strain Designation Age Sex Source/ Reference Chapters 
Balb/c (H-2Kd) Balb/c 6-8 weeks Female ARC, Australia 4, 5, 6 
C57BL/6J  
(H-2Kb) 
C57 6-8 weeks Female ARC, Australia 5, 6, 7 
Tg(Csf1r-EGFP) 1Hume  MacGreen 6-12 weeks Male and 
female 
IMB1, UQ, 
Australia 
4, 7 
ICE-/- Caspase1-/- 
Caspase11-/- C57BL/6J 
(H-2b) [560] 
Caspase1-/-  6-8 weeks Female Stacey lab2, UQ, 
Australia 
7 
Guscott TLR4 -/- 
RAGE-/- C57BL/6J (H-
2b) 
TLR4-/- / 
RAGE -/- 
6-12 weeks Female Phipps lab3, UQ, 
Australia 
7 
NALP3-/- on C57BL/6 NALP3-/- 6-12 weeks Female Schroder lab4, UQ,  7 
                                                 
1 Kindly provided by the IMB at the University of Queensland (UQ), Brisbane, Australia 
2 Kindly provided by Dr. Kate Stacey, UQ, Brisbane, Australia 
3 Kindly provided by Dr. Simon Phipps, UQ, Brisbane, Australia 
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Caspase-1-/- mice were also deficient in caspase-11, resulting in an inability to process the pro-
forms of IL-1β and IL-18 into mature IL-1β and IL-18 [459]. MacGreen mice express enhanced 
green fluorescent protein (eGFP) in within the myeloid lineage including trophoblasts and 
granulocytes as well as all neutrophils, monocytes and differentiated macrophages and LC) from 
bone marrow, blood, intestine, liver, lung and spleen [561], enabling us to study the extent of 
monocytes, neutrophils and macrophages forming part of the dead cell populations. MacGreen mice 
originated from the Hume lab from the IMB (UQ), where transgenic C57BL/6 x CBA F1 mice 
expressed eGFP under the control of the murine M-CSF receptor promoter (csf-1r; c-fms) [562], 
which were crossed with albino Quackenbush Swiss mice. Homozygous offspring were termed 
MacGreen mice [561]. Co-localisation of CD11b with eGFP was indicative of gene expression 
being restricted to myeloid cells. Breeding pairs of MacGreen mice were housed at the IMB and 
homozygous offspring transferred to AIBN’s animal facility.  
3.1.2 Nanopatch™ fabrication 
The NP was fabricated from (1 0 0) silicon using a Deep Reactive Ion Etching (DRIE) process at 
the University of Queensland [2, 348]. The etched silicon was diced to 4x4 mm with approximately 
3364 densely packed projections with a density of >20,000 per cm2 (70 µm spacing, 110 µm length, 
28 µm base diameter). Different projection densities and thicknesses were obtained by using 
different density masks or dot width on the masks in the DRIE process. For all wafers, uniform 
projection morphology was confirmed by Scanning Electron Microscopy (see section 3.3.1).  
3.1.3 Chemicals, reagents and solutions  
3.1.3.1 Chemicals 
Unless stated otherwise, all chemicals were of analytical reagent grade and purchased from 
Invitrogen (including Gibco BRL and Life Technologies; Melbourne, Victoria, Australia); Promega 
Ltd (Madison, WI, USA); Roche (formerly Boehringer Mannheim; Mannheim, Germany); Sigma 
Aldrich Chemicals (St. Louis, MI, USA) and UNIVAR (Ajax Chemicals; NSW, Australia) and 
were stored and used as per manufacturer’s instructions. Water for all media and solutions was 
purified by reverse osmosis (ELGA PURELAB Classic; ELGA LabWater/ Veolia Water VWS 
(UK) Ltd., High Wycombe, UK) to a resistance of 18 mega-ohms and termed Milli-Q water. 
Deionised water was abbreviated as DI H2O and distilled water was used where indicated. Standard 
lab reagents have been listed in Table 3.2 below. 
                                                                                                                                                                  
4 Kindly provided by Dr. Kate Schroder, UQ 
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Table 3.2: Standard lab reagents. 
Reagent name Chemical 
formula 
Concen-
tration 
Grade Manufacturer 
Methanol CH3OH 100% AR RCI Labscan LTd (AR1115) Bangkok, Thailand 
 
Ethanol  C2H5OH 100% AR Fronine Laboratory Supplies (JJO0AB52.5P) 
Taren Point, NSW, Australia. Lower 
concentrations were diluted in DI H2O 
 
Acetone  C3H6O 100% AR Emsure ACS (1000142511), Merck KG, 
Darmstadt, Germany  
 
Hydrochloric acid (37%) HCl 37% AR Sigma (435570-2.5L), St. Louis, MI, USA 
 
Glycerol C3H5(OH)3 100% AR Univar (242-2.5 PL), Ajax Fine Chemicals Pty 
Ltd., Taren Point, NSW, Australia 
 
3.1.3.2 Vaccines 
Seasonal influenza vaccine solutions (Fluvax®) from purified, inactivated, split virions (split virus) 
were purchased from CSL Biotherapies (Melbourne, VIC, Australia), containing 15 μg 
haemagglutinin (HA) per 0.5 mL of each of the following viral strains as outlined in Table 3.3. 
According to the manufacturer’s information, viral preparation and growth took place in the 
allantoic cavity of embryonated eggs, and purified by zonal density centrifugation, followed by 
chemical inactivation using by β-propiolactone and disruption using the detergent sodium 
taurodeoxycholate.  
Table 3.3: Contents of seasonal influenza vaccine solutions used in this thesis (prepared and distributed by CSL).  
Vaccine Strains included 
Fluvax® 2010  
(used in Chapter 6 and Chapter 7) 
A/California/7/2009 (H1N1 like) 
A/Perth/16/2009 (H3N2 like) 
B/Brisbane/60/2008 like) 
 
Fluvax® 2011  
(used in Chapter 7) 
A/California/7/2009 (H1N1 like) 
A/Victoria/361/2011 (H3N2 like) 
B/Wisconsin/1/2010 like) 
 
3.1.3.3 Adjuvants 
Purified saponin (Quil-A, Superfos Biosector, DK-Vedbaek, Denmark) was prepared at 10 mg/ mL 
in endotoxin-free DI H2O and diluted to 3 µg final dose in saline in immunisations based on 
previous studies [350].  
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3.1.3.4 Buffers 
Buffers are listed below with referral to their use in this thesis. 
Table 3.4: Receipes of buffered solutions used in experimental work.  
Buffer Ingredients Total volume pH  Sections 
10x PBS 8.9 g anhydrous NaH2PO4 (Univar Ajax Fine 
Chemicals; 1.9 mM) 
25.5 g anhydrous Na2HPO4 (Fluka; 8.1 mM) 
70.1 g NaCl (Sigma, S9888; 154 mM) in 1 L DI H2O. 
1xPBS diluted in DI H2O 
 
1 L in DI H2O 7.2-7.4 using 
1M NaOH 
or 1M HCl 
3.2.4, 
3.2.7, 
3.2.10-
3.2.17 
10x TBS 2 g KCl (Sigma; 0.02 M) 
30 g Tris base (Fluka; 0.25 M) 
1.27 M NaCl (Sigma; 0.15 M) 
1xPBS diluted in DI H2O 
 
1 L in DI H2O 7.4 using 
1M HCl  
3.2.6 
20x TBS  
 
Alternatively, 20x TBS was obtained from Amresco 
(Solon, OH, USA).  
1xPBS diluted in DI H2O 
 
1 L premade N/A 3.2.6 
1x PBST Addition of 0.02-0.5% v/v Tween 20 (Sigma; St Louis, 
MO, USA) to 1x PBS.  
1 L in PBS 7.2-7.4 using 
1M NaOH 
or 1M HCl 
3.2.7, 
3.2.14, 
3.2.11  
 
1x TBST Addition of 0.02-0.5% v/v Tween 20 to 1x PBS. 
 
   
0.1 M 
NaHCO3 
0.84 g sodium hydrogen carbonate (Sigma, S5761-
500g, NaHCO3)/ 0.1 L DI H2O, filtered through a 
0.2 µm filter (Pall, Acrodisc syringe filter, super 
membrane, low protein binding, non-pyrogenic, 
PN4612) to remove particulate matter. 
 
0.025 L in DI 
H2O 
N/A 3.2.14 
 
TBS instead of PBS was used when the detection system used alkaline phosphatase to reduce the 
phosphate concentration (e.g. when anti-caspase-3 antibody, HMGB-1 antibody in 
immunohistochemistry or Hoechst 33342 for DNA staining was used).  
3.1.3.5 Blocking buffers 
To obtain a blocking solution of 0.4% PBS-BSA, BSA (Sigma) was diluted in PBS. PBS-BSA 
buffer was used as a blocking buffer in ELISAs and Western Blots. To obtain a blocking solution of 
PBS-skim milk, skim milk (5%) was diluted in PBS. PBS-skim milk buffer was used as a blocking 
buffer in Western Blots and immunofluorescence. Alternatively, a 0.4% TBS-BSA blocking 
solution was diluted in TBS. TBS-BSA buffer was used as a blocking buffer in Western Blots and 
immunofluorescence. The choice of blocking buffer was dependent upon the specific protocol. 
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3.1.3.6 Fixative solution 
To prepare a 4% v/v fixation solution, one ampoule of 16% v/v stock solution of electron 
microscope-grade paraformaldehyde (PFA) (Electron Microscopy Sciences, Hatfield, PA, USA), 
was diluted in 1x PBS. The solution was wrapped in aluminium foil for light protection and stored 
for a maximum of 1 month at 4 °C. Alternatively, 10% neutral buffered Formalin (Sigma, 
HT501128-4L, St Louis, MO, USA) was used.  
3.1.3.7 Methyl cellulose 
Methyl cellulose (MC; viscosity of 2 w/v % MC in water is 55 mPa S) was purchased from Sigma-
Aldrich (Castle Hill, NSW, Australia). To prepare a 4% MC (10 mg/ mL) solution, MC was 
dissolved in DI H2O. This solution was used to prepare the vaccine coating for NP, resulting in a 
final working concentration of 1% w/v in NP vaccine delivery studies. 
3.1.3.8 Antibodies 
Antibodies for flow cytometry, Western Blot and ELISA were purchased from various suppliers 
and used at various dilutions (see Table 3.5).  
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Table 3.5: List of antibodies and manufacturers.  
Antibody 
specificity 
Clone Source Ig isotype Conjugate Manufacturer Catalog number Country Dilution used 
CD16/ CD32 
(Fc Block) 
93 Rat  IgG2a, 
lambda 
- eBioscience Ref 14-0161-85; 0.5 mg/ mL San Diego, CA, USA 1:100 
CD45.2 104 
 
Mouse  
 
IgG2a, 
kappa 
PerCP Cy5.5 
 
eBioscience 
 
Ref 45-0454-82; 0.2 mg/ mL 
 
San Diego, CA, USA 
 
1:100 
CD11b M1/70 
 
Rat IgG2b, 
kappa 
Brilliant violet 
605 
Biolegend Cat 101237; 50 µg/ mL San Jose, CA, USA 
 
1:200 
CD11c N418 
 
Rat 
  
IgG PE 
 
eBioscience 
 
Ref 12-0114-82; 0.2 mg/ mL San Diego, CA, USA 
 
1:50 
F4/80  BM8 Rat 
 
IgG2a, 
kappa 
Brilliant violet 
421 
Biolegend Cat 123131; 50 µg/ mL San Jose, CA, USA 1:100 
Ly6G 1A8 Rat  IgG2b 
kappa 
FITC BD Bioscience Cat 551460; 0.5 mg/ mL San Jose, CA, USA 1:200 
Ly6C AL-21 Rat IgM, 
kappa 
APC BD Bioscience Cat 560595; 0.2 mg/ mL San Jose, CA, USA 1:100 
         
β-actin  
(45 kDa) 
13E5 Rabbit  IgG - Cell signalling 4970 Danvers, MA, USA 1:1000 
Caspase-3 
(detects 
uncleaved 
35kDa and cl. 
17 kDa) 
8G10 Rabbit IgG - Cell signalling 9665 Danvers, MA, USA 
Danvers, MA, USA 
1:1000 (WB) 
Cleaved 
caspase 3  
(17, 19 kDa) 
Asp175 Rabbit IgG - Cell signalling 9661 Danvers, MA, USA 1:1000 (WB) or 
1:50 (cover slip; 
see Chapter 10) 
PARP1  
(cleaved 89, 
full length 116 
kDa) 
46D11 Rabbit IgG - Cell signalling 9542 Danvers, MA, USA 1:500 
HMGB-1 (29 
kDa) 
N/A Rabbit IgG - Cell signalling 3935 Danvers, MA, USA 1:500 (WB) or 
1:200 (IHC) 
NALP3 Clone cryo-2 Mouse IgG2b - Sapphire 
Bioscience 
Cat 106-20014 Waterloo, NSW, 
Australia 
1:1000 
IRDye 680CW  N/A Goat IgG 680 nm Li-Cor 926-68021, 0.5 mg Lincoln, NE, USA 1:10,000 
IRDye 800CW  N/A Goat IgG 800 nm Li-Cor 926-32211, 0.5 mg Lincoln, NE, USA 1:10,000 
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3.2 Methods 
3.2.1 Nanopatch™ preparation for immunisation 
3.2.1.1 Nanopatch™ cleaning and coating 
Prior to coating, NPs were soaked in a mixture of DI H2O and glycerol in a 1:1 ratio for 10 min 
followed by two extensive washes with DI H2O [266]. NPs were dried under ambient conditions or 
with a nitrogen gas jet (flow rate of approximately 10 L/ min) after cleaning. Coating solutions were 
prepared as previously described [266, 351], consisting of 4% MC stock solution, DI H2O and 
Fluvax® at various concentrations as outlined in the respective chapters. NPs were coated using a 
nitrogen jet at a flow rate of 6-8 L/ min at an 80° angle followed by a drying process at a 20° angle 
using 10-20 L/ min. Coating parameters including flow rates and times were dependent upon each 
coating solution. Coating formulations were adjusted to deliver the desired vaccine dose based on 
calculated delivery efficiencies using the tracer protein OVA-Methyl 14C-chloride as described in 
section 3.2.13 [345]. Coated projections were examined by Scanning Electron Microscopy (SEM) 
for coating confirmation pre- and post applications (see section 3.3.1).  
3.2.1.2 Dynamic Nanopatch™ application 
NPs were applied dynamically (i.e. applied at a velocity of 2.3 m/ s with a spring-loaded 
mechanical applicator in Chapter 4, (partially Chapter 5), 6 and 7 as outlined by Crichton et al. 
[170]. Briefly, murine ears were placed onto vinyl backing and kept in place with double sided 
adhesive tape (Sellotape, Code: 960602; Liverpool, NSW, Australia). NPs were applied on the 
ventral side of inner lobes of anaesthetised mice using a brass piston spring-loaded impact 
applicator, delivering a brief pressure spike and kept in place for 2 min. The backing material 
consisted of 2 mm thick vinyl (Carpet Call, Loganlea, QLD, Australia) made of two tightly joined 
sub-layers. Velocities of 1.96 m/ s and above were required for ~95% of the NP projections to 
penetrate the skin’s epidermis and dermis [170].  
3.2.1.3 Static Nanopatch™ application  
For static NP application, as specified in Chapter 5, a custom built application system was used, 
based on the applicator used in section 3.2.1.2, except that the spring was removed and either a 
plastic (lower weights) or brass piston (higher weights) were inserted into the applicator mounted 
against a stand. Specifically, four masses were chosen: 6.0 g (NP itself and plastic plunger), 30.0 g 
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(brass piston within the applicator), 85.0 g (brass piston within the applicator with additional weight 
on the applicator) and 500.0 g (brass piston within the applicator with additional weight on the 
applicator) applied to an area of 0.16 cm2. A custom built static ‘weight holder’ was manufactured 
from aluminium to hold the various weights (sections 3.2.1.2, 3.2.1.2 and 3.2.2). The NP was 
applied statically to inner ear lobes (ventral side) of anaesthetised mice using this device. Animals 
were placed in the correct position with the experimenter holding the brass applicator a maximum 
of 1 mm over the NP lying on the tissue. Once weights were loaded into the basket, the applicator 
was carefully lowered onto the ear tissue for a static application and kept in place for 2 min.  
 
Figure 3.1: Static Nanopatch™ application setup. 
This static NP applicator consisted of an aluminium weight basket bearing the various weights with a stainless steel 
cylinder attached to the stand. The NPs were placed on the ear pinnae, with either a round plastic (5 g) or a round steel 
cylinder (30 g) being placed on top of the NP.  
3.2.2 Static flat punch applications  
For static flat punch applications, a flat bevelled punch (Figure 3.2b and inset) was held at a 
maximum distance of 1 mm over the tissue. Using a custom built static ‘mass holder’ (section 
3.2.2), various masses (0.15, 1, 2.5 and 4 kg) were tested; the masses provided mechanical pressure 
and hence mechanical stress. Once weights were loaded into the basked, the applicator was 
carefully lowered onto the inner ear lobes (ventral side), representing a static application, and kept 
in place for 2 min. A bevelled punch was chosen to avoid tissue rupture resulting from sharp edges 
of the punch. The bevelled edges were not visible by eye but confirmed under a light microscope; 
this was important to exclude cutting into the skin otherwise inflicted by sharp edges (90°). After 
quasi-static application for 2 min, murine ear skin tissue was excised and stained with AOEB, as 
previously described (section 3.2.1.2 and 3.2.1.3). 
 93 | P a g e  
 
Figure 3.2: Flat punch application setup. 
The static flat punch applicator setup consisted of a round plastic (<5 g) or steel cylinder (30 g) attached to the stand 
with an aluminium weight basket placed on top of it holding the weights. (b) Stainless steel cylinder of 3 mm diameter. 
3.2.3 Animal work  
3.2.3.1 Animal anaesthesia  
According to UQBR’s guidelines for animal anaesthesia, mice were injected intraperitoneally (i.p.) 
with ketamine hydrochloride (25 mg/ mL) and xylazil hydrochloride (50 mg/ mL) anaesthetic (Troy 
laboratories Pty., Ltd., Smithfield, Australia). Anaesthetic was made up in sterile saline and final 
concentrations of the anaesthetic were dispensed at 50 mg/ kg and 10 mg/ kg bodyweight for 
ketamine and xylazil, respectively. Animals were anaesthetised with injectable anaesthetic for 
immunisations, while animals were anaesthetised with isoflurane (4% for induction and 1-2.5% for 
maintenance) in oxygen from a precision vaporizer during in vivo imaging. To accelerate the 
recovery process of the animals, atipamezole (Antisedan; Pfizer, Australia) was made up 1:10 in 
injectable water (Pfizer) and injected i.p. (the same volume as anaesthetic).  
3.2.3.2 Immunisations 
The NP was applied as outlined by previously described [170] and in section 3.2.1.2. i.d. injections 
were conducted according to the Mantoux technique [188] with a 31G needle (referred to as needle 
hereafter; BD, Ultrafine II, Franklin Lakes, NJ, USA) into the ventral side of the ear, at a 30-45° 
angle, aimed away from the animal’s body. All mice receiving immunisations were dose-matched; 
NP and i.d. groups were dose-matched, receiving haemagglutinin antigen doses of 0.1, 1, 5, 10, 20, 
50 or 100 ng, depending upon the experimental design. Influenza doses were selected based on 
previous studies [3, 345], and were aimed to achieve a significant difference between NP and i.d. 
groups as well as no statistical significant difference between NP and i.m. groups. i.m. injections 
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contained 6000 ng of haemagglutinin antigen. Delivery efficiency assessments for NP groups are 
outlined in section 3.2.13. A maximum of 20 µL [435] was administered, unless stated otherwise; 
i.m. injections were given into both hind legs into the caudal thigh muscle with a 29G needle. The 
volume did not exceed 35 µL per caudal thigh muscle. i.d. and i.m. immunisations were diluted in 
sterile sodium chloride (0.9%, Pfizer) to various concentrations (see Table 3.3).  
3.2.4 Cell Death assay  
To discriminate between live and dead cells, a mixture of metachromatic acridine orange (AO) and 
ethidium bromide (EB) was used [242, 563]. While AO is cell permeable and binds to DNA and 
RNA, EB is membrane-impermeable , allowing discrimination between live and dead cells.AO 
(0.3 mg/ mL; Fluka, Steinheim, Germany), EB (1 mg/ mL; Fluka), and AOEB were prepared 
according to BD Biosciences instructions. Briefly, stains were dissolved in a 50:1 ratio of PBS and 
95% ethanol, aliquotted and stored light protected at -20 °C (AO, AOEB) or at room temperature 
(RT, 23 °C; EB). Working solutions were freshly prepared from stock solutions prior to the 
experiment in PBS with a final concentration of 3 µg/ mL AO and 10 µg/ mL EB, respectively 
[564]. Following euthanisation, ears were excised and split into dorsal and ventral halves at the 
dermis-cartilage-dermis junction while taking care to fully remove the cartilage. Split ears were 
placed dermal side down floating on AO, EB or AOEB solutions. 
Single stain controls were prepared of untreated dorsal and ventral ear halves whereas only ventral 
sides of i.d. and NP-treated samples were retained and imaged. Positive controls were pre-treated 
with ice-cold (-20 ºC) methanol (Merck, NJ, USA) to induce cell death [493] prior to staining. All 
tissue samples were stained for 30 min at 37 ºC followed by three 10 min washes in cold PBS on an 
orbital shaker at 65 rpm (Xtron P/BAS-3.16L, PathTech, VIC, Australia). Live or viable cells 
stained with AO fluoresced green when intercalated with DNA (Ex488/ Em525) [565, 566], while 
cells with an impaired or ruptured cell membrane internalised EB and were interpreted as non-
viable with emitted red fluorescence (Ex300, 360, 514/ Em590, 635), allowing discrimination 
between live and dead cells. Of note, EB has three emission peaks, subject to which lasers and 
filters are used. Here, only one excitation maxima was collected (see Table 3.6).  
Care was taken to protect the stains and stained tissues from light at all times. Other tested viability 
stains included the Live/Dead® Viability Kit (Invitrogen, L3224) using 4 mM calcein AM in 
anhydrous DMSO and 2 mM ethidium homodimer 1D (EthD-1) in DMSO/ H2O (both Invitrogen), 
where non-fluorescent calcein AM is converted by intracellular esterases via acetoxymethyl ester 
hydrolysis to fluorescent calcein. In addition, Annexin V450 (AnV; BD, Cat 560506) at 1:20 and 
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propidium iodide (PI; Sigma, P4864) at 1:100 of a 50 mg/ mL working solution (prepared in DI 
H2O) were also tested. 
3.2.5 Fluorescence microscopy 
Samples were imaged by CLSM or MPM (Zeiss Axiovert LSM 510, Carl Zeiss AG, Jena, 
Germany) as described in section 3.3.3, depending upon the objective and purpose of the study. 
Five different locations were arbitrarily chosen within NP-treated samples while only one location 
per ear was imaged following single i.d. administration/ ear. All samples were imaged immediately 
after staining or within one day when fixed. Reflectance was imaged by collecting endogenous 
fluorescence of extracellular lipids from the SC while a second harmonic generation signal from 
collagen fibres within the dermis allowed depth orientation within each sample. Imaging settings 
were empirically determined and are summarised below in Table 3.6. 
Table 3.6: Fluorescence microscopy settings used in imaging experiments.  
Stain Objectives  Laser  Emission filters Pinholes  Excitation 
AO 10x Argon, 488 nm BP500-550IR 1 a.u. Excited 
sequentially EB 10x Argon, 514 nm BP650-710IR  1 a.u. 
AO 
EB 
20x, 40x Chameleon, 750 nm BP500-550IR, 
BP650-710IR  
Max open 
pinhole  
Excited 
simultaneously 
second harmonic 
generation  of 
collagen 
40x Chameleon, 800 or 
840 nm 
BP390-465 Max open 
pinhole 
Excited 
sequentially from 
others 
Reflectance 20x, 40x  Chameleon, 780 nm all reflected light Max open 
pinhole 
Excited 
sequentially from 
others 
FluoSpheres® 
(green) 
20x, 40x Argon, 488 nm BP500-550 1 a.u.* Excited 
sequentially from 
others 
FluoSpheres® 
(red) 
20x, 40x Helium Neon, 543 nm BP597-694 (Lambda 
mode) 
1 a.u. Excited 
sequentially from 
others 
DyLight® 549 ® 20x, 40x Helium Neon, 543 nm BP554-694 (Lambda 
mode) 
1 a.u. Excited 
sequentially from 
others 
Hoechst33342 20x, 40x Chameleon, 740 nm BP435-485 Max open 
pinhole 
Excited 
sequentially from 
others 
* a.u., arbritrary unit 
3.2.5.1 Image analysis 
Cell death stimulated by NP and i.d. treatment was compared to a 16 mm2 area (to standardise 
readings to an area equivalent to a single NP area). Image analyses including 3D reconstruction of 
the images and cell counts were performed with Imaris software x64 6.3.1 (Bitplane AG, Zurich, 
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Switzerland). Automated quantification was conducted by using Imaris’ spots function to model 
point-like structures that represent the cell nuclei based on an estimated diameter of 4.1 µm. 
Background fluorescence was removed prior to spot detection. Manual counts were performed from 
compressed 3D images obtained from Imaris and counted in Paint software (Microsoft, USA) or 
with the software ImageJ (http://rsb.info.nih.gov/ij/). Cell death over time was assessed as cell death 
per area using ImageJ to account for apoptotic bodies and fragmented cells that would otherwise be 
excluded from the before mentioned quantification method with Imaris. Penetration depth 
measurements were also conducted with LSM 510 Image Browser software version 4.2.0.121 
(Zeiss).  
Multi-tile imaging performed for the cell death kinetics study (section 4.3.5) was accomplished 
using images from which maximum intensity projections (MIP) were prepared. MIPs are images of 
z-stacks compressed into a single plane, displaying only pixels of the highest intensity, and were 
created from the original files in ZEN software resulting in 2D images [567]. Areas of dead cells 
were calculated from MIPs in ImageJ by adjusting the threshold for EB based on control samples. 
Side views of image stacks were created with the ortho-slicer function in an XY plane using Imaris 
(section thickness 9.88 µm).  
3.2.6 Total cell quantification per area of tissue 
To quantify total cell counts per area of tissue and extrapolated to 16 mm2, the surface area of one 
NP. Ear tissues were split and prepared as described in section 3.2.4. Samples were then incubated 
with nuclear stain Hoechst 33342 (12.3 mg/ mL; Thermo Scientific; Rockford, IL, USA) in TBS 
(1:100) for 10 min and subsequently washed 2x with TBS for 10 min. Samples were imaged as 
described in sections 3.3.3 - 3.2.5. 
3.2.7 Histology 
3.2.7.1 Sectioning 
Tissue samples were snap frozen on dry ice before being embedded in moulds filled with OCT 
(Tissue Tek, Thuringowa, QLD, Australia) and stored at -20 °C until ready for cryosectioning. 
Cryosections were prepared on a Hyrax C60 (Zeiss, Germany) at the University of Queensland or a 
Shandon Cryotome FSE (Thermo Scientific, Waltham, MA, USA) with section thicknesses between 
5-15 µm. Sections were collected onto L-lysine coated microscope slides (Menzel Gläser, 
Germany). Paraffin blocks were prepared by QIMR staff (tissues fixed in 10% neutral buffered 
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formalin solution overnight at 4 °C, followed by 3 graded ethanol baths, 2 xylene incubations and 
paraffin embedding at 65 °C for 30 min) and sectioned either by Mr. Glynn Rees, histopathology 
technician at the Queensland Institute of Medical Research, or by the author at AIBN on a Leica 
microtome.  
3.2.7.2 Haematoxylin and Eosin staining of histology sections 
Samples that were subjected to Haematoxylin and Eosin (H&E) staining using haematoxylin (Harris 
haematoxylin, Sigma) and eosin (Eosin Y accustain, Sigma) solutions were fixed either in 4% PFA 
for 2h at RT or O/N at 4 °C (alternatively 10% neutral buffered formalin O/N at 4 °C), rinsed with 
PBS and excess liquid absorbed prior to embedding in OCT. The staining procedure included 
15 steps as outlined below (Table 3.7).  
Table 3.7: Haematoxylin and eosin staining steps of fixed tissues, embedded in OCT.  
Steps Time 
1. Harris Haematoxylin (neat from Sigma bottle) 4 min 15s 
2. Place in tap water, then DI H2O 20s 
3. Acid Alcohol (1.5 mL conc. HCl in 250 mL 70% ethanol) 2s 
4. DI H2O 20s 
5. Scott’s tap water (1:10 in DI H2O) 30s 
6. DI H2O 20s 
7. Eosin (Eosin Y 1% [WasserloslichGelbich]-2.5 g + 
methanol [15%] 37.5 mL + CaCl2.2H2O [2%] 6.625 g in 
250 mL DI H2O) 
90s 
8. 70% ethanol 2 min 
9. 100% ethanol 20s 
10. 100% ethanol 20s 
11. 100% ethanol 20s 
12. Histosolve (HDS scientific Supplies, CliniPure Stains & 
Reagents)  
20s 
13. Histosolve 20s 
14. Histosolve 1 min 
15. Mount in DPX, coverslip, nail polish around the corners 
to seal off; drying 
10 min 
3.2.7.3 Immunohistochemistry of histology sections 
Paraffin slides were rehydrated as follows: placed slides in 37 °C oven for 30 min, submerged in 
Xylene 1 for 5 min, Xylene 2 for 5 min, Xylene 3 for 5 min, then 100% ethanol 2 min, 100% 
ethanol 2 min, 70% EtOH for 2 min followed by storing slides in DI H2O until ready to perform 
antigen retrieval.  
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For antigen retrieval, slides were placed in 0.01M citrate buffer and put in a microwave for 10 min 
at 1000W. Slides were washed with 0.5% PBST for 10 min and then washed 2x with 0.5% PBST 
for 3 min. Sections were blocked with 10% normal goat serum diluted in filtered PBS at RT for 
30 min. Solutions were rinsed off and sections were incubated in a 1:400 rabbit α-mouse HMGB-1 
primary antibody (Table 3.5) dilution (in 10% FCS/ PBS) overnight at 4 °C. Sections were 
subsequently washed once with 0.05% PBST for 10 min, and 2x with 0.05% PBST for 3 min. The 
secondary antibody (anti-rabbit alkaline phosphatase; Sigma, A3687) was added at 1:200 in TBS at 
RT for 40 min, washed off 2x with 0.5% TBST for 10 min, and then 2x with 0.05% TBST for 
3 min. Detection was conducted using SIGMA FASTTM, Fast Red TR/ Naphthol AS-MX (Sigma, 
Alkaline Phosphatase Substrate Tablets Set, Product No. F4523; St. Louis, MI, USA) by dissolving 
one tablet set of Fast Red (A+B) in 10 mL of Milli-Q water, filtering this solution and adding a 
droplet onto each section for 20 min (or until colour developed). Reaction was stopped with DI 
H2O. Sections were counterstained with 1:10 haematoxylin for 3.5 min, and rinsed with tap water. 
Sections were mounted with DPX mounting reagent (Sigma, 44581) or gold ProLong® anti-fade 
(Life Technologies, P-36931) before applying a coverslip.  
3.2.8 Penetration depth measurements 
The penetration depth of NP projections into murine ears was assessed by measuring coated 
fluorescent particles deposited into the skin. NPs were coated with a mixture of 4% MC, DI H2O 
and FluoSpheres® (Invitrogen, Mulgrave, VIC, Australia; F8811 or F8810). FluoSpheres® are 
carboxylate modified microspheres of 0.2 µm diameter and of either yellow-green (Ex505/ Em515) 
or red (Ex580/ Em605) fluorescence containing 2% solids (equivalent to 1010 particles/ mL). NPs 
were applied as per standard protocol (see section 3.2.1.2), removed and tissues prepared as 
outlined in section 3.2.7.1. Care was taken not to expose tissues and tissue sections for extended 
periods of time to light. Sections were imaged with the CLSM/ MPM (see section 3.2.5) using a 
20x air objective with the following settings. Tissue sections were imaged with settings described in 
Table 3.6.  
3.2.9 Transepidermal water loss measurements 
Microchannel or pore closure post NP or i.d. treatment was studied using a MDD4 Tewameter® 
TM300 by Courae Khazaka (CK) electronic GmbH (Cologne, Germany). Briefly, the TEWL probe 
was calibrated to RT with a relative humidity of ~55% within the laboratory prior to being applied 
onto the murine ear with measurements being taken at the indicated time-points for 30s, and 
subsequently averaged. Measurements of ≤10 H2O/ m2/ hr are considered as healthy intact skin 
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according to the instrument’s manufacturer. Animals were anaesthetised prior to the first 
measurement on their ventral ear lobes to obtain background readings followed by NP, NP + MC 
coating, i.d. needle insertion or i.d. saline injection (20 µL). TEWL-measurements were taken 
immediately (t=0h), 0.5h, 3h, 6h, 12h and 24h after respective treatments. Background readings 
were subtracted from all subsequent readings.  
3.2.10 Sample preparation for protein analysis  
3.2.10.1 Whole cell samples 
To extract proteins from murine ear tissue, ears were excised with the area of interest removed by 
punch biopsy (5 mm diameter; ProSciTech, T982-50; Thuringowa, QLD, Australia) and placed in a 
prechilled eppendorf tube on ice. Two ears/ mouse were pooled from n=3 to 5 per group, incubated 
in 200 µL Tissue Protein Extraction Reagent (T-PER buffer, 78510; Thermo Scientific; Rockford, 
IL, USA) containing 1x protease inhibitor (100x EDTA-free Halt Protease Inhibitor Single-Use 
Cocktail, cat. 78425; Thermo Scientific) and 1x phosphatase inhibitor (100x EDTA-free Halt 
Phosphatase Inhibitor Single-Use Cocktail, 78428; Thermo Scientific). Samples were incubated for 
30 min on ice, followed by tissue disruption using an Ultra Turrax homogeniser (T8, IKA 
Labortechnik, IKA Laborwerke; Staufen, Germany) for 30s. Samples were centrifuged for 25 min 
at 16,000 rcf at 4 °C with supernatants collected into pre-chilled eppendorf tubes. Lysates were 
aliquotted and stored at -80 °C until ready for protein analyses.  
3.2.10.2 Cytoplasmic and nuclear protein extraction 
To extract HMGB-1 protein from murine ear tissue, the NE-PER nuclear and cytoplasmic 
extraction reagent kit (Thermo Scientific, 78833, Rockford, IL, USA) was used according to the 
provided protocol with the following amendments. Briefly, ears were excised followed desired 
treatment, weighed, finely chopped into small pieces and washed once with PBS followed by 
centrifugation at 500 rcf at 4 °C for 5 min. Supernatant was completely removed to obtain a dry cell 
pellet. Tissue pellet was homogenised in 100 µL/ 10 mg tissue of cytoplasmic extraction reagent 
(CER) I on ice using an Ultra Turrax homogeniser for 15s. The tissue pellets were incubated for 
10 min on ice, followed by the addition of 5.5 µL ice-cold CER II/ 10 mg tissue. Samples were 
homogenised for 5s, rested on ice for 1 min, again homogenised for 5s, followed by centrifugation 
for 5 min at 16,000 rcf. The supernatant (cytoplasmic extract) was transferred to clean, pre-chilled 
eppendorf tubes and kept on ice for further analysis or stored at -80 °C. The nuclear-containing 
pellet was resuspended in ice-cold nuclear extraction reagent (NER; 50 µL/ 10 mg tissue), vortexed 
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for 15s every 10 min while resting on ice. This step was repeated five times prior to centrifugation 
at 16,000 rcf for 10 min. The supernatant (nuclear fraction) was transferred to clean, pre-chilled 
eppendorf tubes and kept on ice for further analysis or stored at -80 °C. 
3.2.11 Protein analysis 
3.2.11.1 Bicinchoninic acid protein assay to determine protein concentration 
To determine the total protein concentration of each sample, the bicinchoninic acid protein assay 
(BCA; Thermo Scientific, Rockford, IL, USA) was used. A standard curve of BSA ranging from 
5000 µg/ mL to 0 µg/ mL was prepared from a 50 mg/ mL stock prepared in PBS or tissue lysis 
buffer. Duplicates of the standards were added to a 96-well plate and samples were diluted in PBS 
or tissue lysis buffer at 1:10, 1:50 and 1:100 in triplicate. According to the manufacturer’s details, 
reagents A and B were mixed at a 50:1 ratio of which 200 µL were added to each well and 
incubated at 37 °C for 30 min protected from light. Absorbance was read at 562 nm and protein 
contents of the samples calculated based on the standard BSA curve.  
3.2.11.2 SDS-PAGE analysis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed using an 
Invitrogen XCell Lock Mini-Cell Electrophoresis system with precast NuPAGE® SDS-PAGE gels 
(Invitrogen; Carlsbad, CA, USA). Protein samples containing 40 µg of total protein content per 
sample were mixed with NuPAGE® 4x loading buffer (Invitrogen), boiled at 95 °C for 5 min if 
necessary and 1 µL of 100 mM DTT or beta-mercaptoethanol (Sigma) were added if samples were 
to be denatured. Samples (20 µL) were loaded into the wells of a NuPAGE® SDS-PAGE gel  
(4-12%, 1 mm, 12 wells) submersed in NuPAGE® MES SDS running buffer (Invitrogen). If 
reduced samples were required, NuPAGE® antioxidant and SDS were added into the running 
buffer. The protein ladders used included Seeblue Plus2 (Invitrogen), Precision Plus Protein dual 
colour standards and Precision Plus Kaleidoscope standards (both Bio-Rad). Gels were 
electrophoresed at 200 V for 40 min at RT, starting at ~220 mA and ending at ~130 mA.  
3.2.11.3 Western Blot transfer 
Proteins were transferred onto a nitrocellulose membrane (NC) (Hybond ECL, 0.45 µm) following 
SDS-PAGE separation using an Invitrogen transfer system. Carefully, 4 pieces of filter paper 
(Whatman, Grade 3MM Chr) and one NC membrane were cut to the size of the gel. Filter papers, 
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membrane, pads and gel were pre-soaked in NuPAGE® transfer buffer (Invitrogen). From the 
cathode to the anode, the transfer was prepared by submersion in transfer buffer in the following 
order: pads, 2 Whatman filter papers, gel, membrane, another 2 Whatman filter papers and pads. 
This setup was tightly packed in an Invitrogen cartridge, placed in the gel tank and submerged in 
transfer buffer. While the inner chamber of the tank was filled with transfer buffer, DI H2O was 
filled into the outer chamber to reduce heat transfer. Proteins were transferred onto the NC by 
electrophoresis at 30 V for 1h, starting with 170 mA and ending at 110 mA.  
3.2.11.4 Immunoblot analysis 
Following the Western Blot transfer, NC membranes were blocked with 5% skim milk (Diploma, in 
0.5% PBST) for 1h at RT or O/N at 4 °C on an orbital shaker. Following blocking, membranes were 
incubated O/N at 4 °C in 5% skim milk using a 1:1000 dilution of the primary antibody. Following 
primary antibody incubation, membranes were washed 3x in 0.5% PBST for 15 min. Secondary 
antibody (Li-COR) was applied at an appropriate dilution (1:10,000) in blocking buffer at RT for 
1h. Following incubation, blots were washed 3x in 0.5% PBST and 1x in PBS prior to development 
using the Odyssey scanner.  
3.2.11.5 Odyssey detection 
Immunoblots were imaged on the Odyssey infrared imaging system (LI-COR Biosciences GmbH, 
Germany). Following incubation with secondary antibodies conjugated to IRDye 700 (red) or 800 
(green) (LI-COR Biosciences GmbH, Germany), membranes were protected from light to avoid 
signal loss of the secondary protein and imaged either wet or dried (in a fume hood for 10 min). 
Membranes were scanned on the Odyssey infrared imaging system and analysed with Odyssey 
software version 3.0.21 (LI-COR Biosciences GmbH, Germany).  
3.2.12 Flow cytometry 
Ears were excised immediately post sacrifice, split into dorsal and ventral halves and collected into 
5 mL flat bottom tubes. Two ears (of one animal) were pooled and weighed (the average weight of 
two biopsies was 25 mg). Fluorochrome-conjugated antibodies were used as specified in Table 3.5. 
Data acquisition was performed using a FACS LSR II flow cytometer (BD Biosciences, USA) 
equipped with FACS Diva software (Version 6.1.1). Analyses were performed in FlowJo 9.6 
(Treestar, CA). 
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3.2.12.1 Discrimination of viable/ non-viable cells by flow cytometry 
The degree of apoptosis and necrosis in murine ears was examined by flow cytometry [452], 
measuring the binding of AnV to phosphatidyl serine (PS) and inclusion/ exclusion of PI in single 
cell suspensions of murine ear skin. PI only stains cells with compromised membranes (late 
apoptotic or secondary necrotic and necrotic cells). Phosphatidyl serine (PS) is found on the outer 
leaflet of the cell’s membrane undergoing apoptosis. AnV can bind to PS, which then enables the 
distinction between live, apoptotic and necrotic when co-stained with PI [452]. In addition, while PI 
allowed differentiating between early and late apoptosis, PI itself is not a good indicator of 
apoptosis alone as necrotic cells can be stained by PI too. Control groups consisted of naive, 
untreated ears and apoptotic controls from excised skin, split into dorsal-ventral sides and incubated 
in a 1 µM staurosporine solution (Sigma) dermal side down O/N at 37 °C. Necrotic cell death was 
induced by subjecting whole naive ears (split into dorsal-ventral halves) to 4 alternating cycles of 
freeze thawing using liquid nitrogen and a 37 °C water bath [492]. To obtain single cell 
suspensions, all ear tissues enzymatically digested in 2 mL PBS, 200 µg collagenase IV (final 
concentration 1 mg/ mL; Sigma, C5138,; St. Louis, MI, USA) and 40 µg DNAase I (10 mg/ mL; 
DNase I, RNase-free 1000U/ µL, cat. EN0521, Thermo Fisher Scientific, Pittsburgh, PA, USA) for 
30 min in a 37 °C shaking incubator. The digestion was stopped with 200 µL of fetal bovine serum 
(FBS; Sigma) per tube. Tissues were mashed through a 70 µm Falcon cell strainer (BD Bioscience) 
using rubber tip of 5 mL syringe into 50 mL falcon tube until the tissue plug was dry. A further 
40 µg of DNAse were added to all tubes and spun at 370 rcf for 5 min.  
Cells were washed once with cold PBS and the supernatant was poured off carefully. Cells were 
counted using a cell counter and Trypan blue exclusion was used to assess viability. Subsequently, 
cells were resuspended in 1x binding buffer (0.1 M HEPES (pH 7.4), 1.4 M NaCl, 25 mM CaCl2 in 
DI H2O) at 1x 106 cells/ mL. Maintenance of Ca2+ concentration during the staining/ binding 
reaction by using the binding buffer is crucial to avoid dissociation of AnV from PS [568]. 
Approximately 200 µL of each sample (2x105 cells) was transferred into a FACS tube and 1:20 of 
AnV (AnV V450, BD Biosciences, 560506; North Ryde, NSW, Australia) and 1:100 PI (50 µg/ mL 
prepared in DI H2O) was added, gently vortexed and incubated at RT in dark for 15 min. Samples 
were run within 30 min post AnV/ PI addition without any additional binding buffer was added. 
AnV was excited using the UV laser (ex406/ em450 nm) and PI using the argon laser (ex440/ 
em620 nm). PI-/ AnV- cells were considered as viable, PI-/ An V+ as apoptotic and PI+/ AnV+ as 
secondary necrotic, necroptotic or necrotic.  
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3.2.12.2 Analysis of inflammatory infiltrates into skin by flow cytometry 
Cells present in ear skin and auricular draining lymph nodes were prepared for flow cytometry as 
described in section 3.2.12.1 with the following amendments. LNs were not subjected to enzymatic 
collagenase digestion. LNs were dissociated through strainers prior to being washed and centrifuged 
at 370 rcf for 5 min. Single cell suspensions were resuspended in 1x FACS buffer (1x PBS, 
0.05% w/v sodium azide with 0.5% w/v BSA). Aliquots were taken for cell counts before the samples 
were centrifuged at 370 rcf for 5 min. Cells were blocked in anti-mouse CD16/32 antibody 
(eBioscience) to reduce non-specific binding due to Fc receptors prior to surface antibody staining. 
Antibody staining cocktails were prepared as per Table 3.5 (p. 90, with ability to distinguish 
neutrophils, monocytes, macrophages and dendritic cells) and were incubated for 30 min at RT in 
the dark, washed 2x in FACS buffer as before, and resuspended in 200 µL FACS buffer. Data 
acquisition was performed on a BD LSR II flow cytometer with compensation matrices set up using 
anti-rat/ anti-hamster Ig, κ compensation beads (Cat. 552845; BD Bioscience; San Jose, CA, USA).  
3.2.13 Radio-labelled ovalbumin-14C tracer experiment to calculate dose 
delivery efficiency  
3.2.13.1 Radio-labelled 14C-Ovalbumin assay  
To determine the vaccine dose delivered by the NP into the skin, a radioactive tracer experiment 
using Ovalbumin-Methyl 14C-chloride (5 µCi/ mL) in 0.01 M NaH2PO4 (American Radio-labelled 
Chemicals [St Louis, MO, USA], purchased from BioScientific Pty Ltd; Kirrawee, NSW, Australia) 
to measure delivery efficiency was designed by the Kendall group [170, 345].  
Briefly, NPs were coated with approximately 40 nCi of 14C-OVA and varying vaccine 
concentrations depending upon the experiment and estimated/ calculated dose delivery applied as 
previously described (section 3.2.1). After 2 min application time, NPs were removed and collected 
into scintillation vials, and ears were swabbed with a saline-soaked cotton swab. Following NP-
application to both ears, mice were euthanised by cervical dislocation. Ears were excised and 
collected in scintillation vials, which were prefilled with 1 mL of 1x PBS for patches and swabs or 
1 mL of Solvable (Perkin Elmer, Whathan, MA, USA) to solubilise tissue (ears). Four additional 
coated NPs that were not applied onto murine ears were used as elution controls. Swab and NP-
containing vials were stored in the dark O/N at RT while ears submerged in Solvable were kept at 
60 °C O/N for ears to dissolve. The next day, 10 mL of Ultima Gold (Scintillation liquid, Perkin 
Elmer) was added to each vial and vigorously vortexed. Samples were placed in a scintillation 
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analyser (Perkin Elmer liquid; Tri Carb B2810TR), where beta emission was measured for 4 min 
per sample and analysed using the Quanta Smart software V4.00. Scintillation counts as 
disintegration per minute (DPM) were converted into percentages: readings of elution controls were 
set as 100% while NP, swab of the ear surface and ear added together were set as 100%.  
3.2.14 In vivo imaging using the Carestream imaging system  
Animals were anaesthetised with isoflurane (4% for induction and 1-2.5% for maintenance in 
oxygen from a precision vaporizer). Once fully sedated, imaging was performed using the 
Carestream MI in Vivo MS FX PRO instrument (Bruker; Alexandria, NSW, Australia) using 
Carestream MI In Vivo FX Image Software (Version 5.0.7.24). Animals were exposed to X-rays 
with an exposure time of 30s (120 mm FOV, 2.80 f-stop, focal plane 8-9, 0.2 mm Al filter, 35 KVP) 
while fluorescence was collected for 5 or 10s for FluoSpheres® or Rhodamine, respectively, (2 x 2 
binning, multi-wavelength illumination source, 120 mm FOV, focal plane using a tray, ex/ em filter 
480/ 535) or 30-60s for DyLight® 755 (2 x 2 binning, multi-wavelength illumination source, 
120 and 190 mm FOV, focal plane using a tray and ex750/ em830 filters). Image analyses were 
performed with Carestream MI SE Molecular Imaging Software (standard edition, Version 50.6.20) 
and ImageJ.  
3.2.15 Antigen kinetics within the skin and auricular lymph nodes 
To study the kinetics of vaccine distribution within the ears and auricular lymph nodes of mice 
immunised with Fluvax®, mice received fluorescently-labelled Fluvax® by NP or i.d. injections 
(20 µL). Animal ethics allowed studies for up to 10 days only on animals who received radioactive 
labelling treatment. Given this constraint, fluorescently-labelled vaccine was selected for 
comparison purposes and longer time-points (up to 28 days).  
3.2.15.1 Fluorescent labelling of vaccine 
To study the kinetics of vaccine distribution (but not antigenicity) within the ears and auricular 
lymph nodes of Balb/c mice were immunised with Fluvax®, fluorescently-labelled using an 
antibody labelling Kit (DyLight® 755 Antibody Labelling Kit, cat 84539; Thermo Scientific, 
Rockford, IL, USA). Fluvax® (90 µg/ mL) was concentrated approximately 10-fold using a 
Millipore centrifugal filter unit (Amicon Ultra 15 mL, Ultracel 10k Membrane, cat UFC801024, 
Cork, Ireland) by spinning for 20 min at 4000 rcf at 4 °C. Eight µL of the Borate Buffer (0.67M, 
included in the kit) were added to 100 µL of the concentrated Fluvax® before mixing the solution 
with the lyophilised DyLight® NHS-Ester vial. The labelling reaction was thoroughly vortexed and 
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incubated at RT in the dark for 1h. Subsequently, the spin column was preloaded with 100 µL of 
purification resin (from the kit) prior to loading with 108 µL of fluorescently-labelled Fluvax®. The 
columns were thoroughly vortexed before being spun at 1000 rcf at 4 °C for 1 min. Correct 
labelling of Fluvax® was confirmed by imaging using the Carestream MI In Vivo FX (see section 
3.3.4). Fluorescently-labelled Fluvax® was either used immediately or stored for up to one month at 
4 °C. Mice received either one NP per ear or one i.d. injection (20 µL) per ear and were imaged at 
0, 10 and 30 min; 6h, 12h, 24, 48h; day 4, day 7, day 10, day 14, day 21 and day 28 post-treatments. 
Both groups (NP and i.d.) were compared to naive mice.  
To ensure no free dye molecules were left within the labelling reaction, imaging controls were 
included. In brief, fluorescently-labelled Fluvax® was diluted in saline and separated using spin 
columns (Amicon Ultra 15 mL, Ultracel 10k Membrane, cat. 501096, Cork, Ireland). Neat, 
concentrated, stock solution of fluorescently-labelled Fluvax®, filtrate and concentrate were imaged 
for fluorescence intensity. Multiple NPs were coated with half of those being imaged while the 
other half was eluted with 20 µL saline into eppendorf tubes to measure loss of fluorescence 
intensity due to the coating process or usage of MC. As a positive fluorescence imaging control, 
excess coated NPs and i.d. solutions were kept at 37 °C and imaged daily to simulate the animal’s 
body temperature and to verify whether continuous exposure to X-rays and laser light would reduce 
the fluorescence intensity of administered Fluvax® over time. No loss of fluorescence intensity was 
observed (data not shown).  
3.2.16 ELISA enzyme linked immunosorbent assay  
Sera samples were obtained by retro-orbital or cardiac bleeds at day 21, 63 or 102 when sera were 
assayed for total IgG, IgG2a and IgG1. ELISA was performed as previously described [569]. 
Briefly, commercial Fluvax® 2010 (CSL, Melbourne, VIC, Australia) was diluted in binding buffer 
prior to being coated onto ELISA plates (NuncMaxisorp) at 150 ng/ well and incubated overnight at 
4 °C, sealed in cling wrap. Plates were washed once with PBST before being blocked with 
4 mg/ mL BSA (150 µL per well) for 2h at RT. Plates were either used immediately or stored for a 
maximum of 3 months at -20 °C. Following blocking, plates were washed once with PBST before 
sera samples were diluted in dilution buffer. Blanks (no sera), positive (i.m.) and negative controls 
(naive) were included on each plate, while blanks were to be subtracted from all readings. 50 µL of 
the diluted sera samples were added per well onto the plates prior to being covered in cling wrap 
and incubated for 2h at RT on an orbital shaker. After incubation, sera dilutions were discarded, 
plates were washed 4x with PBST and bound antibodies were detected with 50 µL/ well HRP-
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conjugated goat anti-mouse IgG (Invitrogen, Mulgrave, VIC, Australia) diluted 1:600 in PBST-
BSA. Incubation took place for 1.5h at RT.  
Subsequently, plates were washed 3x with PBST and 1x with PBS. The colour development was 
performed using 50 µL/ well of ABTS (2,29-azino-bis[3-ethylbenzthiazoline-6-sulfonic acid]) as 
the substrate. ABTS was prepared from 88.04 mM anhydrous citric acid (C6H8O7; Sigma, Sydney, 
NSW, Australia), 87.44 mM di-Sodium hydrogen phosphate Dodecahydrate (Na2HPO4∙12H2O; 
Fluka, Castle Hill, NSW, Australia), and 9.8 M hydrogen peroxide (30% H2O2; Chem-Supply, 
Gillman, SA, Australia). The reaction was stopped after 3 min by adding 50 µL/ well of a 1% SDS 
solution (10% stock, diluted in Di H2O; Sigma, Sydney, NSW, Australia). A Fluostar Omega BMG 
Labtech reader with Omega software version 1.3 was used to take absorbance readings at 405 nm 
and 490 nm that were measured against control wells containing no antiserum in the reaction. 
Conversion of absorption curves to endpoint titres were plotted as described elsewhere [570]. 
Briefly, background readings of the plates were deducted of absorbance readings. Naive sera 
controls were included on all plates (n=5-10 in total) and diluted alongside the samples. The 
particular cut-off value(s) for each dilution was calculated for a 95% confidence level using dilution 
curves from the naive sera. Using a prediction limit procedure [570], which endpoint titres were 
considered as background reading were calculated based on the background readings of naive 
samples and their standard deviation, multiplied by a certain factor that is dependent upon the 
number of negative controls and its confidence level (1-α). Reference standards were not used, 
however, internal assay controls consisted of sera from mice immunised i.m. with 6000 ng FV. 
‘Positive immunity’ (e.g. seroconversion) was measured as endpoint titres above 100 and compared 
between experimental groups as well as to the i.m. control groups.  
3.2.17 Haemagglutination inhibition assay  
To measure protective immunity in influenza-based immunogenicity studies, virus-neutralising 
antibodies that inhibit the binding between surface glycoprotein HA of influenza and host cell 
receptors [571] were measured by haemagglutination inhibition assay (HI) [67]. The HI assay 
consists of the two parts including the haemagglutination and the haemagglutination inhibition 
which are described below, following closely the recommended protocol by the WHO [571].  
3.2.17.1 Haemagglutination assay  
Sera samples were prepared for HA to remove nonspecific inhibitors of haemagglutination by 
Receptor Destroying Enzyme (RDE). One part of sera was mixed gently with three parts of RDE 
 107 | P a g e  
(RDE [II] by Denka Seiken Co. Ltd., from Sigma Aldrich, cat. N7885-2UN, made up in PBS and 
stored at -20 °C) and incubated at 37 °C for 18h. RDE was heat-inactivated at 56 °C for 45 min 
prior to cooling to 4 °C. Finally, 6 parts of saline were added to obtain a final sample dilution of 
1:10. RDE-treated sera samples were stored at -20 °C until ready for further use. Sufficient 
Chicken/Turkey red blood cells (CRBC; containing a 1:1 mix of C-RBC and Alsevers) from 
Australian SPF, were prepared for an entire HA and HI assay and to determine 4 haemagglutination 
units (4 HAU), requiring ~2.5 mL of 1.1% CRBC solution per 96-well V-bottom plate. Chicken-
RBC were adjusted to 1.1% in Wintrobe hematokrit tubes, followed by up to three washes and 
resuspended in PBS post centrifugation (600 rcf for 5 min) by inverting the tubes to prevent RBC 
lysis. CRBC would not pellet/ form buttons in the assay if less than 1% CRBC final concentration 
and CRBC were used within 24h; otherwise, the HA assay was repeated the next day. 
All three influenza strains from the WHO isolate typing kit (WHO, North Melbourne, Victoria, 
Australia) were used neat, 1:10, 1:25 and 1:50 dilutions in PBS. For a 96- well V-bottom plate 
format, 25 µL of 0.1 mg/ mL PBSA was added to all wells except the 1st column; 50 µL of 
appropriate virus dilutions in duplicate (neat, 1:10, 1:25, 1:50 in PBS) were added to the 1st 
column; serially diluted 1:2 across the plate; adding 25 µL PBSA to all wells; adding 25 µL 1.1% 
CRBC to all wells and incubating for 30-45 min at RT. Endpoints giving 1 HAU were determined 
by selecting the dilution of virus to use that give 4 HAU (droplet formation in a ‘shield, shield, eye, 
button’ pattern). 
3.2.17.2 Haemagglutination inhibition assay 
Antibodies against HA, the viral protein responsible for haemagglutination can prevent 
haemagglutination of erythrocytes, forming the basis behind the haemagglutination-inhibition assay 
(HI). Antibodies present in sera bind to virus, therefore inhibiting the virus agglutinating red blood 
cells and allowing for a quantitative analysis of viral protection. Antigens were used at the 
predetermined dilutions from section 3.2.17.1 to generate 4HAU as described by [572]. Each 96-
well V-bottom plate included negative (naive mouse), positive and 4HAU control samples.  
The 96-well V-bottom plates were set up as follows: 25 µL 0.1 mg/ mL PBSA was added to all 
wells except 1st column; 50 µL of RDE-treated sera samples (rows 1-5), 50 μl naive RDE-treated 
sera as –ve (row 6), 50 μl of A/California/ 07/09 (or other relevant strain) anti-sera from WHO kit 
as +ve (row 7); 50 μl of 4HAU (specific antigen at appropriate dilution) (row 8) and serially diluted 
1:2 across the plates (columns 1-11 only). 25 μl PBSA were added as controls to column 12 and 
Row 8. 25 μl of 4HAU at the predetermined dilution were added to all other wells (columns 1-12 
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and rows 1-7). Plates were incubated at RT for 30 min without movement disruptions, followed by 
addition of 25 μl 1.1% CRBC to all wells and further 30 min incubation. Haemagglutinin inhibition 
was examined by scoring each well with a – (button), +/- (eye) or + (shield) before tilting each plate 
individually at 45° angle for 3 min and observing how fast a tear-shape was forming in the +ve 
control. The HI titre was defined as the reciprocal of the last dilution of sera that completely 
inhibited agglutination, as seen by tear-drop shape formation of pelleted CRBC. HI titres of ≥40 or 
showing a ≥4-fold HI titre increase post vaccination are considered as being protective in humans 
[67]. Here, HI titres of ≥40 were deemed as protective in mice as a corresponding protective titre in 
mice is currently not defined [571]. 
3.2.18 Mathematical and modelling approaches 
The following approaches were used to investigate a correlation between stress and cell death as 
outlined in Chapter 5. First, the stresses were compared by taking the fluorescent images post flat 
punch application (dead, EB-stained cells in magenta; Figure 3.3a) and importing the magenta 
channel, representing relative fluorescence intensity, into MATLAB (Figure 3.3b). Here, blue 
(~<100 pixels) represented background readings and yellow-red represented the fluorescence 
intensity maximum set to 700 pixels, as measured at the edge of the punch. Using MATLAB, a 
smoothing filter was applied to localise the centre within the cell death upon definition of intensity 
thresholds (Figure 3.3c). Subsequently, drawing radial lines from the centre point using the raw 
images (Figure 3.3b) enabled us to measure absolute fluorescence intensities, representing the 
stress maxima. The radial lines were averaged multiple times in order to adequately remove 
background noise (Figure 3.3d and Figure 3.3e right). Averaging of fluorescence intensity 
between 4-36 times (depicted in Figure 3.3e left and middle) resulted in an improved signal to 
noise ratio. However, averaging the intensity thresholds 80-times significantly improved the signal 
to noise ratio by removing background noise, allowing calculations and distributions of distortional 
and hydrostatic stresses. Using MATLAB (Figure 3.3e), the mean radial fluorescent distribution 
was extracted from the images for each weight. The resulting fluorescent-derived mean ‘death 
profiles’ were subsequently compared with radial stresses computed using mathematical 
models[573, 574]. This allowed for testing the correlation between stress and cell death.  
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Figure 3.3: Representative image processing for cell death related stress calculations using a CLSM image 
subjected to a quasi-static flat punch application holding 2.5 kg prior to analysis in MATLAB.  
Acquired fluorescent CLSM images were analysed by measuring the magenta channel (EB; dead cells) only in 
MATLAB. Depicted is a 2.5kg weight application onto a flat punch. (a) Fluorescent CLSM image of cell death post flat 
punch application; (b) imported into MATLAB using a pixel filter, with low pixel counts (<100) in blue and high pixel 
counts (>700) shown in red; (c) Smoothing filter applied; (d) samples were averaged between multiple times in order to 
remove adequately the background noise; (e) multi-averaging (left) and read-out of fluorescence intensities (middle) 
with the resultant mean representative stress curve (right).  
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3.2.19 Statistical analysis 
Statistical analyses of experimental data using parametric or nonparametric tests as indicated were 
performed with Prism software (GraphPad Prism ® Software, San Diego, CA, USA).  
Statistical analyses were performed using the student’s t-test for two groups using a paired t-test for 
same treatments but at different time-points or unpaired parametric t-test comparing two different 
treatments at the same time with Welch’s correction factor for unequal variance; unpaired Mann-
Whitney test for two groups. If multiple groups were to be compared, normality of a Gaussian 
distribution was assessed based on a Kolmogorov-Smirnov or D’Agostino-Pearson test. If results 
passed normality tests, an ordinary one-way non-parametric ANOVA (with Tukey post-
comparisons test) was performed, if normality test was not passed, a Kruskal-Wallis with a Dunn’s 
comparison post-test (parametric) or a Mann-Whitney test (non-parametric) were performed. A 
two-way ANOVA with (repeated measures, no matching) Bonferroni post-comparisons test was 
performed for multiple groups with GraphPad Prism version 5.03 for Windows (GraphPad 
Software, La Jolla, CA, USA). Endpoint titres were acquired according to [570] with statistical 
analyses performed on log transformed data. Data were considered as significant with a p-value of 
less than 0.05 (Table 3.8) (Richardson and Overbaugh, 2005). All error bars are expressed as mean 
± standard deviation (SD) unless otherwise stated.  
Table 3.8: Significance levels used as defined by GraphPad Prism. 
P value Score Significance  
≥0.05 ns Not significant (ns) 
0.01≤ p<0.05 * Significant 
0.001≤ p<0.01 ** Very significant 
0.0001≤ p<0.001 *** Extremely significant 
<0.0001 **** Extremely significant 
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3.3 Instrumentation  
3.3.1 Scanning Electron Microscopy 
Uniform morphology of NP projections, as well as coating before and after NP application was 
confirmed by SEM using a Joel Neoscope, JCM 5000 with a JCM software Version 1.01 at 10 kV, 
30 µm aperture under 1×10-10 torr pressure with samples being tilted at 45° unless stated otherwise. 
Obtained images were analysed with JCM Neoscope software Version 1.01 and ImageJ (NIH, USA, 
Version 1.45s).  
3.3.2 Cryo Scanning Electron Microscopy 
To evaluate skin surface penetration by NP or a needle i.d., cryogenic SEM (cryo-SEM; Oxford 
CT-1500 and Phillips XL30 SEM, Philips, Netherlands) was performed as described previously 
[170]. Briefly, murine ears were freshly excised prior to skin treatments with NP or i.d. injections 
(20 µL saline). The ear skin was frozen in liquid nitrogen with the NP or needle inserted in situ, 
transferred to a cryo-preservation chamber under vacuum and sputter coated with gold prior to 
imaging. Following image acquisition, the treated samples were transferred under vacuum at  
-160 °C to the sample handling chamber whereby the NP or needle was removed from the skin. 
Skin cross sections were obtained by fracturing the sample with a scalpel in a plane normal to the 
surface on relevant samples. The samples were again sputter-coated with gold prior to imaging. 
3.3.3 Confocal and Multiphoton microscopy 
Imaging skin samples can be a challenge due to the light scattering from its inherently different skin 
strata [575]. In particular, using CLSM and reflected light allows visualisation up to 200 µm deep. 
Visualising fluorescence using Two-Photon or MPM, allows for deeper tissue visualisation than 
CLSM [107] with some minor loss of resolution [576-578]. Induction and capture of endogenous 
fluorescence from fibres or molecules assists in the detection of cellular structures such as collagen, 
elastin, NADH and others without the need for specific staining or labelling [107, 579-581]. 
Endogenous fluorescence coupled to minor loss of resolution and no laser-induced tissue damage 
have led to the MPM being commonly used in studies involving cell-cell interactions or deep tissue 
imaging as noted in several recent publications [106, 128, 555, 567, 579, 581-584].  
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For fluorescence imaging of tissue samples, an upright Zeiss Axiovert LSM 510 (CLSM, Carl Zeiss 
AG, Jena, Germany) was used. In addition to the CLSM, the LSM 510 was also used as an MPM 
with a coupled multi-photon excitation source, provided by a Chameleon® titanium/ sapphire NIR 
tuneable (690-1040 nm) laser oscillator (Coherent, Santa Clara, CA) and a photomultiplier tube 
used as a detector. The excitation light was collected from the sample through the objectives  
(10x air or water, 20x air or 40x oil immersion objectives; all Zeiss) coupled to the confocal scan 
head. Samples were placed SC facing up on microscope slides (Menzel, Germany) in the 
appropriate mounting fluid (Zeiss’ immersion oil or PBS) and covered with a cover slip (Menzel, 
Germany). LSM 510 (v4.2.0.121) and ZEN 2009-2011 softwares (both Zeiss, Germany) were used 
for image acquisition and analysis. Images were recorded at 1024×1024 pixels with 12-bit pixel 
depth. The pixel size was 0.84 µm (10x) 0.42 μm (20x), 0.21 µm (40x) along the x and y directions. 
Analyses of CLSM files were performed on deconvoluted (AutoQuant X3; Rockville, MD, USA) 
images while MPM image-based acquisition was not deconvoluted. 3D-images were produced by 
imaging up to 110 µm deep into the tissue taking z-stack slices at 1 µm intervals from the SC to the 
dermis or cartilage – if present (1 µm intervals selected due to lower axial and XY resolution as 
well as optical sectioning effect in MPM than CLSM). Fluorochromes were generally excited 
simultaneously unless stated otherwise. Laser power and pinhole threshold was kept constant 
between all samples while the gain was minimally adjusted to compensate for over and under 
saturation.  
3.3.4 Carestream in vivo imaging system 
Animals were anaesthetised with isoflurane (4% for induction and 1-2.5% for maintenance in 
oxygen from a precision vaporizer). Once fully sedated, imaging was performed using the 
Carestream MI in Vivo MS FX PRO instrument (Bruker; Alexandria, NSW, Australia) using 
Carestream MI In Vivo FX Image Software (Version 5.0.7.24). Animals were exposed to X-rays 
with an exposure time of 30s (120 mm FOV, 2.80 f-stop, focal plane 8-9, 0.2 mm Al filter, 35 KVP) 
while fluorescence was collected for 5 or 10s for FluoSpheres® or Rhodamine, respectively, (2 x 2 
binning, multi-wavelength illumination source, 120 mm FOV, focal plane using a tray, ex/ em filter 
480/ 535) or 30-60s for DyLight® 755 (2 x 2 binning, multi-wavelength illumination source, 120 
and 190 mm FOV, focal plane using a tray, ex/ em filter 750/ 830). Dead cell stain EB was 
collected using ex480/ em600 filters. Image analyses were performed with Carestream MI SE 
Molecular Imaging Software (standard edition, Version 50.6.20) and ImageJ based on mean 
fluorescence intensities (MFI) within regions of interest (ROIs). The initial MFI reading in skin was 
set to 100% with subsequent time-points representing a proportion of it.   
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Chapter 4  
Visualisation, characterisation and evaluation of cell death 
caused by the Nanopatch™ 
4.1 Introduction 
Immunisations are one of the most economic and successful measures in preventing and reducing 
infectious diseases worldwide, saving millions of lives. In the last decade, skin-based vaccination 
has received a lot of attention concurrently with new or improved vaccine delivery methods 
[reviewed in 199]. One approach to improve access to vaccines is by dose-sparing, i.e. a significant 
reduction of antigen required to elicit equivalent immunogenicity compared to other needle-based 
vaccination methods such as i.m. [195]. Specifically, immunisations via the skin by i.d. have 
demonstrated similar or improved immunogenicity against influenza [77, 84], hepatitis B [91] or 
rabies [92] compared to standard i.m. routes. Typical i.d. injection and MN immunisations have 
collectively achieved a ~5-10-fold dose-sparing while inducing a similar or higher immune 
response than i.m. immunisations [3, 77, 86-89, 196, 351].  One approach to improve access to 
vaccines is by dose-sparing, i.e. a significant reduction of antigen required to elicit equivalent 
immunogenicity compared to other needle-based vaccination methods such as i.m. Specifically, 
immunisations via the skin by i.d. have demonstrated similar or improved immunogenicity against 
influenza, Hepatitis B  or rabies compared to standard i.m. routes. Typical i.d. injection and MN 
immunisations have collectively achieved a ~5-10-fold dose-sparing while inducing a similar or 
higher immune response than i.m. immunisations  
With several research groups investigating the roles of APCs, especially LCs and dDCs, in skin-
based vaccination [34, 139, 153, 162-165], antigen transport and antigen processing, the research 
emphasis of this work focussed on investigating potential factors that may lead to APC migration 
and DC activation. More specifically, to investigate the potentially underlying mechanism of 
enhanced immunogenicity to influenza vaccine delivered by needles, MNs and the NP into the skin. 
NP immunisations demonstrated 100-fold dose-sparing over i.m. [3] and ~10-fold dose-sparing 
over i.d. [344] using a inactivated, split virion influenza vaccine. It was hypothesised that 
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inflammation and cell death was likely to play a pivotal role in enhancing immune responses to 
MN-delivered immunogens. This was based upon empirical observations that NP application 
induces damage in form of controlled and localised cell damage or death in skin, which may act as a 
physical adjuvant mediated by the release of intracellular immunogenic factors alongside the 
delivered antigen. The NP is one of the MN arrays with the highest projection density in 
comparison to others [165, 262, 267, 300], and its design is believed to contribute to the previously 
observed dose-sparing effects [3, 304]. Over 95% of the projections penetrate through the SC [170] 
and deposit the dry-coated payload such as antigen into the VE and dermis in close proximity to 
skin’s APCs [3, 349]. In contrast, a 31G needle (hereafter referred to as needle) is commonly used 
for i.d. injections in mice, delivering up to 50 µL of fluid into the skin [198, 585] and forming a 
transient, visible bleb on the ear surface.  
Upon administration of chemical adjuvants, several studies have observed increased cell death at 
the site of adjuvant delivery, acting as a strong endogenous immuno-stimulatory agent [357, 358, 
467, 514]. This coincided with DAMP release [358], which have shown to enhance cellular and 
humoral immune responses in vaccine delivery [358, 511-513]. Presence of apoptotic marker 
proteins such as cleaved PARP [462] and cleaved caspase 3 (cl. casp3) as well as HMGB-1, the 
latter to distinguish between apoptotic and  necrotic cell death [519, 586], can be used to distinguish 
between apoptotic and necrotic cells. Several publications have shown that differentiation between 
apoptotic and necrotic cells was possible based on the amount of cytoplasmic versus nuclear 
HMGB-1 [492, 519, 586-588]; in particular, since HMGB-1 was found to be passively released by 
damaged and necrotic, but not by apoptotic cells due to the HMGB-1 and chromatin complex 
formation [512, 519]. In addition, secretion of TNF-α by monocytes was also reported after HMGB-
1 release by necrotic cells [519]. More recent evidence however indicates that HMGB-1 can also be 
released by apoptotic cells, though with more tolerogenic rather than immunogenic properties due 
to its oxidisation state [589, 590]. Active HMGB-1 secretion by DCs, monocytes and macrophages 
has been reported [591, 592], although macrophages can also actively secrete HMGB-1 upon 
phagocytosis of apoptotic cells [586]. 
Using ballistic vaccine delivery, Raju et al. demonstrated that the higher the particle density (e.g. at 
the centre of the particle bombardment), the higher the cell death, reaching over 90% in the highest 
tested experimental case [242]. Unfortunately, Raju et al. did not deliver any antigen to assess the 
effects of different particle densities (and hence differing cell death levels) on immunogenicity. 
Further, tattooing devices delivering DNA vaccines into the skin showed enhanced humoral and 
cellular immunogenicity using major capsid protein L1 of HPV type 16 with the authors 
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hypothesising that the inflicted trauma may underlying the enhancement [250]. Despite this 
assumption, cell and tissue damage was not specifically assessed in this study. To the best of the 
author’s knowledge, no other studies have investigated cellular damage caused by hypodermic 
needles or MNs with regards to vaccine delivery and immunogenicity. 
On a separate note, the skin’s integrity post incisions or MN applications has been measured by 
several non-invasive techniques such as Trans-Epidermal Water Loss measurements (TEWL) [332, 
593], electrical impedance measurements [594], infrared spectroscopy [595], confocal microscopy 
[223, 596] and optical coherence tomography [597]. TEWL data can assist in defining the required 
time for the skin to re-establish its barrier function. A link between cell death and TEWL readings 
has not been established yet.  
Consequently, the aim of this chapter was to define the level of cell death induced in situ when 
using a conventional i.d. injection compared with NP for transcutaneous delivery in situ, and assess 
the type of cell death as well as its kinetics post NP treatment or i.d. injection. This was achieved 
using techniques including MPM imaging combined with live and dead cell stains. Therefore, a key 
achievement of the work contributing to this chapter and thesis was the optimisation of this method 
(detailed in sections 4.3.2 and 4.3.3), now implemented by many others within the research group 
and company (Vaxxas; a start-up company developing the clinical Nanopatch™ technology that 
originated from Professor Mark Kendall's research group). 
4.2 Methods 
As outlined in Chapter 3, the following methods are applicable to this chapter: sections 3.1, 3.2.1, 
3.2.3, 3.2.4, 3.2.5, 3.2.6, 3.2.10, 3.2.11, 3.2.12 including 3.2.12.1 and 3.2.19.  
4.3 Results  
Intradermal delivery of vaccine into the skin is perhaps the most similar comparator to delivery by 
NP, in the respect that they both deliver antigen into the skin tissue and similar skin strata. 
However, there are also significant differences, such as their scale (as highlighted by SEM images 
in Figure 4.1a and b) and in the effects induced by penetration of the skin surface. 
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4.3.1 Physical differences in skin penetration and payload delivery 
following Nanopatch™ application and intradermal needle injection 
of murine ear skin.............. 
The morphology of the skin’s surface was assessed using cryo-SEM following NP application and 
needle insertion to skin to gain insights into the relative skin perforation induced by each device. 
Cryo-SEM images of untreated skin revealed an intact surface with observable corneocytes (Figure 
4.1c), while delivery into skin by NP formed a regular array of microchannels within the skin 
(Figure 4.1d), with pitch consistent to the spacing of projections on an NP array. In contrast, a bleb 
of saline formed by injection into the dermis by needle (Figure 4.1e), rupturing the skin by needle 
insertion and removal (Figure 4.1f and g). The contact surface area between skin and NP 
projections was measured and calculated to be 17.7 mm2 ± 2.3 mm2, versus 1.60 ± 0.12 mm2 (each 
n=18 penetration points) for the needle tip inserted into the skin – an area comparable to ~1/11th of a 
NP (or approximately 310 of 3364 NP projections). 
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Figure 4.1: Visual comparison of the skin following Nanopatch™ application and i.d. injection by hypodermic 
needle.  
(a) Size comparison of a NP next to a 31G needle used for i.d. injections. (b) SEM image of needle tip over NP 
projections (inset). Cryo-SEM images of murine skin of (c) untreated ear, (d) following NP, (e) bleb formation 
following i.d. delivery of PBS (f) needle i.d. in situ, (g) skin after needle removal following delivery of 20 µL saline. 
Arrows () depict the needle insertion site. Images representative of triplicate repeats with (n=6). Image reproduced 
with permission from [344].  
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Next, the area of payload delivery by NP or i.d. injection was compared, using Coomassie Blue dye 
for visualisation purposes. After application of a dye-coated NP, Coomassie Blue was localised 
precisely around individual projection microchannels, where it had diffused off the projection 
surface and into the skin (Figure 4.2a). In contrast, the needle delivered a 20 µL liquid payload that 
formed an i.d. bleb (Figure 4.2b right). The measured payload delivery area of NP (summing the 
elliptic/ circular dye diffusing from each projection; Figure 4.2a inset) was 1.9 ± 0.1 mm2, which 
was significantly lower than the delivery area of a needle: 27 ± 11 mm2 (p<0.001; Figure 4.2). 
Combined, these data demonstrate significant perforation of skin when using NP to deliver antigen 
compared to i.d. delivery with a needle, while the needle delivered payload to a much larger area in 
the form of a continuous ‘bleb’, compared to the discrete delivery by NP projections.  
 
Figure 4.2: Comparison of the area of affect following Nanopatch™ application to skin and i.d. injection by 
hypodermic needle. 
Photographic images illustrating (a) Coomassie Blue administered into mouse ears by either NP (left) or i.d. injection 
(right). (b) Affected skin surfaces by Coomassie Blue measured in ImageJ image processing program (n=18). i.d., 
intradermal; NP, Nanopatch™. Error bars show means ± SD (*** p<0.001). Image reproduced and adapted with 
permission from [344]. 
4.3.2 Optimisation of parameters for staining of viable and nonviable cells 
in murine skin tissue in situ 
To investigate temporal and spatial distributions of dead cells post NP application compared with 
i.d. injections of murine skin, a MPM-based assay was optimised. Thorough staining optimisation 
procedures (e.g. varying stains; concentrations, incubation temperatures and times; level of 
agitation; skin preparation) were tested empirically to ensure adequate imaging techniques were in 
place prior to quantification and cross-comparisons between different methods of skin 
immunisations (outlined in Table 4.1, pre-optimisation staining illustrated in Figure 4.3a). As 
C57BL/6 mice have pigmented melanocytes within the VE and/ or dermis, absorbed laser light even 
at very low laser power (<2%) resulted in the occurrence of ‘fluorescent speckles’ (data not shown). 
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Therefore, all imaging was conducted in Balb/c mice to reduce the speckling and imaging artefacts 
unless specified otherwise.  
Table 4.1: Tested optimisation parameters to assess tissue viability post Nanopatch™ application.  
Optimised parameters are highlighted in blue. Abbreviations used: AO, Acridine Orange; EB, Ethidium Bromide; AnV, 
Annexin V; PI, Propidium Iodide; EthD-1, Ethidium Homodimer 1D; NP, Nanopatch™. 
Starting 
parameters based 
ony [242]: 
AOEB unknown 3h RT, no 
movement 
Skin  Intact skin Split skin (+ cartilage) Split skin  
(-cartilage) 
Careful tissue 
handling with two 
rounded tweezers 
 
Incubation time 
 
10 min 30 min 1h 3h 
Temperature  
 
4 °C 23 °C 37 °C   
Concentrations  
 
 
AO 0.003 mg/ mL  
EB 0.01 mg/ mL 
AO 0.03 mg/ mL  
EB 0.1 mg/ mL 
AO 0.3 mg/ mL  
EB 1 mg/ mL 
 
Incubation  
 
No movement Orbital shaker rolling  
Dyes 
 
AOEB AnV + PI Calcein AM + EthD-1  
 
Following extensive staining and tissue handling optimisation, viability imaging of murine ears 
subjected to NP treatment yielded significant improvements as can be seen in Figure 4.3a and b, 
showing staining pre- and post-optimisation (detailed in Table 4.1). Figure 4.3c shows untreated 
versus NP-treated skin tissue post staining optimisation, illustrating the dye uptake by dead cells 
(EB). Very few cells took up EB in untreated control tissue, allowing for identification of live and 
dead cells. In contrast, a clear staining pattern of dead cells around microchannels in the NP-treated 
samples was observed (Figure 4.3, white dashed circles). Other tested staining combinations 
included AnV-FITC, AnV and PI as well as calcein AM and EthD-1. Of these, only PI stained cells 
with cells with compromised membranes in situ without extending staining times significantly (data 
not shown). Calcein AM was not detected, which may not have stained sufficiently well due to 
excessive hydrolysis of calcein during the tissue incubation. Z-stack acquisition, visualised here in 
10 µm intervals, clearly illustrated suitable imaging parameters for visualisation and quantification 
purposes of live/ dead cells in murine ears (Figure 4.3d).  
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Figure 4.3: Three-dimensional imaging of cell death in murine skin post Nanopatch™ application.  
NP were applied for 2 min onto each ear of Balb/c mice before being euthanised, ears excised and immediately stained 
with an AOEB cocktail for 30 min prior to imaging by MPM. (a) Viability staining of NP- treated skin pre-and post-
optimisation according to tested parameters (Table 4.1). Pre-conditions included 0.3 mg/ml and 1 mg/ mL of AO and 
EB, respectively, incubated for 60 min with agitation at 23 °C; Post-conditions included 0.003 mg/ mL and 0.01 mg/ 
mL of AO and EB, respectively, incubated for 30 min without agitation at 37 °C. (b) Untreated ears showed 
predominantly viable cells (AO, green) with sparse dead cells (EB, magenta) within both VE and D. (c) NP treated 
samples showed a significant increase of dead cells in a regular pattern consistent with NP geometry. (d) Visualisation 
of cell death at various depths within murine tissue (brightness/ contrast increased when ≥70 µm in depth were 
reached); scale bar (50 µm) representative for all panels in (d). MPM-images were acquired up to a depth of 110 µm in 
murine ears and are representative of at least three independent experiments. AO, acridine orange; EB, ethidium 
bromide; MPM, Multiphoton microscopy; NP, Nanopatch™. 
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To summarise, the optimisation study identified AO and EB as the optimal staining combination to 
distinguish viable from non-viable cells in murine skin tissue, giving best results for viability 
assessment of murine ear skin with staining times of max 30 min compared with the other tested 
stains. Based on the optimisation experiments, viability staining of murine ears in situ were found to 
be most efficient with AO and EB at 0.003 mg/ mL and 0.01 mg/ mL as final working concentration 
on split ears with cartilage completely removed (Figure 4.3). Universal cell staining was achieved 
within 30 min when stained at 37 °C without agitation, followed by three washes in ice-cold PBS 
and immediate image acquisition. These conditions were applied to all subsequent experiments 
unless mentioned otherwise.  
4.3.3 Validation of software-based quantification of Nanopatch™-induced 
cell death  
To quantify the cell death in NP-treated and untreated murine ears, Imaris’ spot forming function 
was used and compared against manual quantification using either ImageJ software or MS Paint (as 
outlined in section 3.2.5.1). In both quantification methods, one stained nucleus was assumed to be 
representative of one cell. In untreated samples, manual quantification of stained cell nuclei yielded 
4.5% ± 1.1% of dead cells within the same area as a NP treated sample, which was non-significant 
in comparison to Imaris automated quantification yielding 4.2% ± 1.2% (data not shown). The cell 
death observed in untreated skin is low, and likely due to tissue handling. In NP-treated samples, 
manual counts of live (72.8% ± 1.5%) and dead (27.2% ± 1.5%) cells did not statistically differ 
from automated quantification using Imaris spots’ function of live (green spots) and dead cells 
(magenta spots) with 76.1% ± 6.6% and 23.9% ± 6.6%, respectively (Figure 4.4a and b). In an NP-
treated sample, the ratio of live to dead cells was approximately 4:1 within an area of 0.16 cm2 of 
the VE and D, Figure 4.4). Due to the undulated nature of the skin, VE and dermis were quantified 
as one layer. Of note, a separate 3D image with its lateral and semi-lateral views to demonstrate the 
unevenness of the skin is shown in Appendix 1, Figure 10.2. Taken together, Imaris was found to 
be a suitable and reproducible method to quantify dead cells in the skin as previously reported 
[598]. 
 122 | P a g e  
 
Figure 4.4: Quantification of cell death post Nanopatch™ application to murine skin based on MPM images 
using Imaris software and spots function.  
Confocal imaging of (a) untreated AOEB-stained samples (left) showed mostly viable cells (green) with very few dead 
cells (magenta), which was mirrored in Imaris spots forming function (right). (b) NP-treated samples (5 min 
application) showed an elevated level of cell death interspersed between viable cells (left), which was reflected in 
Imaris’ spot reproduction (right). (c) Comparison between manual and automated (Imaris software) quantification. Skin 
samples were imaged up to 110 µm in depth. Images are representative of three independent experiments (mean ± SD). 
MPM, Multiphoton microscopy; NP, Nanopatch™. Statistical analyses were performed using an unpaired student’s  
t-test with Welch’s correction; error bars show means + SD (ns, not significant, p>0.05). 
4.3.4 Nanopatch™ application induces higher levels of cell death than 
intradermal injections in murine ear skin 
Analysis of the skin surface by cryo-SEM had indicated that dynamic NP application induced 
discrete microchannels, corresponding to the size and spacing of projections on an NP array 
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(Figure 4.1d). This was consistent with previous studies [170], however, the resultant local cell 
death induced within the skin was not known. Similarly, it was not known how the observed i.d. 
injection bleb (by a needle; Figure 4.1e) within skin related to localised cell death within the tissue. 
To explore this, optimised staining parameters were used (see 3.2.4 and 4.3.2) to quantify cellular 
damage caused within the skin by each device over a 4 x 4 mm area (an area equivalent to the face 
of a single NP) by CLSM/ MPM. Baseline incidence of damaged cells was quantified as  
3.5% ± 1.9% (n=18) (Figure 4.5c). After NP application, 16.5% ± 4.1% (n = 18 projections), of 
epithelial cells were damaged (Figure 4.5c), 4.7-fold greater than the cell damage in untreated skin 
(p<0.001). Dead cells were restricted to a zone of approximately 5 cell radii, or 26 ± 13 µm (n=81 
projections), around each microchannel perforation (3364 in total) with predominantly viable cells 
beyond this ‘dead zone’ (Figure 4.5a and b). In addition, increased levels of cell death were also 
observed on the edges of the NP.   
In contrast, the skin damage caused by i.d. injections was restricted to the individual needle 
perforation site (Figure 4.5a and b), inducing death to 3.7% ± 1.8% (n=18) of epithelial cells within 
the 4 x 4 mm area of interrogation. i.d. injection compared to untreated control skin (3.5% ± 1.9%) 
was insignificant (p=0.16). Cell death within the i.d. bleb was comparable to untreated control 
groups (2.5% ± 1.1%; p>0.05 with n=5). Once adjusted against untreated control groups, the cell 
death attributed to NP application and i.d. is 13% and ~0.2%, respectively, representing a ~65-fold 
difference. Noteworthy, this low level of cell death induced by the needle was not significantly 
different to the i.d. bleb area (2.5% ± 1.1%; p>0.05; Figure 4.5a and b). Further, the cell death was 
localised to the needle insertion site, measuring ~0.07 mm2, while the bleb, representative of the 
vaccine payload, extended considerably further laterally in the skin. For example, in the case of the 
measured i.d. bleb extending to 27 ± 11 mm2 (from Figure 4.2a and b; n=18), the area of dead cells 
within the bleb area skin represented <0.5% of the total bleb area, corresponding to ~60 cell radii. 
Cross-sectional MPM images demonstrated that damaged tissue in NP treated samples was confined 
mostly to the VE, while delivery by needle resulted in cell death spread throughout the VE and 
dermal layers (Figure 4.5b). Collectively, these data showed key differences between the number 
and the location of live and dead cells. Specifically, dynamic application of NP to skin induced 
significantly higher and repeatedly localised cell death, compared to standard, needle-based i.d. 
injection. In the case of i.d. injection, the cell death was not tightly localised with the bulk of the 
payload delivery, while following NP delivery, both were highly localised. The difference in the 
ratio of live to dead cells after delivery by each device was significant, with approximately 6:1 and 
27:1 in NP and i.d. injected samples respectively, based on 16.5% and 3.7% of dead cells for NP 
and ID, respectively.  
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Figure 4.5: Cell viability in untreated, Nanopatch™-treated and i.d. saline-injected murine skin. 
Acridine orange (AO) and ethidium bromide (EB) were used to differentiate between viable (AO, green) and non-viable 
(EB, magenta) cells. (a) (i) MPM images of stained murine ears; untreated, NP-treated and i.d. injected at low 
magnification; (ii) overview at high magnification and (iii) high magnification. (b) Representative side views of 
untreated, NP-treated or i.d. injected samples with collagen (blue, second harmonic generation), section thickness 
9.88 µm. (c) Quantification of cell viability per 16 mm2. Original images magnified 10x and 40x. White arrow () 
depicts i.d. injection site. Images are representative of three independent experiments with n=5-8 replicates. MIP, 
Maximum Intensity Projection; SC, Stratum corneum; VE, viable epidermis; D, dermis; i.d., intradermal; NP, 
Nanopatch™. Statistical analysis performed with a one-way ANOVA with Tukey post-comparisons test with n=5-18, 
representative of at least three independent experiments. Error bars represent means ± SD (*** p<0.001). Image 
reproduced with permission from [344]. 
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4.3.5 Cell death kinetics following Nanopatch™ application and 
intradermal injection 
With significant differences of cell death levels induced by both (vaccine) delivery methods, 
different kinetics of cell death clearance were expected after treatment with either NP or delivery of 
saline i.d. by needle. Cell death caused by NP and needle were studied for over 10 days to measure 
cellular damage/ death over time. First, using MPM, cell death was mostly contained around the 
projection penetration sites post NP application (Figure 4.6a) as described above. The cell death 
was visible predominantly immediately and on day 1 post-treatment, thereafter with a subsequent 
reduction of visible dead cells. When compared with i.d. injection, dead cells remained around the 
needle insertion site until day 6, although when compared over the face of one NP (16 mm2), the 
level of cell death was not significant in comparison to untreated samples (Figure 4.6b). Of note, 
images were acquired at different magnification levels to accommodate the larger site of a single 
i.d. injection/ ear while smaller and faster image acquisitions were acquired from NP-treated 
samples.   
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Figure 4.6: Multiphoton microscopy images comparing cell viability kinetics post Nanopatch™ application and 
i.d. injection in murine skin.  
Murine ears were subjected to NP application or i.d. injection (20 µL saline), excised at indicated time-points post-
treatment, stained with AOEB prior to imaging by MPM and quantified from MIPs by measuring EB-stained area per 
16 mm2. Representative images of (a) NP-treatments and (b) i.d. treatments. Images representative from two 
independent experiments with a minimum of n=25 (NP) and n=8 (i.d.) per time-point. AOEB, acridine orange/ ethidium 
bromide; EB, ethidium bromide; NP, Nanopatch™; i.d., intradermal; MIP, Maximum Intensity Projections. 
Cell death was quantified per device and over an area of 16 mm2, which is the area of skin that 
came into contact with the face of one NP. NP-treated tissue contained 2.0 ± 0.6 mm2 of damaged 
tissue localised around the NP projection holes immediately after treatment (Figure 4.6a and 
Figure 4.7a, day 0). This level of cell death was significantly higher than that caused by i.d. 
injection of saline by needle (Figure 4.6b and Figure 4.7b, p<0.001), which resulted in less than 
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0.01 mm2 of damaged tissue (Figure 4.7b). Cell damage immediately proceding i.d. fluid delivery 
by needle was equivalent to the cellular damage caused by penetration of skin with 21 ± 12 NP 
projections. After 24h, the area of dead cells increased slightly, yet remained localised around 
penetrations of the skin with both devices (Figure 4.6a-b and Figure 4.7a-b, day 1). A significant 
decrease in the number of dead cells 2 days post-treatment in the NP groups was seen (Figure 4.6a 
and Figure 4.7a). It became evident that the cell death persisted over an extended period of time in 
NP treated samples (Figure 4.6a, Figure 4.7a and c). At day 6, NP treated skin returned to pre-
treatment levels, with disrupted corneocyte layers remaining in the skin until approximately day 10 
(Figure 4.6a and Figure 4.7a). Even though cell death caused by needle was not significantly 
higher than baseline, cell death was predominantly visible where the needle penetrated epidermis 
until day 6 (Figure 4.6b and Figure 4.7b). When background levels (calculated as cell death area) 
were subtracted from NP and i.d. and directly compared with each other, significantly higher levels 
of cell death were seen post NP application than i.d. injection for the first 4 days (day 0, p<0.001; 
day 1, p<0.001; day 2, p<0.05; day 4, p<0.001), with cell death levels returning to baseline 
thereafter (Figure 4.7c). Together, these results illustrated that NP-treatment induced shallow 
wounding to the skin with significantly more cell death area than needles inserted i.d. In the time-
points tested with both delivery methods, cell death peaked one day after treatment and returned by 
day 6 (NP) to baseline levels while remaining at baseline levels throughout (i.d.).  
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Figure 4.7: Quantification of cell viability kinetics following Nanopatch™ application and i.d. injection in murine 
skin over time from Multiphoton microscopy images.  
Murine ears were subjected to NP treatment or i.d. injection (20 µL saline), excised at indicated time-points and stained 
with AOEB prior to imaging by MPM, where areas of dead cells were quantified in ImageJ. a) NP treatment induced a 
large area of dead cells peaking at day 1 after NP application but returned to pre-treatment conditions by day 2 while b) 
i.d. injections resulted in a low area of cell death over time per 16 mm2 on the same scale. c) Combined NP and i.d. cell 
death area per device with background cell death of untreated samples removed. Nanopatch™ (▲, blue triangle) and 
i.d. (●, orange circle) samples. Results of two independent experiments are shown with a minimum of n=25 and n=8 per 
time-point for NP and i.d. samples, respectively. NP, Nanopatch™, i.d., intradermal. Error bars show means ± SD (ns 
p>0.05, * p<0.05, *** p<0.001) based on 1-way ANOVA with Tukey post-comparisons test (a+b) or a two-way Anova 
with multiple comparisons test.  
The recovery of the skin’s barrier function was investigated following the wound trauma inflicted 
post microchannel formation following NP application and skin disruption post i.d. injection. NP 
application alone induced a ~5-fold higher TEWL reading (34.7 ± 7.8 g H2O/ m2/ hr) than naive 
control groups (7.7 ± 2.0 g H2O/ m2/ hr; Figure 4.8). Similar measurements were obtained when 
MC-coated NPs were applied to skin (30.5 ± 7.2 g H2O/ m2/ hr). Needle insertion resulted in no 
statistically significant TEWL measurement over naive control groups; thus, i.d. insertion alone did 
not result in a significant pore formation. By contrast, i.d. injection of saline induced a significantly 
higher TEWL reading over naive samples immediately after administration (t=0 h; 52.6 ± 9.9 g 
H2O/ m2/ hr), although their readings returned to baseline levels of naive control groups within 
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30 min. This was partially expected due to the high interstitial pressure delivered by the bolus 
injection partially exiting via the needle injection site. It was postulated that the rapid decrease in 
TEWL readings within the i.d. groups may be due to the rapid drainage of the fluid [175, 176]. In 
uncoated NP or MC-coated NP groups, TEWL readings returned to baseline levels by 12h and 24h 
post-treatment, respectively. To summarise, immediately after application, NP alone induced 5-fold 
higher TEWL readings than i.d. needle insertion alone with NP-readings returning to baseline 
within 12h, while saline injection increased TEWL readings only significantly at earlier time-points.  
 
Figure 4.8: Trans epidermal water loss measurements post Nanopatch™ application and i.d. needle insertion 
into murine ear skin.  
Groups of mice (n=6) received NP or i.d. treatments and TEWL measurements were taken at indicated time-points 
using a MDD4 Tewameter® TM300 for up to 24h post-treatment. TEWL measurements of naive mice at each time-
point were used as reference point for statistical analyses. NP, Nanonpatch™; i.d., intradermal; MC, Methyl cellulose. 
Error bars show means + SD (ns p>0.05, * p<0.05, *** p<0.001, **** p<0.0001) based on a one-way ANOVA with 
Tukey’s multiple comparisons. 
4.3.6 Cell death characterisation following Nanopatch™ application or 
intradermal injection 
Apoptotic and  necrotic cell death was assessed by flow cytometry using AnV and PI post 
application of plain, uncoated NP application or i.d. saline injection, excised at indicated time-
points. Cells were characterised based on their fluorescence intensity as follows: viable (AnV- PI-), 
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early apoptotic (AnV+ PI-) and late apoptotic/ necrotic/ secondary necrotic or necroptotic (AnV+ 
PI+) cells ([599], Figure 4.9a). While there was no significant difference between NP and i.d. 
treated groups at all time-points, it was found that over the course of 72h, i.d. saline groups resulted 
in a higher counts of dead cells (AnV+ PI+; Figure 4.9b) in comparison to NP treated groups 
although the difference was statistically insignificant. A similar trend was seen when comparing 
total cell numbers of early and late apoptotic cells (AnV+ PI-; Figure 4.9c). These results were 
unexpected since high levels of cell death were observed post NP-treatments based on MPM 
imaging (Figure 4.5), stipulated to be of necrotic origin because of an immediate occurrence 
(apoptosis would require more time) in addition to absence of apoptotic features (Figure 4.10). It 
was suggested that the flow cytometric analysis was not sensitive enough due to 1) extensive 
washes that may dilute or wash away necrotic cells and 2) the sample preparation (enzymatic 
digestion), to detect the dead cell difference between NP and needle treated cell suspensions. To 
summarise, the flow cytometric results were deemed as inconclusive; no statistical significant 
difference between NP and i.d. treated skin samples was found, albeit higher mean cell numbers of 
AnV+ PI+ as well as AnV+ PI- cells in i.d. injected groups than NP treatments.  
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Figure 4.9: Apoptotic and necrotic cell death post Nanopatch™ application and i.d. insertion as characterised by 
flow cytometric analysis.  
Characterisation of cell death by flow cytometry using Annexin V (AnV) and Propidium Iodide (PI). a) Gating strategy 
employed to distinguish between live (AnV- PI-), early/ late apoptotic (AnV+ PI-) as well as necrotic, secondary necrotic 
or necroptotic (AnV+ PI+) cells. Viability kinetics of b) dead (double positive AnV+ PI+) cells and c) apoptotic (single 
positive AnV+ PI-) cells post NP application or i.d. saline injection. Results of two independent experiments are shown 
with n=5 (two ears pooled) per time-point for NP and i.d. samples, respectively. NP, Nanopatch™; i.d., intradermal, 
naive (x). Error bars show means + SD (ns p>0.05, * p<0.05, *** p<0.001); statistical analyses were based on 1-way 
Anova with Tukey post-comparison test. 
With the flow cytometry data being inconclusive, MPM images of the kinetic experiments were 
examined for apoptotic/ necrotic cell morphology (see section 2.5.1). Based on image analyses 
(Figure 4.6 and Figure 4.10 below), EB+ cells with normal or enlarged nuclei were identified as 
necrotic while AO+ EB- cells were being classified as viable (e.g. NP 0h). By 6h post NP 
application, crescent-shaped cell nuclei (white arrows, AO+) were slowly increasing in appearance, 
which were previously reported to be representative as early apoptotic stage [600, 601]. Dead cells 
(necrotic or late secondary necrotic) were clearly EB+ stained. By 12h post NP application, cellular 
morphology within the treated areas had changed significantly. Not only were more AO+ crescent-
shaped nuclei visible, but also EB+ crescent-shaped nuclei (open arrow; Figure 4.10). The latter 
were thought to be late apoptotic/ secondary necrotic cells with compromised membranes. Necrotic 
cells were apparent at all time-points, exceeding the amount of apoptotic cells (Figure 4.10). The 
observed increase of apoptotic cells was however consistent with flow cytometric results  
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(Figure 4.9). In summary, cell death induced by the NP appeared to be of necrotic origin 
immediately after application with an increase of apoptotic cell occurrence several hours post NP 
treatment – based on image acquisition. However, apoptotic and necrotic cell morphologies were 
observed concurrently at later time-points (>6h) during imaging (Figure 4.10). Therefore, 
alternative assays such as Western Blot analyses to distinguish apoptotic from necrotic cells were 
investigated. 
 
Figure 4.10: Visual differentiation of apoptotic and necrotic cell death post Nanopatch™ application.  
Murine ears were subjected to 2 min NP applications and culled at indicated time-points post-treatment. MPM image 
acquisitions were ≥110 µm in depth with 10 µm thick z-sections within the VE being depicted here. Apoptotic (white 
filled arrows) and late apoptotic/ secondary necrotic (white open arrows) were visualised by 6 and 12h post NP 
treatment, respectively. Viable (AO, green) and non-viable (EB, magenta) cells; Representative of n=25 (NP) per time-
point. NP, Nanopatch™.  
To further confirm the imaging results presented in Figure 4.9 and Figure 4.10, additional 
characterisation of the type of cell death was investigated by protein expression via Western Blot. 
Here, murine ears were subjected to uncoated NP application or i.d. saline injection with tissues 
collected at 12h, 24h and 48h post-treatment, processed as described in section 3.2.11 and probed 
for cl. casp3, PARP and HMGB-1 with b-actin as loading control. Surprisingly, no cl. casp3 was 
observed following NP or i.d. treatment at all tested time-points (Figure 4.11a) albeit cl. PARP 
(89 kDa) being measured in the NP treated samples at 12h and 24h but not at 48h, while i.d. groups 
showed at an upregulation of cl. PARP with time. Despite fully loaded lanes, as seen in the b-actin 
loading controls, no cl. casp3 could be detected in any samples. This suggested possibly presence of 
proteases during protein extraction or insufficient total protein loading per lane despite protease 
inhibitors and 40 µg total protein content loaded/ lane according to the BCA, respectively. Further, 
as naive mice also indicated active PARP, the Western Blot data was considered to be inconclusive 
with regards to indication of apoptosis pathways being involved and/ or activated. Further, presence 
of HMGB-1 was only found to be present in the cytoplasmic fraction (Figure 4.11bii) of NP and 
i.d. groups 12h post-treatment but not in any other groups (Figure 4.11bi). This was unexpected as 
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HMGB-1 is an abundant protein found within the nucleus that can be actively secreted by DCs, 
macrophages and monocytes, or released passively from injured, necrotic and secondary necrotic 
cells. These cell types were expected to be present in the tissue within the first 48h post-treatment. 
Moreover, recombinant HMGB-1 (rHMGB-1) as positive control did not produce a band either, 
strongly suggesting a problem in the sample preparation albeit in the presence of good b-actin 
loading controls. Collectively, these results did not allow certain characterisation of apoptotic and 
necrotic cell presence based on protein expression; further optimisation studies are necessary to 
draw any conclusions on the type of cell death occurring after NP and i.d. treatments.  
 
Figure 4.11: Protein analysis of cleaved caspase 3, PARP and HMGB-1 post Nanopatch™ application and i.d. 
insertion.  
Mice were treated with NP or i.d needle and sacrificed at indicated time-points (12h, 24h, and 48h post-treatments). 
Positive controls (+ve) included ears incubated in 1 µM staurosporine for 18h (a) or Recombinant HMGB-1 (rHMGB-1) 
with b-actin used as loading controls. (a) Western Blot analysis for PARP and cl. casp3 and b) Western Blot of HMGB-
1 in NP or i.d. treated samples. Expected band sizes were: 17 and 19 kDa for cl. casp3; HMGB-1 at 29 kDa, rHMGB-1 
at 31 kDa; b-actin at 45 kDa; cl. PARP at 86 kDa, PARP at 116 kDa. NP, Nanopatch™; i.d., intradermal. Immunoblots 
are representative for n=4.  
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4.4 Discussion  
4.4.1 Nanopatch™ induces significantly more localised cell death, 
compared to standard needle-based intradermal injection ……. 
It was found that the dynamic application of the NP generated significantly higher levels cell death 
(~65-fold) in skin, compared to i.d. injection (Figure 4.5) within the VE and dermis; specifically,  
that the NP-induced cell death was localised around each projection penetrating the skin in an array 
(Figure 4.1 and Figure 4.2). Consistent with regular penetration pattern [170], dead cells were 
located predominantly around the projections penetrating the skin with interspersed live cells 
(Figure 4.5). In contrast, the markedly lower level of cell death in the i.d. case was localised to a 
single needle insertion site. The higher level of cell death within the skin in NP treated skin samples 
translated into a much larger surface area of live and dead cells than i.d. groups, measuring 
41.2 mm2and 0.07 mm2, respectively. This is schematically represented in Figure 4.12, where i.d. 
causes cellular damage only at the needle insertion site (with some minor interspersed dead cells), 
while the NP induces dead cells in a regular pattern across the whole array. Of note, higher cell 
death levels on the edges were expected due to the tissue deflection and hence higher stresses 
encountered by the cells [602]. It was speculated a higher co-localisation of viable cells, with 
payload (i.e. dye, antigen) and danger signals was achieved by NP than i.d. injections based on the 
number of projections penetrating the skin and the calculated surface areas. 
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Figure 4.12: Schematic of local cell death post Nanopatch™ application and i.d. injections in mouse ears. 
Saline (light blue) administered either by i.d. injection or dissolving off coated NP projections. i.d. injection causes cell 
death (magenta) predominantly around the insertion site within the VE and dermis, causing a bleb formation in the 
latter, with interspersed viable cells (green). NP induces highly localised cell death in the VE and minimally in the 
dermis, live cells. Abbreviations: i.d., intradermal; NP, Nanopatch™; SC, Stratum corneum; VE, Viable Epidermis. 
In the most closely related study investigating cell viability in the skin following vaccine device 
application, Raju et al. measured cell death following the ballistic delivery of micro-particles to skin 
[242]. Specifically, they found a poorly-controlled ‘dead zone’ in the centre of the target site, with 
only the skin target periphery containing both viable and dead cells [242]. The widespread cell 
death observed post ballistic bombardment of high micro-particle density (2 particles/ 1000 µm2) to 
skin resulted in ~90% cell death at the centre. This contrasts the results presented herein in Figure 
4.5, in which localised cell death was observed around the NP penetrating the skin, adjacent to 
viable cells. The highly localised cell death induced by NP application or seen around needle 
insertion has to the best of the author’s knowledge not been previously described. Although particle 
sizes were not disclosed, several studies have trialled particle-based vaccine delivery (e.g. 
PowderJect) for seasonal influenza using an HA-encoding plasmid [603, 604]. Even though the 
same tissue was targeted as with the NP or i.d., immune responses were generally below the 
protection level required to license influenza vaccines in Europe [603] (HI titre increase ≥4-fold in 
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at least 70% of the subjects). These studies however did not include i.m. or i.d. control groups, 
making direct immunogenicity comparisons to existing delivery methods impossible. It could be 
that the level of evoked cell death was excessive [242], that inadequate delivery to, activation or 
death of APCs [162] may have also played a role or that some APCs including LCs and dDC sub-
populations may not be as important in the mode of action of skin vaccination as previously 
proposed [605].  
The smallpox vaccine had been successfully delivered for decades using needles scratched across 
the skin surface before its eradication. Recently, it has been shown that this s.s. process generated 
improved immunity of an orthopoxvirus vaccinia virus vaccine [207], with the physical disruption 
of the epidermis when compared to parenteral or even i.d. vaccination. However, vaccinia is a 
highly virulent virus that has evolved to replicate within the skin; yet, they did not explore the 
effects of the physical interaction alone (i.e. without vaccine), or interrogate cell death as a 
modulator for enhanced immunogenicity. One challenge to carrying this work out is inherent 
variability of s.s. and delivered dose per individual. Widera et al. found after application of  
400-600 µm long MN, that the observed bleeding suggests some tissue damage although no 
infections or scarring was observed [262]. Findings similar to those presented herein showed that 
the cellular damage observed post i.d. injections were also observed during stretchability tests of the 
dermis. Specifically, in reconstructive or cosmetic surgeries, expandable balloons have been 
inserted into the dermis to stretch the skin, causing in morphological changes of keratinocytes and 
basal cells including increased mitotic activities, and resulting in a thinning of the dermis but 
maintained VE thickness with no obvious tissue damage (reviewed in [123, 606]). Yet, this type of 
investigation – directly exploring the link between skin cell death by device insertion and vaccine 
delivery upon enhanced immunogenicity – has not been carried out before, to the best of the 
author’s knowledge. 
4.4.2 Characterisation of cell death 
Classification of the type of cell death is important for characterising and understanding the 
subsequent immune responses [441, 510]. Importantly, co-delivery of apoptotic cells or apoptotic 
gene-encoding plasmids, dead cells in general as well as the release of DAMPs have been described 
in enhancing cellular and/ or humoral immune responses to antigens [358, 392, 393, 511, 558, 607]. 
More recently however, a study found that necrotic rather than apoptotic encoding molecules 
resulted in enhanced systemic immune responses [608]. Specifically, plasmids encoding the HIG-1 
GAG gene under the CMV promoter in addition to perforin (inducing cell lysis; necrosis) were able 
to induce DC activation in dLN coupled to enhanced CD8+ T-cell responses and better viral 
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clearance after challenge with CMV. This was seen to a much lesser extent following delivery of 
plasmids encoding the HIG-1 GAG gene in addition to diphtheria toxin, inhibiting protein synthesis 
and leading [608]. This study was in contrast to others who found pro-apoptotic gene expression 
resulted in enhanced immune responses [511, 558]. Yet, it confirmed studies by others that necrosis 
is known to be more immunogenic than apoptosis [334, 545]. Gargett et al. concluded that a 
threshold of antigen expression in addition to cell death (and thus the resulting release intracellular 
molecules) leading to DC activation contributing to this enhanced immune responses. Importantly, 
it was also stated that their delivery method did not evoke more tissue damage than i.d. injections; 
results however were not shown.  
Injured cell and inflammation can induce tissue damage [509]. Although no cell death was detected 
by histology following non-fractional LVA, enhanced cellular and humoral responses to OVA were 
observed [436]. Subsequently, micro-fractional laser assisted i.d. delivery of the mouse-adapted 
influenza strain PR8 exceeded i.d. or i.d./ LVA-adjuvanted delivery [204]. Chen et al. proposed that 
micro-fractional laser-induced cell death may result in DAMP release evoking improved humoral 
responses and viral clearance in the lung [204]; cellular damage and cell death are yet to be 
confirmed and characterised.  
Here, plasma membrane integrity and permeability was assessed by EB-uptake of skin cells in situ 
by MPM imaging. Due to the immediate uptake of the membrane-impermeable dead stains, it was 
assumed that the dead cells were of necrotic origin following EB-uptake into cells with 
compromised membranes. This however is yet to be confirmed by morphological examination 
using transmission electron microscope or histology and other exclusion methods to distinguish 
from other cell death types. The current characterisations pointing towards necrotic cell death 
around the NP projections and i.d. insertions support findings by others [247]. Gopee et al. 
identified necrotic cells in skin after tattooing of ink by H&E staining [247]. Here, cell death 
immediately post NP application was characterised as necrotic cell death based on morphological 
characterisations, with apoptotic cells occurring at time-points >6h following observation of 
crescent-shaped cells and apoptotic bodies as identified by MPM imaging (Figure 4.3, Figure 4.6 
and Figure 4.10). Apoptotic cells will be further discussed in Chapter 6 with regards to 
inflammatory infiltrates. Details of stress-induced cell death will be further discussed in Chapter 5. 
The flow cytometry and Western Blot results however were inconclusive. Based on image analysis 
post NP application/ i.d. needle insertion, a significantly higher number of necrotic cells post NP 
treatment than i.d. at t=0h were expected, with an increase in apoptotic cells at the subsequent time-
points. It was postulated that these different results obtained were due to the inherently different 
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sample preparation of cell suspension versus image acquisition. In particular, it is possible that 
necrotic cells were washed away or excluded as debris during sample preparation for flow 
cytometric analyses, hence very low numbers of AnV+PI+ cells were observed. The increase of 
AnV+PI- cells was hypothesised to consist predominantly of apoptotic neutrophils. This was based 
on the observed influx of neutrophils to the site of application (see section 7.3.1) followed by their 
apoptosis (within ~24h after NP or i.d. treatment). However, here, only live, apoptotic and necrotic/ 
late apoptotic cells were differentiated. Based on tattooing studies performed by Goopee et al., 
predominantly necrotic cells were expected post NP treatment and minimal necrotic cells around 
the insertion site after i.d. injection. This observation could neither be confirmed by flow cytometry 
not by immuno-blotting although MPM images supported the finding of primarily necrotic cell 
death immediately after NP and i.d. treatment followed by apoptosis at later time-points. As 
different cell death types can occur concurrently, characterisation becomes more difficult. 
Especially with macrophages and monocytes forming part of the innate immune response to tissue 
injury [182]. However, it can be debated whether HMGB-1 is released by apoptotic and secondary 
necrotic cells. In particular, Scaffidi et al. stated that HMGB-1 was not released by apoptotic or 
secondary necrotic cells [519] whereas Bell et al. reported that HMGB-1 was indeed released by 
secondary necrotic cells [589]. 
Additional studies should consider distinguishing between necroptotic, necrotic, secondary necrotic 
and apoptotic cells following NP and i.d. treatments by at least two different methods such as 
immuno-blotting, assessing PARP, cl. casp3, caspase-1, -8, -11, as well as active and inactive forms 
of IL-1β and IL-18 or TUNEL assay to measure DNA fragmentation as recommended by others 
[452]. To differentiate necrosis from other cell death types, exclusion principles should be applied.  
4.4.3 Cell death kinetics 
Skin injury induces local cell damage and cell death, which is quickly followed by wound healing, 
comprising of four distinct phases (coagulation, inflammation, migratory and proliferation stage) 
[609]. Cell death kinetics studies revealed dead cells were present in the VE and dermis until day 4 
post NP application, while cell death remained largely localised post i.d. injections at baseline 
levels. By contrast, Gopee and co-workers, who studied the immunological effect of tattooing with 
ink on dorsal skin in hairless mice, reported increased inflammation and necrosis within the 
epidermis until day 1 followed a decrease by day 3; inflammation and cell death were occurring 
later in the dermis, from day 3 onwards and persisted until day 7-10, depending upon the tested ink 
[247]. These discrepancies of cell death persistence could be attributed to the different needle sizes 
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and geometries used here versus Gopee’s group, as well as comparing dorsal versus ear skin, 
resulting in a ~4-fold skin thickness difference.  
Further, early studies have shown that breaching the SC causes an increase in TEWL through the 
disrupted SC and VE, leading to an immediate repair mechanism [610]. While no cell death was 
reported in other studies, skin recovery (resealing of the SC) following classical MN treatment 
varied upon the geometric shape and size of MN [594, 596, 611]. This suggested that the design of 
MN may have an impact upon the kinetics of wound healing. TEWL measurements post NP 
applications (Figure 4.8) exceeded previous published reports for re-establishing barrier function in 
rats using classical MN [596]; they reported that the barrier function was recovered within 3-4h 
with ~550 µm long MN applied, penetrating ~150 µm into excised abdominal rat skin. This TEWL 
difference may be attributed to the lower number of projections per cm2. Interestingly, no reports 
have investigated the skin’s barrier recovery post i.d. injections, making comparisons difficult. Yet, 
TEWL readings post i.d. injection of fluid indicated exiting of liquid post administration. It was 
postulated that the high interstitial pressure could explain the high TEWL readings, which dropped 
significantly within 30 min – correlating with the fast lymphatic drainage. Further, imaging 
techniques such as CLSM [223] may lead to an underestimation of pore closure, which may be 
reflected in a very short pore closure time (15 min). Also, while occlusion was not applied to the 
treated skin sites here, it was reported that occlusion significantly extends the pore closure time 
[594, 596]. Using human subjects, pore closure related to MN penetration depth was visualised 
using optical coherence tomography [226]. Initial penetration depths of ~160 µm measured ~80 µm 
after 85 min, indicative of a slow pore closure in the skin. The pore closure was to most likely due 
to tissue relaxation following MN application, based on recent evidence provided by Crichton et al. 
[612]. Specifically, Crichton was able to show that tissue relaxation of 60% was achieved within 
~5s [612], suggesting that the observed pore closure by Enfield  was due to tissue relaxation and not 
due to an early onset of wound healing [226].  
Application site may also play a role since MN application to buttocks or forearms in humans were 
reported to regain barrier properties as early as 2h after treatments [594] with upper limits 
exceeding 15h [593, 596]. Different application sites were not investigated in this study. However, 
pore closure can also be significantly affected by increasing MN array size and the projections 
length as well as the selected animal model [268, 594, 596]. Thus, MN shape, geometry and number 
of projections per area greatly affect the skin’s healing time [268, 594]. It is important to note that 
skin resealing studies investigate the skin’s barrier recovery, which does not directly correlate to 
wound healing on the cellular and physiological level [594], as seen in the presented results (Figure 
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4.6 and Figure 4.7). Wound healing comprising inflammatory cell infiltration and accumulation at 
the site of NP application and i.d. needle insertion are further discussed in Chapter 7.  
4.4.4 Skin morphology following Nanopatch™ and intradermal needle 
application to murine ear skin …… 
Consistent with other reports, MN application to human and rat skin results in temporary 
perforation of the skin strata, allowing either diffusion or permeabilisation of payload [332, 593, 
594, 596]. The physical differences between NP and i.d. are extensive, illustrating two very 
different methods of payload (i.e. antigen) delivery to the skin (Figure 4.1 and Figure 4.2). More 
specifically, NP application resulted in greater distortion of the skin leading to corneocyte and 
minor keratinocyte removal (Figure 4.1d and Appendix 1, Figure 10.1), similar to scarification, 
than i.d. needle. It was shown that administration of vaccinia virus by s.s. was essential to induce 
superior cellular and humoral responses than vaccine administered by i.p., i.m., s.c. or even i.d. 
immunisations [207]. Disruption of the epidermis by scarification has recently been demonstrated 
as essential for the elicitation of vaccinia virus vaccine-mediated immunity, and was ineffective 
when delivered by i.m. needle after tumour challenge [207]. Varying immunogenicity of NP and 
i.d. immunisations with differing levels of cell death is discussed in detail in Chapter 6. No major 
disruption of the skin was observed here following a single i.d. injection (Figure 4.1). 
4.4.5 Optimisation of cell death assay  
While cellular viability assays are well established [452], very limited assays were routinely in use 
to assess tissue viability in situ without distorting the tissue. Here, a viability assay was optimised 
based on a previously published method [242], enabling frontal but also lateral visualisation of cell 
death induced by the NP. While other approaches such as histology would allow visualisation of the 
tissue, the user would have to choose and specify whether lateral or vertical sectioning would be 
better. Using MPM imaging of tissue sections allowed visualisation and assessment of local or 
distal cell death of the whole tissue or high magnification post-immunisation. Through rigorous 
optimisation, the best staining parameters were empirically determined (Figure 4.3 and Figure 4.5). 
Since the establishment of this assay, it has been used widely within the research group but also 
within a company, reinforced the importance of this assay.  
Unlike other groups working with MN technologies [289, 311], the use of depilatory creams or 
shavers on the ears prior to NP immunisations has been avoided to minimise any potential variables 
affecting immunogenicity such as afferent (e.g. neutrophils, monocytes) or efferent (APC) cell 
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migration due to inflammation. While Ng and colleagues [143] showed that hair removal did not 
affect the migratory behaviour of dDC in the skin, depilatory creams were not applied as 
thiglycolate is known to recruit neutrophils to sites of injection or application [339, 613].  
4.5 Conclusion  
To conclude, in this chapter a detailed study investigating the cellular damage following NP 
application and i.d. injection in murine skin tissue was reported for the first time. With the sub-
hypothesis 1 being confirmed following visualisation, partial characterisation and quantification of 
local, discrete cell damage in skin following NP application, the work presented in this chapter 
yields insights into how highly localised cell death following NP application could be exploited 
within the skin for altering the immunogenicity of vaccines. This points to the importance of cell 
death following physical injury to skin as endogenous adjuvant: co-delivering cytokines and 
DAMPs (discussed in Chapter 6 and Chapter 7) released from neighbouring live and dead 
epithelial cells, and not only harnessing the skin’s potential by targeting vaccine directly to the 
skin’s APCs. This paradigm of cell death contributing to enhanced immunogenicity has been 
previously proposed and will be studied in more detail in the following chapters. As a result, 
Chapter 5 will explore how cell death can be manipulated by changing the NP application 
parameters and investigate what level of stresses the cells are exposed to before dying.  
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Chapter 5  
Impact of varying application parameters on induction of cell 
death 
5.1 Introduction 
In Chapter 4, an in situ cell death assay was established, which was used to quantify and 
characterise cell death following NP application and i.d. injection in murine tissue. Being able to 
induce different levels of cell death in a controlled manner in situ would enable to study if and to 
what extent cell death affects the resultant immunogenicity in MN-based immunisations. Therefore, 
this chapter addresses the question of whether altering the NP application conditions affect the cell 
death and whether a threshold for the mechanical conditions causing cell death in skin can be 
established. The effects of cell death on immunogenicity using several NP application conditions 
will be further investigated in Chapter 6.  
While i.d. injections are generally considered as a ‘quasi-static applications’, i.e. comparatively 
slow insertion of the needle into the skin with a slow but regular injection of the antigen, MN 
application conditions vary greatly. For example, MN applications have been applied quasi-
statically i.e. manually by some groups, with an applied pressure of as little as 0.2-0.5 N [614] and 
up to 10-20 N [165, 170], whilst others opted for spring-loaded velocity-driven applicators [170, 
262, 266]. High velocity-driven NP application ranged from of ~1.96 m/ s [347] to 2.5 m/ s [350], 
equivalent to a peak application force of ~42 N to ~52 N for 10 ms, respectively. Others have 
reported MN application conditions between 0.05 J/ cm2 [262, 615] and 13 J/ cm2 [616]. The MN 
and NP application velocities are significantly lower than ballistic immunisation strategies, which 
require velocities of 160-640 m/ s [209, 617], 300-600 m/ s [618] and up to 670 ± 70 m/ s [242] for 
particle penetration. At such high application velocities, it is not surprising that tissue and cell 
damage is induced by the gene gun. Indeed, cell death post-immunisation was observed following 
gene gun application to murine skin using gold micro-particles[242].  This work demonstrated that 
the higher the particle numbers per tissue surface area, the higher the cell death, with over 90% of 
dead cells occurring within an area of 1000 µm2 at 4 MPa, 2 particles/ 1000 µm2 (the highest 
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pressure and particle density tested). Immunogenicity studies were not performed in conjunction 
with these mechanical studies; consequently, a correlation with cell death could not be drawn.  
Using oscillating instruments such as tattooing devices, oscillating at 100-145 Hz (100-145 
punctures/ s), dyes [247] plasmid vaccines [245, 253] and therapeutics [619] have successfully been 
delivered into skin. The mechanical disruption of the epidermis and upper dermal layers caused by 
tattooing was reported to cause oedema, necrosis, and local inflammation with inflammatory cell 
infiltration from 12h post-treatment but healed within 14 days based on histological examination 
[247]. Bins and colleagues hypothesised that the trauma inflicted to the skin by tattooing may serve 
as an immune stimulant, similar to an adjuvant [253]. Bins’ hypothesis was based on results 
indicating the more tattoo needle oscillations, i.e. needle penetrations into skin, the higher DNA 
expression of and specific CD8+ T-cell responses to influenza A nucleoprotein. Local inflammation, 
tissue damage and necrotic cell death – as observed following cutaneous adjuvant delivery [206] – 
were seen in the VE and dermis post-tattooing of inks [247]. The generated stresses following gene 
gun versus tattooing device are expected to be considerably higher than after NP application based 
on the oscillation frequency of the needle.  
Understanding how cell death varies as a function of NP array design and application conditions 
was the next objective. Using a mathematical model, the findings have been generalised by 
attempting to define mechanical parameters directly correlated with cell death (i.e. defining the 
mechanical stress threshold of epithelial cells). Therefore, the overall aim of this chapter was to 
conduct a detailed mechanical stress-dependent impact analysis of cell death following NP 
application to examine, quantify and assess varying levels of cell death by altering application 
parameters. This understanding will be useful to rationally design arrays and application conditions 
to generate customised death patterns, and hence, maximise the potential for increased 
immunogenicity exploring the physical immune enhancer effect (discussed in Chapter 6 and 
Chapter 7). 
5.2 Methods 
As outlined in Chapter 3, the following methods are applicable to this chapter: sections 3.1, 3.2.1 – 
3.2.8, 3.2.18 and 3.2.19.  
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5.3 Results  
Previous results using dynamic NP application illustrated highly localised cell death around the 
projections and the edges of the NPs (see section 3.3, Figure 4.5). To investigate the pressure-
dependence (as opposed to mechanical sheering caused by NP projections entering the skin) of 
cutaneous induced cell death, a flat-ended cylindrical punch was applied quasi-statically. Most 
importantly, this provided a more simple and controlled mechanical stimulus, compared to array 
application, and would allow a less complex mechanical approach to investigate a correlate between 
stress and cell death. 
5.3.1 Pressure-dependence of cell death by means of flat punch 
application 
First, skin tissue was studied to examine the maximum bearable pressure induced by masses before 
succumbing to distortional and/ or hydrostatic stresses. First, viability of the tissue was assessed 
after a flat bevelled punch (Figure 5.1a) was applied onto the murine ear skin. Preliminary 
experiments indicated no visible damage following application of <100 g in static flat punch 
applications (see Appendix 2, Figure 10.2). By increasing the mass to 0.15 kg, marginal cell death 
was visible at the edges of the flat punch (white arrows, Figure 5.1b). The observed cell death area 
and its radius increased significantly with an increase in weight. As expected, the increase in cell 
death area incurred underneath the flat punch but not beyond the 3 mm diameter of the punch, as 
indicated with a black pen (yellow arrows; Figure 5.1b). Interestingly, masses of 2.5 kg and above 
also induced cell death in the dorsal skin sides (see Appendix 2, Figure 10.3). This suggested high 
stresses localised across the whole ear, which were in agreement with the mechanical calculations 
(not shown). With increasing mass, the width of cell death also increased towards the centre of the 
flat punch application. To summarise, the higher the loaded mass, the greater the cell death 
observed on the ear skin. Cell death remained highly localised around the edges of the punch, 
suggesting that edges were subjected to higher stresses, though cell death was distributed further 
towards its centre with higher weight loads.  
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Figure 5.1: Multiphoton image analysis of cell death induced by flat punch application onto murine ear skin. 
Murine ventral ear skin was exposed to flat punch application (see section 3.2.2) with different masses applied to 
induce different stresses; tissues were stained for cell viability using AOEB. (a) Flat punch made from stainless steel; 
(b) Schematic of a flat punch applied onto murine ear skin. (c) Murine tissue post flat punch application illustrating an 
increase of cell death with increased weight applied on top of the flat punch. Area of flat punch application was 
encircled with a pen (yellow arrows) while cell death (magenta) is highlighted by white arrows while.  
5.3.2 Correlation of cell death and stress calculation  
Based on the visualisation of cell death in murine tissue post flat punch applications, a quantitative 
analysis was performed to compare the fluorescence intensity profile with computed distortional 
and hydrostatic stress distributions. Stress is a measure of force per unit area, given as  
𝝈 = 𝑭
𝑨
 ,  
where σ is the stress, F the force and A the area of applied stress. Within this study, two forms of 
stresses were investigated, namely the Von-Mises (i.e. a distortional component, representing the 
distortion of a body) and the octahedral normal stress (i.e. a hydrostatic component, representing the 
compression of a body) as schematically represented in Figure 5.2a. The stresses were measured by 
quantifying the intensity thresholds of cell death post flat punch application on murine ear skin. 
Note that, the Von-Mises stress component was chosen also because has been used to model failure 
and fracture of ductile materials, including the skin. On the other hand the octahedral normal stress 
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is the hydrostatic counterpart, and was also studied to assess the role of non-distortional stress on 
cell death [602, 620, 621], (Figure 5.2a). Importantly, a significant correlation between stress and 
cell death would further support the stress-death causality hypothesis of and allow determination of 
a stress-threshold for skin cell death.  
The mean radial fluorescent distribution was extracted from the images for each weight (see Figure 
5.1b left) using MATLAB and compared with radial stresses computed using mathematical models. 
This allowed for qualitative investigation of the correlation between stress and cell death. More 
specifically, the distortional and hydrostatic stresses (that are of different magnitudes) resulting 
from quasi-static application of flat cylinder onto a linear-elastic infinite half-space (i.e. 
Boussinesq’s problem; [602]), were calculated. A stress-measure that combines the distortional and 
hydrostatic components was also calculated as explained in the methods (see section 3.2.18). 
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Figure 5.2: Computational analysis of distortional and hydrostatic stresses cause by flat punch application to 
murine ear skin.  
Analytical calculation of distortional and hydrostatic stresses caused by flat punch application to murine ear skin. 
(a) Schematic of distortional and hydrostatic stress generation. (b) Radial distortional and hydrostatic and combined 
stress curves; (c) Correlation between mean radial death fluorescence intensity (left; the vertical line marks the punch 
edge), and radial hydrostatic stress caused by punch (right).  
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As expected, the distortional stress resulted in a sharp peak at the edge of the punch (r =1.5 mm), 
with increasing mass resulting in higher Von-Mises stresses (Figure 5.2b left). The highest mass of 
4.0 kg on a flat punch resulted in 14 MPa. By contrast, the octahedral stresses were elevated over 
the flat punch surface and increased towards the outer edges of the punch (r = 1.5 mm) with a sharp 
drop off thereafter (Figure 5.2b right). Figure 5.2c (left) shows the mean radial death distribution 
(i.e. EB fluorescence intensity) below the punch for different weights, based on the fluorescent 
images. Hence, Figure 5.2c shows that there is a qualitative correlation between cell death 
distribution and hydrostatic stress distribution (a qualitatively better correlation than with other 
components). This suggests that, in a static flat punch application, high compressive stress induces 
cell death. In addition, negligible death was observed for the lowest weight, indicating that ~1 MPa 
is the threshold of cell death in murine ear skin. Of note, hydrostatic stresses of ~5 MPa caused 
100% of cell death. While this did not indicate that distortional stress does not affect cell death, this 
may point towards a threshold over which cell death is elicited by distortional stress. Yet, it is 
important to acknowledge that skin is lacking shear connections due to its fibered architecture, 
which prevents formation of high shear stresses. In conclusion, an approximated threshold of cell 
death for skin cells was defined as a load of ≥1 MPa by comparing in situ imaging with mechanical 
modelling.  
5.3.3  Varied application parameters to induce different levels of cell 
death 
Establishing varying levels of cell death was essential to study the correlation between cell death 
and immunogenicity studies (discussed in Chapter 6). Since a range of cell death levels were 
inducible using differing weights, several factors for NP application were altered to observe such an 
effect. To achieve this, various NP application parameters were tested including quasi-static and 
dynamic NP application, varying application velocities and number of projections.  
5.3.3.1  Quasi-static Nanopatch™ application 
The effect of mechanical load on cell death was explored by applying the NP to skin with lower, 
quasi-static loads. This analysis would assist in determining how much damage is induced by 
projections rather than the dynamic application velocity. NPs were applied as outlined in section 
3.2.1.3. Four masses were applied to an area of 0.16 cm2. Lower loads of 0-30 g neither induced cell 
death in an array pattern resembling NP projections nor yielded quantifiable levels of cell death 
above background levels (see Appendix 2, Figure 10.4). Masses of 85.0 g plus the NP yielded 
8.6 ± 1.3% of dead cells with low distortional and hydrostatic stresses (Figure 5.3a). Cell stress 
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levels were much more pronounced when 500 g was statically applied above the NP, resulting in 
27.5 ± 3.7% cell death (Table 5.1) – statistically more than with a dynamic NP application (Figure 
5.3b).  
Separately, the Von-Mises (octahedral and combined) stresses caused by static application of NPs 
were computed as explained in section 3.2.18 and [602]. Figure 5.3 shows the resulting stress 
curves for the two masses that induced measurable levels of cell death (85.0 g and 500 g) with an 
outline of the stress curves of three representative NP projections (spaced 70 µm apart, intersecting 
the x-axis at -70, 0, 70 µm; Figure 5.3a and b). More specifically, it was found that, irrespective of 
the weight, the SC (blue curve) was exposed to significantly higher levels of stresses than the VE 
(magenta curve). This was expected considering the SC is considered as the stiffest skin layer with 
an approximate Young’s modulus of 1-30 MPa [612], and that it is in direct contact with the tip; its 
failure is representative as the skin’s breakage due to stress, hence penetration into the underlying 
skin strata [621]. By contrast, the VE experienced much lower stresses than the SC prior to 
succumbing to cell death. Interestingly, 5-fold higher weights induced approximately 5-fold higher 
stresses in the SC, while only 2-3-fold higher in the VE. In agreement with the results from flat 
punch applications, cells experiencing ≥1 MPa stained positive with EB, indicating cell death. 
However, cell death thresholds in quasi-static NP applications differed depending upon the applied 
masses (0.05-0.15 MPa) and appeared to be much lower than with flat punch applications. This 
could be due to the errors in estimating the stress induced by the sharp NP projections. In fact, the 
small-strain linear-elastic model cannot account for the large-strains caused by contact with sharp 
tips. To summarise, the data does not suggest a correlation or dependence of applied weights and 
stresses upon cell death in skin strata, with cell death thresholds being defined as 0.05-0.15 MPa in 
quasi-static NP applications.  
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Figure 5.3: Different levels of cell damage caused to skin following static Nanopatch™ application.  
Four masses (6.0 g, 30.0 g, 85.0 g and 500.0 g) were placed above a NP to mimic static application conditions. 
Immediately after a 2 min application, tissues were excised, stained with AOEB and imaged by CLSM/ MPM. 
Observed cell death and elevated stresses incurred after the addition of loaded mass of (a) 85.0 g and (b) 500.0 g above 
the NPs. Stress curves of the SC (blue) and VE (magenta) with average width of cell death as border (pink box). NP, 
Nanopatch™; SC, Stratum Corneum; VE, Viable Epidermis. Original magnification: 20x; Images representative of n=2 
with 6 x 36 projections being measured while stress curves are representative of n=4.  
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In addition to the weight-dependent cell death dependence, it was found that with increased static 
weight load, the radii of cell death increased as depicted in Figure 5.3 and Table 5.1. This 
represents a significant increase of live-dead cell interface area as well as significant increase of cell 
death volume – based on calculated approximations (see Table 5.1). This could be of potential 
significance regarding quantification of payload delivery (i.e. antigens, dyes and other molecules) to 
individual cells and/ or skin strata, which will be further discussed in Chapter 6. Not surprisingly, 
using 500.0 g load in static NP applications, the resulting penetration depths were also significantly 
deeper (69 ± 6 µm) in comparison to lower mass of 85.0 g (27 ± 7 µm) (see Appendix 2, Figure 
10.5). This deeper penetration into the lower dermis also further supports the higher cell death level 
observed with a 500 g load. To summarise, static mass application of ≤30 g did not result in 
measurable cell death or stresses; while an increase of static weight loads resulted in more 
consistent skin penetration, all tested parameters including cell death, distortional and hydrostatic 
stresses as well as live-dead cell interface areas and volumes increased with higher loaded weights 
during static NP applications.  
Table 5.1: Cell death caused to skin following quasi-static Nanopatch™ application.  
Quasi-static NP application approximated of a 1) live-dead cell interface as cylinder with a thickness of 20 and 75 µm 
for the low and heavy masses tested, respectively; 2) live-dead cell volume of a cylinder with a thickness of 20 and 
75 µm for the low and high masses tested, respectively (n=2 ears; 15 data points each, shown as means ± SD).  
 Total mass 
placed on NP 
(A= 0.16 cm2) 
Cell death Radii of 
cell death 
(µm) 
Live-dead 
interface 
area1 
Volume of 
cell death2 
Penetration 
depth 
Static NP 6.0 g  
(~37.5 g/ cm2) 
background 
levels (~3%) 
N/A N/A N/A N/A 
Static NP 30.0 g 
(~188 g/ cm2) 
background 
levels (~3%) 
N/A N/A N/A N/A 
Static NP 85.0 g 
(~530 g/ cm2) 
8.6 ± 1.3% 12.1 ± 3.3 
µm 
~5.1 mm2  ~30.4 mm3 25 ± 18 µm 
Static NP 500.0 g 
(~3125 g/ cm2) 
27.5 ± 3.7% 19.4 ± 5.6 
µm 
~30.1 mm2 ~286.1 mm3 60 ± 18 µm 
 
5.3.3.2 Effects of dynamic Nanopatch™ application with varying projection 
shapes 
Application methods for consistent penetration of all skin strata into murine ears [170] and 
quantified the resulting cell death levels have been previously established (see Chapter 4 and 
[344]). Dynamic NP application using conical projection shapes (see Figure 4.1 and Figure 5.4a.i) 
were next compared against different projection shapes available within the D2G2 research group 
(Figure 5.4b-d.i). Note that due to the large variation of penetration depth using quasi-static NP 
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application, only dynamic NP applications were used to ensure sufficient penetration depth and 
penetration of >95% of the projections [170] in this and the following experimental setups. All 
projection shapes were applied with the same application parameters as outlined in section 3.2.1.2 
and resulting cell death analysed as described in sections 3.2.4-3.2.5.  
SEM imaging revealed that standard NP projections consisted of a straight shaft of approximately 
23 µm width and 75 µm length with a tapered tip of 35 µm length (Figure 5.4a.i). 2-step 
projections averaged 23 µm in width and 75 µm length with a tapered tip of ~18 µm width at the 
step and 35 µm in length (Figure 5.4b.i). The 1-step projections averaged 25 µm in width and 
narrowed continuously toward the tip (Figure 5.4c.i). Lastly, thin projections measured 13-15 µm 
in width (Figure 5.4d.i). All projections measured ~110 µm in length with the exception of the thin 
projections measuring ~ 100 µm with tip radii of ~ 1 µm. Using MPM imaging of AOEB stained 
tissue, no statistical significant difference in cell death was detected between the standard and  
1-step or thin NP projection shapes, causing 14.6% ± 2.5%, 15.0% ± 1.6% and 15.7% ± 2.2% of 
cell death, with p=0.58 and p=0.42, respectively (Figure 5.4a.ii, c.ii, d.ii and e). However, 2-step 
projections resulted in a significantly higher level of cell death with 22.5% ± 5.1% (Figure 5.4b.ii 
and e) when compared to the standard projections (**, p=0.0057). A significant difference was also 
observed when 2-step projections were compared to the other groups (1-step versus 2-step  
*, p=0.004 and 2-step versus thin *, p=0.0125). It was speculated that the additional sharp step 
induced increased stresses and pressure around each projection, leading to more localised cell death 
within the VE and dermis. Unexpectedly, thin projections did not significantly reduce the total 
amount of cell death per area, measuring 15.7% ± 2.2% (ns, p=0.419) in comparison to the standard 
projections. This may be due to similar penetration depth of the NP and little distortion of the tissue 
around each projection. Taken together, significantly higher levels of cell death were induced with 
2-step projections while no significant differences were measured by MPM using the standard,  
1-step or thin NP projections shapes. However, due to limited supply and difficulties experienced in 
manufacturing reproducible 1-step, 2-step or thin projections, all subsequent work was carried out 
with the ‘standard’ NP projections, unless noted otherwise.  
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Figure 5.4: Scanning electron microscopy images of various Nanopatch™ projection shapes and their effect of 
cell death generation in murine ear skin.  
Through variations of the etching process within the DRIE process, various Nanopatch™ projection shapes were 
produced [348]. These were imaged by SEM; left row, denoted with i) and subsequently applied to murine ear skin. 
Ears were excised and stained with AOEB for cell viability as analysed by MPM-based. The tested projections shapes 
are represented as (a) standard projections, (b) 2-step projections, (c) 1-step projections and (d) thin projections. Images 
representative of n=3 (naive) or 6 (NP groups). NP, Nanopatch™; MIP, Maximum Intensity Projection; SEM, Scanning 
Electron Microscope. Quantifications of cell death were based on n=3 (naive) or n=6-7 (NP) using Imaris; shown are 
maximum intensity images (MIP). Statistical analysis performed based on a one-way ANOVA with Tukey post-
comparisons test (ns p>0.05, ** p<0.01). 
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5.3.3.3 Effects of varying application velocity using a plastic or brass piston 
applicator on cell death in dynamic Nanopatch™ application 
With a defined NP projection shape, reproducible penetration depths and levels of cell death were 
obtained. Application velocity as a potential cell death modulator was subsequently investigated. By 
maintaining the application parameters (standard NP, 2 min application on vinyl backing) but 
comparing a lower (1.8 m/s) and higher velocity (3 m/s) against the standard NP application settings 
(2.3 m/s), the first objective was to quantify varying levels of cell death. In addition, examination of 
penetration depths into murine ear skin were performed to ensure that the same skin strata and 
approximately the same number of cells were targeted (see section 3.2.7). 
First, the varying levels of cell death post NP applications were investigated. Using an increased 
application velocity (3 m/s), no statistically significant increase of cell death was seen  
(16.4% ± 2.2%) compared to the standard application velocity (2.3 m/s; 16.5% ± 4.0%; Figure 5.5a 
and c). This was unexpected as a higher level of cell death was expected due to the faster 
application and hence higher stresses. This is possibly due to the fact that skin rupture relaxes stress 
in the layers, preventing generation of large areas of high stress and should be further investigated 
using a mechanical model implementing penetration behaviour. Further, lower application velocity 
(1.8 m/s) resulted in only marginally lower cell death levels (15.7% ± 1.9%) compared to the 
standard application method (p=0.46). Second, measuring penetration depths at lower and higher 
velocities differed statistically significantly from the standard NP application condition 
(68.8 ± 15.0 µm), penetrating 49.6 ± 11.4 µm and 84.3 ± 10.4 µm deep into the tissue, respectively 
(Figure 5.5b and c; **** p<0.0001). It was observed that the higher the application velocity, the 
more corneocytes of the SC had been removed upon NP application (Figure 5.5c). Representative 
images are given in Figure 5.5c. These results are partially in agreement with the quasi-static NP 
applications (Figure 5.3), where cell death levels increased when projections penetrated into the VE 
and dermis rather than the VE alone. Together, these results indicate that using standard NPs (see 
Figure 5.4), no statistically significant different cell death levels were obtained by applying NPs at 
higher or lower velocities despite significantly different penetration depths. The obtained results 
further suggest that velocity and force play only a role in cell death if they enable NP penetration 
from VE into D. But there is no significant difference in cell death when NPs penetrate papillary or 
reticular dermis.  
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Figure 5.5: Impact of varying Nanopatch™ application velocity upon cell death and penetration depths. 
Lower (1.8 m/s) and higher (3 m/s) NP application velocities were altered by using brass and plastic pistons in addition 
to different springs within the respective applicators with standard conditions defined in section 3.2.1.2. 
(a) Quantification of cell death following a 2 min application of uncoated NP to ear skin. Skin was excised and stained 
with an AOEB cocktail as previously described (section 3.2.4). (b) Penetration depth measurements were taken from 
murine ears to which coated NPs (1% 505/515 FluoSpheres® solution; green) were applied. Ears were embedded in 
OCT, 10 µm sections collected and penetration depth measurements completed using CLSM/ MPM. Penetration depths 
were measured from the breach of the SC until the lower FluoSpheres® deposition in the dermis, distinguishable by the 
collagen (blue). (c) Representative images of (a) left or (b) right. Images representative of at least n=5 (cell death) or 
n=4 with 10 slides each for penetration depth measurements. Represented are mean ± SD and statistical analyses were 
performed based on a Kruskal-Wallis test with Dunn’s multiple post-comparisons test (a) or an ordinary one-way 
ANOVA with Tukey multiple post-comparisons test (****, p<0.0001).  
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5.3.3.4 Altering number of Nanopatch™ projections by increasing the projection 
spacing  
As shown in section 5.3.3.3 (Figure 5.5), generation of statistically significant differences in cell 
death levels by altering the dynamic NP application velocities as assessed by MPM imaging were 
unsuccessful. An obvious alternative to alter the cell death was to amend the total number of 
projections per NP. Therefore, to investigate the relationship between cell death and NP projections, 
the NP design was altered by varying the projection densities and hence cell death profiles. By 
increasing the spacing from 70 to 100 µm between projections, the total number of projections was 
consequently reduced from 21,000 to 10,000 projections/ cm2, respectively. Due to the lower 
number of projections on the array, the application force and hence application velocity was scaled 
back. In particular, because the array contained half of the projections, the application force was 
halved to maintain the overall force per projection constant based on: 
𝐸 = 𝐽 ×  𝐴, 
where E is the energy, J the fracture toughness and A the area of fracture; A increases 
proportionally per NP projection). This enabled sufficient penetration depth as verified by 
penetration depth measurements, although marginally shallower than a standard NP (see Appendix 
2, Figure 10.6). On the other hand, more dense arrays would have reduced penetration depths and 
hindered consistent penetration into skin. Therefore, to enable studies with a higher proportion of 
dead cells, 3 standard NP applications were applied sequentially (3x 21,000), resulting in up to 
~63,000 projections/ cm2 partially overlapping. In this experiment, groups of 5 mice were subjected 
to NP application using the standard projection shapes with varying projection numbers as 
previously mentioned. Excised tissues were stained with AOEB, imaged by MPM and quantified as 
described above.  
As expected, an increased number of projections/ cm2 correlated with an increase in cell death 
(Figure 5.6a). Quantification of cell death yielded 8.2% ± 1.1%, 13.2% ± 0.8% and 45.4% ± 4.0% 
of dead cells induced by 10,000, 21,000 and ~63,000 projections/ cm2 as shown in Figure 5.6b. 
Interestingly, the ratios of cell death per projection remained approximately constant, representing 
0.6-0.8% of dead cells per 1000 projections, or in absolute numbers 23.5 ± 4.5 dead cells/ 
projection, penetrating the skin. To summarise, an increased number of projections resulted in 
increased levels of cell death by maintaining a constant ratio of cell death per projection.  
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Figure 5.6: Association between Nanopatch™ projection density and induced cell death.  
Nanopatch™ containing 10,000, 21,000 or 3x 21,000 projections/ cm2 were applied onto murine ears for 2 min, tissues 
excised, stained with AOEB and imaged by MPM. (a) MPM images were compressed into MIPs with live (green) and 
dead (magenta) cells clearly distinguishable. (b) Quantification of cell death per 16 mm2 calculated as described in 
3.2.5.1. Experiments were performed in duplicate with n=3-5; depicted are replicates with their means and statistical 
analyses were performed based on ordinary one-way ANOVA with Tukey multiple post-comparisons test (** p<0.01, 
**** p<0.0001).  
5.4 Discussion  
5.4.1 Variation of cell death levels following static application of a flat 
punch and the Nanopatch™ 
The skin as one of the largest human organs is continuously subjected to forces, pressures and 
deformations due to constant movements and daily activities. Skin is difficult to tear due to its lack 
of shear connections, meaning that it can be ‘easily’ cut or pierced but not torn [622]. This is due to 
the skin’s structure, including its network of collagen and elastin fibres. These fibres serve as 
cushion, providing tensile elasticity and strength to the dermis and enabling its stretching and 
compression to a certain degree [623, 624]. The presented results illustrated that after flat punch 
application, cell death was induced by the applied pressure although no penetration occurred 
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(Figure 5.1). Yet, cell death occurs following prolonged exposure to pressure or penetration of the 
skin layers as seen with masses exceeding 1 kg (flat punch) or 85 g (static NP). Indeed, the results 
presented in this chapter further support this as seen in the highly localised cell death around the 
projection insertion sites, irrespective of the shapes and weights as shown in Figure 5.1 and Figure 
5.3. This finding was also consistent with mathematical models supported by experimental data 
[574]. Meliga et al. found that by maintaining a constant number of microprojections but varying 
their spacing, stress levels did not significantly alter although penetration depths were inversely 
proportional to the size of the array [574]. 
The cell death threshold of skin tissue was approximated as ≥1 MPa in murine ear skin using a 
cylindrical flat punch (Figure 5.2). While still at a preliminary stage, this raised the question of if 
and how stresses and cell death induced by the NP application were comparable. Based on an 
approximated peak force of 42 N, divided by the surface area of the projections, the stresses 
induced by dynamic NP application measured 1.8 MPa, which is above the calculated ≥1 MPa 
threshold of cell death. However, the mathematical modelling of static NP applications yielded 
much lower stress thresholds for cell death in quasi-static NP applications, calculated as  
0.05-0.15 MPa. Firstly, this demonstrates that not the same thresholds for stresses were found when 
different weights were applied; this could be due to limitation of the mathematical model. Models 
such as a Finite Element Model have demonstrated to be of better suitability by incorporating the 
shape and velocity used for MN (or here NPs) projections penetrating the skin in addition to the 
stiffness of the various skin layers [277, 573, 574]. Secondly, that the estimations of cell death 
radius (as measured by EB-stained cells) were not representative enough as to what level of stress 
the epithelial cells can survive, die instantaneous (e.g. necrotic) or undergo a programmed form of 
cell death apoptotic/ pyroptotic/ necroptotic cell death. To address these questions, future work 
should use advanced Finite Element Models to create better models inclusive of the heterogeneous 
skin strata in addition to detailed analysis on the protein level in addition to image acquisitions. 
Separately, while not addressed in this thesis, it must be acknowledged that the impulse (force x 
time) between quasi-static and dynamic NP application could possibly be approximated. While 
dynamic NP application (high peak force over a short time) resulted in 36-fold higher stresses than 
quasi-static (low peak force over extended time) NP application, the 2 min longer application time 
would not yield the same impulse. However, these preliminary findings should be further 
investigated, in particular measurements of force over time following quasi-static NP application. 
A dependence between applied time, pressure load and tissue damage have been extensively studied 
in pressure ulcers and deep pressure sores caused by tissue deformation, inadequate supply of blood 
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and lymphatics, reperfusion and ischemia [625-629]. Using various animal models [628, 630-633], 
44 g/ cm2 were sufficient to induce mild ischemia tissue while muscle cell death were being induced 
by as little as 60-80 g/ cm2 (6-8 kPa) and complete anoxia and tissue necrosis were induced by 
200 g/ cm2 [634]. These loads were much lower than loads required to induce cell death in static NP 
applications, where 85 g (530 g/ cm2) and 500 g (3125 g/ cm2) induced cell death in the skin. By 
contrast, static load of 30 g (200 g/ cm2) did not result in any cell death levels above background 
levels, suggesting that shorter exposures to pressure loads (NP application: 2min) allows for higher 
loading onto tissue without inducing cell death (i.e. 30 g static NP application). This has been 
previously been postulated, although in different animal models [625, 631]. For instance, ≥32 kPa 
load for 15 to 60 min were required to induce muscular cell death in gluteus maximus muscle of rats 
while 9 kPa were sufficient to induce muscular cell death when pressures were applied for over 2h 
[631]. In pigs however, ~140 g/ cm2 applied for 10h or 680 g/ cm2 for 4h induced muscle damage 
but no obvious damage or cell death to the skin. By contrast, 280 g/ cm2 applied for 16h or 
830 g/ cm2 for 11h induced massive tissue necrosis and muscle damage due to ischemia reperfusion 
(arteriolar occlusion pressure; restriction of blood supply) [625].  
Further, the location of pressure application can also significantly affect the tolerable pressure; 
while ‘hard sites’ with little padded skin over soft tissue (hips or heels) are more susceptible to 
pressure loading, ‘soft sites’ (abdomen, thighs) have much higher tolerance levels for tissue 
compression [634]. Here, murine ears were considered as soft sites, especially when using a vinyl 
backing. The induced cell death by quasi-static NPs correlated with published studies where soft 
tissue sites could endure higher pressure loads (30 g or 200 g/ cm2) before developing tissue 
damage (90 g or 560 g/ cm2). However, it needs to be acknowledged that tissue necrosis due to 
ischemia reperfusion and anoxia and tissue necrosis due to mechanical rupture (i.e. needles, MN or 
NP projections penetrating the skin) are of different origin and therefore limit a direct comparison.  
Several reports indicated that muscle has a less lateral mechanical compression tolerance than skin, 
a multi-layered composite material, leading to earlier cell death detection in muscle than skin [625, 
626, 632]. This was demonstrated in an experimental in vivo setup using rats studying local 
responses by histology of the skin and subcutaneous tissues following exposure to continuous 
pressure loading of 13.3 kPa 6h daily for 4 days at the greater trochanter and tibialis areas [626]. In 
a similar study, 13.3 kPa were applied to the tibialis muscle 6h daily for 2 days assessing cell death 
in muscle due to pressure [635]. After this repeated and long-lasting pressure application, apoptotic 
cell death was found to be upregulated in the muscle as seen in cl. casp3 gene expression, TUNEL-
positive nuclei and increased Bcl-2 and Bax protein expression; unfortunately, presence of 
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inflammatory cells in muscle tissue were not investigated. Kwan and colleagues found that that 
epidermal pressure loading caused an approximately 70% and 50% reduced blood flow during 
compression in the trochanteric and tibialis muscle areas, respectively [626] with similar results 
reported by others [635]. Histological examination revealed no cutaneous tissue damage 
(characterised as thicker epidermis, accumulation of fluids, fibrosis, nuclear condensation and 
fragmentation) post 1 day of loading but was observed around the trochanter after 2 days of loading 
with damage persisting up to 7 days after the initial pressure loading. Time of pressure application 
therefore strongly influences tissue damage (e.g. through ischemia) and subsequently cellular death 
[631]. Since in the present study NP or flat punches were only applied for 2 min (significantly less 
than any other studies measuring pressure loads), it was speculated that it was sufficient to induce 
local cell death but short enough to not induce wide-spread cell death in the skin. Further studies 
should be carried out investigating a time dependence of cell death post static and/ or dynamic NP 
applications but also characterise the cell death at various time-points post quasi-static flat punch/ 
NP application. If possible, other animal models, e.g. pig skin models, which are considered as most 
representative of young human skin while rat skin was described to be most suitable as surrogate 
model for elderly skin [628] due to their respective skin thickness levels, should be considered as a 
more appropriate model for future clinical work (see Chapter 8).  
Thus, it was found that quasi-static flat punch and NP application induced cell death in murine ear 
tissue when stresses exceeded 1 MPa based on in situ MPM and stress-based impact analyses. In 
static flat punch and NP applications, cell death was highly dependent upon the applied weights 
(hence pressure). In particular, as demonstrated in Figure 5.1 and Figure 3.3, death distribution 
qualitatively correlated with hydrostatic stress distribution, indicating that compression stress 
contributes significantly to cell death with an estimated death threshold of ≥1 MPa, while this is 
significantly lower than previously reported values for individual cells such as E. coli bacteria with 
300-500 MPa, depending upon the strain and growth phase [636]. While the skin tissue is known to 
have the highest tolerance to pressure – compared to muscle or fat - [632], a dependence between 
cell death and pressure suggests that cells and tissue have specific levels of stress endurance. 
Considering that the skin is a heterogeneous layer, detailed studies identifying the individual stress-
thresholds for each strata would have implications for dermatologists and vaccinologists interested 
in cutaneous delivery routes.  
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5.4.2 Implications of geometric changes and dynamic Nanopatch™ 
application on cell death 
Manual insertion or low application velocity of MN yielded inconsistent penetration into tissue, 
partially due to tissue deflection, which has been observed by Martanto and others [262, 637]. 
Increasing application velocities from 1 to 3 m/ s indeed resulted in higher delivery of dyes and 
particles. Unfortunately, no penetration depth measurements were conducted [637]. One could 
assume that more consistent and/ or deeper penetration depth would result in higher levels of cell 
death. This however was not the case. In comparison to standard NP applications, lower application 
force was expected to result in marginally lower penetration depths and less cell death while higher 
application force should have induced more cell death. The cell death however, did not alter with 
the selected application velocities. This was expected as stresses do not change with velocity due to 
the resulting penetration (also known as fracture-driven stress relaxation). One possible explanation 
for the significant differences in penetration depths using higher and lower velocities but no 
differences in cell death could be that NP projections penetrating (i.e. through friction) the SC, VE 
and dermis cause the majority of cell death and not the application velocity. In other words, when 
tissue deflects, stresses increase within the tissue, but as soon as the tissue ruptures (i.e. NP 
projections penetrate the skin), the skin ‘relaxes’ and hence the stresses decrease.  
Using a flat punch, no penetration occurs, thus allowing uncoupling an increase in mechanical 
stresses and hence cell death of skin tissue. Therefore, higher application energy (as seen by 
applying the NPs at higher velocity) does not necessarily translate into greater stress. In terms of 
cell death, stress cannot be much higher than the skin breaking threshold. If stress exceeds the 
skin’s threshold, the skin will deflect and eventually break, resulting in a decrease of measured 
stress. This however requires a more sophisticated penetration model accounting for skin deflection 
followed by the SC rupture such as a finite element model with a hyperelastic layered model of skin 
[277, 574, 602, 621]. To increase the stress distribution and hence cell death, one would have to 
make blunt projections, or apply the array with enough force so that the base ‘hits’ the SC and 
causes widespread compression i.e. stress and cell death. Still, this would apply mostly to the edges 
of the array and particularly in the corners. Thus, it was concluded that during the penetration 
process into the VE and dermis, the shearing of the cells and/ or cell membranes was the primary 
cause for cell death rather than application velocity or force. 
 Dynamic application of MN resulted in more consistent penetration pattern into skin than static 
application (Figure 5.5). These results are in agreement with previous published studies, suggesting 
that short impact applications at an elevated velocity enable the breaking of the SC and penetration 
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of MN projection arrays into skin [170, 295]. Although cell death was found not to be proportional 
to penetration depth, higher levels of cell death were obtained with dynamic NP application when 
the same skin strata are targeted and low weights are applied (10 N or less). Investigating cell death 
in other murine skin sites following NP application was beyond the scope of this thesis. However, 
other sites containing thicker VE and dermal strata in murine skin sites such as flank should be 
explored to assess varying penetration depths and the resulting cell viability post NP and i.d. 
injections. This may enable testing of broader NP application conditions and hence the resulting cell 
death levels.  
Different MN of various geometric shapes, tip sharpness’s and projection lengths have been 
successfully applied to animal and human skin [262, 271, 638, 639]. While no other MN-based 
vaccine delivery studies have investigated skin-based damage upon MN application, it seems 
plausible that changing application velocity or projection geometries separately only play a minor 
role in altering quantifiable cell death with a lower frequency of cells in the dermis than VE. 
Locally increased stresses imposed onto skin such as by 2-step NPs are therefore likely to induce 
higher compression stresses associated with elevated shear forces and tearing of the skin. More 
specifically, the shoulder in the 2-step projections may create a blunt-forced entry point, where 
stresses propagate over a larger area, hence induce more stresses, which was seen in higher cell 
death. By contrast, the number or projections/ area did significantly affect the resulting levels of cell 
death. While significantly different levels of cell death were caused by 2-step projections in 
comparison to the other tested projection shapes, 2-step projections were not further investigated 
within this thesis; this was related due to inconsistencies in the manufacturing process leading to 
irregularities in the produced shapes. More recently, progress has been made by others in the 
research group regarding consistent production of several projection shapes. These NP 
configurations will be used for future immunogenicity studies repeating experiments presented in 
Chapter 6 and Chapter 7, which were beyond the timeline of this thesis. More advanced 
modelling approaches would be well received to predict interactions of MN with skin and cells, 
which have recently been set up by Meliga et al. [573, 574] due to the encountered limitations of 
the analytical model chosen in this chapter. 
5.5 Conclusion 
To conclude, the collective findings of this chapter indicated that the action of quasi-static flat 
punch or NP application induced less reproducible cell death while dynamically applying the high 
density MN projection array to skin inflicts reproducible cell death. This partially confirmed the 
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overall hypothesis that cell death can be modulated by changing application parameters. In 
particular, cell death was dependent upon the number of projections penetrating but independent of 
different application velocity, variable penetration depth, within the dermis or projection shapes. 
Cell death was observed when ≥1 MPa stress was applied using a small-strain linear-elastic model 
although the latter was not suitable for stress measurements following dynamic NP applications. 
While impulse was not directly assessed, a relationship of stress versus time based on the area of 
under the curve is likely. The possibility of altering levels of cell death will open possibilities of 
studying the effects of varying cell death on the immune responses using influenza as model 
antigen. These preliminary variations in application parameters require further investigation to 
ascertain an accurate cell death threshold for the skin. In Chapter 6, early innate immune responses 
will be studied followed by investigating whether altered cell death levels may function as physical 
immune enhancer.  
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Chapter 6  
The effect of cell death on vaccine immunogenicity: 
comparison of Nanopatch™ to intradermal injection 
6.1 Introduction 
Endogenous danger signals released from dead/ dying cells can enhance immune responses. 
Chemical adjuvants such as Alum, tomatine or L121 can induce cell death upon administration by 
acting as strong endogenous immuno-stimulatory agents (i.e. DAMPs) [357, 358, 467, 514]. Co-
administration of apoptotic cells or DNA vaccines encoding apoptotic genes [511, 558] as well as 
immuno-stimulatory molecules such as CpG sequences have resulted in enhanced cellular and 
humoral immune responses [640, 641]. Further, necrotic cells have shown to release danger signals 
functioning as endogenous adjuvants [392, 393], which contribute to APC maturation [334, 335, 
545] and enhanced antigen presentation [544]. This is thought to be due to a cascade of events 
initiated by released danger signals including HSP, ATP and HMGB-1 amongst others, resulting in 
cytokine and chemokine secretion leading ultimately to APC activation and migration [513]. 
Possible pathways for cell death induced signalling and downstream effects are described in more 
detail in Chapter 2, section 2.5.1. 
Separately, recent evidence suggests that delivery methods, which generate dead or dying cells, may 
also contribute to increased immuno-stimulatory effects. Following plasmid-based DNA vaccine 
delivery into the skin by tattooing devices, enhanced antigen-specific humoral and cellular 
immunogenicity over i.m. and s.c. routes have been observed using proteins of HPV type 16 [245, 
246, 249, 250] and influenza A-encoding nucleoprotein [253]. Bins and colleagues later 
hypothesised that the trauma inflicted to the skin from the multiple penetrations of the tattooing 
needle may have an immuno-stimulatory effect [255]. This hypothesis correlated with Gopee et 
al.’s earlier findings who reported cell and tissue damage post tattooing [247], although no link to 
enhanced immunogenicity was made. Gene gun-based particle delivery reportedly induced high 
levels of cell death upon cutaneous delivery [242], however, good transfection and gene expression 
rates following DNA vaccine delivery were generally achieved in addition to predominantly Th2 
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responses [reviewed in 642]. Furthermore, disruption of the epidermis by scarification has been 
demonstrated as essential for the elicitation of vaccinia virus-mediated immunity, and vaccination 
was not protective against tumour challenge when i.m. delivered by needle [207]. Similarly, 
directing a laser against skin followed by an OVA or influenza injection i.d. enhanced significantly 
humoral and cellular immune responses when compared to unadjuvanted control groups [436]. This 
increase was synergistically enhanced by the addition of chemical adjuvants [206], suggesting that 
LVA had similar immuno-stimulatory properties to adjuvants. Cell death and damage were later 
proposed to have a possible role in the LVA-enhanced immunogenicity due to the induction of pro-
inflammatory cytokines and inflammatory tissue [reviewed in 204]. To date, no other studies have 
investigated cellular damage caused by hypodermic needles or MNs with regards to vaccine 
delivery and its effect upon immunogenicity.  
Apoptosis, an immunologically silent form of cell death, does generally not result in an 
inflammatory response, although some reports have shown that apoptotic cells can induce DC 
maturation [643]. Necrosis, necroptosis or pyroptosis have been shown to be of inflammatory 
nature [187, 443, 513] due to the release of danger signals like DNA, ATP, MSU, HMGB-1 etc. 
These DAMPs have been shown to result in inflammatory cell infiltration, inflammasome activation 
that lead to caspase-1 activation and further chemokine and cytokine release (IL-1b and IL-18) and 
DC activation [187, 334, 509, 644]. Sensation of exposed F-actin filaments [645] from necrotic 
cells, and its binding to the Clec9A receptor on DCs, resulted in DC migration and activation [520, 
522, 523]. In addition, it has been show that cell death induced DC activation may result in 
enhanced T-cell responses. Lahoud et al. demonstrated that antigen delivery directly to Clec9A lead 
to enhanced CD4 T-cell and humoral responses, while delivery to other DC receptors such as 
DEC205 or Clec12A was not as efficient [173]. It is therefore possible that increased levels of cell 
death such as after NP immunisation lead to higher levels of inflammation that promote DC 
activation and CD4 T-cell responses. By contrast, i.d. injection resulted in very little cell death. 
Based on the enhanced immunogenicity results following delivery of unadjuvanted influenza 
vaccine by NP [3], the known induction of cell death by tattooing devices [247] and the immuno-
stimulatory effects of cell death [187], inflammation and cell death were hypothesised to play an 
important role in enhancing immune responses to MN and NP-delivered immunogens.  
With the cell death visualised and evaluated in the skin post NP application and i.d. injections 
(Chapter 4), understanding the effects on cell death on immunogenicity was the next objective. 
Therefore, the aim of the research described in this chapter was to determine antibody-mediated 
immunogenicity post influenza vaccine administration with respect to different levels of cell death 
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induced by NP and i.d. injections. It was proposed that cell death may act as a potential physical 
immune enhancer, leading to higher immunogenicity in NP than i.d. immunised groups.  
6.2 Methods 
As outlined in Chapter 3, the following methods are applicable to this chapter: sections 3.1, 3.2.1, 
3.2.3 – 3.2.6, 3.2.13, 3.2.16, 3.2.17 and 3.2.19.  
6.3 Results  
6.3.1 Anti-influenza antibody responses by Nanopatch™ delivery versus 
intradermal injection  
6.3.1.1 Delivery of vaccine to skin by Nanopatch™ induces a significantly greater 
IgG antibody response than standard intradermal delivery by needle  
Previous influenza immunisation studies compared only NP with i.m. groups [3, 280, 345], but not 
other needle-based routes. With the local skin cell death (Figure 4.5) and delivered payload profiles 
of NP and i.d. found to be highly contrasting (Figure 4.2), the subsequent step was to compare the 
resultant systemic immune responses between the two skin-based routes. Prior to application, the 
consistency of the coating morphology of NPs was assessed by SEM (Appendix 2, Figure 10.7). 
Coating delivery efficiencies were assessed, resulting in delivered doses being dose-matched 
between all NP and i.d. groups (Appendix 3, Figure 10.8). Antibody responses to Fluvax® elicited 
by NP delivery or by i.d. delivery using a needle to one ear per mouse were compared by ELISA. 
Overall, the resulting endpoint titres from all doses of Fluvax® tested were higher after NP delivery 
than those elicited by i.d. delivery with statistically significant differences detected with delivered 
doses of 1 ng (p=0.04), 5 ng (p=0.003), 10 ng (p=0.01), 20 ng (p=0.01), 50 ng (p=0.01) and 100 ng 
(p=0.04). Fluvax® delivery by NP elicited seroconversion in 100% of mice immunised with a 
single 5 ng dose, 80% seroconversion with 1 ng and 40% seroconversion with a 0.1 ng dose 
(Figure 6.1a-c). Standard i.m. delivery as control group correlated with previous published reports 
that used Fluvax® 2008 [3, 280]. Endpoint titres of ≥10 ng delivered by NP did not statistically 
differ from a standard i.m. Fluvax® dose of 6000 ng. In contrast, 50 ng of Fluvax® delivered i.d. by 
needle was required to achieve seroconversion in 100% of mice, which did not differ statistically 
from the i.m. control group (Figure 6.1a and b). The average endpoint titres in mice immunised 
with 10 ng and 20 ng of NP-delivered Fluvax® were significantly higher than mice immunised i.d. 
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with Fluvax® using a needle (p<0.001). Of note, ~15-fold higher titres were elicited by delivery of 
10 ng of Fluvax® by NP, compared to 10 ng delivered i.d. by needle. Alternatively, a 10-fold dose-
sparing effect was achieved when using NP compared to i.d. delivered Fluvax® (p<0.001). 
Together, these data demonstrated robust antibody responses in mice immunised with NP-delivered 
Fluvax®, compared to i.d. injected mice, illustrated in a 10-fold dose-sparing effect. This trend of 
higher immunogenicity in NP- than i.d.-immunised groups was similar to the observed trend of 
higher cell death levels in NP treated samples than i.d. injected tissues (see Chapter 4).  
  
Figure 6.1: Increased dose-sensitivity to antigen in Nanopatch™ immunised mice compared to i.d. injection.  
Endpoint titres of influenza vaccine (Fluvax® 2010) administered by NP or i.d. injections at various doses (0.1, 1, 5, 10, 
20, 50 and 100 ng; i.m. 6000 ng). (a) Dose response curve on log scale depicting the dose differences between i.d., NP 
and i.m.; (b) Same data as in a) plotted as endpoint titres to illustrate outliers; (c) Seroconversion of data from (a) and 
(b). NP, Nanopatch™ (▲), i.d., intradermal () and i.m., intramuscular (♦). Representative of two independent 
experiments; error bars show means + SD (a) or means ± SD (b). Statistical analyses between NP and i.d. groups were 
performed based on an ordinary one-way ANOVA followed by unpaired t-tests (*p<0.05, ** p<0.01, *** p<0.001). 
Image adapted and reproduced with permission from [344].  
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6.3.1.2 Functional antibody responses following Nanopatch™ and intradermal-
mediated vaccination 
To measure protective immunity in influenza-based immunogenicity studies, virus-neutralising 
antibodies against HA of influenza virus were measured from sera obtained in section 6.3.1 were 
used, and assayed for HI against all three influenza strains present in Fluvax®. Overall, 
A/California and A/Perth strains resulted in higher mean HI titres in NP than i.d. groups (Figure 
6.2). NP groups also induced higher HI titres than i.d. groups against A/Perth/16/2009 strain after 
delivery of 10 ng, 50 ng and 100 ng. Further, doses of 5 ng or above yielded HI titres of ≥40 in at 
least 60% of tested mice, with 100% above an HI titre of 40 receiving 100 ng Fluvax®. 
Surprisingly, the HI titre of the B-strain resulted in only one responder in each of the following 
groups: NP 50 ng, NP 100 ng and i.d. 100 ng, resulting in HI titres of 40, 40 and 20, respectively. 
Generally, i.d. groups did not result in any protective HI titres at any of the tested doses. 
Importantly, the non-responders in the i.d. groups (except for the 100 ng groups) and the large 
variation of the HI titres within each group resulted in no statistical significant difference. Together, 
these results indicated overall higher HI titres in NP than i.d. immunised groups as tested against 
A/California, partially higher HI titres of NP than i.d. immunised groups with A/Perth at 10 ng, 
50 ng and 100 ng influenza vaccine administered; however, no HI titres were measurable against 
the B/Brisbane strain other than in 3 individual mice.  
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Figure 6.2: Haemagglutination inhibition assay of all three influenza strains following immunisation by 
Nanopatch™ or i.d. injection. 
Measurement of haemagglutination inhibition (HI) post influenza immunisation with Fluvax® 2010. Titres above 40 
are considered as protective for the respective influenza strains in humans. NP, Nanopatch™ (▲), i.d., intradermal () 
and naive (X). Shown are individual data points and their means (black line). Statistical analyses comparing between 
NP and i.d. groups using a Kruskal-Wallis test with a Dunn’s post-comparisons test were not possible due to the non-
responders within the i.d. groups as well as due to the large variation within the NP groups.  
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6.3.2 Effect of Nanopatch-mediated cell death on immunogenicity 
6.3.2.1 Enhanced immunogenicity following controlled increase of cell death  
Since application of a single NP induced significantly higher influenza-specific IgG responses than 
single i.d. injections, the effect of doubling the cell death levels was investigated by implementing 
uni- versus bilateral immunisations with NP or i.d. injections to each animal. In particular, the 
delivery of one NP or i.d. injection to one or two ears was assessed while maintaining the same total 
amount of delivered antigen. It was hypothesised that an increased level of cell death resulting from 
two NP applications, but not i.d. injections, could further increase influenza-specific IgG responses. 
Thus, to assess the effect of applying to one versus two ears (hence doubling the cell death and 
therefore the number of targeted cells while halving the antigen concentration/ NP or i.d.), 5 ng 
Fluvax® were delivered to each mouse by means of 1 NP per mouse (1 ear), 2 NP per mouse (1 NP 
per ear), 1 i.d. per mouse (1 ear) or 2 i.d. per mouse (1 i.d. per ear) or 100 ng influenza vaccine 
(Fluvax® 2010) to each mouse by means of 1 NP per mouse (1 ear), 2 NP per mouse (1 NP per ear) 
as a control group and were assessed by ELISA at day 21 post-immunisation. This is schematically 
represented in Figure 6.3a. 
Overall, NP induced significantly higher influenza-specific antibody responses than i.d. 
immunisations. Single immunisations to one ear per mouse resulted in a larger variation within each 
respective group than immunisations to both ears (Figure 6.3b). This variation was not significant 
at low influenza doses of 5 ng within both NP (p=0.21) and i.d. (p=0.07) groups as assessed by 
student’s t-test. However, an upwards trend of bi- over unilateral immunisations was apparent. The 
delivery of 100 ng of influenza vaccine resulted in a marginally significant difference (p=0.04) 
between NP and i.d. immunised groups. Delivering bilaterally may enable antigen and APCs to 
migrate to two, rather than one LN, offering two times the number of available naive T-cells to 
prime. By contrast, a lower antibody concentration per site – due to halving of the antigen 
concentration to allow immunisations to both ears – appeared not to reduce the resulting antibody 
titres, suggesting that lower antigen concentration did not adversely affect the immunogenicity. 
However, it must be acknowledged that in this experimental setup, two LNs were accounted for but 
not twice the number of APCs. In summary, these results indicated that bilateral administration of 
NPs and i.d. resulting in twice the amount of cell death, led to a marginally higher endpoint titres at 
lower antigen concentrations and significantly higher antibody titres at high antigen concentrations.  
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Figure 6.3: Bilateral immunisations resulted in marginally higher and more consistent endpoint titres than 
unilateral immunisations. 
Mice received either 5 ng or 100 ng Fluvax® 2010 by NP or i.d. injection to one (unilateral) or both ears (bilateral), 
where immunisations delivered to both ears (bilaterally) reduced the variation of systemic influenza-specific antibody 
responses within the groups in comparison with one ear (unilateral) immunisations. NP, Nanopatch™ (▲), i.d., 
intradermal () and i.m., intramuscular (♦). Shown are n=4-5 individual data points and their means. Statistical 
analyses were performed using an unpaired student’s t test with Welch’s correction (ns, not significant; *p<0.05).  
6.3.2.2 Cell death as a key factor for the improvement of bi- over unilateral 
Nanopatch™ immunisations 
Bilateral immunisations induced marginally higher endpoint titres at low doses and significantly 
higher endpoint titres at high doses. However, it was not clear whether the increased cell death or 
targeting two LN alongside with more APCs was the predominant contributing factor. By 
decoupling the contributing effects of uni- or bilateral LNs, antigen concentration and induced 
levels of cell death, the proposed hypothesis that co-localisation of antigen with dead cells enhances 
immune responses, could be further explored. To address this hypothesis, single and double 
 172 | P a g e  
immunisations were performed unilaterally to exclude the contribution of two LN. Bilateral 
immunisations were also tested as a control group. As multiple i.d. injections per ear were not 
possible due to the elevated interstitial pressure leading to vaccine escaping through the previous 
immunisation site, only NP immunisations were assessed. Mice received 5 ng in total, with sera 
analysed on day 21 post-immunisation for influenza-specific total IgG as described above.  
The level of co-localising cell death with antigen upon the antibody-mediated immune responses 
was assessed: antigen concentration/ mm2 remained constant but the level of cell death was doubled 
by applying either one coated NP to one ear or one coated and one uncoated NP to one ear (Figure 
6.4a). As expected, no statistically significant difference (p=0.65; Figure 6.4b left) between both 
groups was detected, further reinforcing observations that co-localisation of cell death with antigen 
adjacent to live cells is important to enhance antibody responses (Figure 7.4). To investigate the 
contributing effects of LNs, two NPs were applied either uni- or bilaterally, therefore doubling the 
number of targeted LNs but maintaining the same antigen concentration, amount of dead cells and 
number of targeted skin cells (Figure 6.4a). Surprisingly, no statistically significant difference was 
measured based on endpoint titre analysis (p=0.31; Figure 6.4b centre). These results suggested 
that at low antigen doses, delivering into the vicinity of one or two LNs did not play a significant 
role in yielding increased antibody titres.  
Lastly, as maintaining the antigen concentration, total targeted cell number and NP-induced cell 
death constant – but targeting the LN uni- or bilaterally – did not significantly affect antibody titres 
with low antigen doses (Figure 6.4b centre), the impact of increasing the level of NP-induced cell 
death on antibody responses was assessed. Influenza antigen was delivered the one ear/ LN using 
2NP or two ears/ LN using 4NPs which is schematically represented in Figure 6.4a. Interestingly, 
and in accordance with the herein presented hypothesis, antibody titres revealed a statistically 
significantly higher endpoint titre following immunisation with 4 NPs rather than 2 NPs (Figure 
6.4b right). Overall, these results suggest that cell death induced by NP co-localising with antigen 
adjacent to viable cells contributes to higher immunogenicity. Further, the antigen concentration as 
well as targeting LN uni- or bilaterally does not significantly affect the humoral immune responses 
at the tested doses with influenza vaccine.  
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Figure 6.4: Co-localisation of cell death with antigen to one or both ears enhances the systemic influenza-specific 
antibody responses in Nanopatch™ immunised mice.  
Assessment of one versus two NP immunisations per murine ear given uni- or bilaterally. (a) Schematic of experimental 
groups. (b) Influenza-specific antibody responses of sera to 5 ng Fluvax® 2010 plotted as endpoint titres. NP, 
Nanopatch™, closed symbols (▲, ) received 1 NP/ ear; open and semi-open symbols ( , , ) received 2 NP/ ear. 
Plotted are n=4 and their means. Statistical analyses were performed based on an unpaired student’s t-test with Welch’s 
correction test.  
6.3.2.3 Co-localising Nanopatch™-mediated cell death, adjacent live cells and 
vaccine enhances systemic immunogenicity 
Comparison of generated antibody responses to influenza vaccine (see section 6.3.1.1) revealed that 
NP delivery of vaccine generated improved immunogenicity for any given dose, compared with 
both i.d. and i.m. delivery. The NP had a significantly higher vaccine-live/ dead-cell  
co-localisation than i.d. (Figure 4.5), and more antigen co-localised with dead cells following NP 
than i.d. immunisations (Figure 7.4) [344]. However, it was not clear whether co-localisation of 
antigen with dead cells interspersed with live cells was essential for enhanced antibody production. 
To explore this, antibody responses between mice using NP, i.d. or with a combination, as depicted 
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in Figure 6.5a, were compared. In the combined groups, i.d. delivery (20 µL) of vaccine was 
followed by either NP or flat patch (FP) as illustrated in Figure 6.5a.  
In accordance with Figure 6.1, 10 ng of Fluvax® delivered by NP elicited higher antibody 
responses than the i.d. route (Figure 6.5b left; p<0.05), corresponding with previous 
immunogenicity results (Figure 6.1) and are in agreement with the cell death data (Figure 4.4). 
Increasing the amount of cell death immediately prior to i.d. Fluvax® delivery by applying an NP 
or an FP did not enhance the resultant immunogenicity generated by standard i.d. delivery of 
Fluvax® (Figure 6.5b). Of note, NP and FP were applied with the same force to skin to apply the 
same stresses without projections penetrating the skin. FP application induced ~3.5% of cell death 
within the application area, localised along the edges of the FP (Figure 6.5c), which was not 
significantly different to naive cell death levels. Similar immunogenicity results were obtained 
when repeated with a 1 ng Fluvax® dose (Figure 6.5b right). The significant differences in 
influenza endpoint titres between NP and i.d. immunised animals at low doses corresponded to the 
observed levels of cell death (section 4.3.4). Vaccine distribution and kinetics studies are discussed 
in more detail in Chapter 7, section 7.3.2.2. Taken together, the data demonstrated that  
co-localisation of antigen with NP-induced cellular damage correlated with enhanced 
immunogenicity of NP-delivered Fluvax®.  
The results in Figure 6.3-Figure 6.5 suggested a trend where cell death co-localising with antigen 
contributed to enhanced antibody-specific endpoint titres while antigen concentration in NP 
immunised groups contributed only minimally. To assess whether the vaccine concentration may 
affect the systemic immunogenicity in i.d. immunisations, varying vaccine concentrations were 
tested in i.d. immunisations; 5 ng Fluvax® were administered i.d. at 1 ng/ µL, 0.5 ng/ µL, 
0.25 ng/ µL and 0.1 ng/ µL. No statistically significant differences were seen between any i.d. 
groups (p>0.05; Figure 6.5d). Together, these data illustrated that vaccine concentration (ranging 
between 1-0.1 ng/ µL) did not affect the immunogenicity of i.d. immunisations. These results 
further supported the hypothesis that co-localisation of cell death with antigen, rather than antigen 
concentration, was a significant effect for enhanced immunogenicity observed in NP-based 
immunisations.  
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Figure 6.5: Co-localisation of antigen with cell death enhances immune responses to influenza vaccine.  
(a) Schematic of immunisations. (b) 10 ng Fluvax® 2010 were delivered by coated NPs, i.d. or a combination thereof 
(in each case, i.d. delivery of vaccine followed by either NP or FP) into murine ears (control group i.m. 6000 ng). 
(c) Viability staining post FP application onto murine ear stained with AOEB cocktail, with cell death localised only at 
the edges of the FP. (d) Various Fluvax® concentrations administered i.d. did not affect immunogenicity following i.d. 
immunisation delivering a total of 5 ng Fluvax®. All samples were analysed by ELISA on day 21 post-immunisation 
with endpoint titres of tested groups plotted. NP, Nanopatch™; FP, flat patch; i.d., intradermal; i.m., intramuscular. 
Image is representative of n=3. Statistical analyses were performed based on an one-way ANOVA with Tukey post-
comparisons test (ns: not significant,*p<0.05, ** p<0.01, *** p<0.001). Image adapted and reproduced with permission 
from [344].  
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To further examine the correlation between cell death and enhanced immunogenicity, these NP 
conditions were extended to provide lower and higher levels of cell death by changing the number 
of projections/ cm2 while maintaining all other parameters constant (see Chapter 5, Figure 5.6). As 
described in section 5.3.3.4, i.d. injection or NPs of varying projections/ cm2 ranging from 10,000, 
21,000 to 3x 21,000 were applied onto murine skin. The latter contained a dose-matched application 
of 3 regular NPs with 21,000 projections/ cm2. Cell death was imaged as previously described 
(Chapter 4 and [344]), while influenza-specific IgG was assessed following delivery of 1 ng 
Fluvax®. In agreement with section 5.3.3.4, cell death increased with increasing numbers of 
projections/ cm2, resulting in 2.3% ± 1.0%, 3.1% ± 1.0%, 8.1% ± 1.1%, 16.2% ± 1.7%,  
45.4% ± 4.0% in untreated, i.d., 10,000, 21,000 or 3x 21,000 projections/ cm2, respectively (Figure 
6.6a and b). Cell death increased almost linearly (R2=0.89) with the increased number of 
projections, indicating the localised cell death per projection being approximately constant. This 
increase of cell death correlated well with an increase of total IgG responses (Figure 6.6b). 
Unexpectedly, high levels of cell death, induced by 3x 21,000 NP projections/ cm2, led to a 
significant decrease in antibody response compared to a single NP with 21,000 projections 
(p=0.0074). This may suggest a threshold up to which the cell death level can be immuno-
stimulatory before becoming detrimental to the induction of immune responses; high levels of cell 
death may therefore decrease antibody-specific immunogenicity results. Further assessments of the 
impact upon cellular immune responses should be carried out in the future. To summarise, the 
results suggested a correlation between NP-induced cell death co-localising with antigen resulting 
in enhanced immunogenicity; varying antigen concentration per area and cells in i.d. injections did 
not significantly affect the antibody responses.  
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Figure 6.6: Immune responses to influenza vaccine following different levels of cell death induced by varying 
numbers of projections/ cm2.  
Fluvax® 2010 (1 ng) was delivered by coated NPs or i.d. injection into one ear/ mouse. (a) MPM images of AOEB 
stained tissue to visualise viability after NPs of varying projection density: 10,000; 21,000 or 3x 21,000 projections/ 
cm2. (b) Cell death quantification based on MPM image acquisition as previously explained (left); Fluvax-specific total 
IgG of the corresponding NPs of varying projection densities analysed with endpoint titres plotted (right). NP, 
Nanopatch™; i.d., intradermal; FV, Fluvax®. Images representative of at least two independent experiments; depicted 
are means ± SD (cell death) and mean + SD (endpoint titres). Statistical analyses performed based on a 1-way ANOVA 
with Tukey post-comparison test (** p<0.01, *** p<0.001, **** p<0.0001**** p<0.0001). Image adapted and 
reproduced with permission from [344]. 
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6.3.2.4 Quil-A-adjuvanted Fluvax® delivery increases cell death and antibody 
responses 
Previous results indicated an enhanced immunogenicity when antigen co-localised with dead cells 
adjacent to live cells (section 6.3.1). Thus, the addition of the adjuvant saponin-based adjuvant QA 
as an immuno-stimulant and potential cell death inducer was further investigated. Three µg of QA 
were delivered per mouse and NP with 10 ng Fluvax® 2010. Since QA is known to cause pore 
formation in cellular membranes [413], cells treated with QA would stain positively for EB in 
viability studies were carried out at t=0h and t=12h as described in Chapter 4. Antibody-specific 
endpoint titres were assessed by ELISA as previously described.  
As expected, the addition of Fluvax® did not significantly increase the level of quantifiable cell 
death over uncoated NP application in murine ear skin as seen in Figure 6.7a, with 17.8% ± 3.0% 
and 16.0% ± 3.0%, respectively (Figure 6.7b). However, addition of QA (NPFVQA) induced 
statistically significantly higher cell death 25.9% ± 4.2% than NP or NPFV (***, p=0.0007 and **, 
p=0.003). It is important to note that with NPFV and even with NPFVQA, the cell death remained 
predominantly localised around the projections penetrating the tissue (Figure 6.7a). NPFVQA 
resulted in statistically significantly higher levels of cell death at 12h post application  
(35.4% ± 5.0%) than NP alone (22.6% ± 4.5%; ***, p=0.0007) or NPFV application  
(18.1% ± 4.5%; ***, p=0.0001; Figure 6.7b). Together, these results suggest that QA administered 
by NP in conjunction with FV increases localised cell death within murine tissue at 0h and 12h 
post-immunisation. This may indicate a higher inflammatory environment is created when FV + QA 
is administered by NP.  
Following the increased levels of cell death post QA delivery by NP, the adjuvanting effect of QA 
on Fluvax®-specific antibody responses was investigated by delivering 10 ng FV 2010 ± QA by 
either i.d. or NP. Cell death (Figure 6.7b) and endpoint titres were plotted together on a two-way 
axis graph (Figure 6.7c). As expected, antibody titres of i.d. immunised groups were statistically 
significantly lower than NP groups (p=0.0006). While the addition of FV to the NP represents a 
stimulation of the immune system with DAMPs and PAMPs, the addition of QA to i.d. FV groups 
resulted in a synergistic effect, leading to significantly higher endpoint titres (p=0.028) than i.d. FV 
alone. Interestingly, i.d.-delivered FVQA did not statistically differ (p=0.41) from NPFV delivery. 
In agreement with previous results, including QA as adjuvant in NPFV-immunised groups resulted 
in a further statistically significant increase in Fluvax®-specific endpoint titres (p=0.0073; Figure 
6.7c). The increase of cell death observed following the addition of QA to Fluvax® vaccine 
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correlated strongly with higher endpoint titres, indicating a synergistic effect of DAMPs and 
PAMPs. Together, these results demonstrate that FV + QA induced higher levels of cell death than 
NP alone or NP with Fluvax®, which correlated with enhanced antibody-specific responses. Whilst 
it is acknowledged that other mechanisms may play a role in the adjuvanticity of QA, these data 
further support a correlation between cell death and enhanced immunogenicity. 
 
Figure 6.7: Co-delivery of Quil-A increased local cell death and synergistically enhanced immune responses.  
Mice received 10 ng Fluvax® 2010 ± 3 µg QA by either NP or i.d. injection (one immunisation per animal). (a) MPM 
image of AOEB-stained tissue immediately post NP application with FV ± QA at 0h (upper panel) and 12h (lower 
panel) post application. (b) Cell death quantifications obtained from (a); (c) Comparison of cell death and the resulting 
antigen-specific total IgG endpoint titres. Image acquisition, cell death quantifications and endpoint titres are 
representative of n=3-6 replicates. NP, Nanopatch™; i.d., intradermal; FV, Fluvax®; QA, Quil-A. Statistical analyses 
were performed based on a one-way ANOVA with Tukey post-comparison test; error bars show means + SD (ns, not 
significant p>0.05, *p<0.05, *** p<0.001, **** p<0.0001). 
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6.4 Discussion  
In this chapter, the application of two distinct transcutaneous immunisation devices, NP or standard 
needle-based i.d. injection into skin, and the resulting systemic immunogenicity generated by 
vaccination was investigated. To the best of the author’s knowledge, a direct exploration of the link 
between skin cell death by device application and vaccine delivery upon enhanced immunogenicity 
has not been carried out before.  
6.4.1 Enhanced influenza-specific antibody immunogenicity after 
Nanopatch™ compared to intradermal immunisation 
Vaccine delivery by the NP induced consistently higher antibody titres than standard needle-based 
i.d. immunisations (Figure 6.1), resulting in a ~10-fold dose-sparing of NP over id., which was a 
significant finding. Using a trivalent influenza vaccine, Hung and colleagues compared two i.d. 
devices at low doses consisting of either a single needle (BD SoluviaTM, 1.5 mm in length) or an 
array of three MN (MicronJet600TM, 0.6 mm in length) against i.m. immunisations [195]. 
Interestingly, the highest seroprotection rates and geometric mean titre-fold increase were generated 
by a MN array using 3 µg, which is in agreement with the experiments that directly compared a 
high density NP with typical i.d. delivery (Figure 4.1) using an influenza vaccine (Figure 6.1). 
Notably, antibody responses elicited to vaccine doses as low as 0.1 ng and 1 ng of Fluvax® 2010 
have not been reported previously, irrespective of administration route. In a previous study, 0.3 ng 
Fluvax® 2008 co-delivered with QA as adjuvant by NP did not elicit a measureable immune 
response [345] despite significantly higher antibody responses being obtained with 6.5 ng [3]. This 
discrepancy may be due to the strain differences between HA protein included in the vaccines 
(Fluvax® 2008 versus Fluvax® 2010), excessively low doses delivered in the previous study 
(1.4 µg QA with 0.3 ng Fluvax® 2008), the slightly different projection shapes and application 
conditions or a combination of these factors. Other studies using MN immunised mice with 
significantly higher influenza vaccine doses, ranging from 0.3 to 6 µg, although the vaccines were 
prepared from VLPs or whole inactivated virus [89, 196, 197].  
Unfortunately, the Fluvax® 2010 resulted in unforeseen side effects when administered to humans 
(not within this doctoral study), leading to an increased number of febrile seizures in children under 
the age of 5 years [431, 433]. Investigations did not find any changes in the manufacturing process 
to previous years or between batch variations, no chemical/ bacterial contamination was found, nor 
deviations from the standard viral splitting process were found; except three new A- and B- 
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influenza strains were incorporated into the 2010 vaccine season [432, 433]. CSL’s trivalent 
influenza vaccines were found to induce a higher level of pro-inflammatory cytokines and 
chemokines with a large variation in magnitude, caused predominantly by the B-strain and H1N1-
strain (Table 3.3) [433]; increased changes in gene signatures compared to some comparators were 
also noted [433]. However, investigations on identifying the source of the febrile seizures have not 
been clearly identified yet and are subject to ongoing investigations. With the first CSL results 
published in 2012, half of the studies presented in this thesis were already undertaken; the 
remaining experiments were continued therefore continued with Fluvax® 2010 until stocks were 
depleted and switched to Fluvax® 2011 (Chapter 7). Thus, the high dose-sparing results seen within 
this chapter may have been in part due to the higher pro-inflammatory state induced by Fluvax® 
2010.  
Varying the numbers of NP projections/ cm2 increased projection numbers penetrating the skin 
caused almost linearly (Figure 6.6). Therefore, increasing levels of localised cell death led to 
increased immunogenicity, until a plateau was reached, where after the immunogenicity started to 
decrease (Figure 6.6). Bins et al. conducted a DNA-based vaccine immunogenicity study with 
multiple needle insertions by a tattooing device and found that using an oscillating tattooing device 
repeatedly at short-intervals (3x 4s exposure) over several days resulted in higher primary  
CD8+ T-cell responses against influenza A nucleoprotein than one long-interval (16s) immunisation 
[253]. Whilst cell damage was not assessed, it can be assumed that repeated tattooing increases 
cellular damage. Hence, a release of danger signals may have contributed to the reported enhanced 
immunogenicity based on Gopee’s findings that tattooing induces local tissue damage [247]. While 
an increased number of projections did not correlate with an increased antibody response [262], this 
could be explained by rapid lateral diffusion of the small molecule OVA [263]. Similarly, Widera et 
al. observed in bilateral delivery of OVA by MN arrays to hairless guinea pigs statistically 
significantly higher antibody responses with high antigen doses, but not at low doses [262]. In 
contrast, no statistical difference was seen with lower antigen doses, which supports the presented 
findings of single versus double NP immunisation at low doses (Figure 6.3 and Figure 6.4). This 
may suggest that the level of cell death and possibly the number of targeted cells or available APCs 
in the skin may affect the influenza-specific antibody responses. Further studies with high antigen 
doses should be repeated to assess whether the increased amount of cell death, the exposure to two 
dLNs, targeting of more APCs or larger antigen diffusion area may contribute to the enhanced 
immunogenicity. 
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Assessment of total antigen-specific IgG gives only partial insight into the humoral immune 
response. HI assays that assessed neutralising abilities of the virus were performed. While the HI 
titres were generally low in both, NP and i.d. groups, NP groups resulted in higher mean titres than 
dose-matched i.d. groups in both tested A-strains, but not the B-strain. Importantly, a lack within 
the presented study is the missing HI titres for the experiments performed in sections 6.3.2.1, 
6.3.2.2, 6.3.2.3 and 6.3.2.4. This was due to the lack of reagents available at the time of the study 
completion. Sourcing of reagents is currently underway, with the missing experiments expected to 
be completed before the end of this year. However, it must be acknowledged that the integrity, 
functionality and structure of the HA protein within Fluvax® post coating onto the NP was not 
assessed – even though other studies have demonstrated significant HA loss if influenza VLPs when 
not stabilised with disaccharides such as trehalose [301, 310]. Additional studies should to be 
undertaken to assess the effects of MC as well as trehalose with/ without sucrose [347] as stabilising 
agent and their effects upon antibody in addition to HA activity and HI titres in NP-based delivery.  
The immuno-stimulatory properties of apoptotic and necrotic cells in inducing DC maturation and 
activation are well established, and include amongst others HMGB-1, extracellular DNA, ATP, 
MSU etc [reviewed in 169, 513]. Increased adaptive CD4+ and CD8+ T-cell responses following 
injection of antigen-pulsed dead cells have provided evidence that endogenous immuno-stimulants 
are present in dead cells, by promoting DC maturation and migration into dLN in mice [392, 393]. 
This contrasts findings by Raju et al. who reported a ‘dead zone’ in the centre of the gene gun 
application site, while only the periphery where particles penetrated contained live and dead cells 
[242]. To the best of the author’s knowledge, other studies cross-comparing cell death by gene gun 
or other immunisation methods such as MN or needles with the effects on the immune responses 
have not been performed yet.  
6.4.2 The effects of varied, discrete and localised cell damage on adaptive 
immunity 
The increase of cell death observed following the addition of QA to Fluvax® vaccine correlated 
strongly with higher endpoint titres in NP and i.d. groups, indicating a synergistic effect of DAMPs 
and PAMPs. Additionally, increased endpoint titres to influenza-specific antibodies were noted in 
all groups given QA, which was associated with an increased cell death levels. The conformation of 
functional groups such as aldehydes within in the hydrophobic aglycones and hydrophilic sugar side 
chains have previously been reported to contribute to the adjuvanting effect of QA [reviewed in 
407, 415]. In addition, saponins have been shown to induce macrophage, lymphocytes and 
predominantly neutrophil infiltrations post i.d. injection into skin [186] that could lead to increased 
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antigen shuttling to the LN, similar as with the adjuvant MF59 [373], and merits further 
investigations. 
The delivery of conventional protein and live viral vaccines using MNs, a tattooing device or the 
gene gun has resulted in comparable systemic immune responses to those achieved by standard i.d. 
injection [165, 184, 195, 209, 246] while inducing local tissue damage and cell death [247]. In the 
past, the smallpox vaccine containing vaccinia virus was delivered using a bifurcated needle, 
disrupting the skin’s barrier. In a recent study using s.s, vaccinia virus delivery was shown to 
significantly improve effector memory T-cell responses [207]. Importantly, s.s. was essential for the 
elicitation of the vaccinia virus-mediated immunity and protection against challenge, while i.d. 
delivery was less protective while i.m. immunisations were not protective [207]. This further 
suggests that physical disruption of the epidermis may have distinct advantages over conventional 
vaccination routes, including the i.d. route. However, it must be acknowledged that vaccinia is 
highly replicative virus in the skin. Whilst Liu and co-workers did not assess cell death caused by 
scarification [207], these findings further support the author’s hypothesis that in skin, the 
localisation of antigen within areas of cell damage could be beneficial to promote adaptive 
immunity to foreign antigen. However, it must be noted that vaccinia (used by Liu et al. and Gargett 
et al.) is a virulent, inflammatory virus that easily replicates in the skin [207, 608]. The enhanced 
responses of s.s. over other routes remain yet to be seen with other viruses and protein-based 
vaccines [207, 608]. Based on the PAMPs contained within each virus or viral-based vaccine, it is 
likely that the results by Liu et al. [207] can be reproduced with other viruses. Moreover, through a 
currently unknown mechanism, laser-beam adjuvanted immunisations have also shown enhanced 
immunogenicity to influenza and OVA [436, 438], but only when antigen co-localised with the site 
of laser treatment. Chen et al. later suggested that tissue damage and hence inflammation may 
contribute to this effect [reviewed in 204]. 
It was proposed that the improved immunogenicity in NP groups was linked to antigen co-localising 
within defined areas of live cells adjacent to dead cells and therefore DAMPs resulted within 
epidermal and dermal tissue. This co-localisation was not, or to a lesser extent, seen after i.d. 
injection. i.d. injection generated significantly lower cell death, therefore resulted in less co-
localisation of antigen, live cells – and possibly DAMPs. These results are in agreement with the 
data presented in Chapter 4 (Figure 4.3) and Chapter 6 (Figure 6.3-Figure 6.5). However, this is 
not the first time that co-localisation of antigen with danger signals has been described as essential 
to induce an immuno-potentiating effect [97, 382, 410]. Both, DT [97] and adjuvants [382, 410] 
have resulted in enhanced immunogenicity when they were administered together or in a co-
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localising manner with antigen. Didierlaurent et al. showed that the adjuvant AS04 only exerted its 
stimulatory functions when both, antigen and AS04 co-localised [382]. In particular, as adjuvants 
are known to induce release danger signals or induce cell death, which eventually leads to DAMP 
release that synergistically function with adjuvants [14, 94, 95]. Thus, the results presented in this 
chapter as well as studies by others using diphtheria toxin [97] or adjuvants including QA, MPL, 
CpG or Alum [410], further supported the finding that co-localisation of antigen with danger signals 
was required for immuno-stimulatory effects. This strengthens the hypothesis that the NP-induced 
cell death acts as physical immune enhancer contributing to enhanced immunogenicity, compared 
to standard i.d. injection (Figure 6.1). This correlation was further supported by the observation that 
localised cell death by NP to the skin site followed by i.d. injection of vaccine did not enhance the 
systemic immunogenicity compared with i.d. alone (Figure 6.5 and Figure 6.6). While the NP 
achieved higher levels of cell death interspersed with live cells that co-localised with antigen; i.d. 
injections resulted in less co-localisation of antigen with adjacent live cells. Increasing the 
concentration of vaccine delivered by i.d. (Figure 6.5) did not affect the systemic immune response 
either. It is likely that i.d. injected-vaccines diffuse more rapidly from the skin than NP-delivered 
vaccines. Thus, the difference in antigenicity may also be attributed to presence and distribution of 
antigen within the tissue as well as the time required for the vaccine to reach the dLN [646].This is 
yet to be explored, although it is known that 75% of NP delivered vaccine is transported away from 
the mouse ear within 48h [647], whilst 70% of MHC II+ cells have also migrated from the skin 
within the same time period [648]. However, as Carey et al. suggested, high interstitial pressure 
caused by i.d. injection may result in higher drainage to LN than payload delivered via MN [165]. 
This is in agreement with del Pilar Martin et al.’s studies, where payload delivered via MN 
remained in the skin for up to 7 days [164].  
Different MN of various geometric shapes, tip sharpness’ and projection lengths have been 
successfully applied to animal and human skin [262, 271, 638, 639]. Previous studies have 
investigated the impact of MN morphology upon antibody production [262] and T-cell responses 
[165]. Widera et al. found after application of long (400-600 µm) MN that the observed bleeding 
suggested some tissue damage although no infections or scarring were observed [262]. 
Interestingly, no significant difference in antibody responses to OVA using different MN designs or 
MN lengths were seen, albeit different penetration depths [262]. Although different shapes of NP 
projections were not assessed in immunogenicity studies, Widera’s findings endorse the results 
presented in Chapter 5, i.e. no significant differences of cell death were seen despite significantly 
different penetration depths. Carey et al. also applied MN of different lengths, projection densities 
and widths onto murine skin which did not have a great impact of specific T-cell responses using 
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live viral vector vaccine [165]. However, they found that MN with a small pore volume  
(a combination of MN patch area, projection length, and total number of projection/ area) induced 
higher T-cell responses of a central memory phenotype. Unfortunately, it was not possible to clearly 
separate the effects of MN shapes and projection lengths on T-cell responses as multiple parameters 
were changed simultaneously. While others have not investigated skin-based damage upon MN 
application, it seems plausible that changing application velocities or projection geometries on a 
small scale only play a minor role in altering quantifiable cell death in the tested murine ear skin. 
Locally increased stresses imposed onto skin such as increasing the number of projections/ cm2 are 
therefore likely to induce more cell death, hence enhanced immune responses.  
Antigen-delivery using laser-adjuvanted i.d. injections [206, 436, 649] or laser-based micropore 
formation [438] yielded contrasting results regarding thermal tissue damage. While Chen et al. 
noted tissue damage with high laser power (>0.4 W) [436], Weiss et al. noted no tissue damage as 
assessed by H&E stained histology sections [438]. However, both noted significantly increased 
humoral and cellular immune responses when laser-adjuvanted delivery methods were assessed in 
comparison to standard i.d. or s.c. injection. With respect to Th1/ Th2/ Th17 biased immune 
responses however, Weiss et al. found that the depth of antigen delivery mattered [438]. Based on 
cytokine analyses following OVA administration, targeting the deeper dermal layers appeared to 
enhance Th1/ Th17 responses while targeting the epidermal layers favoured predominantly Th2 
responses. These observations are in accordance with others studying human skin, suggesting 
functional specialisations of various DC subsets, leading to a polarised T-cell activation [650, 651]. 
It must be acknowledged that insights into which DCs are activated and take up antigen following 
NP immunisation are currently lacking; although this is currently under investigation. This 
information would be highly relevant understanding the underlying mechanism of the physical 
immune enhancer.  
Administration of QA was investigated as 1) an adjuvant and 2) as a cell death enhancer. As 
expected, both, endpoint titres and cell death levels increased, even though cell death remained 
relatively localised around the projections. The exact mechanism of how saponin-based adjuvants 
enhance immune responses is currently not known, and conflicting results regarding the 
adjuvanticity effects of the side chains have been presented [406, 407]. However, it is possible that 
QA traps antigen at the site of administration following NP application based on the increased 
presence of dead cells at the application site (Figure 6.7). This may result in a prolonged antigen 
reservoir formation, which would further support the increased antibody responses to FVQA. 
However, further research is required to investigate this hypothesis. These findings were interpreted 
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as that the antigen reservoir formation alongside with increased cell death levels suggests a 
threshold of cell death that is beneficial to increase humoral immune responses. Based on the 
existing data, cell death above 16% but below 45% within an area of 16 mm2 resulted in enhanced 
antibody responses in comparison to i.d. dose-matched groups. Specifically, a trend of increased the 
cell death following administration of QA was similar to the trend observed in higher influenza-
specific antibody responses. Excessive levels of cell death measuring ~45% following 3x NP 
application resulted in reduced immunogenicity. What types of cells were dying was not assessed 
due to difficulties in distinguishing dying cells change due to changes in surface marker expression 
[652, 653]. However, it is possible that more APCs may have died following 3x NP application. 
These results may suggest that levels of cell death above a certain threshold may be detrimental to 
the immune system. This hypothesis requires further investigation, enabling a direct link or 
correlate between level of cell death and immunogenicity.  
6.5 Future outlook  
In collaboration with Vaxxas, experimental work has been undertaken in a larger animal model. 
Optimisation of NP application parameters alongside with cell death and immunogenicity studies 
were performed in pigs, because of the higher resemblance with human skin. Preliminary data of 
cell death and influenza studies in Landrace Large White pigs were collated and are presented 
below.  
For cell death studies, uncoated NPs were applied to inguinal skin regions of live pigs followed by 
excision of the treated skin area. Viability staining (section 3.2.4) was adapted to ensure complete 
dye penetration through pig skin. Similarly to the murine data (Chapter 4), cell death was found to 
be highly localised around the NP projection tracks in pig skin (Figure 6.8a). Imaris quantification 
yielded approximately 8-12% of dead cells per NP-treated area in excised full thickness inguinal pig 
skin. This was below the cell death quantification of NP to murine skin (~16.5%). The lower cell 
death percentage could be attributable to the significantly thicker skin strata of pig skin, a larger 
ratio between projection length and skin thickness and hence higher total cell number/ mm2 or a 
lower projection density (10,000 projections/ cm2). Overall, this preliminary data was in agreement 
with murine studies. These results are promising and clearly highlight the need for further studies 
linking the induced cell death to the observed immunogenicity results.  
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Figure 6.8: Preliminary data of cell death and antigen-specific antibody response following Nanopatch™ 
application to Landrace Large White pigs.  
NPs were applied to inguinal areas of Landrace Large White pigs. Cell death was assessed following uncoated NP 
application as previously described with live (green) and dead (magenta) cells depicted.  
6.6 Conclusion  
To conclude, the results presented within this chapter further support the hypothesis that dynamic 
application of high density NP arrays to skin results in cell death that co-localises with antigen and 
live cells, indicating function as a physical immune enhancer. Importantly, it appeared that a 
particular threshold (>16%) enhanced, while excessive cell death (~45%) decreased antigenicity. 
This yields insights into how physically-induced inflammation (discussed in Chapter 7) – via cell 
death – can be exploited within the skin for significantly improving the immunogenicity of 
vaccines. In addition, an increased number of LNs or targeted skin area did not significantly affect 
immune responses at low doses. This points to the importance of not only harnessing the skin’s 
potential by targeting vaccine directly to the skin’s APCs (as outlined in [3] based on a probability-
based analysis) but also co-delivering to these cells DAMPs, which result in cytokine and 
chemokine release from neighbouring cells as a result of physical stress-induced tissue damage. 
This is a significant departure from the current adjuvant paradigm, generated by chemical or 
biological reagents (e.g. alum or bacteria-derived MPL) added to antigens to enhance immune 
responses that are delivered into the body. Indeed, this physical immune enhancer system has 
potential implications for the improved efficacy, distribution and access to vaccines, as well as the 
understanding of the mechanisms of skin immunity.  
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Chapter 7  
Characterisation of early innate immune events in the skin, 
followed by antigen uptake from skin to lymph nodes 
7.1 Introduction 
The concept of the immune system responding to danger signals forms the basis on how the 
immune system mounts immune responses in response to damage [169, 439, 440]. In Chapter 6, 
humoral immune responses after influenza vaccine administration were examined with respect to 
different levels of cell death induced by NP and i.d. immunisations, and found to correlate with the 
amount of induced cell death by the immunisation device. This understanding of the generation of 
customised cell death patterns elaborates the potential for increased immunogenicity, exploring a 
physical immune enhancer effect.  
The level of inflammation in an injured tissue is generally proportional to the level of inflicted 
trauma, followed by regeneration and repair of damaged tissues [654]. Tissue injury consisting of 
stressed, dying or dead cells can lead to many events including cytokine and chemokine release, 
DAMP release and as a result, cellular infiltration [404, 655, 656]. This infiltration consists of 
predominantly macrophages, monocytes and neutrophils amongst other cells [404, 655, 656] even if 
no antigen is present [45]. This infiltration triggers a further cascade of events, including further 
pro- and anti-inflammatory cytokine and chemokine release [644], attracting more neutrophils to 
the site of injury inflammatory infiltration. A similar occurrence has also been described following 
administration of adjuvants. Alum and MF59 have been shown to result in neutrophil and monocyte 
infiltration [373], while macrophages are predominantly induced by alum [373].  
Similar to tissue damage, adjuvants and vaccines can cause local inflammatory responses due to 
PAMPs contained within viral particles, bacteria, etc [47]. Vaccines, especially recombinant protein 
or peptide antigens, occasionally require adjuvants to potentiate the adaptive immune responses 
towards a desired immune response and can be of chemical, bacterial as well as endogenous origins 
[334, 512, 657]. Saponins such as QA [15, 406], as well as FDA-approved adjuvants such as 
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aluminium salts [15, 365, 366, 658] and MF59 [373-375], have been shown to result in high local 
inflammatory responses and induce partial cytotoxicity, even leading to cell death in tissue [95]. 
Several mechanisms of action of adjuvants have been described. These include binding to TLRs or 
NLRs that lead to inflammasome activation but also slow release of antigen over time, leading to a 
antigen depot formation [reviewed in 14, 371]. Alum, for instance, has also long been described as 
effective due to an antigen depot formation at the site of injection [reviewed in 14, 371, 389], 
although this was recently refuted in favour of soluble antigen draining to LNs and the 
inflammatory environment evoked by alum [364].  
The current known adjuvant mechanisms (except for depot formation) have also been linked to 
damaged or dead cells and the resultant DAMP release such as MSU or caspase-1 activation, 
illustrating the potential of DAMPs as endogenous adjuvants [187, 334, 335, 398, 513, 553, 659]. 
DAMPs have also been linked to inflammasome activation, in particular NALP3 [95, 394, 396, 398, 
525]. Co-delivered apoptotic cells [558, 607], necrotic cells [544], Bax-encoding plasmids [511], 
cytolytic protein perforin [608] have been reported to contribute to enhanced antigen presentation as 
well as cellular and humoral immune responses. However, administration of and approval for 
cytolytic proteins as a suitable adjuvant candidate for use in humans by the FDA is a challenge. 
More recently, a new category of physical adjuvants has been described, in particular in the context 
of laser-beam adjuvantation [204, 436]. Administration of LVA prior to i.d. injection of OVA or 
i.m. injection of seasonal influenza vaccine induced superior cellular and humoral immune 
responses than i.d. alone [436]. Using the delivery device as the physical adjuvant in itself may be a 
safer and more economical option. Previous published work has demonstrated enhanced antibody 
responses with influenza antigen delivered by NP over i.m., which was further increased by the 
addition of adjuvants [3, 345, 350].  
As illustrated in Chapter 4 and Chapter 5, an analysis of cell and tissue viability provided 
evidence for a greater level of cellular damage and cell death caused to the tissue by NP application 
than i.d. injection. Hence, it was hypothesised that following localised cell death inflicted by the 
NP, the physical immune enhancer effect of the NP induces an inflammatory micro-environment in 
the skin. In particular, where antigen depot formation and co-localisation of cell death with antigen 
in skin would lead to enhanced humoral responses (Chapter 6), similar to an adjuvant. Therefore, 
the aim of this chapter was to provide a detailed study of the early innate immune events post NP 
application (and i.d. injections) locally within the skin and in the auricular dLN (dLN), including 
inflammatory infiltration of skin, cytokine secretion as well as vaccine distribution and kinetics 
using influenza vaccine as model antigen. 
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7.2 Methods 
As outlined in Chapter 3, the following methods are applicable to this chapter: sections 3.1, 3.2.1, 
3.2.3 – 3.2.7, 3.2.12 – 3.2.15 and 3.2.19.  
7.3 Results  
7.3.1 Local inflammation within the skin following Nanopatch™ 
application and intradermal injection 
7.3.1.1 Microscopic analysis of cell infiltration 
Any late apoptotic and necrotic cells can lose their specific surface markers or alter their expression 
[652, 653], which makes a clear identification difficult. Therefore, MacGreen mice were 
investigated [561, 562, 660]. eGFP+ cell infiltration and viability using EB was assessed by MPM 
over time following plain NP applications or i.d. saline injections. eGFP+ cells from untreated 
MacGreen mice were found in a regular arrangement, exhibiting a DC-like morphology with 
multiple elongated dendrites extending throughout the tissue (Figure 7.1a and b, naive). Post NP 
application (t=0h), very few double eGFP+/ EB-stained cells were observed at 0h along with a 
subtle change in morphology such as retracted dendrites in some cells with other, rounder cells 
present. A decrease of eGFP+ cells was noted 6h post-treatment while an increase of reinfiltrating 
eGFP+ cells was observed by 12h post NP application (Figure 7.1a). Interestingly, eGFP+ cells 
were highly localised around the NP projection insertion sites (Figure 7.1a, 12h) with a distinct and 
different morphology in comparison to eGFP+ cells in naive samples, forming a ‘plug’ within the 
VE [661] as previously described of neutrophils infiltrating skin following sand-fly bites [661]. The 
majority of eGFP+ cells within the field of view did not display dendrites at time-points beyond 0h, 
but instead showed a smaller round shape, similar to that of neutrophils/ monocytes. Subsequent 
time-points (24-48h) depicted fewer eGFP+ cells than naive cells, which suggested that eGFP+ cells 
had not repopulated NP-treated tissue by this point. This is in agreement with previous observations 
that MHC II+ were absent from NP-treated tissue within the first ~72h post NP application [648]. In 
i.d. injected tissue, eGFP+ cells accumulated at the site of i.d. needle insertion. eGFP+ efflux was 
much less pronounced after i.d. injection of saline with no significant changes of total eGFP+ 
numbers (Figure 7.1b). Similar to NP treated tissue, a change of cell morphology was also 
observed by 6h post injections although cells of round appearance were visibly as early as t=0h, 
suggestive of neutrophilic infiltration, the latter known to infiltrate sites of tissue injury within 
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minutes [555]. However, these could also be DCs pulling in dendrites. However, these could also be 
DCs pulling in dendrites [662]. eGFP+ cells in tissue adjacent to the injection site exhibited similar 
morphology to those of untreated samples.  
Second, the viability of eGFP+ cells post-treatments was examined. Few double positive eGFP+/ 
EB-stained cells were observed immediately after NP or i.d. treatment (Figure 7.1a and b). 
However, a marginal increase of double eGFP+/ EB-stained cells was observed in NP-treated 
samples as early as 6h post application. By 12h, the majority of EB-stained cells were also eGFP+, 
suggesting that predominantly cells of the myeloid lineage were dying, probably in late apoptosis. 
Predominantly double eGFP+/ EB-stained cells rather than single positive cells (EB or eGFP+) were 
observed at 24 and 48h time-points. Additional studies, especially in vivo, should be performed to 
investigate a kinetic-dependent dynamic migration pattern of eGFP+ cells, to verify that eGFP+ cells 
did not migrate due to thermal damage caused by the laser to melanocytes. In summary, these 
results indicated an early increase of eGFP+ cells of various morphologies within the site of 
treatment, surrounding microchannel tracks and forming epidermal plugs; by 24h post-treatment, an 
increase of dead cells at the treatment sites correlates with a decrease of eGFP+ cells. These 
observations were more pronounced in NP-treated samples than after i.d. injections.  
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Figure 7.1: Expression of eGFP+ in cells MacGreen mice following Nanopatch™ application but not after i.d. 
administration of saline.  
MacGreen mice express (Csf1r) eGFP+ (green) under the c-fms promoter were either naive, treated with uncoated NP or 
i.d. injection (saline) and sacrificed at indicated time-points (0, 6h, 12h, 24h, 48h post-treatments), ears collected, split 
into dorsal and ventral halves and subjected to EB (magenta) staining. (a) MPM images of naive and NP-treated ears. 
(b) MPM images of naive i.d. injected with saline. Original images magnified 40x. Images are representative of n=4. 
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7.3.1.2 Flow cytometric analysis of inflammatory cell infiltration  
The dead cell and eGFP+ cell accumulation around NP projection sites suggested a higher and more 
localised inflammation following NP application than after i.d. injection. With uncoated NP, or 
coated NP with FV ± QA, it was hypothesised that more innate inflammatory immune cells would 
infiltrate into the treated skin areas. To characterise local inflammation following uncoated NP, 
NPFV and NPFVQA application, cellular infiltrates over time were studied by flow cytometry. 
Mice received FV or FVQA by NP application. A kinetics study for up to 7 days was performed on 
skin infiltrates using the haematopoietic CD45.2 and myeloid CD11b surface markers.  
Representative flow cytometry plots of NP-treated samples are shown in Figure 7.2a. An 
infiltration of inflammatory cells was observed at selected time-points. The first wave of observed 
inflammatory cells peaked at 6h post-treatments in the NPFV and NPFVQA groups while NP alone 
showed a marginally higher peak at 12h post-treatment. Two smaller peaks following at 24h post-
treatment were observed in in the NPFV and NPFVQA groups (Figure 7.2b). NP-treated groups 
did not exhibit a second wave of inflammatory infiltration (Figure 7.2b). As expected, groups 
containing QA resulted in a higher inflammatory cell infiltration than untreated, uncoated NP or 
NPFV groups, which is consistent with other reports As expected, groups containing QA resulted in 
a higher inflammatory cell infiltration than untreated, uncoated NP or NPFV groups, which is 
consistent with other reports [186]. To summarise, these results illustrated that NP application alone 
induced an inflammatory infiltrate which was further increased by the addition of FV and QA; this 
suggests that cells are infiltrating in response to both, DAMP and PAMP signals.  
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Figure 7.2: Cellular infiltration into the skin post Nanopatch™ immunisation with Fluvax® 2011 ± Quil-A 
administration.  
Flow cytometric analysis of inflammatory infiltrates into murine ear skin post Nanopatch™ or i.d. injections assessed 
by CD45.2 and CD11b markers. Pre-gating included removal of doublets (FSC versus SSC) and dead cells (PI versus 
SSC-A), MHC II+ and the selected surface markers (i.e. this does not represent all acquired total events). Mice received 
either uncoated NP, or 10 ng influenza vaccine (FV) with or without the adjuvant QA at indicated time-points. (a) 
Gating strategy and representative plots of three time-points of a NP sample. (b) Kinetics of inflammatory infiltrates (c) 
or macrophages (F4/80+) post NP. NP, Nanopatch™; FV, Fluvax®; QA, Quil-A.  
Cellular infiltrates into the skin were further phenotyped following NP application or i.d. injection ± 
FV ± QA based on their surface markers at t=24h. The following myeloid sub-groups (CD45.2+ 
CD11b+) were of particular interest, which included inflammatory monocytes (Ly6Chigh Ly6G-), 
neutrophils (Ly6C+ Ly6G+; [663]), macrophages (F4/80+) and DCs (CD45.2+ CD11c+). A 
representative gating strategy is depicted in Figure 7.3a. The largest difference at t=24h between 
NP and i.d. groups was seen in neutrophil numbers. Significantly more neutrophils were seen post 
NP, NPFV, NPFVQA administration as well as after i.d. delivery of FVQA, but in much lower 
numbers after i.d. saline or i.d. FV injections (Figure 7.3b). A similar trend was observed seen with 
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infiltrating inflammatory monocytes. Using the F4/80+ marker, an increased yet statistically 
insignificant infiltration of macrophages was seen post NP and i.d. injections with FV ± QA 
(Figure 7.3b). However, the macrophage kinetic was dependent upon the group, with FVQA 
immunised tissue resulting in a delayed peak of macrophage infiltration when compared to 
uncoated NP or NPFV (F. Pearson, personal communication). In addition, the DC dynamic was 
found to be higher after NP application than i.d. injection (Figure 7.3b). A statistically significant 
increase of neutrophils was observed post NP, NPFV and NPFVQA immunisation but in i.d 
injections only when FVQA was given (Figure 7.3b). Overall, these results indicated that NP 
application induced a much higher elevated level of inflammatory infiltrates in the skin (containing 
neutrophils, inflammatory monocytes and DCs); delivery of QA further increased this infiltration. 
By contrast, i.d. injection resulted in minuscule changes when compared to naive samples.  
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Figure 7.3: Infiltration of monocytes (Ly6Chigh Ly6G-), macrophages (F4/80+), DCs (CD11c+) and neutrophils 
(Ly6C+ Ly6G+) into skin 24h after Nanopatch™ and i.d. injections of Fluvax® 2011 ± Quil-A administration.  
Flow cytometric analysis of inflammatory infiltrates into murine ear skin post Nanopatch™ or i.d. injections as assessed 
by CD45.2, CD11, Ly6G, Ly6C, F4/80 and CD11c phenotyping. Mice received 10 ng FV with or without the adjuvant 
QA at indicated time-points. (a) Gating strategy. (b) Differentiation of infiltrating inflammatory monocytes, 
macrophages, DC and neutrophils based on their surface marker expression. NP, Nanopatch™; i.d., intradermal; FV, 
Fluvax®; QA, Quil-A; DC, dendritic cell. Error bars represent means + SD.  
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7.3.2 Distribution of antigen and cell death in the skin 
7.3.2.1 Co-localisation of antigen with cell death 
Co-localisation of danger signals from diphtheria toxin [97]  or adjuvants (AS04; [382, 410]) with 
antigen have been described as essential to induce an immuno-potentiating effect. It was 
hypothesised that co-localisation of NP-mediated skin damage adjacent to live cells and antigen 
were also key contributing factors to enhanced systemic immunogenicity. To test this hypothesis, 
co-localisation of NP-mediated cell death, live cells and fluorescently-labelled (DyLight® 755) 
Fluvax® 2010 antigen was imaged. A labelling kit (DyLight®) was used to visualise the labelled 
Fluvax® in the near infrared region to significantly reduce the effect of the skin’s auto-fluorescence 
[664] using the Carestream in vivo imaging system. Based on preliminary experiments, the vaccine 
was concentrated ≥5-fold to maximise fluorescence during image acquisition of antigen in skin and 
the dLN.  
First, fluorescent labelling efficiency was assessed by measuring dye to protein ratio (according to 
the manufacturer’s instructions) and by measuring remaining fluorescence of eluates (Appendix 3, 
Figure 10.9). With the regular fluorescence and coating pattern confirmed, the co-localisation of 
antigen with cell death was then investigated. Using Balb/c mice, 10-600 ng of concentrated 
fluorescent FV (cflFV)/ ear was delivered by NP or i.d.. The NP application or i.d. injection site 
was superfused with EB for 2 min and animals and imaged in vivo within 5 min post-immunisation 
(to limit diffusion of the cflFV in vivo) using the FX MS Pro system (Figure 7.4). Due to the 
detection limits of the system, only data with 600 ng cflFV delivered was being detected, which is 
shown below. X-ray images of the animals were used to identify locations of the head and ears. As 
expected, in NP-treated samples, NP application alone resulted only in detectable cell death 
(orange) at the application site; no fluorescence was detected in naive samples, although minor 
autofluorescence from fur was detected in the EB channels (Figure 7.4). By contrast, in i.d. 
injections, only a minor area (<0.5%) was EB-positive, representing dead cells at the needle 
insertion site only as indicated by the white arrows. Administration of cflFV (DyLight® 755) by NP 
clearly illustrated the co-localisation of cell death with antigen in murine ears (100%), covering an 
area of 16 mm2; this was much less pronounced in i.d. groups. The co-localisation of cell death and 
payload delivery was in agreement with the previous payload and viability data, illustrating larger 
area of affect and higher cell death in NP groups, respectively (Chapter 4 and Chapter 7). Taken 
together, in vivo imaging of cflFV with cell death illustrated 100% co-localisation of cell death with 
antigen post NP but only minor (<0.5%) co-localisation of cell death with antigen post i.d. injection. 
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These results further supported the hypothesis that co-localisation of cell death correlates with 
enhanced immunogenicity since NP immunisations were significantly higher than i.d.  
 
Figure 7.4: In vivo imaging of fluorescently labeled Fluvax® antigen co-localising with cell death following 
Nanopatch™ or i.d. immunisation.  
Approximately 400 ng cflFV 2010 (colour intensity scale, to depict concentration intensities) were administered by NP 
or via i.d. injection and superfused with EB to stain for dead cells. X-ray and fluorescent images were acquired 
immediately after superfusion of EB on the Carestream FX MS Pro System. cflFV, fluorescently-labelled Fluvax®; NP, 
Nanopatch™; i.d., intradermal; EB, ethidium bromide. Images representative of n=3. Image reproduced with 
permission [344]. 
These in vivo imaging results encouraged further ex vivo antigen diffusion studies. A semi-
qualitative image analysis was employed to visualise diffusion of cflFV delivered by NP and i.d., 
alongside with viability markers in murine ear skin by CLSM/ MPM. Groups were immunised and 
imaged sequentially to minimise diffusion of the antigen. First, cflFV (DyLight® 755; orange) was 
delivered by NP or i.d. and imaged immediately (t=2 min post NP application time) or 20 min post-
immunisation by CLSM/ MPM. An increase in antigen diffusion was observed within both, VE and 
dermis, from 2-20 min (Figure 7.5a), adjoining the diffusion fronts of neighbouring projections. 
This was in strong contrast to i.d.-delivered cflFV, where the the antigen diffused minimally beyond 
the injection site between the two time-points (Figure 7.5a). Further, limited uptake and diffusion 
was visible within the VE, with some diffusion seen in the dermis. This may be explained by the 
sample preparation (separation dorsal from ventral ear halves), suggesting that the delivered antigen 
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drained from the dermis. To summarise, NP-based antigen delivery demonstrated fast lateral 
diffusion between adjoining projections in the VE and dermis while only limited diffusion was 
observed post i.d. injections.  
Raphael et al. suggested fast lateral diffusion of antigen [263] rather than drainage as observed post 
i.d. injection (Figure 7.5a) [165, 176]. Therefore, assessment of viability staining alongside of 
antigen diffusion was only performed on NP-treated samples. Mice were culled 20 min post NP-
based delivery of cflFV, ears excised and subjected to viability staining. Viability staining depicted 
dead cells arranged in a pattern consistent with NP projections penetrating the skin (Figure 7.5b; 
AO and EB) as previously demonstrated (Chapter 4). As seen in Figure 7.5a, the diffusion of 
cflFV from coated NPs within 20 min post application exceeded the neighbouring diffusion fronts, 
suggesting a rapid diffusion of cflFV within both skin strata (VE and dermis) over time (see Figure 
7.5b; DyLight®, orange). Importantly, the diffusion of cflFV exceeded the dead cells around each 
projection and co-localised with the dispersed live cells (Figure 7.5b; merged view). Co-
localisation of EB and cflFV was separately depicted in Figure 7.5b. Since damaged cells release 
DAMPs  [169, 489], their diffusion in tissue was approximated using mathematical modelling as 
previously elsewhere [263]. For size approximations, a medium-sized DAMP molecule was 
estimated to be larger than a 70 kDa yet smaller than a 2 MDa dextran [263]. Predicted DAMPs 
diffusion (blue contours) was overlaid above Figure 7.5b to give an approximate estimate of lateral 
diffusion. Of note, i.d. injections were not investigated due to the inherently different antigen 
concentration between the injection site and the periphery, alongside with varying diffusion profiles 
across the skin strata. 
Working with an estimated molecular weight (MW) of the split virus influenza vaccine used here of 
max 2 MDa (approximated based on split virions forming aggregates), the approximate diffusion of 
Fluvax® was calculated over time using mathematical modelling based on Raphael et al.’s 
published work [263]. Raphael et al. found that diffusion of low MW (70 kDa dextran) molecules 
coated onto NP exceeded 35 µm laterally within 2 min, while high MW molecules (2 MDa dextran) 
reached the same diffusion within 7 min post administration within the VE [263]. Here, it was 
found that Fluvax® diffused slower than the 70 kDa molecules although faster than the 2 MDa 
dextran (Figure 7.5c), diffusing approximately 35 µm in 2-7 min. In contrast, within the i.d. bleb, 
approximately ≤0.1% of the antigen was calculated to encounter and interact with DAMPs, live and 
dead cells. Antigen diffusion (blue) and cell death (magenta) were exceeded by diffusion of low 
MW danger signals (i.e. DAMPs; pale pink) as mathematically modelled (Figure 7.5c). This was 
based on the estimated ratio between: 1) the volume of the vaccine-distribution at the live-dead 
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interface, and 2) the bleb volume. Concurrent visualisation of DAMPs (e.g. extracellular ATP or 
HMGB-1) with antigen and dead cells in situ was attempted but not successful. To summarise, in 
vivo and in situ imaging of fluorescently-labelled Fluvax® 2010 and cell death illustrated rapid 
vaccine diffusion while modelling further illustrated a faster diffusion of DAMPs than antigen. 
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Figure 7.5: Diffusion of fluorescently-labelled Fluvax® 2010 by Nanopatch™ and i.d. and co-stained for viability 
and modelled diffusion characteristic of vaccine and DAMPs.  
Representative CLSM/ MPM images of cflFV® (DyLight® 755) diffusion interspersed with live/ dead cells (AOEB) in 
ventral ear lobes of Balb/c mice culled at t=2 min and t=20 min post application (n=3). (a) fluorescently-labelled 
Fluvax® (DyLight® 755) delivered by NP or i.d. injection into murine ear skin at t=2 min and t=20 min post 
application; (b) fluorescently-labelled Fluvax® (DyLight® 755) at t=20 min post application co-stained with AOEB. (c) 
Predicted DAMPs diffusion based on mathematical modelling of diffusion fronts following the delivery of 
fluorescently-labelled Fluvax® at various time-points after NP application, where DAMPs diffusion (pale pink) exceeds 
diffusion of vaccine (blue) and dead cells (magenta). Original magnification of images 20x; images representative of 
n=3. NP, Nanopatch; i.d., intradermal; FV, Fluvax®; cflFV, concentrated fluorescently labelled FV; DAMPs, danger 
associated molecular patterns; AO, acridine orange; EB, ethidium bromide.  
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7.3.2.2 Antigen depot formation and vaccine kinetics in skin following 
Nanopatch™ application and intradermal injection ……. 
The inherently different immune responses between NP and i.d. (Chapter 6) were hypothesised to 
be the result of different antigen kinetics between the two immunisation routes. Particularly since 
fast lymphatic drainage has been reported following i.d. injection [175]. To explore whether 
different antigen uptake mechanisms may contribute to the significantly higher immunogenicity 
levels post NP immunisation than i.d. injection as recently reported [344] and illustrated in Chapter 
6, antigen kinetics within the skin and dLN post-immunisations were investigated. Two approaches 
were selected: 1) radioactive-labelled proteins using OVA and Fluvax® vaccine and  
2) fluorescently-labelled Fluvax® vaccine. Based on preliminary results using delivering 
Coomassie Blue, the dye was not detectable within 5 min of NP-treated mice (Figure 7.6a) visually 
in the dLN as indicated by the white arrows. By contrast, i.d. delivered Coomassie Blue reached the 
dLN within 5 min as indicated by the white arrows (Figure 7.6b). These results indicated faster 
drainage of Coomassie Blue via the lymphatics to the dLN by i.d. than by the NP.  
 
Figure 7.6: Delivery and appearance of Coomassie Blue following Nanopatch™ and i.d. in the draining lymph 
node post-delivery.  
Coomassie Blue coated onto NP or delivered i.d. (20 µL) and animals dissected 5 min post-delivery. (a) NP-based 
delivery of Coomassie Blue was not visually detectable in the auricular dLN (white arrows) although (b) was clearly 
visible by eye as early as 5 min post i.d. injection. Images representative of n=3 mice.  
Due to the low detection limits of beta emitters (i.e. 14C), administration of 14C-OVA was 
investigated as a suitable proxy to study antigen kinetics post NP and i.d. delivery. The maximum 
14C-OVA dose to be administered was dictated by the maximum amount that could be coated onto 
the NPs, resulting in 60 nCi coated and approximately 15 nCi delivered per mouse ear; i.d. groups 
were accordingly dose-matched. Mice received one i.d. or NP per ear and were culled by cervical 
dislocation at the indicated time-points with ears and dLN collected, dissolved and analysed with a 
beta counter. Upon NP application, a fast reduction of 14C-OVA scintillation counts, measured as 
DPM was noted. This resulted in an approximately 10-fold DPM reduction from the 0h time-point 
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(immediately after NP application) reaching the detection limit of the beta counter within 6h post-
delivery counting <200 DPM (Figure 7.7a upper panel). Throughout the course of the study, no 
DPM signal of 14C-OVA above background levels was measured in dLN over the 10-day course 
study.  
When the percentage of total delivered 14C-OVA within the skin and dLN was assessed, ~35% was 
measured within the skin while <1% of the total 14C-OVA was measured in dLN (Figure 7.7a 
lower panel). 14C-OVA in the skin reduced very rapidly and measured <5% by 6h and thereafter. 
By contrast, i.d. injection of 14C-OVA resulted in high DPM signals in the skin for the first 30 min, 
followed by a stark reduction at 6h and thereafter (Figure 7.7b upper panel). In contrast to NP 
application, i.d. readings were higher in the skin than NP over an extended period of time – 
although below the detection limit of the instrument (Figure 7.7a and b, upper panels). However, 
only small amounts of 14C (<50 DPM) were measured in the dLN at t=0h post i.d. injection of  
14C-OVA and <20 DPM 30 min later. Looking at the data with respect to total percentage of  
14C-OVA within the skin and dLN, over 80% of i.d. injected 14C-OVA remained in the skin, while a 
significant reduction was measured at the 30 min time-point, with only ~28% remaining in the skin. 
By 6h and 12h post i.d. injection, less than 5% and 2%, respectively, of the 14C-OVA remained in 
the skin (Figure 7.7b lower panel). Overall, these observations did not reflect the Coomassie Blue 
staining observed in the dLN after i.d. injection (Figure 7.6). It is possible that 14C may be 
uncoupled or cleaved from OVA, resulting in such high 14C-OVA readings in the skin but not above 
the detection limits in the dLN. These data suggested that 14C-OVA following NP and i.d. delivery 
remained in both cases for at least 6h in the skin while no traceable amounts of 14C-OVA were 
found in dLN at all indicated time-points. In summary, 14C-OVA was found to give conflicting 
results regarding antigen trafficking to the LN post NP and i.d. immunisations; another method was 
sought to verify these results.  
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Figure 7.7: Measurements of 14C-OVA retention in skin and auricular draining lymph nodes post Nanopatch™ 
and i.d. delivery. 
Antigen kinetic tracer experiment using 14C-OVA to measure antigen delivery within the murine ear skin and dLN post 
NP and i.d. delivery. 14C-OVA was delivered by NP or i.d. in two separate experiments. Elution controls contained 
coated NPs eluted in PBS, or 20 µL of the equivalent amount of 14C-OVA which were set to 100%. Results shown are 
mean ± SD (upper panels) or mean only (lower panels) of n=3 mice (6 ears per group).  
The 14C-OVA counts within the dLN were below the detection limit (200 DPM), at 5 min and even 
at 24h post injection (Figure 7.8). To exclude the possibility of 14C-OVA being either spliced or 
cleaved from OVA, and being cleared via the blood, kidney or other organs, a study was set up to 
examine 14C-OVA content in several tissues and organs (ears, dLN, spleen, kidney, liver and 
blood). A group of mice (n=3) received either NP or i.d. injections as described above, with tissues/ 
organs collected and assayed for beta emission of 14C-OVA. As expected, no DPM above detection 
levels (200 DPM) was measured at 0h and 24h post-immunisation of the mice in any organ 
(including dLN, spleen, kidney, liver and blood; Figure 7.8). Of note, more systematic delivered 
14C-OVA was observed in i.d. groups. Therefore, the 14C-OVA results were inconclusive regarding 
antigen being retained in the skin, drainage to the dLN and filtration by or retention in any other 
organs.  
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Figure 7.8: Assessment of antigen kinetics using 14C-OVA post Nanopatch™ and i.d. delivery. 
Delivery of 15 nCi of 14C-OVA within the auricular LN was below the detection limit (200 DPM) of the beta counter 
immediately (0h) and 24h post administration, deeming this method unsuitable to study antigen kinetics. Assessment of 
other organs (blood, spleen kidneys and liver) for 14C-OVA remained below the detection limit at both time-points. 
Based on n=3 replicates, shown are bars + SD. 
A separate approach to study antigen kinetics involved fluorescently labelled antigen delivery. 
Fluvax® was fluorescently-labelled with DyLight® 755 (sections 3.2.15.1 and 3.2.14). The 
presence of fluorescently-labelled FV delivered by NP or i.d. in ear skin was assessed by in vivo 
imaging of mice on the MS FX Pro system using fluorescence microscopy overlayed with X-rays. 
Initial fluorescence signal intensity was set as high as possible by concentrating FV prior to 
labelling; approximately 600 ng cflFV were delivered by NP or i.d.. The first study investigated 
antigen retention within the skin using n=5 (NP and i.d.) or n=3 (naive) per group. The same 
animals were imaged over 28 days (0, 10 and 30 min; 6h, 12h, 24h, 48h; days 4, 7, 10, 14, 17, 21 
and 28 post-treatments). The MFI immediately after antigen delivery was set to 100%, with the 
following time-points representing the remaining cflFV as a percentage. As expected, the highest 
fluorescence intensities in the ears were detectable at the i.d. injection and NP application site but 
not in tissue from the same mice at sites distal to the cflFV delivery site (Figure 7.9). Following NP 
application, no decrease of MFI was observed until day 4, remaining around 100% of the initial 
delivered antigen dose (Table 7.1). A sudden decrease to 30% of antigen remaining within the skin 
was noted by day 7, with a subsequent, gradual decrease in fluorescence intensity thereafter (Table 
7.1 and Figure 7.10). However, it must be acknowledged that some fluorescence intensity may 
come from the dLN. Taken together, the 14C-OVA data and these data suggest that antigen was 
retained for longer in the skin post NP immunisation than i.d. – although both were visible in the 
skin by in vivo imaging until day 21. 
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Figure 7.9: Antigen kinetics of fluorescently labelled influenza vaccine assessed in vivo in skin post Nanopatch™ 
and i.d. immunisations.  
Semi-quantitative analysis of antigen kinetics in murine ear skin. Mice were immunised with (dose-matched) 600 ng 
cflFV by coated NP or resuspended in saline for i.d. injections (20 µL) and imaged in vivo under isoflurane anaesthesia 
on a Carestream Imaging system MS FX Pro at the indicated time-points. X-ray and NIR spectra were collected, 
overlaid and analysed as described in sections 3.2.14 and 3.2.15.1. Exposure signals of NIR were doubled from 30s to 
60s at indicated (*) time-points. cflFV, concentrated fluorescent Fluvax®; NP, Nanopatch™; i.d., intradermal; dLN, 
auricular draining lymph node; MFI, mean fluorescent intensity; ROI, region of interest. Groups of 5 were imaged, with 
10 data points being measured. 
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By doubling the exposure time from day 10 onwards, fluorescent-labelled antigen was still detected 
by day 28 albeit very low signals (<1%). By contrast, i.d. delivery of cflFV resulted in a much faster 
decrease of fluorescence intensity, notably after 12h post immunisations (Table 7.1) and decreasing 
even further to 21% by day 4. Overall, both immunisation routes resulted in quantifiable labelled 
antigen within the skin for ~10 days (decreasing from 100% to ~10%) and even up to 28 days post-
immunisation (~1%; Figure 7.10). These results contrast the 14C-OVA results presented above and 
may be attributed to spliced or cleaved 14C from OVA. Further studies are necessary to investigate 
the cause of such contradicting results, if deliveries of radio-labelled agents are to be pursued. 
Larger variation within i.d. samples could be explained by the injection of a bolus, leading to blebs 
within the skin. In addition, MFI of NP groups were approximately half of those measured in i.d. 
groups. This difference in MFI can be explained by the selected analysis method using identical 
ROIs to analyse NP and i.d. immunisation groups. As the NP covered a smaller area than i.d. 
injections (16 mm2 versus 27 mm2; Figure 4.2), and with both diffusing over time, an ROI large 
enough to capture the radial and lateral diffused antigen was used. Despite the differences in MFI 
values, the percentage of remaining antigen in the skin allowed for comparisons between NP and 
i.d. groups. Together, these results indicated prolonged antigen retention (~4-7 days) within the 
murine ear skin after NP immunisation; by contrast, i.d. immunisations dropped to ≤50% by day 2. 
Overall, MFI readings indicated extended antigen presence in the skin post NP immunisation with a 
significant drop of labelled antigen in the skin by day 7 despite being measurable until day 21; 
antigen persistence post i.d. immunisations gradually decreased from 6h as measured by in vivo 
imaging until day 21. 
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Figure 7.10: Mean fluorescence intensity measured after DyLight®755-labelled antigen delivered by 
Nanopatch™ or i.d. injection. 
Graphical representation of Table 7.1 with the mean percentage of labelled antigen remaining in the skin represented. 
Data representative of n=10 measurements. Results are representative of two independent experiments.  
 
Table 7.1: Mean fluorescence intensity measured after DyLight®755-labelled antigen delivered by Nanopatch™ 
or intradermal injection in vivo on the Carestream Imaging system. 
Mice received labelled antigen by NP or i.d. injection on both ears and were imaged at the indicated time-points in vivo 
under isoflurane anaesthesia. Images (see Figure 7.9) were analysed in ImageJ and Carestream Imaging software by 
drawing ROIs around the site of antigen deposition. ROIs were kept constant between all groups and images. The MFI 
immediately after antigen delivery was set to 100%, with the subsequent samples calculated as % of the remaining 
antigen within the skin. Laser exposure time to the antigen was doubled from 30s to 60s after 10 days (time-points 
below the dotted line) to increase signal detection. MFI, mean fluorescence intensity; ROI, region of interest. Groups of 
5 were imaged, with 10 data points being measured; shown are mean ± SD.  
Time-point Exposure time MFI – Nanopatch™ % MFI – i.d. % 
0 min 30 s 672.4 ± 202.7 100 1156.3 ± 606.3 100 
10 min 30 s 644.6 ± 211.9 96 1723.5 ± 534.8 111 
30 min 30 s 655.4 ± 237.9 97 1792.5 ± 526.9 115 
6h 30 s 793.4 ± 471.3 117 1532.5 ± 778.3 98 
12h  30 s 886.4 ± 240.4 131 1452.4 ± 678.7 93 
24h 30 s 797.4 ± 327.0 118 1310.0 ± 622.4 84 
48h 30 s 730.7 ± 207.9 109 732.2 ± 302.2 47 
Day 4 30 s 734.0 ± 211.4 109 339.1 ± 121.9 21 
Day 7 30 s 202.8 ± 129.4 30 111.7 ± 63.7 7 
Day 10 60 s 44.1 ± 26.7 7 103.1 ± 68.5 7 
Day 14 60 s 16.7 ± 10.4 3 56.3 ± 28.1 4 
Day 17 60 s 6.9 ± 10.0 1 38.0 ± 24.3 2 
Day 21 60 s 0.9 ± 5.4 <1 27.0 ± 12.0 1 
Day 28 60 s 2.2 ± 4.4 <1 20.5 ± 12.0 1 
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With reports having observed drainage via the lymphatics within seconds upon i.d. delivery of 
antigen or quantum dots [175, 176, 665], and due to the close proximity of dLN to the ears, no in 
vivo studies of antigen kinetics within the dLN could be conducted. A separate experiment was set 
up to image dLN and ear skin. Groups of n=3 were immunised by NP or i.d. injection for each time-
point (10 and 30 min; 6h, 12h, 24h, day 2, day 4 and day 7 post-treatments; based on results 
obtained in Figure 7.11). Mice were culled at indicated time-points, tissues collected from the 
administration sites (whole ears), naive ear samples as well as dLN excised and imaged on the 
Carestream Imaging system. Interestingly, and in agreement with the Coomassie Blue data (Figure 
7.6), cflFV migrated most likely through the skin lymphatics towards regional dLN following i.d. 
injection, and was measurable as early as 10 min post administration in the dLN by i.d., but not post 
NP application (Figure 7.11a and b). Overall, skin and dLN following i.d. injection remained 
highly fluorescent at the early time-points (from 10 min to 6h), but reduced quickly over time (>6h).  
The kinetic profiles of dLN showed a fast migration of i.d. delivered antigen (presumably through 
lymphatics) into dLN, detectable as early as 10 min post i.d. injection. The MFI in the dLN of i.d. 
injected groups reached its maximum at 6h post antigen delivery with an MFI of ~75 a.u., followed 
by a gradual decrease in intensity thereafter until day 7 (MFI ≤1 a.u.). By contrast, fluorescence 
within dLN in NP groups was only detectable from 30 min onwards, but remained at a constant  
2-5 a.u. MFI throughout the kinetics study, with measurements from 30 min to day 7. Further 
studies are quired to assess the antigen diffusion via lymphatics versus active cellular uptake. 
Overall, this data demonstrated that i.d. delivered antigen reached the dLN faster than NP groups, 
with a steady decrease thereafter. This contrasts NP-based delivery of antigen, where a steady influx 
of antigen was measurable in the dLN over the length of this study. This could indicate that antigen 
predominantly drains via the lymphatics rather than being taken up by DCs. In particular as it has 
been shown that dDCs peak at 24-48h [130, 162], while LCs peak at 72-96h [132] for migration to 
the dLN. However, others have demonstrated that DCs are capable of fast migration [164] and 
should be further assessed in the context of antigen uptake and shuttling to the dLN by DCs. 
Collectively, these results indicate that soluble antigen reaches the dLN faster post i.d. injection 
than NP, with the former peaking at 6h post-immunisation.  
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Figure 7.11: Antigen kinetics of labelled vaccine in the auricular draining lymph nodes post-immunisations via 
Nanopatch™ and i.d. over 7 days.  
Mice were immunised with dose-matched cflFV antigen (Fluvax®, 600 ng) by NP or i.d. injection (20 µL) on both ears 
and were imaged at the indicated time-points in vivo under isoflurane anaesthesia on a Carestream Imaging system MS 
FX Pro at various time-points. Following asphyxiation, ears and dLN were dissected and again visualised. Images were 
analysed in Carestream Imaging software by drawing ROIs around the site of antigen deposition. ROIs were kept 
constant between all groups and images. (a) Representative images of in vivo (left panel) and ex vivo imaging (middle 
and right panel) post sacrifice of ears, dLN and the remaining body. X-ray and NIR spectra were collected, overlaid and 
analysed as described in sections 3.2.14 and 3.2.15.1. Fluorescence (red arrows), no fluorescence (white arrows), ears 
(open arrows) and dLN (arrows). (b) MFI of dLN. cflFV, concentrated fluorescent Fluvax®; NP, Nanopatch™; i.d., 
intradermal; dLN, auricular draining lymph node; MFI, mean fluorescence intensity; ROI, region of interest. Groups 
with n=3 were imaged, with 6 data points being measured; shown are mean + SD.  
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7.3.3 Danger signals and associated pathways following Nanopatch™ 
application and intradermal injection 
7.3.3.1 Release of DAMPs following Nanopatch™ application 
Danger signals have been shown to be released by dying and dead cells, specifically necrotic as 
well as necroptotic cells [169, 358, 396, 439, 489-491, 502, 513, 529, 534, 553, 640, 666-668]. 
Based on the Western Blot data (Chapter 4, Figure 4.11), some elevated HMGB-1 levels were 
seen 12h post NP and i.d. treatment but not at later time-points, suggesting a fast release of HMGB-
1 by necrotic cells. Immunohistochemistry was used here to visualise and confirm HMGB-1 release 
following NP and i.d. injection at 10 h post-treatment. Tissue samples were collected and prepared 
for paraffin sectioning (sections 3.2.7 and 3.2.7.3). As can be seen from Figure 7.12, HMGB-1 
(red) remained intracellular and intranuclear within the basal keratinocytes in naive samples as 
indicated by the black arrows in agreement with others [529]. Following NP application, very small 
amounts of nuclear and cytoplasmic HMGB-1 were found, with the majority predominantly being 
released into the extracellular space (Figure 7.12 middle, white arrows). HMGB-1 was mostly 
confined to the nucleus with very little HMGB-1 in the cytoplasm following i.d. injection (Figure 
7.12 right). This data is in agreement with the Western Blot data (Figure 4.11), with more  
HMGB-1 released into the cytoplasm following NP than i.d. application. Extended time course 
studies assessing HMGB-1 release and other DAMPs (such as ATP, HSP and MSU) following NP 
and i.d. immunisations will be required to determine the extent of DAMP release and their effects 
upon the immunogenicity. Together, these data indicate a high release of HMGB-1 into the 
extracellular space post NP application, in comparison to i.d. or naive control groups, suggesting 
that DAMPs are released from cells following NP application.  
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Figure 7.12: HMGB-1 released from cells post Nanopatch™ application but not after i.d. injection.  
Murine tissue was subjected to NP treatment and i.d. injection with 10 ng Fluvax® 2011 (FV). Tissues were collected 
10h post-treatment, fixed, paraffin-embedded (section thickness 10 µm), incubated with HMGB-1 (red, black arrows) 
and counterstained with haematoxylin. HMGB-1 was retained mostly within the cytoplasm in naive mice (left panel) 
but was only found in small amounts in the cytoplasm of NP-treated samples (middle panel, white arrows) while i.d. 
samples contained most HMGB-1 within the cells (right panel) Histological sections following i.d. injections were 
taken ~200 µm from the injection site. NP, Nanopatch™; i.d., intradermal; HMGB-1, high mobility group box 
protein 1. Original magnification 20x; upper panels scale bar 150 µm, lower panels scale bar 50 µm.  
7.3.3.2 The role of caspase-1, NALP3 and TLR4/ RAGE on antibody responses in 
Nanopatch™ and intradermal immunisation 
Several studies have noted that necrotic cell death could lead to NALP3 inflammasome activation 
through release of DAMPs such as ATP, HSPs, HMGB-1, uric acid crystals etc as described in 
Chapter 2, section 2.5.2 [398, 551, 553]. Based on the observed cell death profiles, cell 
morphologies and Western Blot data obtained in Chapter 4, it was proposed that predominantly 
necrotic cell death was induced upon NP application. Thus, based on the immunohistochemistry 
data (Figure 7.12) and on the immunogenicity results (section 6.3.1), it was hypothesised that NP 
application could lead to NALP3-inflammasome activation through necrotic cell death [398] and 
DAMP release in a caspase1-dependent manner [398, 553]. To investigate whether the enhanced 
immune responses following NP immunisations (10 ng Fluvax® 2011) were mediated via a 
caspase-1-dependant pathway, influenza-specific antibody responses were assessed following 
immunisation by NP and i.d. using caspase-1-/- mice and C57Bl/6 wild type (WT) mice. No 
statistically significant differences between WT and caspase-1-/- mice following NP application 
were seen based on endpoint titres (Figure 7.13). Similarly, no statistical significantly differences 
was observed in i.d. immunised groups of caspase-1-/- and WT mice. The hypothesis that caspase-1 
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was essential in mounting enhanced immune responses to influenza vaccine delivered by the NP 
was therefore disproved. This suggested that caspase-1 did not play an essential role in mounting 
influenza-specific antibody responses. More specifically, it suggested the involvement of other 
pathways in absence of essential caspase-1 function such as IL-1R via IL-1α [554]. Unfortunately, 
neither IL-1α-/- nor IL-1R-/- mice were available at the time of the study, and are therefore further 
discussed in Chapter 8.  
 
Figure 7.13: Influenza-specific antibody responses after Nanopatch™ and i.d. immunisation were caspase-1-
independent.  
Mice received 10 ng Fluvax 2011 delivered by NP (blue) or i.d. (orange) to one ear/ mouse. Caspase-1-/- were compared 
to wild type mice (C57Bl/6) following immunisation by NP or i.d. Sera were collected on day 21 and antigen-specific 
antibody responses were assessed by ELISA. NP, Nanopatch™; i.d. intradermal; WT, wild type C57Bl/6 mice. Data 
representative of two independent experiments. Statistical analysis was performed using an unpaired student’s t-test 
with Welch’s correction factor (all groups p>0.05). 
NALP3 inflammasome activation has been reported following influenza A infections [669] as well 
as exposure to DAMPs from necrotic cells, resulting in increased production of pro-inflammatory 
cytokines such as IL-1β and IL-18 [553]. While NALP3 inflammasome activation involves  
caspase-1 activation, leading to the secretion of mature IL-1β, more recent evidence suggested the 
possibility of a caspase-1-independent NALP3 activation [670]. Therefore, it was hypothesised that 
NALP3 inflammasome activation would occur via a caspase-1-independent pathway. To assess if 
NALP3 activation was contributing to the enhanced immunogenicity post influenza vaccination, 
NALP3-/- mice were immunised with 10 ng FV2011 by NP or i.d. injection as described above with 
Fluvax®-specific antibody responses assessed by ELISA. Consistent with previous results 
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(Chapter 6), WT mice showed elevated endpoint titres (Figure 7.14a). However, no statistical 
significantly differences in antibody responses between WT and NALP3-/- were observed (Figure 
7.14a), suggesting no involvement of the NALP3 inflammasome to the enhanced immunogenicity 
following NP immunisations despite the necrotic cell death. These results are in agreement with a 
recent study by Ellebedy et al. who found that MF59-adjuvanted influenza vaccine in ASC-/- mice, 
but not NALP3-/- or caspase-1-/- mice, elicited significantly lower HI titres and antibody responses 
[377]. It was suggested that ASC (in a caspase-1 inflammasome independent manner) was explicitly 
required for the optimal generation of antigen-specific antibodies in response to MF59-adjuvanted 
H5N1 influenza subvirion vaccines [377]. These results indicate that the neither NALP3 nor 
caspase-1 were required for the enhanced immunogenicity (i.e. antigen-specific antibody responses 
to split-virion influenza vaccine) observed in NP but not i.d. immunised groups. This suggests that 
the physical adjuvant effect of the NP using influenza vaccine is NALP3 inflammasome activation-
independent, i.e. the NALP3 inflammasome/ caspase-1 pathway in not involved in generating 
enhanced humoral responses.  
With a significant amount of HMGB-1 released at 6h and 12h post NP application (Figure 4.11 and 
Figure 7.12), the role of HMGB-1 as an immuno-stimulant in NP-mediated immune responses was 
considered. With HMGB-1-/- mice dying soon after birth, and HMGB-1 floxed mice [671] 
unavailable at the time of the study, the approach included the use of RAGE/ TLR4 double 
knockout mice. Both, RAGE and TLR4 amongst several others are key receptors for HMGB-1 
[527] while TLR4 is also important in wound healing while TLR4 is also important in wound 
healing [672]. RAGE-/-/ TLR4-/- and C57Bl/6 mice received 10 ng Fluvax® by NP or i.d. and 
antibody responses were measured. Surprisingly, RAGE-/-/ TLR4-/- mice showed no statistically 
significant differences in their antibody responses based on endpoint titres (Figure 7.14b). This 
may be attributed to several surface receptors that HMGB-1 can bind to that include TLR4, TLR2, 
RAGE, CD24, TIM-3 and TREM1 but also the redox status of HMGB-1 [531]; a repeat study with 
ablated HMGB-1 should therefore be repeated to investigate the potential contribution of HMGB-1 
to the elevated humoral responses following NP immunisations. Collectively, these results indicated 
that neither RAGE nor TLR4 surface receptors resulted in a reduced antibody-mediated response to 
influenza antigen.  
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Figure 7.14: Influenza-specific antibody responses after Nanopatch™ immunisation were independent of the 
NALP3 inflammasome and TLR4/ RAGE receptors. 
Mice received 10 ng Fluvax 2011 delivered by NP (blue) or i.d. (orange) to one ear/ mouse. Knockout strains (NALP3-/- 
and TLR4-/-/RAGE-/-) were compared to wild type mice (C57Bl/6). Sera were collected on day 21 and analysed by 
ELISA antigen-specific IgG responses. NP, Nanopatch™; i.d. intradermal; WT, wild type. Statistical analysis was 
performed using an unpaired student’s t-test with Welch’s correction factor (all groups p>0.05). 
7.4 Discussion  
7.4.1 Nanopatch™ application induces an inflammatory micro-
environment 
Previous studies on skin injury, physical stimuli to skin and inflammation (e.g. adjuvantation) have 
examined the infiltration of myeloid cells, including inflammatory monocytes, DCs, neutrophils as 
well as cytokine and chemokine release [186, 221, 247, 555, 667, 673]. Here, flow cytometric 
examination of skin following uncoated or coated NP applications revealed a much higher 
inflammatory microenvironment than after i.d. immunisations. The infiltration of CD45.2+ CD11b+ 
cells (depicted in Figure 7.2 and Figure 7.3) into the NP-treated skin took place over the course of 
5 days, decreasing by day 7; with the dominating phenotype being neutrophils. Local inflammation 
and cellular infiltration following NP application – and to a very minor extent after i.d. injection but 
no difference over naive levels – was confirmed by flow cytometry and MPM imaging.  
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Neutrophils represented the largest component of the inflammatory infiltrations, depicting higher 
infiltration into the skin post NP but to a much lesser extent after i.d. injection. Neutrophils are the 
first responders to an injury and assist in the wound healing process by secreting cytokines that 
attracting other cells such as macrophages and mast cells, which in turn assist in the wound healing 
process. Following NP application, two prominent waves of infiltrating cells were seen in the skin 
at 6h and 24h (Figure 7.1-Figure 7.3). This neutrophil infiltration was in agreement with 
observations by others who assayed neutrophil influx to the site of sterile tissue injury within 
minutes [404, 555] that steadily increased over several hours [404]. This coincides with the findings 
of cellular infiltration post NP application to skin. In particular, at the 24h time-point, neutrophils 
represented almost 30% of live cells. Similarly, solid MNs and dMNs used for antigen delivery into 
skin have also shown to cause inflammatory cell infiltration alongside with cytokine and chemokine 
release post-immunisations [164, 165, 322]. Applications of dMN with or without antigen 
encapsulated in nanoparticles have also been shown to result monocyte and neutrophil infiltration 
into the skin [322]. Neutrophils are known to respond to extracellular ATP via P2X7 receptor, a 
danger signal released by damaged or dead cells. The higher incidence neutrophils in NP groups or 
groups co-delivering QA correlated indeed with the observed cell death. Specifically, Chapter 4 
and Chapter 6 demonstrated increased levels of cell death following NP application [344] or QA 
delivery (Figure 6.7), respectively. Interestingly, ATP has also been shown to activate the NALP3 
inflammasome [398, 674], a multi-protein complex that forms in response to injury or cellular 
stresses [400]. 
The dynamic flux of inflammatory infiltrates measured by flow cytometry was consistent with the 
migration of csf-1r eGFP+ cells [660, 675] to the site of injury as seen around the NP projection and 
i.d. needle insertion sites (Figure 7.1). The cellular infiltration was higher after NP than after i.d. 
injections, forming ‘plugs’ to seal the microchannels, similar to sand-fly bites in skin [661]. 
Notably, this migration of monocytes, neutrophils and DCs to the site of injury (NP microchannels), 
but to a lesser extent after i.d. needle insertion, was consistent with reports by others investigating 
adjuvant delivery to skin or muscle [186, 373, 382]. This could indicate that NP application results 
in innate immune responses comparable to chemical adjuvants. For example, i.d. administration of 
saponins, MPL or IFA resulted in a pro-inflammatory environment in murine skin, dominated by 
neutrophil infiltration in the first 12-24h, followed by macrophages after ~48h [186]. Similarly, i.m. 
injection of MF59 resulted in monocyte and neutrophil infiltration into the muscle, with neutrophils 
peaking at 16h, followed by monocytes and macrophages by day 2-3 as well as myeloid DCs by day 
3 [373]. Interestingly, neutrophils were dispensable for adjuvanticity of MF59, suggesting other 
 217 | P a g e  
innate immune cells (e.g. macrophages, monocytes or even mast cells) may exert similar roles to 
neutrophils including cytokine secretion [373].  
Establishing the local environment based on cytokine profiles is important as they are guiding and 
directing the immune responses, thus influencing the cellular infiltration into the NP and i.d. 
immunised tissue. Therefore, further studies are essential to assess and distinguish cytokine and 
chemokine release from NP and i.d. immunised tissue by RT-PCR, which are currently being 
examined. Cellular activation, migration and infiltration of cells after MN application at the 
treatment site were further supported by elevated cytokine levels in skin or dLN [322] as measured 
by CBA or RT-PCR [164, 165]. Measured cytokines and chemokines included IL-1β, IL-4, IFN-γ, 
CXCL-1, G-CSF, IP-10, MIP-1α, MIP-2 and MCP amongst others. For example, mechanical skin 
disruption by MNs (5 needles, 700 µm long) led to the secretion of chemo-attractants activating and 
inducing migration of neutrophils (CXCL-1, MIP-2), monocytes (MCP-2) and macrophages  
(MIP-1α, MIP-2) in skin [164]. In a study by Vitoriano-Souza and colleagues, i.d. delivery of 
adjuvants also resulted in cytokine production high levels of pro-inflammatory cytokines TNF-α, 
IFN-γ, IL-2 and IL-6 as well as anti-inflammatory cytokine IL-10 amongst others (IL-4, IL-17) as 
measured by CBA [186]. Notably, MN and NP immunisations induce a pro-inflammatory 
environment. Here, the author suggests that NP application most likely induces an inflammatory 
environment similar to adjuvants, which both lead to infiltration of monocytes, neutrophils but also 
DCs to the site of application [186, 322].  
Recently, Pearton et al. investigated gene expression following H1N1 VLP delivery via MN 
application or i.d. injection to excised human skin [614]. They concluded that, based on the large 
number of upregulated genes of the innate immune response, the stimulation of the innate system in 
the skin may arise from both, device and antigen delivery, with more pronounced responses in i.d. 
groups. This contrasted Carey et al.’s findings who observed a lower pro-inflammatory 
environment after manual MN application than after i.d. injection of a live viral malaria vector, as 
assessed by RT-PCR in the skin and dLN [165]. The lower inflammation levels post MN delivery 
may be attributed to the inherently different application methods, using a manual application of  
10-20 N [165] versus spring-loaded applicator device ~50 N (NP). The difficulty of dose-matching 
the MVA delivery may have resulted in a higher delivered dose by i.d. than MN, thus evoking a 
more pro-inflammatory environment after i.d. injection. Other possible factors affecting the 
inflammatory responses to i.d. and MN-based delivery could include different volumes of antigen 
delivered, dry versus solid state antigen formulation, uptake by different skin DC subsets, antigen 
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retention in the skin and time of application (~10s for i.d. versus 2-10 min for MN/ NP 
applications). 
While the i.d. injections cover a larger area than the NP, the NP’s significantly larger surface area 
than i.d. needles may suggest that more antigen is in contact with APCs (particularly DCs) in NP 
groups than i.d. groups. This could be verified by assessing the immunogenicity by matching the 
‘surface area of affect’ between both devices, i.e. injecting a dose i.d. in a volume (~1 µl) that 
matches the affected area of a NP. The immunogenicity data alongside with quantification of APCs 
(and labelled antigen) within the skin could also provide insights whether more APCs are 
interacting with antigen within the larger surface area. By contrast, matching the contact surface 
area of NP with i.d. may not be possible due to the required 10-fold increase in gauge size of an i.d. 
needle or 10-fold NP surface area reduction.   
Lastly, a high inflammatory micro-environment was evident based on the level of local and  
HMGB-1 release after NP immunisation. HMGB-1 can be released by necrotic [512, 519], 
apoptotic and even pyroptotic cells [676] in response to tissue injury and cellular damage [169]. In 
particular as HMGB-1 release has been associated with inflammatory cell infiltration into damaged 
tissue [677] and can activate inflammasomes, provoking an inflammatory environment which 
subsequently release pro-inflammatory cytokines (e.g. IL-1β and IL-18) [678]. It was not surprising 
that NP released more HMGB-1. This DAMP release also correlated well with the cell death levels 
at the tested time-point. In contrast, HMGB-1 release was much less pronounced after i.d. injection. 
Other DAMPs such as ATP, HSP, IL-33, extracellular DNA amongst others have been measured 
following tape-stripping of skin [221, 667] or adjuvant delivery [358, 395]. Whilst currently under 
evaluation, it is likely that several DAMPs are released following NP application, and to a lesser 
extent following i.d. injections. Recent studies with MF59 demonstrated that release of the danger 
signal ATP contributes to its potentiating immune responses to influenza vaccine [94]. This effect 
was confirmed when apyrase (enzyme that hydrolyses ATP to AMP) was administered. However, 
administration of ATP with antigen did not boost the responses significantly. Vono et al. proposed 
that a concentration gradient of extracellular ATP for chemotaxis of inflammatory cells towards 
danger signals may be required to exert the stimulatory effects [94]. Release of danger signals 
following sterile inflammation also indicated a similar concentration gradient of DAMPs released 
by necrotic cells leading to neutrophil chemotaxis [404]. Thus, a fine balance of danger signals 
released by damaged cells co-localising with antigen further sustain the hypothesis of cell death 
induced by the NP enhancing immune responses and correspond well with other reports where 
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gradients of danger signals [94, 404] or co-localisation of adjuvant (evoking DAMPs; [94]) with 
antigen potentiated the immune responses.  
7.4.2 Co-localisation of antigen with cell death and an antigen reservoir 
within the skin correlate with enhanced immunogenicity 
Antigen delivery by NP resulted in extended antigen retention within the skin remaining 
approximately constant for 4 days, while i.d. groups drastically decreased after 24h. Although both, 
i.d. and NP-based deliveries of labelled antigen were measurable for much longer in the skin: up to 
21 and 17 days, respectively. The results indicated that the NP created an enhanced antigen depot 
effect within the skin than i.d. injection, leading to a continuous and slow release of the antigen for 
several days. Retention and drainage following immunisation by NP and i.d. were in accordance 
with reports by others. i.d. delivery of Q-dots and OVA-particles led to fast drainage from the skin 
to the dLN [175, 176]. These results are in accordance with other published studies reporting fast 
antigen migration/ transport to the lymphatics and dLN post i.d. or s.c. [175, 176]. The measured 
fluorescence in dLN following NP immunisation appears faster than other MN-based deliveries 
when measured in dLN or other dLN [165, 665]. Others did not observe cells carrying fluorescently 
labelled antigen within 3 days in dLN post MN delivery [164]. Separately, MN-based delivery of 
OVA and influenza-VLPs delivery resulted in antigen persistence for up to 7 days in the skin [164]. 
The antigen retention following MN (and possibly NPs) is also in agreement with observations by 
Zaric et al., who suggested that antigen-encapsulated nanoparticle delivery remains highly localised 
in the skin, unless the particles are actively taken up by skin-resident DCs and transported to dLN 
[322]. Moreover, particle delivery containing DiD-fluorescent-microparticles encapsulated within 
PLGA-MN or PAA-encapsulated AF488 in PLGA-dMN was measureable in skin for over 18 days 
[323]. The extended antigen retention time may have been the result of penetration depths of 300-
400 µm, passing through almost the full ear thickness and due to trapped particles within the 
cartilage [323]. Both MN-studies however did not investigate the effects of the antigen retention 
time on immunogenicity.  
Retention of antigen at the injection site allows time for inflammatory cells and APCs to 
accumulate at the injection site and to interact with and take up antigens. Whether this could 
represent a potential antigen reservoir formation in NP but not i.d. immunisations, similar to reports 
with alum [358], remains yet to be tested. Antigen depot formation has long been hypothesised as 
fundamental component contributing to alum’s adjuvanticity [389]. However, this was recently 
challenged by Hutchison et al., when removal of the alum-adjuvanted antigen site by dissection did 
neither reduce OVA-specific primary B- and T-cell responses, nor recall memory responses or 
 220 | P a g e  
antigen presentation in general [364]. Despite Hutchinson et al.’s findings, it cannot be excluded 
that the excision of the adjuvant-containing site itself resulted in sufficiently high inflammatory 
signals and DAMP release that stimulated the innate immune system. Further studies examining to 
what extent tissue damage and cell death may be the predominant contributing factor are essential. 
Repeating Hutchison’s experiment by including control groups with and without excision of the 
antigen site [364] to assess the antigen kinetics and trafficking along cellular infiltration would be 
interesting and could provide important answers to relevance and contribution of the antigen depot 
effect. While no antigen depot effect was essential for alum’s adjuvanticity, others have reported 
co-localisation of antigen with adjuvants or DAMPs as necessity for immuno-stimulatory effects.  
Co-localisation of antigen with adjuvant or cell death has been proposed as essential for immuno-
stimulatory effects in NP-based immunisations. Didierlaurent et al. has shown that the adjuvanticity 
of AS04 was dependent upon co-localisation of adjuvant and antigen for its potentiating effects 
[382]. Similarly, administration of an enterotoxin-containing patch over the s.c., i.d. or i.m. delivery 
site of influenza vaccine resulted in increased serum titres [97]. In addition, and in agreement with 
the proposed co-localisation model in NP immunisations, enhanced humoral and cellular immune 
responses to LVA-assisted antigen delivery were only observed when i.d. injections were given in 
the same area that was subjected laser treatment [436]. Interestingly, administration of necrotic cells 
resulted in immuno-stimulatory effects only when antigen and necrotic cells co-localised [608]. 
While resting DCs have been shown to take up apoptotic and necrotic cells, DCs can be activated 
and present antigen by taking up necrotic cells [334]. Similarly, necrotic cells including neutrophils, 
have been shown to enhance antigen uptake and presentation by macrophages to T-cells due to fast 
upregulation of CD40 and CD86 [679]. In contrast, apoptotic cells phagocytosed by macrophages 
were ineffective APCs. It was speculated that anti-inflammatory cytokines could be the reason for 
this [679]. Thus, and in accordance with the cellular infiltration data (Figure 7.2 and Figure 7.3), 
presence of predominantly necrotic cells (Figure 4.9) post NP application may indicate increased 
antigen exposure to necrotic cells that co-localise with more danger signals and antigen in 
comparison to i.d. injections.  
The difference in antigen retention between NP and i.d. groups in the skin also reflects on the 
amount of antigen measured in the dLN. The location of the antigen deposition may also contribute 
to the antigen persistence in the skin. Specifically, the NP delivers the antigen a dried form into 
both VE and dermis, where no change of interstitial or capillary pressure is anticipated. i.d. is 
predominantly delivered into the dermis, causing elevated pressures in tissue [175, 176, 665, 680]. 
This is due to the capillary forces in the dermal layers of the skin: i.d. injection of liquid has been 
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shown to increase local interstitial pressure, leading to enhanced drainage of antigens via the 
lymphatics to the dLN within minutes [175, 176, 646, 681]. Thus, i.d. injected antigen rapidly 
drains directly to the adLN, where interaction of antigen with DCs and T-cell priming occurs, with 
less antigen remaining in the skin and being taken up by APCs. By contrast, antigen persistence in 
the skin post NP immunisation may result in more antigen uptake by DCs, before being transported 
into the adLN. Others found that extended antigen expression was essential for mounting a high  
T-cell response as seen in DNA vaccine-based delivery via tattooing devices [253]. These 
observations of co-localisation requirement are in agreement with the physical immune enhancer 
model presented throughout this doctoral thesis, proposing the requirement of co-localisation of cell 
death with antigen adjacent to live cells. Whether the slow antigen release in NP-immunised groups 
contributed to the observed enhanced immunogenicity results presented within this doctoral thesis 
and elsewhere [3, 344, 345, 350] remains yet to be confirmed. A similar experimental setup to 
Hutchison’s will be elucidated to investigate the antigen depot effect on immunogenicity [364]. 
Despite the data pointing towards different antigen uptake mechanisms and kinetics, further studies 
are necessary to assess whether the fluorescent data is true data, or possibly biased. Specifically, the 
assessment of antigen uptake, processing, trafficking and draining to the adLN of labelled antigen 
may differ from unlabelled antigen. This was not evaluated within this work: no antigenicity studies 
were performed assessing the antigenicity of the labelled antigen. Second, cleavage of the 
fluorescent label from the antigen could have occurred, thus the results could represent a false 
representation of antigen remaining in the skin or draining to the adLN. This is a limitation that was 
not addressed here. An approach to address this question could be by using Q-dots or other 
fluorescent particles as done by others [164, 323], where the fluorophore cannot be cleaved and 
hence the fluorescence represents a true ‘presence’ of the particle in skin and adLN. Nevertheless, 
the Q-dot or particle size may also affect its (preferential) cellular uptake.  
While beyond the scope of this thesis, the in vivo uptake of antigen by skin-resident, LN-resident or 
circulating (non-skin-draining) DC subsets [151, 162, 322] as well as the migration of those cells 
and antigen transport to dLN is of inherent importance to understand the differences between NP 
and i.d. based immunisations. The currently most complete study investigating cellular uptake of 
delivered antigen by MNs/ dMNs into skin was performed by Zaric et al., who reported that skin-
derived DCs with CD11c+ MHC II+ CD11b+ EpCAM- CD207- seemed the only DC subset able to 
present antigen following MN-based delivery of OVA-antigen [322]. Interestingly, this contrasts a 
study by Seneschal et al. who noted that CD207+ skin dDCs, but not LCs or to a lesser extent 
CD207- dDCs, were essential to generate CD8+ T-cell responses following s.s. with vaccinia virus 
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[151]. This may be attributed to the viruses’ different origin, although both are highly virulent and 
were delivered cutaneously. Moreover, a newly identified subset of dDCs that express CD301 have 
shown to result in high antibody responses (complementary to CD103+ dDCs) while skewing 
immunity towards Th2 [160, 161]. This Th2 bias is also seen after NP application without adjuvants 
(unpublished observations of the D2G2 group and Appendix 4, Figure 10.10).  
7.4.3 Associated pathways and effects of Caspase-1, NALP3 and TLR4/ 
RAGE on antibody responses  
Adjuvants [368, 403] and necrotic cells [553] have been reported to activate the NALP3 
inflammasome following exposure to PAMPs (LPS) and DAMPs (HMGB-1, dsDNA etc) amongst 
others [400, 553, 682], with caspase-1 forming an integral part of activated inflammasomes [400]. 
NALP3 inflammasome formation is disabled in NALP3-/- mice, and similar to caspase-1-/- mice, 
restricts the conversion of pro IL-1β and IL-18 into their mature forms [537, 553, 683]. Neither 
caspase-1 nor NALP3 were required to elicit enhanced antibody responses to NP-delivered 
influenza vaccine, indicating that that neither caspase-1 nor NALP3 were essential responding to 
the dead cells by inflammasome formation or exerting immuno-stimulating functions by converting 
pro-IL-1β/ IL-18 into their mature forms. Recent reports have emerged showing that IL-1β 
maturation can occur independently of caspase-1 or even the inflammasome formation, requiring 
other proteases, for example neutrophil-derived serine proteases [539, 670].  
That caspase-1 was not essential for mediating inflammatory responses to dead cells was published 
recently by Chen et al. [554]. It was suggested that IL-1R (along with IL-1α) may be more 
important in response to cell death, tissue injury and inflammatory infiltrates [554, 684]. In 
particular, IL-1α has been shown to be released from necrotic cells but is also contained in apoptotic 
bodies as well as membrane particles. Thus, IL-1α can be released during apoptosis/ secondary 
necrosis in sterile inflammation, leading to neutrophil infiltration [685]. The results of increased 
neutrophil infiltration, as seen following NP immunisations, may indicate excessive IL-1α release 
and require further investigation. It remains yet to be verified which other proteases can activate 
NALP3 and/ or caspase-1 in response to inflammation and trauma in tissue, resulting in IL-1α,  
IL-1β and IL-18 secretion.  
Studies addressing the question if adjuvants (e.g. alum, MF59) activated the NALP3 inflammasome 
emerged [95, 365, 368, 403, 553]. A dependency of alum-adjuvant mediated humoral immune 
responses to uric acid release [395] and mature caspase-1 via an activated NALP3 inflammasome 
[95, 368, 403] were reported. Shortly afterwards however, considerable controversial results 
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appeared with reports proposing alum’s adjuvanticity was independent of NALP3 [365, 369, 371]. 
More specifically, McKee et al. illustrated that alum’s adjuvanticity, B- and T-cell responses were 
independent of caspase-1 and NALP3 [365]. MF59 could not activate the NALP3 inflammasome 
although their immuno-stimulating effects were MyD88 – but not NALP3 – dependent [397]. Due 
to the constantly emerging novel insights into the NALP3 inflammasome, involved proteases and 
potential inflammasome activators (e.g. uric acid [395]), further investigations of other involved 
inflammasomes and their activation may be required to investigate the potential mode of action of 
the NP. Thus, enhanced immunogenicity in NP-immunised groups may therefore be NALP3- and 
caspase-1-independent but MyD88-dependent and should receive further attention.  
Cellular infiltration is also mediated by DAMPs, such as HMGB-1 and HSP via their PPRs and 
TLRs [686, 687]. Depending upon which molecule HMGB-1 associates with (e.g. LPS, DNA, 
nucleosomes etc), HMGB-1 can bind to various TLRs and RAGE or IL-1R. Chen et al. found that 
the inflammatory responses to necrotic cells were independent in mice deficient in individual TLRs 
and marginally different to TLR2/ TLR4 double knockout mice based on neutrophil infiltration 
[554]. With more HMGB-1 protein being released following NP than after i.d. immunisation, it was 
hypothesised that by using specific HMGB-1-receptor knockout mice (RAGE-/-/ TLR4-/-), the 
relevance of HMGB-1 as DAMPs following NP could be assessed. Overall, no difference between 
RAGE-/-/ TLR4-/- and WT mice was seen. Thus, HMGB-1 seemed not to contribute to an increased 
inflammatory environment. 
To add complexity, the redox state of HMGB-1 may result in chemo-attractant or immuno-
stimulating abilities [531, 542, 688]. HMGB-1 in its reduced form (containing thiol groups) is 
released actively by inflammatory cells (e.g. macrophages), exhibiting a chemo-attractant activity 
leading to leukocyte recruitment in a RAGE- [689] and CXCR4-dependent manner [531, 542, 677]. 
Although the different redox-states of HMGB-1 were not further investigated here, preliminary 
experiments indicated that at 6h post NP treatment, reduced (all thiol) and disulphide-HMGB-1 was 
present (Appendix 4, Figure 10.11). This contradicts studies by others, where HMGB-1 containing 
disulphide bonds, led to cytokine secretion and thus inflammation by binding via its TLR4 receptor, 
especially after forming inflammatory complexes of DNA-HMGB-1 [531, 542, 677]. HMGB-1 
passively released by necrotic cells have been reported to be RAGE-independent [531, 677, 688, 
689], while HMGB-1 associated with nucleosomes and/ or following secondary necrosis have been 
reported to be TLR2-dependent [530]. These findings of redox-state dependency further add to the 
complexity of understanding the underlying mechanism of the physical immune enhancer as 
encountered with the NP. A kinetics study incorporating the redox status of HMGB-1 may assist in 
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assessing what form of HMGB-1 is present post NP and i.d. immunisations to assess its effect on 
cellular infiltrations and inflammatory microenvironment.  
7.5 Future outlook 
Based on the results presented in the previous chapters, the overall correlation between cell death 
co-localising with antigen and enhanced immune responses has been demonstrated. The key 
difference in the presented study in comparison to others exploring alternative immune stimulators 
was that the immune enhancer effect was generated by the NP application itself, generating 
localised cell death and release of DAMPs. The markedly lower cell death after i.d. injection was 
localised to a single needle insertion site and therefore less DAMPs, where fewer antigens  
co-localised with live and dead cells and DAMPs. This is summarised schematically in Figure 
7.15a. The presented results illustrated similarities between the physical immune enhancer of NP 
and the mechanism of chemical adjuvants and formed the working hypothesis throughout this study.  
Previous investigations of skin cell death induced by mechanical vaccine delivery devices such as 
tattooing devices were reported to induce necrosis and inflammatory cell infiltration [247] with 
increased cellular and humoral immune responses [250]. Ballistic delivery of micro-particles 
produced over >90% dead cells in the centre of the particle bombardment site [242]. The cell death 
profile of NPs contrast Raju et al.’s findings, most likely due to the inherently different device and 
application velocities (2.3 ms-1 vs. >100 ms-1). By using mathematical modelling to predict stress-
contours induced by NP application to skin (Figure 7.15b), a model for accurate prediction of cell 
death and possibly DAMP release along with antigen uptake or diffusion may be possible. Thus far, 
experimental findings are consistent with the mathematical model, in which cell death and highest 
simulated stress levels (red) overlap at the site of projections penetrating the skin [applying 
previously published mechanical models; 573]. Qualitative comparison of the spatial distributions 
of theoretical stress with measured cell death suggests that cells die in regions where Von-Mises 
stresses of at least 1-10 MPa are generated, subject to modelling assumptions [573]. To the best of 
the author’s knowledge, this is the only time that skin cell death has been linked to a specific stress 
distribution and magnitude. Future work modelling different projection shapes and application 
conditions along with DAMP release in response to cell death, antigen uptake and diffusion is likely 
to enable far-reaching predictions on how the immune system may respond to tissue damage 
induced alongside a vaccination.  
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Figure 7.15: Schematic of enhanced immune responses to Fluvax® following co-localisation of viable skin cells 
with vaccine and DAMPs.  
(a) Vaccine (blue) administered either by i.d. injection or dissolving off coated NP projections. i.d. injection causes cell 
death (magenta) predominantly around the insertion site within the VE and Dermis, causing a bleb formation in the 
latter, with minimal co-localisation of DAMPs (magenta stars) with vaccine and viable cells (green). NP induces highly 
localised cell death in the VE and minimally in the dermis, with co-localisation of DAMPs with antigen and live cells. 
(b) Correlation and predictability of experimentally induced cell death with mathematical modelling. Abbreviations: 
i.d., intradermal; NP, Nanopatch™; DAMPs, damage associated molecular patterns; SC, Stratum corneum; VE, Viable 
Epidermis; DAMPs, danger associated molecular patterns. Image reproduced with permission from [344].  
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7.6 Conclusion  
To conclude, this chapter investigated the early innate immune responses following immunisation 
with the NP and i.d. injection. Overall, it was found that the NP induced a significantly higher pro-
inflammatory environment and cell infiltration in the skin than i.d. injections, supporting the overall 
hypothesis of this chapter. This inflammation and inflammatory cell migration correlated well with 
the induced levels of death. Importantly, immunisations by NP resulted in longer antigen retention 
in the skin than i.d. with a slow-steady stream to the dLN. In contrast, administration of antigen by 
i.d. resulted in fast drainage to the dLN. Further, neither the surface receptors RAGE, TLR4, nor the 
protein caspase-1 or protein complex NALP3 appear to be involved in key signalling pathways for 
enhanced humoral immunity against influenza vaccines seen in NP-based immunisations. This 
suggests that other pathways such as ASC and IL-1R (IL-1α) that have shown involvement in other 
adjuvant-mediated immunogenicity [377, 554], should be investigated as a potential pathway in the 
NP’s mode of action. Although the detection of cytokines and chemokines was unsuccessful, 
additional approaches are currently being investigated. Overall, these results elucidate to the NP as 
a potentially new class of adjuvants as a physical immune enhancer. Understanding how the innate 
immune system responds to cell death induced by the vaccine delivery device (i.e. NP and i.d. 
injections) will contribute to a better understanding of the correlation between (innate) immune 
responses, the resulting inflammation and device-specific inflicted cell death contributing to 
enhanced immunogenicity.  
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Chapter 8  
Thesis conclusions and future directions 
The focus of this thesis was to examine the role of cutaneous cell death in the generation of vaccine-
related enhanced immune responses, following skin-based vaccination. Specifically, the interaction 
of skin with NP application or i.d. injection as well as immune response following delivery of a 
model vaccine (seasonal trivalent influenza) was investigated. The performed experiments included 
quantifying and characterising the cell death in skin after payload delivery using conventional 
needles for i.d. delivery and the NP (Chapter 4), and studying the impact of varying application 
parameters on cell death (Chapter 5). Influenza-specific antibody responses were measured while 
assessing cell death as a contributing factor (Chapter 6) in addition to characterising early innate 
immune responses after skin immunisations (Chapter 7). These investigations contributed to a 
better understanding of the potential mode of action of the NP. As such, NP immunisations showed 
that immunogenicity correlated with the co-localisation of antigen with live and dead cells, 
exceeding i.d.-based immunisations. The major findings are highlighted in the following sections 
and discussed in the perspective of future work. 
8.1 General discussion 
The studies presented within this thesis were designed to examine the four key objectives listed in 
Chapter 1 in the application of the Nanopatch™ as a physical immune enhancer. The main 
findings of each chapter are summarised below:  
i. Characterisation, evaluation and quantification of cell death (Chapter 4): NP induced 
significantly higher levels of cell death than i.d. at the application/ insertion site, which were 
predominantly of necrotic origin – based on morphological examination.  
ii. Manipulation of cell death levels by varying NP application parameters (Chapter 5): 
different projection densities resulted in varying levels of cell death, while variation of 
application velocity, dermal penetration depths and projection shapes did not significantly 
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alter cell death levels (in the tested ranges); the threshold for cell death of skin cells was 
found to be approximately ≥1 MPa.  
iii. Humoral immunogenicity to influenza vaccine (Chapter 6): comparison of NP to i.d. 
injection illustrated enhanced influenza-specific antibody-mediated immunogenicity in NP 
groups; enhanced immunogenicity was dependent upon level of induced cell death and 
concurrent co-localisation of cell death with antigen. 
iv. Early innate immune events (Chapter 7): increased inflammatory infiltrates and DAMP 
release were measured following NP immunisations in addition to prolonged antigen 
retention in skin; i.d. immunisations resulted in significantly less inflammatory infiltrates in 
skin and antigen drained faster from the skin to the dLN than NP. 
8.1.1 Evaluation and characterisation of cell death in skin 
As hypothesised at the beginning of this thesis, fundamental differences following NP application 
and i.d. injection into skin were seen, with particular emphasis on the level of cell death induced by 
each method. NP application induced 65-fold higher cell death levels than i.d., both of 
predominantly necrotic origin based on morphological examination in situ. Visualisation of the 
dead cells suggested necrotic cell death upon penetration of the projection and needle although at 
later time-points the presence of apoptotic cells was noted. However, based on current knowledge, 
it is possible that several cell death forms may occur simultaneously or sequentially, and therefore 
lead to multiple DAMPs being released (HSP, ATP, HMGB-1 etc) and/ or caspase activation. 
Previous investigations of skin cell death induced by mechanical vaccine delivery devices such as 
tattooing instruments were reported to induce necrosis and inflammatory cell infiltration alongside 
with increased cellular and humoral immune responses  alongside with increased cellular and 
humoral immune responses [250] due to the repeated needle puncturing of the skin. Further, 
ballistic delivery of micro-particles found >90% dead cells in the centre of the target site with only 
the skin target periphery containing both live and dead cells [242]. This contrasts the experimental 
findings of the NP, showing cell death regions tightly localised around the microprojections sites, 
most likely due to the inherently different application design and application velocities (2.3 m/ s vs. 
>100 m/ s). Future work would use electron microscopy or histology to visually identify the cell 
types. The type of cell death (apoptotsis, necrotsis, necroptosis and pyroptosis) could be assayed by 
BrdU, Western Blot (caspase-1, RIP-1, -2, -3), histology and immunofluorescence [452, 690]. 
These experiments should confirm the presented results and further characterise the cell death over 
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time. This is important as the type of cell death has shown to have implications on immunogenicity, 
but also maturation and activation of DCs and release of DAMPs [187, 334, 393, 509, 551]. 
Interestingly, the extended presence of dying (e.g. apoptosing neutrophils) and dead cells (necrotic 
or secondary necrotic cells) in the skin may also contribute to the antigen depot effect as discussed 
in Chapter 7, with overall implications on the immuno-stimulatory effect of cell death following 
NP application.  
8.1.2 Insights into cell death modulation by changing Nanopatch™ 
application parameters  
The qualitative comparison of the spatial distributions of theoretical stress with measured cell death, 
suggests that cells die in regions where Von-Mises stresses in (or above) the range of 1-10 MPa are 
generated, subject to the accuracy of the theoretical model [discussed in 573]. To the author’s 
knowledge, this was the first time that skin cell death has been linked to the underlying stress 
distribution and magnitude. Other more advanced mathematical models based on [573] should be 
incorporated to experimentally assess and verify if the modelling accurately predicted the level of 
cell death. If the model could take into account the cell death type as well as potential release of 
danger signals and co-localisation of antigen, these results would contribute significantly to predict 
the level of immune enhancement of the NP – and other MN. Previous cell death studies and basic 
models assessing pressure-dependency of cells are predominantly confined to in vitro cell cultures 
[636] or pressure ulcer studies performed on muscle or combined skin and muscle samples [627, 
635]. These studies are difficult to compare due to the large variations in the experimental setup 
(exposure times to pressure lasting several minutes to hours or even days, tissue area, tissue and 
muscle type etc). 
Modulation of cell death by changing the application parameters was only partially achievable. In 
particular, projection shapes did not significantly affect cell death levels except for the 2-step 
projections. Further, the tested application velocities (1.8-3.1 m/ s) did not affect viability levels. In 
contrast, varying the projection densities did result in significant differences of induced cell death 
levels. To the best of the author’s knowledge, no MN studies have investigated the effect of 
different shapes or densities on immunogenicity or tissue viability. However, it has been shown that 
the projection length and arrangement but also skin thickness and the MW of the delivered payload 
may affect tissue penetration and drug diffusion [268]. Overall, a low aspect-ratio was likely to 
yield higher drug permeability within the skin [268].  
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Further studies testing different projection shapes, projection densities (2,500-20,000/ cm2) and NP 
array sizes (4, 9 and 25 mm2) were not achievable within the given time frame. Future 
investigations would therefore include manufacture of these arrays and projection shapes. 
Additional studies are intended to further examine the correlation between cell death and modulated 
projection parameters with respect to the resulting immunogenicity, e.g. innate and adaptive 
immune responses to influenza vaccine. If a clear trend between application force and energy 
corresponds to the induced cell death (alongside with mathematical modelling [263, 602], this 
would potentially enable predictions using mathematical modelling of cellular damage and DAMP 
release as immuno-stimulant alongside with antigen uptake in NP and other MN-based 
immunisation strategies [5].  
8.1.3 Correlation of immunogenicity to enhanced antibody responses 
Here, using Fluvax® 2010 as the model antigen, a 10-fold dose-sparing potential of NP over i.d. 
was measured, which has not previously been reported when comparing two skin-based 
immunisation routes. In particular, this is the only dose-matched immunisation study comparing NP 
and i.d. directly. Another direct comparison of NP with i.d. injections delivering live viral vector 
vaccines (adenovirus and MVA) were not dose-matched due to formulation differences [347]. Yet, 
single NP and i.d. immunisations did not statistically significantly differ from each other in CD8+ 
T-cell responses. After a boost immunisation, i.d./ i.d. and NP/ i.d. performed significantly better 
than NP/ NP, an effect most likely evoked by the variation in delivered dose between both routes 
[347].  
Bilateral immunisations by NPs causing twice the amount of cell death resulted in significantly 
higher antibody titres than unilateral single NP immunisations at a high Fluvax® dose. This effect 
was much less pronounced at low Fluvax® doses albeit tighter variation and an increase in antibody 
titres. Bilateral immunisations resulted in an increase of total number of targeted cells, cell death 
levels and number of targeted dLN while the antigen concentration per cell or tissue area was 
decreased. These results mirrors findings by Widera et al., where OVA delivery to both lateral 
thorax sites in hairless guinea pigs yielded significantly higher antibody responses at high OVA 
doses, but not at medium or lower doses [262]. In addition, by applying NPs to both ears rather than 
two NPs pear ear, the antibody responses did not differ, suggesting that the two instead of one 
targeted dLN may not be as relevant for the generated immune response at low doses. Increasing the 
number of NPs (i.e. number of projections) per ear and hence delivering antigen to a larger skin 
surface area resulted in an increased antibody response despite decreased antigen concentration per 
area. In general, limited studies are available investigating uni- or bilateral immunisations using i.d. 
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or MN-based designs [262]. Thus, comparisons to others are restricted. The presented results and 
additional carefully planned experiments may separate implications of e.g. dLN, tissue thickness 
and number of targeted cells would provide more insights into which factors (antigen concentration, 
number of targeted cells and LN) may be important to consider in future immunisation studies, 
especially in larger animal models and eventually humans.  
Co-localisation of cell death with antigen was found to be essential to enhance influenza-specific 
antibody titres as tested with NP, FP, i.d. and combinations of them. Studies by others that 
investigated the spatio-temporal relationship between adjuvant [97, 410] or laser-adjuvanted 
delivery [436] and antigen, indicated that co-localisation of antigen with adjuvant (of chemical of 
physical nature) was essential for generating enhanced immunogenicity. Moreover, i.m. delivery of 
trivalent influenza vaccine adjuvanted with MF59 resulted in the release of ATP, an endogenous 
adjuvant (i.e. DAMP), in the muscle. Replication of co-injection of ATP however did not result in 
enhanced T-cell or antibody responses, most likely due to inherent differences of the concentration 
between injected versus cellular released ATP [94]. This points to the importance of not only 
harnessing the skin’s potential by targeting vaccine directly to the skin’s APCs (as outlined in [3] 
based on a probability-based analysis) but also co-delivering to these cells key cytokines and 
DAMPs – produced by nearby cell death (induced by a physical stress; not chemicals). Overall 
these data indicate that cell death plays an important role in enhancing immunogenicity, while 
highlighting that many other factors (cell numbers, dLN, antigen concentration, presence of 
DAMPs and PAMPs) are interlinked with the enhanced immunogenicity. These complex 
interactions should be investigated as part of a future project.  
8.1.4 Innate immune responses 
Lastly, as hypothesised at the beginning of this thesis, the vast differences in cell death between NP 
and i.d. were also reflected in the measured influenza-specific antibody responses. As a physical 
immune enhancer effect by the NP was postulated, the early innate immune responses to NP 
application in skin were assessed based on common mode of action of adjuvants [70]. Adjuvants 
like alum, MF59 etc are known to result in inflammatory cell infiltration at the injection site [373], 
induction of cell death [95], release of endogenous adjuvants [94, 95], DC activation [334, 364], 
inflammasome activation (NALP3 or ASC) [70, 95] etc. Investigating the pro-inflammatory effects 
of NP application to skin resulted in two waves of inflammatory cell infiltration into NP-treated 
tissue at 6h and 24h post-treatment, containing predominantly neutrophils. Comparison of infiltrates 
at 24h post immunisation demonstrated increased infiltration of neutrophils, monocytes and DCs 
after NP with significantly less after i.d. immunisations. Cellular infiltrations were more 
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pronounced with FV or FV + QA, indicating that DAMPs and PAMPs may have synergistic effects, 
especially on neutrophil infiltration. These effects illustrated similarities with other chemical 
adjuvants, inducing local inflammation and infiltration of neutrophils, macrophages, monocytes as 
well as DCs [186, 373, 382]. Importantly, release of DAMPs (possibly suggesting the presence of 
dead cells) has also been reported after delivery of adjuvants [94, 95]. These similarities underpin 
the physical immune enhancer effect of the NP.  
The pursuit of cytokine and chemokine release by CBA assay however was inconclusive, most 
likely was due to sample preparation. MN applications have shown a local transient pro-
inflammatory environment [164, 614], although others found higher pro-inflammatory cytokines 
post i.d. than MN [165]. Other avenues including RT-PCR and tissue ELISAs to assess cytokine 
secretion post NP and i.d. in skin and blood should be investigated, with the former currently under 
investigation. This data is essential in not only determining the pro- and anti-inflammatory 
environment, but also the magnitude of inflammation within the immunised tissue (and dLN) as this 
can influence the immune responses (e.g. bias towards Th1 or Th2 responses).  
DAMPs such as HMGB-1, dsDNA, ATP, HSP, uric acid and MSU etc have been shown to induce 
inflammation and inflammasome activation, as do adjuvants [403, 489, 492, 553, 666]. With 
frequently new emerging knowledge of inflammasome activation and their role in immunisations, a 
potential debate of DAMPs being non-redundant in inflammation [528] has emerged. HMGB-1, 
known to bind to TLR4, 9 as well as RAGE [530], was released following NP but to a much smaller 
extent after i.d. injections. Ablation of HMGB-1 was not performed. However, using RAGE-/-/ 
TLR4-/- surprisingly demonstrated that both, RAGE and TLR4 were dispensable in NP and i.d.-
immunised groups. While the release of other DAMPs (HSPs, ATP release or uric acid crystals) 
after NP and i.d. injections has not been assessed yet, it would certainly provide essential 
information regarding what cell death type may be present, but also what cells and inflammatory 
environment (cytokines & DAMPs) has been created at the immunisation site. This is of particular 
interest since ATP-release following MF59 administration was shown to potentiate the immune 
responses to a trivalent influenza vaccine [94]. Interestingly, studies using knockout mice indicated 
the irrelevance of active NALP3 and caspase-1 in influenza NP or i.d. immunised mice. This 
contradicts current knowledge of dead or dying cells releasing DAMPs, which commonly activate 
the inflammasome following caspase-1 activation [360, 549, 691, 692]. However, mechanisms 
using alternative proteases may enable inflammasome activation without the need for caspase-1 or 
enable activation of other inflammasomes (e.g. ASC and AIM2 [549, 551, 692]) that are known to 
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be activated during inflammation or infections in skin should be investigated. These findings are 
essential to understand the underlying mechanism of skin-based vaccinations (by i.d. and NPs). 
8.2 Limitations within this study 
This study aimed to use exclusively one trivalent influenza vaccine to reduce variables between 
seasonal strain variations and batch differences. Due to unexpected side effects caused by Fluvax® 
2010, some key experiments within this thesis should be repeated with a different influenza vaccine 
of a different manufacturer to ensure that the immunogenicity results were not solely antigen-
specific. These results may also indicate that the high dose-sparing potential of the NP over i.d. may 
have been due to the seasonal vaccine. Although it must be acknowledged that dose-sparing of NP 
over i.m. had been previously reported with Fluvax® 2008. Repeating the key immunogenicity 
studies with a different antigen (e.g. OVA or HPV), an influenza vaccine manufactured in a 
different year or by another manufacturer to assert the herein presented findings, shall be 
commenced in the near future. Using a different antigen (e.g. OVA or HPV) would enable more 
general conclusions from the NP mode of action with regards to innate and adaptive immune 
response. This shall be implemented into the future work plan.  
The observed antibody-mediated immune responses in this thesis give only partial insight into the 
humoral and cellular immune responses. True protection of influenza immunised mice was not 
assessed, hence the superiority of the NP over i.d. groups is solely based on the resulting antibody 
responses and limited HI titres obtained. This is an important limitation of this work. Future work 
addressing long term memory T- and B-cells following influenza vaccine administration and 
challenge studies investigating viral lung clearance with a mouse-susceptible influenza strain (e.g. 
PR8) should be investigated. Of note, the attempt of setting up set up challenge studies using PR8 
was not achieved within this doctoral work but it is expected that a challenge model will be 
available by the end of this year. 
Assessing antigenicity solely by ELISA is insufficient and merits further asserting assays, 
validating protection. With no external reference antibody standards, no quantitative measurements 
of influenza- specific total IgG responses were measured. Including reference antibodies would 
have enabled to measure endpoint titres as well as quantitatively assess IgG production. Moreover, 
HI assays were performed that assessed neutralisation of the virus. Unfortunately, with limited 
stocks and supply of HI reagents, not all experimental groups (e.g. Chapter 6) were able to be 
tested for HI activity. This represents a large gap of experimental work. Experimental repeats with 
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another antigen of which sufficient HI reagents are readily available should be repeated to confirm 
the previous trends and antibody responses. 
Separately, the integrity, functionality and structure of the HA protein within Fluvax® post coating 
onto the NP was not assessed. Additional studies are proposed to assess the effects of trehalose ± 
sucrose [347] as stabilising agent and their effects upon antibody responses as well as HA activity 
and HI titres. While it would have been beneficial to study other animal models (e.g. rats or pigs) in 
more detail, only preliminary studies assessing tissue viability and antibody titres were performed in 
pigs (see section 6.5, Figure 6.8); the results illustrated the need for improved, species- and site-
specific NP design alongside with appropriate NP application conditions to mimic the obtained 
results in mice.  
Characterising and investigating the role of the DC subsets present in the VE and dermis in addition 
to antigen uptake, migration and antigen (cross-) presentation in the dLN are vital in understanding 
the mode of action of the NP and the difference between NP and i.d. immunised animals. Current 
knowledge on DCs in the skin suggests that dDCs may have a more functional role than LCs 
although cross-presentation by keratinocytes may also be occurring [44]. In addition, whether 
recognition of necrotic DCs (that bind to Clec9A) using Clec9A-/- mice or in capability of apoptotic 
cell clearance (NOD mice) are forming part of an essential pathway in NP-mediated immunity 
would be of interest. Using s.s. may further illustrate that local skin damage enhances the 
immunogenicity and may be an alternative approach to induce local cell death and investigate its 
effect upon immunogenicity as alternative skin-based immunisation route. Although most of these 
limitations were beyond of the scope of this doctoral thesis or not possible to thoroughly investigate 
within the given time frame, these are important considerations that must be taken into account 
when drawing conclusions from the data obtained.  
Assessing the adjuvanting effect of the NP itself has only partially been shown: co-localisation of 
cell death with antigen was shown to be required to elicit enhanced immune responses when 
compared with i.d. immunisation (Figure 6.5 and Figure 7.4). Experimentally, proving the 
adjuvantation effect of NP following i.d. injections proved to be difficult due to the antigen 
trafficking rapidly to the dLN due to the capillary pressure within the tissue. Assessing i.d. injected 
vaccine followed b y application of an uncoated NP may therefore not demonstrate a good spatial 
and temporal co-localisation of cell death with antigen. This must be acknowledged in itself.  
Direct comparisons of the NP with other MN systems would have been interesting, assessing and 
comparing immunogenicity with respect to the different animal’s immunisation sites, MN 
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geometries and application conditions. These altogether may also contribute to the immunogenicity 
– and protection in influenza studies. While the feasibility of the NP for larger animal models and 
even humans is an important feature of a possible new immunisation tool, it was beyond the scope 
of this thesis. However, preliminary studies have been carried out by others. In particular, 
amendments in the NP design and projections/ cm2, testing of different application sites, application 
conditions as well as various antigens, adjuvants and doses (including a full human dose coated 
onto NPs) are being investigated.  
Lastly, while comparisons of NP with i.d. have been presented within this thesis, other cutaneous 
immunisation devices have not been assessed. Upon comparison with other conventional and 
cutaneous techniques, the NP appears to induce higher immune responses than i.m. groups as 
reported elsewhere or when compared with i.d. groups as compared within this thesis. A definitive 
dose-sparing cannot be claimed as other conventional routes such as i.m. or s.c. with dose-matched 
groups were not included in this work. This would have been beneficial to investigate the ‘true’ 
dose-sparing over conventional immunisation routes.  
8.3 Future directions  
The work here introduced the NP device as a physical immune enhancer in skin-based 
immunisations. Further studies investigating the mode of action to understand the underlying 
mechanisms relevant in skin and NP immunisations are essential. As discussed above, the 
limitations of this doctoral study represent the first obvious future work to complete this study. 
Obviously, challenge studies and viral neutralisations are required to complement the existing 
antibody responses and HI titres, to assess the overall protection of the animal against influenza 
virus infections. Additional immunogenicity and cell death studies in mouse flank but also different 
antigens and other animal models (similar to the preliminary pig study, Chapter 7) would be 
beneficial to endorse the proposed concept that co-localisation of antigen with NP-induced cell 
death is essential for enhanced immunogenicity. As previously mentioned, of high importance are 
challenge studies to assess true protection, followed by dissecting the adjuvanting properties of the 
NP.  
Studying APCs, in particular LCs, mDCs and dDCs involved in antigen uptake, presentation and 
shuffling were beyond the scope of this thesis. However, APC activation and uptake must be 
explored as (necrotic) cell death has been shown to activate APCs. Differences between APC 
activation and antigen uptake could further elucidate the differences between NP and i.d. 
immunisations. The role of APCs in NP and i.d. immunisations is currently being investigated. 
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Moreover, studies investigating the maturation and activation of DC in conjunction with sensing 
necrotic cells with their Clec9A surface receptor via F-actin would contribute to investigate the 
direct effect of NP-induced necrotic cells upon the immunogenicity. Overall, these studies would 
provide valuable insights in defining the signal transduction pathways following NP-induced tissue 
injury, evoked dead cells and antigen delivery.  
Since an increased amount of antigen remained at the site of immunisation a ‘short-lived’ antigen 
depot of several days in addition to innate immune cells infiltrating that site may contribute to the 
NPs enhanced immunogenicity in comparison to i.d. injections. To test whether the cell death and 
tissue trauma following NP alone or longer antigen exposure in the skin may contribute to the 
physical adjuvanting effect, ears shall be excised at different time-points following immunisation by 
NP or i.d. to study whether the antigen exposure or the amount of inflicted cell death (hence innate 
immune responses incl. infiltrating cells) contribute to the immune responses.  
Cytokine and chemokine secretion following NP and i.d. immunisations in tissue and serum could 
indicate the type of local and systemic immune response to the devices themselves and in response 
to the administered antigen. Lastly, investigation of device-specific DAMP release (HMGB-1, HSP 
and ATP) in tissue could provide interesting parallels between chemical adjuvants and the proposed 
physical adjuvanting effect of NP application to skin. This may further indicate whether the tissue 
trauma in itself induces inflammatory stimuli that fuel the development of the cellular/ humoral 
immune response similar to adjuvants.  
8.4 Concluding remarks 
This thesis has given a comprehensive insight of vaccine device-induced cell death and its 
immunogenic implications on the resulting immune responses. In particular, studying the NP-
induced cell death representing a possible physical immune enhancer, the presented results 
contributed considerably to the existing body of knowledge on skin-based adjuvant-free vaccine 
delivery. In particular, the presented results underpinned the feasibility of using the NP as a 
physical immune enhancer given the results obtained in murine studies. Exciting research 
opportunities lie ahead addressing the limitations of this study but also further investigating the 
underlying mechanism of enhanced immunogenicity encountered following NP immunisations and 
challenging the existing models obtained and hypotheses proposed herein. With the core focus of 
the future work lying on studying the NP-induced cell death and its mode of action, this may indeed 
represent a potential ‘physical immune enhancer’ suitable for use in humans. This knowledge will 
be beneficial to the fields of vaccination, chemical-adjuvant-free immunisations and immunology. 
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Chapter 10  
Appendix 1 
Supplementary data to Chapter 4. 
10.1 Corneocyte removal following Nanopatch™ application to skin 
 
Figure 10.1: Nanopatch™ application to skin results in partial corneocyte removal. 
Corneocytes, distinguishable by their hexagonal shape were partially removed following piercing of NP projections 
piercing through the SC layer of murine ear skin.  
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10.2 Three dimentional images and rendering of image stacks 
 
Figure 10.2: Surface rendering and 3D image representation of Nanopatch-treated skin. 
Image stacks visualised in 3D format and surface rendered indicated the ondulated skin surfaces.    
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Appendix 2 
Supplementary data to Chapter 5. 
10.3 Static flat punch application does not induce cell death 
 
Figure 10.3: Static flat punch application of ≤100 g does not induce cell death. 
A flat punch measuring 3 mm in diameter was applied onto ventral murine ear skin for 2 min and subjected to ≤100 g 
(see section 3.2.2 for experimental set up). A black semi-circle was drawn around the area of flat punch application. 
Tissues were subjected to viability staining using AOEB (green, viable; magenta, dead) and imaged by CLSM. No cell 
death was observed with applied weights of ≤100 g within the flat punch application area.  
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10.4 Flat punch induced cell death in dorsal ear skin 
 
Figure 10.4: Cell death induced by flat punch application onto murine ear skin. 
A flat punch was applied onto ventral murine ear skin for 2 min and subjected to bear various weights (see sections 
3.2.2 and 5.3.1) with tissues subjected to viability staining using AOEB. Cell death was also observed in dorsal ear skin 
after flat punch application of 2.5 and 4 kg weights, respectively.  
10.5 Static Nanopatch™ application with low weights does not induce 
cell death  
 
Figure 10.5: Static Nanopatch™ application of ≤30 g to murine ear skin.  
Representative image of a static Nanopatch™ application with less than 30 g of weight. No cell death was noticeable in 
the skin.  
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10.6 Penetration depths of static Nanopatch™ application exposed to 
weights 
 
Figure 10.6: Penetration depth measurements of static Nanopatch™ application in murine ear skin.  
10.7 Penetration depth of a 10K Nanopatch™  
 
Figure 10.7: Penetration depth of a Nanopatch™ with 10,000 projections/ cm2.  
The 10K (10,000 projections/ cm2) NP where applied with half of the application energy due to the reduced number of 
projections penetrating. (a) The penetration depth was measured following application of FluoSpheres®-coated NPs 
onto murine ears, measuring 62.8 ± 15.0 µm and (b) representative penetration depth image from murine ears to which 
coated NPs (1% 505/515 FluoSpheres® solution; green) were applied. Ears were embedded in OCT, 10 µm sections 
collected and penetration depth measurements completed using CLSM/ MPM. Penetration depths were measured from 
the breach of the SC until the lower FluoSpheres® deposition in the dermis, distinguishable from the VE by the 
collagen (blue). 
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Appendix 3 
Supplementary data to Chapter 6. 
10.8 Coating and vaccine formulations delivered by Nanopatch™ 
 
Figure 10.8: Nanopatch™ morphology before and after coating of trivalent influenza vaccine.  
Coating morphologies of NPs containing MC and Fluvax® (FV) were verified by SEM prior to cell death 
quantification. SEM images of (a) clean, uncoated NPs and (b) coated NPs illustrating consistent coating morphology 
irrespective of coated medium as shown with 4% MC (final concentration of 1% MC) or (c) 40 ng of a trivalent split 
virion influenza vaccine (Fluvax®; equivalent to 10 ng delivered) prior to application. Delivery efficacy of ~25% 
resulted in approximately 10 ng of influenza vaccine being delivered into murine ear skin post application for 2 min 
(see Figure 10.8). NP, Nanopatch™; MC, methyl cellulose; FV, Fluvax®.s 
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10.9 Delivery efficiencies by Nanopatch™  
 
Figure 10.9: Nanopatch™ delivery efficiencies into mouse ear based on 14C-OVA co-delivery with Fluvax® 2010.  
Dose delivery of Fluvax® 2010 was assessed prior to immunisation studies with influenza vaccine using radiolabeled 
14C-OVA as a tracer protein in conjunction with methyl cellulose (MC) as visco-enhancer and Fluvax®. Fluvax® 
concentrations ranged from 0.1-540ng, to calculate the effective delivery efficiencies of the antigen coated onto NPs. 
The delivery efficiency was defined as total amount of coated antigen per NP (elution controls, 100%) – remaining on 
the NP after application – remaining on the ear’s surface = total amount of antigen delivered into the ear (see section 
3.2.13 for further details). Delivery efficiencies were defined for each coating formulation containing Fluvax® and 1% 
w/w MC, resulting in approximately 20-25% of the coated solution being delivered into murine ear skin. Hence, all 
doses quoted within this chapter refer to the delivered amount of HA. *Max concentration represents the maximum 
amount of undiluted Fluvax® coated (6 µL = 540 ng) onto one NP. Elution controls (n=4) included 8 µL of each 
coating solution applied onto NPs and elution into PBS, representing 100% delivery efficiency. Error bars represent 
means ± SD with n=6 per group, n=3 for maximum concentration and n=4 for each group collated in the elution control 
(total n=32). Statistical analyses were performed based on an ordinary one-way ANOVA with Tukey multiple post-
comparisons test. 
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10.10 Fluorescent labelling of antigen  
 
Figure 10.10: Scanning electron and Multiphoton microscopy images of fluorescently-labelled Fluvax® 2010. 
Representative X-ray and fluorescence images were collected of DyLight® 755-labelled Fluvax® (FV) antigen. (a) 
containing 1) neat FV), 2) concentrated FV with its filtrate with its 3) eluate of the cflFV, 4) cflFV and its 5) filtrate and 
6) a 1:100 dilution of cflFV and 7) the column used between steps 5) and 6). Representative SEM images of (b) 
uncoated NPs and (c) coated NPs with some bridging (white arrows) between projections as well as a (d) CLSM image 
of coated NPs. Similar results were obtained using DyLight® 755. FV, Fluvax®; cflFV, concentrated fluorescent FV; 
NP, Nanopatch™. 
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Appendix 4 
Supplementary data to Chapter 7. 
10.11 Nanopatch™ and intradermal delivery are biased towards Th2 
isotype responses  
 
Figure 10.11: Th2-biased immune responses post skin immunisation routes.  
Influenza vaccine (Fluvax®) was administered by NP or i.d. injections at various doses at two doses and compared to 
an  i.m. injection of 6000 ng; IgG isotypes (IgG1 and IgG2) were assayed by ELISA on day 21 post-immunisation. 
(a) Absorbance readings of NP and i.d. immunised mice; (b) Ratio of IgG2:IgG1. NP, Nanopatch™, i.d., intradermal 
and i.m., intramuscular. Error bars show means + SD (*p<0.05, ** p<0.01, *** p<0.001).  
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10.12 Different redox states of HMGB-1 in skin following Nanopatch™ 
treatment  
 
Figure 10.12: HMGB-1 secretion from murine ear tissue.  
Six hours following Fluvax®-immunisation by Nanopatch™ HMGB-1 was assessed by Western Blot and compared to 
naive C57BL/6 mouse ears. Lanes: ladder (1), cytoplasmic fractions of NP (2, 4) and naive mice (3, 5), nuclear 
fractions of NP (6, 8) and naive mice (7, 9), recombinant HMGB-1 control (10).  
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Appendix 5: Awards and Prizes awarded based on the research 
conducted within this doctoral study 
1. Women in Technology: PhD Career Award: Finalist 2013, 2012 and 2011 
2. Glaxo Smith Kline: GSK student excellence award: Queensland Finalist 2012  
3. AIBN image competition; highest artistic merit for ‘Fluorescently stained "live" skin 
cells’, 2011.  
4. AIBN Student Conference, Brisbane, Queensland, 23rd September 2011. Localised skin cell 
death in generating improved immune responses during Nanopatch™ targeted vaccine 
delivery. Winner best poster presentation 
5. AIBN Student Conference, Brisbane, Queensland, 23rd September 2011. Spatial and 
quantitative analysis of localised cell death in the skin following Nanopatch™ application. 
Highly recommended: oral presentation 
6. International Nanomedicine Conference, Sydney, New South Wales, 30th June to 2nd July 
2010. Localised skin cell death in generating improved immune responses during 
Nanopatch™ targeted vaccine delivery.’ Winner ‘NSW PhD Student Researcher Award 
for Excellence in Nanomedicine Research’ 
7. ASMR Postgraduate Conference, Brisbane, Queensland, 2nd of June 2010. Improved 
vaccination by targeting skin cells: the importance of cell death. Poster Finalist 
 
